EP2906539A1 - Inhibitors of viral replication, their process of preparation and their therapeutical uses - Google Patents

Inhibitors of viral replication, their process of preparation and their therapeutical uses

Info

Publication number
EP2906539A1
EP2906539A1 EP13774453.8A EP13774453A EP2906539A1 EP 2906539 A1 EP2906539 A1 EP 2906539A1 EP 13774453 A EP13774453 A EP 13774453A EP 2906539 A1 EP2906539 A1 EP 2906539A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
butoxy
benzopyran
trifluoromethyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13774453.8A
Other languages
German (de)
French (fr)
Other versions
EP2906539B1 (en
Inventor
Richard Benarous
Francis Chevreuil
Benoit Ledoussal
Sophie Chasset
Frédéric LE STRAT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hivih
Original Assignee
Laboratoire Biodim SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Biodim SAS filed Critical Laboratoire Biodim SAS
Priority to EP13774453.8A priority Critical patent/EP2906539B1/en
Publication of EP2906539A1 publication Critical patent/EP2906539A1/en
Application granted granted Critical
Publication of EP2906539B1 publication Critical patent/EP2906539B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.
  • the present invention also relates to methods for the preparation of such compounds.
  • the present invention also relates to pharmaceutical compositions comprising such compounds.
  • the present invention also relates to the treatment of viral infections by the administration of a therapeutically efficient amount of such compounds.
  • HIV Human Immunodeficiency Virus
  • HIV-1 HIV-1
  • HIV-2 HIV-1 is responsible for the larger part of the AIDS global epidemic in the world, with virtually every country reporting cases.
  • Reverse Transcriptase inhibitors include two different classes, Nucleoside/Nucleotide RT Inhibitors (NRTI) and Non Nucleoside RT Inhibitors (NNRTI).
  • NRTI Nucleoside/Nucleotide RT Inhibitors
  • NRTI Non Nucleoside RT Inhibitors
  • the inventors have identified and prepared compounds having an improved antiviral activity, especially against HIV in comparison with prior art compounds.
  • the present invention relates to compounds that are able to totally or partially solve the above-mentioned problems and drawbacks.
  • the present invention provides antiviral agents, especially anti-retroviral agents, and more particularly anti-HIV compounds.
  • the compounds according the invention are inhibitors of HIV replication as assessed by HIV-1 replication assay as herein-detailed. These compounds are thus useful agents for treating or preventing virus, such as HIV, or other viral pathogenic diseases or disorders, by inhibiting replication of the virus into the host infected cells. Therefore, the compounds according to the invention constitute a useful class of new potent antiviral compounds that can be used in the treatment and/or prevention of viral infections in animals, mammals and humans, more specifically for the treatment and/or prevention of HIV in humans.
  • the present invention further relates to such compounds for their use as a medicament (medicine), to the use of such compounds as medicaments (medicines), more specifically as antiviral agents, and to their use for the manufacture of medicaments for treating and/or preventing viral infections, in particular retroviral infections such as, but not limited to, HIV in humans.
  • the invention also relates to pharmaceutical composition comprising such compound as an active ingredient and at least a pharmaceutically acceptable carrier. This pharmaceutical composition further comprises at least a further antiviral agent.
  • the invention also relates to pharmaceutical compositions comprising such compounds in an antiviral effective amount, optionally in combination with at least one further antiviral agent.
  • the present invention further relates to such pharmaceutical composition for use for the prevention and/or the treatment of viral infection, preferably for the prevention and/or the treatment of retroviral infection, more preferably for the prevention and/or the treatment of an HIV infection.
  • the present invention further relates to such pharmaceutical composition for its use for the treatment of an HIV infection in a mammal being infected or having a risk to be infected by the HIV.
  • the present invention also relates to a method of treatment or prevention of viral infections, in particular retroviral infections such as, but not limited to HIV in humans by the administration of one or more such compounds, optionally in combination with one or more other antiviral agents, to a patient in need thereof.
  • retroviral infections such as, but not limited to HIV in humans
  • the present invention also relates to a method of inhibiting the replication of HIV comprising exposing the virus to an effective amount of one or more such compounds under conditions where replication of HIV is inhibited.
  • the invention provides compounds comprising a 6-membered carbocycle, said compounds having a structure according to formula (I):
  • R 1 and R 6 identical or different, independently represent a hydrogen atom; - CN; -OH; -CF 3 ; a halogen atom; a linear or branched C-
  • R 2 non-substituted or substituted by at least one T 1 , represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or
  • R 3 non-substituted or substituted by at least one T 2 represents an aryl; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7- membered carbocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7- membered heterocycle and further fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; a heteroaryl; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5- , 6- or 7-membered carbocycle; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a C 5 -C 7 cycloalkenyl; a C 5 -C 7 cycloalkenyl;
  • R 4 represents a linear or branched Ci-C 6 -alkyl; a linear or branched C-
  • R 5 represents a halogen atom; -CF 3 ; a linear or branched CrC 6 alkyl; a linear or branched C 2 -C 6 alkenyl; a linear or branched C 2 -C 6 alkynyl; a linear or branched fluoroalkyl; a C 3 -C 6 cycloalkyl; -CH 2 OH; or -CH 2 -0-CH 3 ;
  • T 1 independently represents a hydrogen atom; a halogen atom; an alkyl; - (X) x -Ci-C 6 alkyl; a linear or branched fluoroalkyl; a linear or branched -O-Cr
  • T 2 independently represents a hydrogen atom; a halogen atom; a linear or branched -0-Ci-C 3 alkyl; a linear or branched C C 3 fluoroalkyl; a linear or branched -0-Ci-C 3 fluoroalkyl; a linear or branched C C 3 alkyl; or -CN; optionally two geminal T 2 form with the carbon atom to which they are bonded, a C 3 -C 7 cycloalkyl;
  • T 3 and T 4 identical or different, independently represent a hydrogen atom; a branched or linear C C 6 alkyl or a C 3 -C 6 cycloalkyl; optionally T 3 , T 4 and the nitrogen atom to which they are bonded form a C 4 -C 6 heterocycloalkyl;
  • T 5 and T 6 identical or different, independently represent a hydrogen atom; a fluorine atom or a linear or branched C C 3 alkyl or a C 3 -C 6 cycloalkyl; optionally T 5 , T 6 and the carbon atom to which they are bonded form a cyclopropyl;
  • R 5 and R 6 form, with the carbon atoms to which they are bonded, a heteroaryl comprising at least one nitrogen atom;
  • R 1 and R 6 represent a hydrogen atom
  • R 2 non-substituted or substituted by at least one T 1 , represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle ; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic
  • 5-, 6- or 7-membered heterocycle a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle ;
  • R 3 non-substituted or substituted by at least one T 2 , represents an aryl; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7- membered heterocycle and further fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; a heteroaryl; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5- , 6- or 7-membered carbocycle; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a C 5 -C 7 cycloalkenyl; a C 5 -C 7 cycloal
  • R 5 represents a halogen atom; a linear or branched C-
  • T 1 independently represents a hydrogen atom; a halogen atom; an alkyl; - (X) x -Ci-C 6 alkyl; a linear or branched fluoroalkyl; a linear or branched -O-Cr
  • T 2 independently represents a hydrogen atom; a halogen atom; a linear or branched -O-C1-C3 alkyl; a linear or branched Ci-C 3 fluoroalkyi; a linear or branched -O-C1-C3 fluoroalkyi; a linear or branched Ci-C 3 alkyl; or -CN; optionally two geminal T 2 form with the carbon atom to which they are bonded, a C 3 -C 7 cycloalkyl;
  • T 3 and T 4 identical or different, independently represent a hydrogen atom; a branched or linear C C 6 alkyl or a C 3 -C 6 cycloalkyl; optionally T 3 , T 4 and the nitrogen atom to which they are bonded form a C 4 -C 6 heterocycloalkyl;
  • T 5 and T 6 identical or different, independently represent a hydrogen atom; a fluorine atom or a linear or branched C C 3 alkyl or a C 3 -C 6 cycloalkyl; optionally T 5 , T 6 and the carbon atom to which they are bonded form a cyclopropyl;
  • ⁇ x independently represents 0 or 1 ;
  • the invention also provides compounds of formula (I) wherein;
  • R 1 and R 6 identical or different, independently represent a hydrogen atom; - CN; -OH; -CF 3 ; a halogen atom; a linear or branched C C 3 alkyl a linear or branched C C 3 heteroalkyl;
  • R 2 non-substituted or substituted by at least one T 1 , represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle ; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7- membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7- membered carbo
  • R 3 non-substituted or substituted by at least one T 2 , represents an aryl; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a heteroaryl; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5- , 6- or 7-membered carbocycle; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle or a C 3 -C 7 cycloalkenyl;
  • R 4 represents a linear or branched CrC 6 -alkyl; a linear or branched CrC 6 fluoroalkyl or a C 3 -C 6 cycloalkyl;
  • R 5 represents a halogen atom; a linear or branched C-
  • R 5 and R 6 form, with the carbon atoms to which they are bonded, a heteroaryl comprising at least one nitrogen atom;
  • T 1 represents a hydrogen atom; a halogen atom; an alkyl; -(X) x -d-C 6 alkyl; a linear or branched fluoroalkyl; a linear or branched -O-C1-C3 fluoroalkyl; -(X) x - C 3 -C 6 cycloalkyl; -(X) x -(CT 5 T 6 ) y -aryl; -(X) x -(CT 5 T 6 ) y CN; -(X) x -(CT 5 T 6 ) y OT 3 ; - (X) x -(CT 5 T 6 ) y ST 3 ; -(X) x -(CT 5 T 6 ) y S(0)T 3 ; -(X) x -(CT 5 T 6 ) y S(0) 2 T 3 ; -(X) x -
  • ⁇ T 2 represents a hydrogen atom; a halogen atom; a linear or branched -O-Cr
  • C 3 alkyl a linear or branched C C 3 fluoroalkyl; a linear or branched -0-C-
  • T 3 and T 4 identical or different, independently represent a hydrogen atom; a branched or linear CrC 6 alkyl or a C 3 -C 6 cycloalkyl;
  • T 3 , T 4 and the nitrogen atom to which they are bonded form a C 4 -C 6 heterocycloalkyl
  • T 5 and T 6 identical or different, independently represent a hydrogen atom; a fluorine atom or a linear or branched C C 3 alkyl or a C 3 -C 6 cycloalkyl;
  • y represents 0, 1 , 2 or 3; and a racemate, enantiomer, isomer, atropisomer or diastereoisomer or a pharmaceutically acceptable salt thereof.
  • alkyl as used herein, either alone or in combination with another radical, refers to acyclic, linear or branched chain alkyl radicals.
  • heteroalkyl refers to an acyclic alkyl wherein one or more carbon atoms are replaced by an oxygen, nitrogen or sulphur atom.
  • cycloalkyl refers to a monocyclic or polycyclic saturated hydrocarbon radical.
  • aryl refers to a carbocyclic aromatic monocyclic group containing 6 carbon atoms which can be fused with at least another saturated, unsaturated or aromatic carbocycle.
  • Carbocycle refers to a 3- to 8-membered saturated, unsaturated or aromatic cyclic radical in which all of the ring members are carbon atoms and which can be fused with at least another carbocycle.
  • heterocycle as used herein means a saturated, unsaturated or aromatic ring system of 3 to 18 atoms including at least one N, O or S and which can be fused with at least another carbocycle or heterocycle.
  • pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • enantiomer is employed herein to refer to one of the two specific stereoisomers which is a non-superimposable mirror image with one other but is related to one other by reflection.
  • diastereoisomer is employed herein to refer to one of the stereoisomers which is a non-superimposable mirror image with one other but is not related to one other by reflection.
  • racemate is employed herein to refer to an equal amount of two specific enantiomers.
  • atropisomer is employed herein to refer to stereoisomer obtained by a sterically hindered single bond whereby the free rotation of functional groups on either side of this bond is not allowed.
  • tautomer is employed herein to refer to constitutional isomer obtained by a formal migration of a hydrogen atom or a proton accompanied by a switch of a single bond and adjacent double bond.
  • treatment as used herein is intended to mean the administration of a compound or composition according to the present invention to alleviate or eliminate symptoms of HIV infection and/or to reduce viral load in a patient.
  • treatment also encompasses the administration of a compound or composition according to the present invention post-exposure of the individual to the virus but before the appearance of symptoms of the disease, and/or prior to the detection of the virus in the blood, to prevent the appearance of symptoms of the disease and/or to prevent the virus from reaching detectible levels in the blood, and the administration of a compound or composition according to the present invention to prevent perinatal transmission of HIV from mother to baby, by administration to the mother before giving birth and to the child within the first days of life.
  • therapeutically effective amount refers to an amount of a compound according to the invention, which when administered to a patient in need thereof, is sufficient to effect treatment for disease-states, conditions, or disorders for which the compounds have utility.
  • Such an amount would be sufficient to elicit the biological or medical response of a tissue system, or patient that is sought by a researcher or clinician.
  • the amount of a compound according to the invention which constitutes a therapeutically effective amount will vary depending on such factors as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of the treatment, the type of disease-state or disorder being treated and its severity, drugs used in combination with or coincidentally with the compounds of the invention, and the age, body weight, general health, sex and diet of the patient
  • a therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the state of the art, and this disclosure.
  • mammal as used herein is intended to encompass humans, as well as non-human mammals which are susceptible to infection by HIV or non human equivalents of HIV.
  • Non-human mammals include but are not limited to domestic animals, such as cows, pigs, dogs, cats, rabbits, rats and mice, and non domestic animals.
  • the compounds according to the invention are compounds of formula (I) as defined and including the embodiments described in the summary of the invention.
  • the compounds according to the invention are compounds of formula (I) wherein R 4 represents tBu.
  • the compounds according to the invention are compounds of formula (I) wherein
  • R 2 non-substituted or substituted by at least one T 1 , represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle or a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7-membered heterocycle;
  • T 1 represents a hydrogen atom; a halogen atom; -CH 3; -CH 2 F; -CHF 2 ; -CF 3 ; - OMe; -OCH 2 F; -OCHF 2 ; -OCF 3 ; -(X) x -C 3 -C 6 cycloalkyl;-(X) x -(CT 5 T 6 ) y -aryl; - (X) x -(CT 5 T 6 ) y CN; -(X) x -(CT 5 T 6 ) y OT 3 ; -(X) x -(CT 5 T 6 ) y ST 3 ; -(X) x -(CT 5 T 6 ) y S(0)T 3 ;
  • T 3 and T 4 identical or different, independently represent a hydrogen atom; a branched or linear C C 6 alkyl or a C 3 -C 6 cycloalkyl;
  • T 3 , T 4 and the nitrogen atom to which they are bonded form a C 4 -C 6 heterocycloalkyl
  • T 5 and T 6 identical or different, independently represent a hydrogen atom; a fluorine atom or methyl;
  • the compounds according to the invention are compounds of formula (I) wherein
  • R 2 represents a partially or totally unsaturated or aromatic 5-, 6- or 7- membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7- membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or
  • T 1 independently represents a hydrogen atom; a halogen atom; -CH 3 ; - CH 2 CH 3 ; -(CH 2 ) 2 CH 3 ; -CH(CH 3 ) 2 ; -CH 2 CF 3 ; -OCH 3 ; -NH 2 ; -N(CH 3 ) 2; -CH 2 F; - CHF 2 ; -CF 3 ; -OCH 2 F; -OCHF 2 ; -OCF 3 ; -(X) x -C 3 -C 6 cycloalkyl; -(X) x -(CT 5 T 6 ) y - C 3 -C 6 cycloalkyl; -(X) x -(CT 5 T 6 ) y -aryl; -(X) x -(CT 5 T 6 ) y -aryl; -(X) x -(CT 5 T 6 ) y CN; -(X)
  • T 3 and T 4 identical or different, independently represent a hydrogen atom; a branched or linear CrC 6 alkyl or a C 3 -C 6 cycloalkyl;
  • T 5 and T 6 identical or different, independently represent a hydrogen atom; a fluorine atom or methyl;
  • ⁇ y independently represents 0, 1 , 2 or 3.
  • the invention provides compounds of formula (I), wherein R 3 , non-substituted or substituted by at least one T 2 , represents an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; or a C 5 -C 7 cycloalkenyl.
  • the invention provides compounds of formula (I), wherein R 3 , non-substituted or substituted by at least one T 2 , represents a cyclohexenyl or a dihydrobenzopyranyl.
  • the invention provides compounds of formula (I), wherein R 2 , non-substituted or substituted by at least one T 1 , represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; or a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle.
  • the invention provides compounds of formula (I), wherein R 2 , non-substituted or substituted by at least one T 1 , represents a phenyl, a cyclohexenyl, a cyclopentenyl, a thiophenyl, a pyrazolyl, an isothiazolyl, a benzothiazolyl, a pyridinyl, a thiazolyl, an imidazolyl, a pyridinopyrazolyl, a pyrimidinyl, a pyranyl, a pyridinonyl, or a pyridazinyl.
  • the invention provides compounds of formula (I), wherein R 2 , non-substituted or substituted by at least one T 1 , represents a thiophenyl, a pyrazolyl, an isothiazolyl, a benzothiazolyl, a pyridinyl, a thiazolyl, an imidazolyl, a pyridinopyrazolyl, a pyrimidinyl, a pyranyl, a pyridinonyl,or a pyridazinyl.
  • the invention provides compounds of formula (I), wherein:
  • T 1 independently represents a hydrogen atom; a halogen atom; an alkyl; - (X)x-Ci-C 6 alkyl; a linear or branched fluoroalkyl; -(X) x -C 3 -C 6 cycloalkyl; -(X) x - (CT 5 T 6 ) y -C 3 -C 6 cycloalkyl; -(X) x -(CT 5 T 6 ) y OT 3 ; -(X) x -(CT 5 T 6 ) y -aryl; -(X) x - (CT 5 T 6 ) y NT 3 T 4 ; -(X) x -(CT 5 T 6 ) y C(0)OT 3 ; -(X) x -(CT 5 T 6 ) y C(0)NT 3 T 4 ; or -(X) x - (CT 5 T 6 ) y NT 3 C(0)T
  • T 2 independently represents a hydrogen atom; a halogen atom; a linear or branched C1-C3 fluoroalkyl; or a linear or branched Ci-C 3 alkyl;
  • T 3 and T 4 identical or different, independently represent a hydrogen atom; or a branched or linear d-C 6 alkyl;
  • T 1 independently represents a hydrogen atom; a fluorine atom; a bromine atom; a chlorine atom; -CH 3 ; -CH 2 CH 3 ; -(CH 2 )2CH 3 ; -CH 2 CH(CH 3 ) 2 ; -CF 3 ; - CH 2 CF 3 ; -OCH 3 ; -NH 2 ; -N(CH 3 ) 2 ; a cyclopropyl; a phenyl; a benzyloxy; a benzyl; a methylcyclopropane; an ethylcyclopropane; a methylcyclobutane; - C(0)OH; -C(0)NH 2 ; -C(0)NH(CH 3 ); or -NHC(0)CH 3 ;
  • T 2 represents a hydrogen atom
  • the invention provides compounds of formula (I) wherein R 5 represent methyl; ethyl; -CH 2 F; -CHF 2 ; -CF 3 ; -CH 2 CH 2 F; - CH 2 CHF 2 ; -CH 2 CF 3 ; -CH 2 OH.
  • the invention provides compounds of formula (I) wherein R 5 represents methyl or -CF 3 .
  • the invention provides compounds of formula (I) comprising the two features: (a) and (b); (a) and (c); (a) and (d); (a) and (e); (a) and (f); (a) and (g); (a) and (h); (a) and (i); (a) and (j); (a) and (k); (a) and (I); (a) and (m); (a) and (n); (b) and
  • the invention provides compounds of formula (I) comprising the three features: (a), (b) and (d); (a), (b) and (e); (a), (b) and (k); (a), (b) and (I); (a), (b) and (m); (a), (b) and (n); (a), (c) and (d); (a), (c) and (e); (a), (c) and (k); (a), (c) and (I); (a), (c) and (m); (a), (c) and (n); (a), (d) and (f); (a), (d) and (h); (a), (d) and (i); (a), (d) and 0; (a), (d) and (k); (a), (d) and (I); (a), (d) and (m); (a), (d) and (n); (a), (e) and (f); (a), (e) and (g); (a), (e) and (i); (a), (e)
  • the invention provides compounds of formula (I) comprising the four features: (a), (d), (f) and (i); (a), (d), (f) and (j); (a), (d), (f) and (k); (a), (d), (f) and (I); (a), (d), (f) and (m); (a), (d), (f) and (n); (a), (d), (g) and (i); (a), (d), (g) and Q); (a), (d), (g) and (k); (a), (d), (g) and (I); (a), (d), (g) and (m); (a), (d), (g) and (n); (a), (d), (h) and (i); (a), (d), (h) and Q); (a), (d), (h) and (k); (a), (d), (h) and (I); (a), (d), (h) and (m); (a), (d), (h) and (n); (a), (d), (
  • the invention provides compounds of formula (I) comprising the five features: (a), (d), (f), (i) and (k); (a), (d), (f), (i) and (I); (a), (d), (f), (i) and (m); (a), (d), (f), (i) and (n); (a), (e), (f), (i) and (k); (a), (e), (f), (i) and (I); (a), (e), (f), (i) and (m); (a), (e), (f), (i) and (n); (a), (d), (g), (i) and (k); (a), (d), (g), (i) and (I); (a), (d), (g), (i) and (m); (a), (d), (g), (i) and (m); (a), (d), (g), (i) and (m); (a), (d), (g), (i) and (n); (a), (e), (g), (i) and (m
  • the invention provides compounds of formula (A), (B), (C), (D), (E) or (F)
  • ⁇ V represents a substituted or non-substituted partially or totally unsaturated carbocycle or a partially or totally unsaturated or aromatic heterocycle
  • W represents a substituted or non-substituted partially unsaturated carbo- or heterocycle
  • ⁇ Q 2 represents CR 8 or N
  • Q 11 represents C, CR 17 , N;
  • R 20 R 21 and R 22 identical or different, independently represent a hydrogen atom; a halogen atom; ; -CH 3 ; -CH 2 CH 3 ; -(CH 2 ) 2 CH 3 ; -CH(CH 3 ) 2 ; -CH 2 CF 3 ; -OCH 3 ; -NH 2 ; - N(CH 3 ) 2; -CH 2 F; -CHF 2 ; -CF 3 ; -OCH 2 F; -OCHF 2 ; -OCF 3 ; -(X) x -C 3 -C 6 cycloalkyl; -(X) x -(CT 5 T 6 ) y -C 3 -C 6 cycloalkyl; -(X) x -(CT 5 T 6 ) y -ary
  • T 2 independently represents a hydrogen atom; a halogen atom; a linear or branched C C 3 alkyl; -CH 2 F; -CHF 2 ; -CF 3 ; -OMe; -OCH 2 F; -OCHF 2 ; -OCF 3 ; or -CN; optionally two geminal T 2 form with the carbon atom to which they are bonded, a C 3 -C 7 cycloalkyl;
  • R 1 , R 3 , R 5 , R 6 , X, x, y and T 3 to T 6 are independently defined as for the compounds of formula (I).
  • the invention provides compounds of formula (A), (B), (C), (D), (E) or (F), wherein :
  • R 7 , Q 1 , Q 2 and R 8 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle
  • R 8 , Q 2 Q 3 and R 9 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle
  • R 9 , Q 3 Q 4 and R 10 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle
  • R 10 , Q 4 Q 5 and R 11 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle
  • R 13 , Q 7 Q 8 and R 14 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle; • R 14 , Q 8 Q 9 and R 15 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
  • R 15 , Q 9 Q 10 and R 16 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle
  • R 18 , Q 12 Q 13 and R 19 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle
  • R 19 , Q 13 Q 14 and R 20 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle
  • R 20 , Q 14 Q 15 and R 21 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
  • R 21 , Q 15 Q 16 and R 22 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle.
  • the invention provides compounds of formula (A), (B), (C), (D), (E) or (F), wherein R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 and R 22 , identical or different, independently represent a hydrogen atom; a halogen atom; a linear or branched Ci-C 6 alkyl; a linear or branched -0-CrC 6 alkyl; -(X) x - (CT 5 T 6 ) y -aryl; -C(0)NH 2 .
  • the invention provides compounds of formula (A), (B), (C), (D), (E) or (F), wherein R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 and R 22 , identical or different, independently represent a hydrogen atom; a halogen atom; a linear or branched Ci-C 6 alkyl; a linear or branched -0-CrC 6 alkyl; -(X) x -C 3 - C 6 cycloalkyl; -(X) x -(CT 5 T 6 ) y -C 3 -C 6 cycloalkyl; -(X) x -(CT 5 T 6 ) y -aryl; -C(0)OH; - C(0)NH 2 ; -C(0)NH(CH 3 ); or -NHC(0)
  • the invention provides compounds of formulae (A1 ) to (A10), (B1 ) to (B15), (C1 ) to (C9), (D1 ) to (D10), (E1 ) to (E7) or (F1 ) to (F8)
  • T 2 represents a hydrogen artom; a halogen atom; -CH 2 F; -CHF 2 ; -CF 3 ; -OMe; - OCH 2 F; -OCHF 2 ; -OCF 3 ; an alkyl; a linear or branched alkyl; a cycloalkyl; an alkoxy; a halogenoalkoxy or -CN;
  • R 1 , R 5 , R 6 , T 3 , T 4 , T 5 , T 6 , X, x, y, g, h, i, I, m, n, o, p are as defined for compounds of formula (I), (A), (B), (C), (D), (E) or (F).
  • the invention also provides compounds of formulae (A1 ) to (A10), (B1 ) to (B15), (C1 ) to (C9), (D1 ) to (D10), (E1 ) to (E7) or (F1 ) to (F8) wherein:
  • R 7 , R 8 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
  • R 8 , R 9 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle
  • R 9 , R 10 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
  • R 10 , R 11 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle; or
  • the invention provides compounds of formulae (A1 ) to (A10), (B1 ) to (B15), (C1 ) to (C9), (D1 ) to (D10), (E1 ) to (E7) or (F1 ) to (F8) wherein R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 and R 22 , identical or different, independently represent a hydrogen atom; a halogen atom; a linear or branched C C 6 alkyl; a linear or branched -0-CrC 6 alkyl; a linear or branched -O-C 1 -C 10 alkylaryl; -(X) x -C 3 -C 6 cycloalkyl; -(X) x -(CT 5 T 6 ) y -C 3 -
  • the invention provides compounds of formulae (A1 a) to (A10a), (A1 b) to (A10b), (A1 c) to (A10c), (Ai d) to (A10d), (B1 a) to (B15a), (B1 b) to (B15b), (B1c) to(B15c), (B1d)to(B15d), (C1a) to (C9a), (C1b) to (C9b), (C1c) to (C9c), (C1d) to (C9d), (D1a) to (D10a), (D1b) to (D10b), (D1c) to (D10c), (Did) to (D10d), (E1a) to (E7a), (E1b) to (E7b), (E1c) to (E7c), (E1d) to (E7d), (F1a) to (F8a), (F1b) to (F
  • R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 and R 22 identical or different, independently represent a hydrogen atom; a halogen atom; -CH 3 ; -CH 2 CH 3 ; -(CH 2 ) 2 CH 3 ; -CH(CH 3 ) 2 ; -CH 2 CF 3 ; -OCH 3 ; -NH 2 ; - N(CH 3 ) 2; -CH 2 F; -CHF 2 ; -CF 3 ; -OCH 2 F; -OCHF 2 ; -OCF 3 ; -(X) x -C 3 -C 6 cycloalkyl;
  • R 1 , R 5 , R 6 , X, x, y and T 3 to T 6 are independtly defined as for the compounds of formula (I), (A), (B), (C), (D), (E), (F), (A1) to (A10), (B1) to (B15), (C1) to (C9), (D1) to (D10), (E1) to (E7) or (F1) to (F8).
  • the invention also provides compounds of formula (A1a) to (A10a), (A1b) to (A10b), (A1c) to (A10c), (Aid) to (A10d), (B1a) to (B15a), (B1b) to (B15b), (B1c) to (B15c), (Bid) to (B15d), (C1a) to (C9a), (C1b) to (C9b), (C1c) to (C9c), (C1d) to (C9d), (D1a) to (D10a), (D1b) to (D10b), (D1c) to (D10c), (Did) to (D10d), (E1a) to (E7a), (E1b) to (E7b), (E1c) to (E7c), (E1d) to (E7d), (F1a) to (F8a), (F1b) to (F8b), (F1c)
  • R 8 , R 9 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
  • R 9 , R 10 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
  • R 10 , R 11 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
  • R 12 , R 13 and the carbon or nitrogen atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
  • R 13 , R 14 and the carbon or nitrogen atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle; or
  • R 14 , R 15 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle.
  • the invention also provides compounds of formula (A1 a) to (A10a), (A1 b) to (A10b), (A1 c) to (A10c), (Ai d) to (A10d), (B1 a) to (B15a), (B1 b) to (B15b), (B1 c) to (B15c), (Bi d) to (B15d), (C1 a) to (C9a), (C1 b) to (C9b), (C1 c) to (C9c), (C1 d) to (C9d), (D1 a) to (D10a), (D1 b) to (D10b), (D1 c) to (D10c), (Di d) to (D10d), (E1 a) to (E7a), (E1 b) to (E7b), (E1 c) to (E7c), (E1 d) to (E7d), (F1 a) to
  • R 40 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 and R 53 identical or different, independently represent a hydrogen atom or a linear or branched C
  • R 24 , R 25 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
  • R 25 , R 26 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle; or
  • R 31 , R 32 and the carbon atom to which they are bounded form a saturated 3-, 4-, 5- or 6-membered carbocyle.
  • the invention also provides compounds of formulae (A1 a) to (A10a), (A1 b) to (A10b), (A1 c) to (A10c), (Ai d) to (A10d), (B1 a) to (B15a), (B1 b) to (B15b), (B1 c) to (B15c), (B1 d) to (B15d), (C1 a) to (C9a), (C1 b) to (C9b), (C1 c) to (C9c), (C1 d) to (C9d), (D1 a) to (D10a), (D1 b) to (D10b), (D1 c) to (D10c), (Di d) to (D10d), (E1 a) to (E7a), (E1 b) to (E7b), (E1 c) to (E7c), (E1 d) to (E7d), (F1 a)
  • the invention provides 2-(ie f-butoxy)-
  • the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyrimidin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyridazin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(thiophen-2-yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2,5-dimethyl-thiophen-3-yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides:
  • the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 H-imidazol-1 -yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides 2-(ierf- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,2-thiazol-4-yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-imidazol-4-yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides 2-(ie f-butoxy)-2- [2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3- ⁇ pyrazolo[1 ,5-a]pyridin-3-yl ⁇ -6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-pyrrol-3-yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides 2-(ie f- butoxy)-2-[3-(cyclopent-1-en-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the invention provides 2-(iert-butoxy)- 2- ⁇ 3-[1 -(cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-2-yl]-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl ⁇ acetic acid.
  • the invention provides 2-(ie f-butoxy)- 2- ⁇ 3-[1 -(cyclobutylmethyl)-2-oxo-1 ,2-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl) phenyl ⁇ acetic acid.
  • the invention provides 2-(ie f-butoxy)- 2-[3-(cyclohex-1 -en-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid.
  • the first part represents the preparation of the compounds (intermediates and final compounds) whereas the second part describes the evaluation of antiviral activity of compounds according to the invention.
  • TLC Thin Layer Chromatography Example 1 : synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- phenyl-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate 1-fluoro-2-(methoxymethoxy)-4-(trifluoro methyl)benzene (1a)
  • Step 2 preparation of intermediate ethyl 2-[3-fluoro-2-(methoxymethoxy)-6- (trifluoromethyl)phenyl]-2-oxoacetate (1 b)
  • Step 3 preparation of intermediate ethyl 2-[3-fluoro-2-hydroxy-6- (trifluoromethyl)phenyl]-2-oxoacetate (1 c)
  • Step 4 preparation of intermediate ethyl 2- ⁇ 3-fluoro-2-[(trifluoromethane) sulfonyloxy]-6-(trif luoromethyl)phenyl ⁇ -2-oxoacetate (1 d)
  • Step 5 preparation of intermediate 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro- 6-(trifluoromethyl)phenyl]-2-oxoacetic acid (1e)
  • Step 6 preparation of intermediate methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (1f)
  • Step 7 preparation of intermediate methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (1g)
  • Step 8 preparation of intermediate methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert-butoxy)acetate (1 h)
  • Step 9 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-hydroxy-6-(trifluoromethyl)phenyl]acetate (1 i)
  • Step 10 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl)phenyl]acetate
  • Step 11 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-phenyl-6-(trifluoromethyl)phenyl]acetate (1 k)
  • Step 12 preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- phenyl-6-(trifluoromethyl)phenyl]acetic acid (example 1)
  • a lithium hydroxide aqueous solution (2N, 257 ⁇ , 0.513 mmol) was added to a solution of methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-phenyl-6- trifluoromethyl)phenyl]acetate (1 k) (128 mg, 0.256 mmol) in a mixture of tetrahydrofurane (1 .5 mL) and methanol (1.5 mL). The mixture was then heated at 60 °C for 4 hours.
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetate (2a)
  • step 1 1 the intermediate methyl 2-(iert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (95 mg, 0.166 mmol) is converted by reaction with pyridin-4-ylboronic acid (26 mg, 0.2 mmol) into methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(pyridin-4-yl)-6-(trifluoromethyl) phenyl]acetate (2a) (57 mg, 0.1 14 mmol, 69%) as a white solid, after purification by preparative TLC (cyclohexane/ethyl acetate 70/30).
  • Step 2 preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 2)
  • methyl 2-(fe/t-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetate (57 mg, 0.1 14 mmol) in a mixture of dioxane (1 mL) and water (0.5 mL) was added lithium hydroxide (14 mg, 0.333 mmol).
  • reaction mixture was heated at 95 °C overnight.
  • Dioxane (0.5mL) and water (0.2 mL) were added and the mixture was stirred at 100°C for 9 hours.
  • Further lithium hydroxide (5 mg, 0.1 1 1 mmol) was added and the mixture was stirred at 100 °C for 3 hours.
  • the reaction mixture was cooled to room temperature and concentrated in vacuo. Water (4 mL) was added to the residue and the solution was acidified with a 1 M hydrochloric acid solution until pH 5 followed by extraction with ethyl acetate (4x5mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo.
  • Example 3 synthesis of 2-(te f-butoxy)-2-r3-(cvclopent-1 -en-1 -yl)-2-(3,4-dihvdro-2H- -benzopyran-6-yl)-6-(trifluoromethyl)phenvHacetic acid
  • Step 1 preparation of intermediate methyl 2-(fe/t-butoxy)-2-[3-(cyclopent-1 -en-1 -yl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (3a)
  • step 1 1 the intermediate methyl 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (120 mg, 0.210 mmol) is converted by reaction with 1-cyclopentenyl boronic acid (28 mg, 0.252 mmol) into methyl 2-(ie f-butoxy)-2- [3-(cyclopent-1 -en-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (3a) (69 mg, 0.141 mmol, 67%) as a colourless oil, after purification by preparative TLC (cyclohexane/ethyl acetate 90/10).
  • Step 2 preparation of 2-(iert-butoxy)-2-[3-(cyclopent-1-en-1-yl)-2-(3,4-di hydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 3)
  • step 2 the intermediate methyl 2-(tert- butoxy)-2-[3-(cyclopent-1-en-1-yl)-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoro methyl)phenyl]acetate (3a) (69 mg, 0.141 mmol) is converted into 2-(ie f-butoxy)-2-[3- (cyclopent-1-en-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetic acid (example 3) (40 mg, 0.084 mmol, 59%) as a white solid.
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenyl]acetate (4a)
  • (1j) 100 mg, 0.175 mmol
  • 1-methylpyrazole-4-boronic acid pinacol ester 43 mg, 0.210 mmol
  • Step 2 preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 - methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 4)
  • step 2 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 -methyl-1 H-pyrazol-4-yl)-6- (trifluoromethyl)phenyl]acetate (4a) (44 mg, 0.087 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 -methyl-1 H-pyrazol-4-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 4) (30 mg, 0.061 mmol, 70%) as a white solid.
  • Step 1 preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran 3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (5a)
  • 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetic acid (1e) (124 mg, 0.34 mmol) and 3-phenyl-1 H- pyrazole (97 mg, 0.67 mmol) in anhydrous dimethylacetamide (2 mL) at room temperature under nitrogen atmosphere, was added sodium hydride 60% in oil (40 mg, 1.01 mmol).
  • the reaction mixture was heated at 90°C overnight then poured in water (10 mL).
  • the mixture was acidified with 1 M hydrochloric acid until pH 2 and extracted with ethyl acetate (2x10 mL).
  • the organic layer was washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuo.
  • the residue was dissolved in a mixture of methanol (2 mL) and cyclohexane (4 mL) and a 2 M solution of tnmethylsilyldiazomethane in diethyl ether (0.5 mL, 1 mmol) was added.
  • the mixture was stirred at 0°C for 30 minutes and a few drops of acetic acid was added.
  • the mixture was concentrated in vacuo.
  • Step 2 preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (5b)
  • Step 3 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetate (5c)
  • the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl) phenyl]-2-hydroxy acetate (5b) (42 mg, 0.082 mmol) is converted into methyl 2-(ierf- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (5c) (21 mg,
  • Step 4 preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3- phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetic acid (example 5)
  • Step 1 preparation of intermediate methyl 2- ⁇ 3-[2-(benzyloxy)pyridin-4-yl]-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl ⁇ -2-(iert-butoxy)acetate (6a)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (120 mg, 0.210 mmol) is converted by reaction with 2-(benzyloxy)-4-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (78 mg, 0.252 mmol) into methyl 2- ⁇ 3-[2-(benzyloxy)pyridin-4-yl]-2-(3,4-
  • Step 2 preparation of 2- ⁇ 3-[2-(benzyloxy)pyridin-4-yl]-2-(3,4-dihydro-2H-1-benzo pyran-6-yl)-6-(trifluoromethyl)phenyl ⁇ -2-(ie f-butoxy)acetic acid (example 6)
  • step 2 the methyl 2- ⁇ 3-[2- (benzyloxy)pyridin-4-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoro
  • Example 7 synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (thiophen-2-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(thiophen-2-yl)-6-(trifluoromethyl)phenyl]acetate (7a)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (120 mg, 0.210 mmol) is converted by reaction with (thiophen-2-yl)boronic acid (32 mg, 0.252 mmol) into methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(thiophen-2-yl)-6-(trifluoromethyl) phenyl] acetate (7a) (71 mg, 0.141 mmol, 67%) as a colourless oil after purification by preparative TLC (cyclohexane/ethyl acetate 85/15).
  • step 2 the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(thiophen-2-yl)-6-(trifluoromethyl)phenyl] acetate (7a) (65 mg, 0.128 mmol) is converted into 2-(ie f-butoxy)-2-[2-(3,4-dihydro- 2H-1 -benzopyran-6-yl)-3-(thiophen-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 7) (62 mg, 0.126 mmol, 98%) as a white solid.
  • Example 8 synthesis of 2-(te/ -butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3-(4- methoxyphenyl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(4-methoxyphenyl)-6-(trifluoromethyl)phenyl]acetate (8a)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (100 mg, 0.175 mmol) is converted by reaction with (4-methoxyphenyl)boronic acid (32 mg, 0.210 mmol) into methyl 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-methoxyphenyl)-6-(trifluoromethyl) phenyl]acetate (8a) (71 mg, 0.134 mmol, 76%) as a colourless oil, after purification by preparative TLC (cyclohexane/ethyl acetate 80/20).
  • Step 2 preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4- methoxyphenyl)-6-(trifluoromethyl)phenyl]acetic acid (example 8)
  • step 2 the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(4-methoxyphenyl)-6-(trifluoromethyl) phenyl]acetate (8a) (71 mg, 0.134 mmol) is converted into 2-(ie/f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(4-methoxyphenyl)-6-(trifluoromethyl)phenyl]acetic acid (example 8) (65 mg, 0.126 mmol, 94%) as a white solid.
  • Step 1 preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran 3-fluoro-6-(trifluoromethyl)phenyl]-2-oxoacetate (9a)
  • Step 2 preparation of intermediate methyl 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (9b)
  • methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetate (300 mg, 0.78 mmol) and 4-bromo-1 H- pyrazole (231 mg, 1.57 mmol) in anhydrous dimethylacetamide (3 mL), under nitrogen atmosphere, was added sodium hydride 60% in oil (94 mg, 2.35 mmol).
  • the mixture was heated at 70°C for 1 hour then at 100°C for 4 hours.
  • the mixture was then poured in water (10 mL) and 1 M hydrochloric acid was added until pH 2.
  • the reaction mixture was extracted with ethyl acetate (2x10 mL).
  • the organic layer was washed with brine (5 mL), dried over sodium sulfate and concentrated in vacuo.
  • the residue was dissolved in a mixture of cyclohexane (6 mL) and methanol (3 mL) at 0°C and a 2 M solution of trimethylsilyldiazomethane in diethyl ether (1 mL, 2.0 mmol) was added.
  • Step 3 preparation of intermediate methyl 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (9c)
  • step 2 the intermediate methyl 2-[3-(4- bromo-1 H-pyrazol-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]-2-oxoacetate (9b) (200 mg, 0.39 mmol) is converted into methyl 2-[2-(3,4- dihydro-2/-/-1-benzopyran-6-yl)-3-(4-bromo-1 H-pyrazol-1-yl)-6-(trifluoromethyl) phenyl]-2-hydroxyacetate (9c) (196 mg, 0.38 mmol, 97%).
  • Step 4 preparation of intermediate methyl 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (9d) To a solution of methyl 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (9c) (196 mg, 0.38 mmol) in fe/t-butyl acetate (2 mL) at 0°C was added perchloric acid (0.25 mL).
  • the mixture was stirred at 0°C for 2 hours and 30 minutes before being poured into a saturated aqueous solution of sodium hydrogenocarbonate (15 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 10 mL). The organic layers were washed with brine, dried over sodium sulfate and concentrated in vacuo.
  • step 4 methyl 2-[3-(4-bromo-1 H- pyrazol-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f- butoxy)acetate (9d) (85 mg, 0.15 mmol) is converted into 2-[3-(4-bromo-1 H-pyrazol-1- yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoro methyl)phenyl]-2-(ferf- butoxy)acetic acid (example 9) (63 mg, 0.1 1 mmol, 76%) as a white solid.
  • Example 10 synthesis of 2-r3-(4-chloro-1 H-pyrazol-1 -yl)-2-(3,4-dihvdro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyll-2-(te -butoxy)acetic acid
  • Step 1 preparation of intermediate methyl 2-[3-(4-chloro-1 H-pyrazol-1 -yl)-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (10a)
  • Step 2 preparation of intermediate methyl 2-[3-(4-chloro-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (10b)
  • Step 3 preparation of intermediate methyl 2-[3-(4-chloro-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (10c)
  • step 4 the intermediate methyl 2-[3-(4- chloro-1 H-pyrazol-1 -yl)-2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]-2-hydroxyacetate (10b) (131 mg, 0.28 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 80/20) into methyl 2-[3-(4-chloro-1 H- pyrazol-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phen
  • Step 4 preparation of 2-[3-(4-chloro-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert-butoxy)acetic acid (example 10)
  • step 4 the intermediate methyl 2-[3-(4- chloro-1 H-pyrazol-1 -yl)-2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]-2-(ie f-butoxy)acetate (10c) (70 mg, 0.13 mmol) is converted, after purification by preparative TLC (dichloromethane/methanol 97/3) into 2-[3-(4-chloro- 1 H-pyrazol-1-yl)-2-(3,4-dihydro-2/-/-1 -benzopyran-6-yl)-6-
  • Step 1 preparation of intermediate ethyl 2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3- fluoro-6-(trifluoromethyl)phenyl]-2-oxoacetate (11a)
  • Step 3 preparation of intermediate methyl 2-[3-(benzyloxy)-2-(4,4-dimethylcyclohex- 1 -en-1 -yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (11c)
  • Step 4 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex- 1-en-1-yl)-3-hydroxy-6-(trifluoromethyl)phenyl]acetate (11 d)
  • Step 5 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex- 1-en-1-yl)-3-[(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl) phenyl]acetate (11e)
  • methyl 2-(fe/t-butoxy)-2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3- hydroxy-6-(trifluoromethyl)phenyl]acetate (11d) (1 1 1 mg, 0.267 mmol) in anhydrous dichloromethane (3 mL) under nitrogen atmosphere at -78°C were successively added triethylamine (45 ⁇ _, 0.330 mmol) and triflic anhydride (50 ⁇ _, 0.297 mmol).
  • Step 7 preparation of 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3-(pyridin-
  • step 2 the methyl 2-(ie f-butoxy)-2-[2-
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3- ⁇ pyrazolo[1 ,5-a]pyridin-3-yl ⁇ -6-(trifluoromethyl) phenyl]acetate
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (100 mg, 0.175 mmol) is converted by reaction with 3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyrazolo[1 ,5-a]pyridine (64 mg, 0.263 mmol, prepared using the procedure described in Tetrahedron, 2012, 68, 5434-5444), after purification by preparative TLC (cyclohexane/ethyl acetate 50/50), into methyl 2- (ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- ⁇ pyrazolo[1 ,5-a
  • Step 2 preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- ⁇ pyrazolo[1 ,5-a]pyridin-3-yl ⁇ -6-(trifluoromethyl)phenyl]acetic acid (example 12)
  • step 2 methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3- ⁇ pyrazolo[1 ,5-a]pyridin-3-yl ⁇ -6- (trifluoromethyl)phenyl]acetate (12a) (83 mg, 0.154 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- ⁇ pyrazolo [1 ,5-a]pyridine-3-yl ⁇ -6- (trifluoromethyl)phenyl]acetic acid (example 12) (65 mg, 0.124 mmol, 81 %).
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(4-carbamoylphenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (13a)
  • step 1 1 the intermediate methyl 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (75 mg, 0.131 mmol) is converted by reaction with (4-carbamoylphenyl)boronic acid (32.5 mg, 0.197 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 50/50) into methyl 2-(ie f-butoxy)-2-[3-(4- carbamoylphenyl)-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl] acetate (13a) (58.8 mg, 0.108 mmol, 82%).
  • Step 2 preparation of intermediate benzyl 2-(ie f-butoxy)-2-[3-(4-carbamoylphenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (13b)
  • Step 3 preparation of 2-(ie/f-butoxy)-2-[3-(4-carbamoylphenyl)-2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 13)
  • Example 14 synthesis of 2-(te f-butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2/-/- 1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(3-carbamoylphenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl] acetate (14a)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (79 mg, 0.138 mmol) is converted by reaction with (3-carbamoylphenyl)boronic acid (34 mg, 0.206 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 20/80) into methyl 2-(ie f-butoxy)-2-[3-(3- carbamoylphenyl)-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl] acetate (14a) (54 mg, 0.099 mmol, 72%).
  • Step 2 preparation of intermediate benzyl 2-(ie f-butoxy)-2-[3-(3-carbamoylphenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (14b)
  • step 2 the intermediate methyl 2-(ie f- butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (14a) (54 mg, 0.099 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 40/60) into benzyl 2-(tert- butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzo pyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (14b) (20 mg, 0.032 mmol, 32%).
  • Step 3 preparation of 2-(ie/f-butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 14)
  • step 3 the intermediate benzyl 2-(tert- butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoro methyl)phenyl]acetate (14b) (20 mg, 0.032 mmol) is converted into 2-(ie f-butoxy)-2- [3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetic acid (example 14) (13 mg, 0.024 mmol, 77%).
  • Example 15 synthesis of 2-(te f-butoxy)-2-[2-(4,4-dimethylcvclohex-1-en-1 -yl)-3-(1 - methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 Preparation of intermediate methyl 2-(fe/t-butoxy)-2-[2-(4,4-dimethylcyclohex- 1 -en-1 -yl)-3-(1 -methyl-1 H-pyrazol-4-yl)-6-(trif luoromethyl)phenyl] acetate (15a)
  • step 6 methyl 2-(ie f-butoxy)-2-[2-(4,4- dimethylcyclohex-1 -en-1-yl)-3-[(trifluoromethane)sulfonyloxy]-6-
  • step 2 the methyl 2-(ie f-butoxy)-2-[2- (4,4-dimethylcyclohex-1-en-1 -yl)-3-(1-methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl) phenyl]acetate (15a) (44 mg, 0.092 mmol) is converted into 2-(ie/f-butoxy)-2-[2-(4,4- dimethylcyclohex-1 -en-1-yl)-3-(1-methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenyl] acetic acid (example 15) (26 mg, 0.056 mmol, 60%) as a white solid.
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6-
  • Step 2 preparation of intermediate intermediate methyl 2-(fe/t-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(pyrimidin-4-yl)-6-(trifluoromethyl) phenyl]acetate (16b)
  • step 2 the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(pyrimidin-4-yl)-6-(trifluoro
  • Example 17 synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -fluoropyridin-4-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(3-f luoropyridin-4-yl)-6-(trifluoromethyl)phenyl]acetate (17a)
  • step 2 the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6- (trifluoromethyl)phenyl]acetate (16a) (48 mg, 0.087 mmol) is converted by reaction with 4-bromo-3-fluoro-pyridine hydrochloride (37 mg, 0.174 mmol) into methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-fluoropyridin-4-yl)-6-
  • step 2 the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(3-fluoropyridin-4-yl)-6- (trifluoromethyl)phenyl]acetate (17a) (36 mg, 0.069 mmol) is converted into 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-fluoropyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 17) (26 mg, 0.051 mmol, 74%) as a white solid.
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1-methyl-1 H-pyridin-2-one-5-yl)-6-(trifluoromethyl) phenyl]acetate (18a)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.122 mmol) is converted, by reaction with /V-methyl-1 H-pyridin-2-one-5-boronic acid, pinacol ester (43 mg, 0.183 mmol) into methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H- pyridin-2-one-5-yl)-6-(trifluoromethyl)phenyl] acetate (18a) (35 mg, 0.066 mmol, 54%), after purification by preparative TLC (ethyl acetate).
  • step 2 the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1-methyl-1 /-/-pyridin-2-one-5-yl)-6-
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[4-(methylcarbamoyl)phenyl]-6-(trifluoromethyl)phenyl]acetate (19a)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with [4-(methylcarbamoyl)phenyl]boronic acid (33 mg, 0.184 mmol) into the methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzo pyran-6-yl)-3-[4-(methylcarbamoyl)phenyl]-6- (trifluoromethyl)phenyl]acetate (19a) (65 mg, 0.1 17 mmol, 95%) after purification by preparative TLC (cyclohexane/ethyl acetate 30/70).
  • step 2 methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-[4-(methylcarbamoyl)phenyl]-6- (trifluoromethyl)phenyl]acetate (19a) (65 mg, 0.1 17 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[4-(methylcarbamoyl) phenyl]-6- (trifluoromethyl)phenyl]acetic acid (32.5 mg, 0.060 mmol, 51 %) after purification by preparative TLC (cyclohexane/ethyl acetate 20/80).
  • Example 21 synthesis of 2-(te f-butoxy)-2-[3-(4-acetamidophenyl)-2-(3,4-dihvdro-2H- 1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(4-acetamidophenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (20a)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with (4-acetamidophenyl)boronic acid (33 mg, 0.184 mmol) into the methyl 2-(ie f-butoxy)- 2-[3-(4-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (20a) (63 mg, 0.1 13 mmol, 92%) after purification by preparative TLC (cyclohexane/ethyl acetate 50/50).
  • Step 2 preparation of 2-[3-(4-aminophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic acid (example 20) and 2-(ie f-butoxy)-2- [3-(4-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 21)
  • Step 1 preparation of intermediate 4-(4,4,5,5,-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 - (2,2,2-trifluoroethyl)-1 H-pyrazole (22a)
  • Step 2 preparation of intermediate methyl 2-(ie f-butoxy)-2- ⁇ 2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[1 -(2,2,2-trifluoroethyl)- 1 H-pyrazol-4-yl]-6-(trifluoro
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (62 mg, 0.108 mmol) is converted by reaction with 4-(4,4,5,5,-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 -(2,2,2-trifluoroethyl)- 1 H-pyrazole
  • Step 3 preparation of 2-(iert-butoxy)-2- ⁇ 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1 - (2,2,2-trifluoroethyl)-1 H-pyrazol-4-yl]-6-(trifluoromethyl)phenyl ⁇ acetic acid (example 22)
  • step 2 the methyl 2-(ierf-butoxy)-2- ⁇ 2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1-(2,2,2-trifluoroethyl)-1 H-pyrazol-4-yl]-6- (trifluoromethyl)phenyl ⁇ acetate (22b) (59 mg, 0.101 mmol) is converted into 2-(tert- butoxy)-2- ⁇ 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1-(2,2,2-trifluoroethyl)-1 H-pyrazol- 4-yl]-6-(trifluoromethyl)phenyl ⁇ acetic acid (10 mg, 0.018 mmol, 18%) (example 22) as a white solid after purification by preparative TLC (dichloromethane/methanol 90/10).
  • Example 23 synthesis of 2-r3-(3-aminophenyl)-2-(3,4-dihvdro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl)phenyll-2-(te -butoxy)acetic acid
  • Example 24 synthesis of 2-(te f-butoxy)-2-[3-(3-acetamidophenyl)-2-(3,4-dihvdro-2H- 1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(3-acetamidophenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (23a)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with (3-acetamidophenyl)boronic acid (33 mg, 0.184 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 70/30) into methyl 2-(ie f-butoxy)-2- [3-(3-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (23a) (46 mg, 0.082 mmol, 67%).
  • Step 2 preparation of 2-[3-(3-aminophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic acid (example 23) and 2-(ie f-butoxy)-2- [3-(3-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 24)
  • step 2 methyl 2-(fe/t-butoxy)-2-[3-(3- acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-
  • Example 25 synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -oxo-1-propyl-1 ,6-dihvdropyridin-3-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate 5-bromo-1-propyl-1 ,2-dihydropyridin-2-one (25a) Under a nitrogen atmosphere, sodium hydride 60% in oil (0.23 g, 5.75 mmol) was added portionwise to a solution of 5-bromo-2(1 H)-pyridone (1 .00 g, 5.75 mmol) in dry tetrahydrofuran (20 mL). After 10 minutes stirring, iodopropane (1.68 mL, 17.24 mmol) was added and the reaction mixture was stirred at 50°C for 40 hours. Water (10 mL) was added and the mixture was extracted with ethyl acetate (2 x 15 mL).
  • Step 2 preparation of intermediate 1-propyl-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 ,2-dihydropyridin-2-one (25b)
  • Step 3 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-3-(6-oxo-1-propyl-1 ,6-dihydropyridin-3-yl)-6- (trifluoromethyl)phenyl]acetate (25c)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2/-/-1 -benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1 -propyl-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (25b) (64 mg, 0.245 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 50/50) to methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(6-oxo-1 - propyl-1 ,6-dihydropyri
  • Step 4 preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(6- oxo-1 -propyl-1 ,6-dihydropyridin-3-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 25)
  • Example 26 synthesis of 2-[3-(1-benzyl-6-oxo-1 ,6-dihvdropyridin-3-yl)-2-(3,4- dihvdro-2/-/-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyll-2-(te f-butoxy)acetic acid
  • Step 1 preparation of intermediate 1-benzyl-5-bromo-1 ,2-dihydropyridin-2-one (26a) Under a nitrogen atmosphere, sodium hydride 60% in oil (0.23 g, 5.75 mmol) was added portionwise to a solution of 5-bromo-2(1 H)-pyridone (1 .00 g, 5.75 mmol) in anhydrous tetrahydrofuran (20 mL). After 10 minutes stirring, benzyl bromide (2.05 mL, 17.24 mmol) was added and the reaction mixture was stirred at 50°C for 5 hours. Water (10 mL) was added and the mixture was extracted with ethyl acetate (2 x 15 mL).
  • step 2 the intermediate 1 -benzyl-5- bromo-1 ,2-dihydropyridin-2-one (26a) (1.45 g, 5.49 mmol) is converted, after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20), and trituration in diethyl ether, to 1-benzyl-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (26b) (734 mg, 2.36 mmol, 43%).
  • Step 3 preparation of intermediate methyl 2-[3-(1 -benzyl-6-oxo-1 ,6-dihydropyridin-3- yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert- butoxy)acetate (26c)
  • (1j) 70 mg, 0.123 mmol
  • step 4 the intermediate methyl 2-[3-(1- benzyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetate (26c) (48 mg, 0.079 mmol) is converted to 2-[3-(1 -benzyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid (example 26) (43 mg, 0.073 mmol, 62%).
  • Step 1 preparation of intermediate 5-bromo-1-(cyclopropylmethyl)-1 ,2- dihydropyridin-2-one (27a)
  • Step 2 preparation of intermediate 1 -(cyclopropylmethyl)-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (27b)
  • step 2 the intermediate 5-bromo-1- (cyclopropylmethyl)-l ,2-dihydropyridin-2-one (27a) (0.70 g, 3.07 mmol) is converted, after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20), into 1-(cyclopropylmethyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 ,2-dihydropyridin-2-one (27b) (384 mg, 1.40 mmol, 45%).
  • Step 3 preparation of intermediate methyl 2-(fe/t-butoxy)-2- ⁇ 3-[1-(cyclopropylmethyl)- 6-OXO-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl ⁇ acetate (27c)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1-(cyclopropylmethyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2- one (27b) (68 mg, 0.245 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 50/50) to methyl 2-(ie/f-butoxy)-2- ⁇ 3-[1 - (cyclopropylmethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydr
  • Step 4 preparation of 2-(ie f-butoxy)-2- ⁇ 3-[1 -(cyclopropylmethyl)-6-oxo-1 ,6- dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl ⁇ acetic acid (example 27)
  • step 4 the intermediate methyl 2-(tert- butoxy)-2- ⁇ 3-[1-(cyclopropylmethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H- 1-benzopyran-6-yl)-6-(trifluoromethyl) phenyljacetate (27c) (42 mg, 0.074 mmol) is converted into 2-(ie f-butoxy)-2- ⁇ 3-[1-(cyclopropylmethyl)-6-oxo-1 ,6-dihydropyridin-3- yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyljacetic acid (example 27) (39 mg, 0.070 mmol, 95%).
  • Example 28 synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (2-propylpyridin-4-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate 4-bromo-2-propylpyridine (28a)
  • the organic layer was extracted with 1 N hydrochloric acid (2 x 10 mL).
  • the acidic aqueous layer was washed with ethyl acetate (2 x 10 mL), basified with 1 N sodium hydroxide until pH 10, and extracted with ethyl acetate (2 x 10 mL).
  • the combined organic layers were dried over sodium sulfate and concentrated in vacuo.
  • the residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 100/0 to 95/5) to provide 4-bromo-2-propylpyridine (28a) (649 mg, 3.24 mmol, 63%) as a colorless oil.
  • Step 2 preparation of intermediate 2-propyl-4-(tetramethyl-1 ,3,2-dioxaborolan-2- yl)pyridine
  • 28b Di(1-adamantyl)-n-butylphosphine (8.1 mg, 0.022 mmol) and tris(dibenzylideneacetone)dipalladium(0) (6.8 mg, 0.007 mmol) were added to a previously degassed solution of 4-bromo-2-propylpyridine (28a) (150 mg, 0.75 mmol), bis(pinacolato)diboron (228 mg, 0.90 mmol) and potassium acetate (221 mg, 2.25 mmol) in anhydrous dimethylacetamide (0.5 mL).
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (80 mg, 0.140 mmol) is converted by reaction with 2-propyl-4-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (28b) (69 mg, 0.280 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 80/20) to methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2-propylpyridin-4-yl)-6- (trifluoromethyl) phenyl]acetate (28c) (45 mg,
  • Step 4 preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2- propylpyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 28)
  • step 2 methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2/-/-1-benzopyran-6-yl)-3-(2-propylpyridin-4-yl)-6- (trifluoromethyl)phenyl]acetate (28c) (45 mg, 0.083 mmol) is converted into 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2-propylpyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 28) (35 mg, 0.066 mmol, 80%).
  • Step 1 preparation of intermediate 1-(3-bromophenyl)propan-1-ol (29a)
  • step 2 the intermediate 1 -bromo-3- propylbenzene (29b) (100 mg, 0.50 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 95/5) to 4,4,5,5-tetramethyl-2-(3- propylphenyl)-1 ,3,2-dioxaborolane (29c) (122 mg, 0.49 mmol, 99%).
  • Step 4 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-3-(3-propylphenyl)-6-(trifluoromethyl)phenyl]acetate (29d)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (80 mg, 0.140 mmol) is converted by reaction with 4,4,5,5-tetramethyl-2-(3-propylphenyl)-1 ,3,2-dioxaborolane (29c) (69 mg, 0.280 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 75/25) to methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-propylphenyl)-6- (trifluoromethyl) phenyl]acetate (29d) (62 mg,
  • Step 5 preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-(3- propylphenyl)-6-(trifluoromethyl)phenyl]acetic acid (example 29)
  • step 2 methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2/-/-1-benzopyran-6-yl)-3-(3-propylphenyl)-6-(trifluoromethyl) phenyl]acetate (29d) (62 mg, 0.1 1 mmol) is converted, after purification by 2 preparative TLC (dichloromethane/methanol 98/2) and (cyclohexane/ethyl acetate 55/45) to 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(3-propylphenyl)-6- (trifluoromethyl)phenyl]acetic acid (language 29) (20 mg, 0.038 mmol, 33%).
  • Example 30 synthesis of 2-(te f-butoxy)-2- ⁇ 3-[1 -(cvclobutylmethyl)-6-oxo-1 ,6- dihvdropyridin-3-yll-2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl)acetic acid
  • Step 1 preparation of intermediate 5-bromo-1-(cyclobutylmethyl)-1 ,2-dihydropyridin- 2-one (30a)
  • Step 2 preparation of intermediate 1 -(cyclobutylmethyl)-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (30b)
  • step 2 the intermediate 5-bromo-1- (cyclobutylmethyl)-l ,2-dihydropyridin-2-one (30a) (1.0 g, 4.13 mmol) is converted into 1-(cyclobutylmethyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (30b) (554 mg, 1 .92 mmol, 46%), after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20) and trituration in pentane.
  • Step 3 preparation of intermediate methyl 2-(ie f-butoxy)-2- ⁇ 3-[1-(cyclobutylmethyl)- 6-OXO-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl ⁇ acetate (30c)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1-(cyclobutylmethyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (30b) (53 mg, 0.183 mmol) into methyl 2-(ie/f-butoxy)-2- ⁇ 3-[1-(cyclobutylmethyl)-6- oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6- (trifluoromethyl)phenyl ⁇ a
  • Step 4 preparation of 2-(ie f-butoxy)-2- ⁇ 3-[1 -(cyclobutylmethyl)-6-oxo-1 ,6- dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl ⁇ acetic acid (example 30)
  • step 4 the intermediate methyl 2-(iert- butoxy)-2- ⁇ 3-[1-(cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro -2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl ⁇ acetate (30c) (59 mg, 0.101 mmol) is converted into 2-(fe/t-butoxy)-2- ⁇ 3-[1-(cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-3- yl]-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl ⁇ acetic acid (example 30) (37 mg, 0.065 mmol, 63%) as a white solid.
  • Example 31 synthesis of 2-(te f-butoxy)-2- ⁇ 3-[1-(2-cvclopropylethyl)-6-oxo-1 ,6- dihvdropyridin-3-yll-2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-6- (trifluoromethvDphenvDacetic acid
  • Step 1 preparation of intermediate 2-cyclopropylethyl-4-methylbenzene-1 -sulfonate (31 a)
  • step 1 the intermediate 2- cyclopropylethyl 4-methylbenzene-1 -sulfonate (31a) (2.02 g, 8.40 mmol) is converted by reaction with 5-bromo-2(1 H)-pyridone (0.75 g, 4.31 mmol) into 5-bromo-1-(2- cyclopropylethyl)-1 ,2-dihydropyridin-2-one (31 b) (743 mg, 3.07 mmol, 71 %) after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 85/15).
  • step 2 the intermediate 5-bromo-1 -(2- cyclopropylethyl)-1 ,2-dihydropyridin-2-one (31 b) (800 mg, 3.31 mmol) is converted into 1-(2-cyclopropylethyl)-5-(tetramethyl-1 ,3,2-dioxa borolan-2-yl)-1 ,2-dihydropyridin- 2-one (31 c) (677 mg, 2.34 mmol, 71 %) after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate: 100/0 to 75/25).
  • Step 4 preparation of intermediate methyl 2-(ie f-butoxy)-2- ⁇ 3-[1 -(2-cyclopropylethyl)- 6-OXO-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl ⁇ acetate (31 d)
  • step 1 1 the intermediate methyl 2-(iert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1 -(cyclopropylethyl)- 5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (31c) (89 mg, 0.31 mmol) into methyl 2-(ie/f-butoxy)-2- ⁇ 3-[1-(2-cyclopropylethyl)-6- oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-
  • Step 5 preparation of 2-(ie f-butoxy)-2- ⁇ 3-[1-(2-cyclopropylethyl)-6-oxo-1 ,6- dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl ⁇ acetic acid (example31)
  • step 4 the methyl 2-(ie f-butoxy)-2- ⁇ 3- [1-(2-cyclopropylethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl ⁇ acetate (31 d) (54 mg, 0.092 mmol) is converted into 2-(fe/t-butoxy)-2- ⁇ 3-[1 -(2-cyclopropylethyl)-6-oxo-1 ,6-dihydropyridin-3- yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoro methyl) phenyl ⁇ acetic acid (example 31) (35 mg, 0.061 mmol, 66%) as a white solid.
  • Step 1 preparation of intermediate 5-bromo-1-(2-methylpropyl)-1 ,2-dihydropyridin-2- one (32a)
  • step 1 5-bromo-2(1 H)-pyridone (0.5 g, 2.87 mmol) is converted by reaction with 1-bromo-2-methylpropane (0.63 mL, 5.75 mmol), after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20) to 5-bromo-1 -(2-methylpropyl)-1 ,2-dihydropyridin-2-one (32a) (416 mg, 1 .81 mmol, 63%).
  • Step 2 preparation of intermediate 1-(2-methylpropyl)-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (32b)
  • step 2 the intermediate 5-bromo-1 -(2- methylpropyl)-1 ,2-dihydropyridin-2-one (32a) (400 mg, 1 .74 mmol) is converted, after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate
  • Step 3 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[1 -(2-methylpropyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-6- (trifluoromethyl)phenyl]acetate (32c)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1 -(2-methylpropyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (32b) (85 mg, 0.307 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 60/40) to methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H- 1 -benzopyran-6-yl)-3-[1-(2-methylpropyl)-6-oxo-1
  • step 4 methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-[1-(2-methylpropyl)-6-oxo-1 ,6-dihyd ropyridin-3-yl]-6- (trifluoromethyl)phenyl]acetate (32c) (57 mg, 0.100 mmol) is converted to 2-(ierf- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1-(2-methylpropyl)-6-oxo-1 ,6- dihydropyridin-3-yl]-6-(trifluoromethyl) phenyljacetic acid (example 32) (45 mg, 0.081 mmol, 80%).
  • Step 1 preparation of intermediate 4-bromo-1-ethyl-1 ,2-dihydropyridin-2-one (33a) Using the procedure described in example 25, step 1 , 2-hydroxy-4-bromopyridine (1.00 g, 5.75 mmol) is converted by reaction with iodoethane (1.39 ml_, 17.24 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 100/0 to 85/15) into 4-bromo-1 -ethyl-1 ,2-dihydropyridin-2-one (33a) (981 mg, 4.86 mmol, 84%).
  • step 2 4-bromo-1 -ethyl-1 ,2- dihydropyridin-2-one (33a) (300 mg, 1.48 mmol) is converted , after purification by preparative TLC (dichloromethane/methanol 95/5), into 1 -ethyl-4-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (33b) (70 mg, 0.28 mmol, 19%).
  • Step 3 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1-ethyl-2-oxo-1 ,2-dihydropyridin-4-yl)-6- (trifluoromethyl)phenyl]acetate (33c)
  • step 1 1 the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1-ethyl-4-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (33b) (37 mg, 0.147 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 50/50) to methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-ethyl-2- oxo-1 ,2-dihydropyridin-4-
  • Step 4 preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 - ethyl-2-oxo-1 ,2-dihydropyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 33) Using the procedure described in example 25, step 4, methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(1 -ethyl-2-oxo-1 ,2-dihydropyridin-4-yl)-6-
  • Step 1 preparation of intermediate 2-bromo-4-methoxymethoxy-1 -methyl-benzene (34a)
  • Step 2 preparation of intermediate 5-methoxymethox-2-methyl-benzaldehyde (34b)
  • a solution of 2-bromo-4-methoxymethoxy-1 -methyl-benzene (34a) (4.54 g, 19.6 mmol) in anhydrous tetrahydrofuran (100 mL) under nitrogen atmosphere at -78°C was dropwise added a 1.6 M n-butyllithium solution in hexanes (15.3 mL, 24.5 mmol). The mixture was stirred at -78°C for 30 minutes and ⁇ /,/V-dimethylformamide (2.3 mL, 29.7 mmol) was added.
  • Step 3 preparation of intermediate 2-bromo-3-methoxymethox-6-methyl- benzaldehyde (34c)
  • Step 4 preparation of intermediate 2-(2-bromo-3-methoxymethoxy-6-methylphenyl)- 2-trimethylsilanyloxy-acetonitrile (34d)
  • Step 5 preparation of intermediate methyl 2-(2-bromo-3-hydroxy-6-methylphenyl)-2- hydroxyacetate (34e)
  • Step 6 preparation of intermediate methyl 2-(3-benzyloxy-2-bromo-6-methylphenyl)- 2-hydroxyacetate (34f)
  • Step 7 preparation of intermediate methyl 2-[3-benzyloxy-2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-6-methylphenyl]-2-hydroxyacetate (34g)
  • Step 8 preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-benzyloxy-2-(3,4- dihydro-2/-/-1 -benzopyran-6-yl)-6-methylphenyl]acetate (34h)
  • step 8 the intermediate methyl 2-[3- benzyloxy-2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-6-methylphenyl]-2-hydroxyacetate (34g) (347 mg, 0.83 mmol) is converted into the intermediate methyl 2-(ie f-butoxy)-2- [3-benzyloxy-2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-6-methylphenyl]acetate (34h) (263 mg, 0.55 mmol, 66%) after purification by preparative TLC (cyclohexane/ethyl acetate 80/20).
  • Step 9 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-hydroxy-6-methylphenyl]acetate (34i)
  • Step 10 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-methyl-3-trifluoromethanesulfonyloxy-phenyl]acetate (34j)
  • Step 11 preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(1-cyclobutylmethyl- 6-OXO-1 ,6-dihydro-pyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- methylphenyl]acetate (34k)
  • Step 12 Preparation of 2-(ie f-butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro- pyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-methylphenyl]acetic acid (example 34)
  • step 4 the methyl 2-(ie f-butoxy)-2-[3- (1-cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran- 6-yl)-6-methylphenyl]acetate (34k) (21 mg, 0.039 mmol) is converted into 2-(ie f- butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)-2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-6-methylphenyl]acetic acid (example 34) (9 mg, 0.017 mmol, 45%) as a white solid.
  • Example 35 synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2/-/-1-benzopyran-6-yl)-3- -propylpyridin-2-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 Preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6- (trifluoromethyl)phenyl]acetate (35a)
  • Step 2 Preparation of intermediate methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(6-propylpyridin-2-yl)-6-(trifluoromethyl) phenyl]acetate (35b)
  • Step 3 preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(6- propylpyridin-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 35)
  • step 4 the intermediate methyl 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(6-propylpyridin-2-yl)-6- (trifluoromethyl)phenyl]acetate (35b) (22 mg, 0.041 mmol) is converted, after purification by trituration in diethyl ether into 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(6-propylpyridin-2-yl)-6-(trifluoromethyl) phenyl]acetic acid (example 35) (20 mg, 0.038 mmol, 93%) as a white solid.
  • Example 36 synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -propylpyridin-2-yl)-6-(trifluoromethyl)phenyllacetic acid
  • Step 1 preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(4-propylpyridin-2-yl)-6-(trifluoromethyl) phenyl]acetate (36a)
  • step 2 the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6-
  • Step 2 preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4- propylpyridin-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 36)
  • step 4 the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(4-propylpyridin-2-yl)-6-
  • Example 37 synthesis of 2-(te f-butoxy)-2-[3-(1-cvclobutylmethyl-6-oxo-1 ,6-dihvdro- pyridin-3-yl)-6-methyl-2-r5-methyl-(3,4-dihvdro-2H-1-benzopyran-6-yl)lphenyllacetic acid
  • Step 1 preparation of intermediate 1-chloro-4-methyl-2-(prop-2-en-1-yloxy)benzene (37a)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Inhibitors of viral replication of formula (I), their process of preparation and their therapeutical uses. The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

Description

Inhibitors of viral replication, their process of preparation
and their therapeutical uses
The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV. The present invention also relates to methods for the preparation of such compounds. The present invention also relates to pharmaceutical compositions comprising such compounds. The present invention also relates to the treatment of viral infections by the administration of a therapeutically efficient amount of such compounds.
The Acquired Immuno Deficiency Syndrome (AIDS) is a disease due to infection by the Human Immunodeficiency Virus (HIV). HIV is a retrovirus, belonging to the subclass of primate lentiviruses. Two types of HIV have been identified, HIV-1 and HIV-2. HIV-1 is responsible for the larger part of the AIDS global epidemic in the world, with virtually every country reporting cases.
Currently HIV infected patients are treated with Highly Active Anti Retroviral Therapies (HAART) that rely on a combination of several drugs belonging to different classes. Up to 2003, all approved anti-HIV drugs were inhibitors of the catalytic activity of two viral enzymes, Reverse Transcriptase (RT) inhibitors and Protease (PR) inhibitors. Reverse Transcriptase inhibitors include two different classes, Nucleoside/Nucleotide RT Inhibitors (NRTI) and Non Nucleoside RT Inhibitors (NNRTI). In 2003 a new class of Anti-retroviral drug (ARV), Fusion inhibitor (Enfuvirtide) was introduced (Cervia et al, Clin Infect Dis., 2003, 37(8): 1 102-6). And lately, in 2007, two other classes of ARV were approved, Entry inhibitors (Maraviroc (Pfizer)) targeting the CCR5 co-receptor, and Integrase inhibitors (Raltegravir (Merck)) (Hughes et al, J Infect., 2008, 57(1 ):1-10.)- Although these three novel drugs were very useful to treat patients in therapeutic failure due to multiresistance to RT and PR inhibitors, resistance mutations against these drugs have already been reported.
Although the development of these potent anti-HIV drugs, has allowed HIV-infected people to live longer and to benefit of a higher quality of life, it is clear that these drugs do not cure the HIV infection. Moreover, their prolonged use often results in significant toxicity and in the emergence of drug-resistant viruses. Importantly, the ability of HIV to establish latent reservoirs early in the course of infection ensures the persistence of the virus even in the face of intensive drug therapy and vigorous antiviral immune response. Thus, there is a continuous need for the development of novel anti-HIV therapies or a 2008, 13(3):393-416.). Document of Christ et al (Christ et al, Nat. Chem. Biol., 2010, 6: 442.) and documents WO 2007/131350, WO 2009/062285, WO 2009/062288, WO 2009/062289, WO 2009/062308, WO 2010/130034, WO 2010/130842, WO 201 1/015641 , WO201 1/076765, WO 2012/003498, WO 2012/0033735, WO 2012/102985 describe partially or totally unsaturated heterocyclic derivatives as anti-HIV agents.
Document WO 2012/003497 describes naphtyl derivatives as anti-HIV agents.
However, these compounds are different from the compounds according to the invention.
Surprisingly, the inventors have identified and prepared compounds having an improved antiviral activity, especially against HIV in comparison with prior art compounds.
Summary of the Invention
The present invention relates to compounds that are able to totally or partially solve the above-mentioned problems and drawbacks.
The present invention provides antiviral agents, especially anti-retroviral agents, and more particularly anti-HIV compounds. The compounds according the invention are inhibitors of HIV replication as assessed by HIV-1 replication assay as herein-detailed. These compounds are thus useful agents for treating or preventing virus, such as HIV, or other viral pathogenic diseases or disorders, by inhibiting replication of the virus into the host infected cells. Therefore, the compounds according to the invention constitute a useful class of new potent antiviral compounds that can be used in the treatment and/or prevention of viral infections in animals, mammals and humans, more specifically for the treatment and/or prevention of HIV in humans. The present invention further relates to such compounds for their use as a medicament (medicine), to the use of such compounds as medicaments (medicines), more specifically as antiviral agents, and to their use for the manufacture of medicaments for treating and/or preventing viral infections, in particular retroviral infections such as, but not limited to, HIV in humans. The invention also relates to pharmaceutical composition comprising such compound as an active ingredient and at least a pharmaceutically acceptable carrier. This pharmaceutical composition further comprises at least a further antiviral agent.
The invention also relates to pharmaceutical compositions comprising such compounds in an antiviral effective amount, optionally in combination with at least one further antiviral agent.
The present invention further relates to such pharmaceutical composition for use for the prevention and/or the treatment of viral infection, preferably for the prevention and/or the treatment of retroviral infection, more preferably for the prevention and/or the treatment of an HIV infection.
The present invention further relates to such pharmaceutical composition for its use for the treatment of an HIV infection in a mammal being infected or having a risk to be infected by the HIV.
The present invention also relates to a method of treatment or prevention of viral infections, in particular retroviral infections such as, but not limited to HIV in humans by the administration of one or more such compounds, optionally in combination with one or more other antiviral agents, to a patient in need thereof.
The present invention also relates to a method of inhibiting the replication of HIV comprising exposing the virus to an effective amount of one or more such compounds under conditions where replication of HIV is inhibited.
The invention provides compounds comprising a 6-membered carbocycle, said compounds having a structure according to formula (I):
(I)
wherein :
• R1 and R6, identical or different, independently represent a hydrogen atom; - CN; -OH; -CF3; a halogen atom; a linear or branched C-|-C3 alkyl a linear or branched C-|-C3 heteroalkyl;
• R2, non-substituted or substituted by at least one T1, represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle;
• R3 non-substituted or substituted by at least one T2, represents an aryl; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7- membered carbocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7- membered heterocycle and further fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; a heteroaryl; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5- , 6- or 7-membered carbocycle; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a C5-C7 cycloalkenyl; a C5-C7 cycloalkenyl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; or a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle;
• R4 represents a linear or branched Ci-C6-alkyl; a linear or branched C-|-C6 fluoroalkyl or a C3-C6 cycloalkyl;
• R5 represents a halogen atom; -CF3; a linear or branched CrC6 alkyl; a linear or branched C2-C6 alkenyl; a linear or branched C2-C6 alkynyl; a linear or branched fluoroalkyl; a C3-C6 cycloalkyl; -CH2OH; or -CH2-0-CH3;
• T1 independently represents a hydrogen atom; a halogen atom; an alkyl; - (X)x-Ci-C6 alkyl; a linear or branched fluoroalkyl; a linear or branched -O-Cr
C3 fluoroalkyl; -(X)x-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-C3-C6 cycloalkyl; -(X)x- (CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x-(CT5T6)yOT3; -(X)x-(CT5T6)yST3; -(X)x- (CT5T6)yS(0)T3; -(X)x-(CT5T6)yS(0)2T3; -(X)x-(CT5T6)yNT3T4; -(X)x- (CT5T6)yC(0)T3; -(X)x-(CT5T6)yC(0)OT3; -(X)x-(CT5T6)yC(0)NT3T4; -(X)x- (CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; -(X)x-(CT5T6)yNT3C(0)OT4;
-(X)x-(CT5T6)yOC(0)NT3T4; _(X)x-(CT5T6)y S(0)2NT3T4 or -(X)x- (CT5T6)yNT3S(0)2T4;
• T2 independently represents a hydrogen atom; a halogen atom; a linear or branched -0-Ci-C3 alkyl; a linear or branched C C3 fluoroalkyl; a linear or branched -0-Ci-C3 fluoroalkyl; a linear or branched C C3 alkyl; or -CN; optionally two geminal T2 form with the carbon atom to which they are bonded, a C3-C7 cycloalkyl;
• X independently represents an oxygen atom; a sulphur atom; NT3; S=0 or S(0)2;
· T3 and T4, identical or different, independently represent a hydrogen atom; a branched or linear C C6 alkyl or a C3-C6 cycloalkyl; optionally T3, T4 and the nitrogen atom to which they are bonded form a C4-C6 heterocycloalkyl;
• T5 and T6, identical or different, independently represent a hydrogen atom; a fluorine atom or a linear or branched C C3 alkyl or a C3-C6 cycloalkyl; optionally T5, T6 and the carbon atom to which they are bonded form a cyclopropyl;
• x independently represents 0 or 1 ;
• y independently represents 0, 1 , 2 or 3; or
• R5 and R6 form, with the carbon atoms to which they are bonded, a heteroaryl comprising at least one nitrogen atom;
and a racemate, enantiomer, atropisomer, diastereoisomer or a pharmaceutically acceptable salt thereof. The invention also provides compounds of formula (I) wherein;
• R1 and R6 represent a hydrogen atom;
• R2, non-substituted or substituted by at least one T1, represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle ; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic
5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle ;
• R3, non-substituted or substituted by at least one T2, represents an aryl; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7- membered heterocycle and further fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; a heteroaryl; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5- , 6- or 7-membered carbocycle; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a C5-C7 cycloalkenyl; a C5-C7 cycloalkenyl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; or a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; · R4 represents a linear or branched Ci-C6-alkyl; a linear or branched C-|-C6 fluoroalkyl or a C3-C6 cycloalkyl;
• R5 represents a halogen atom; a linear or branched C-|-C6 alkyl; a linear or branched fluoroalkyl; a C3-C6 cycloalkyl or -CH2OH;
• T1 independently represents a hydrogen atom; a halogen atom; an alkyl; - (X)x-Ci-C6 alkyl; a linear or branched fluoroalkyl; a linear or branched -O-Cr
C3 fluoroalkyl; -(X)x-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-C3-C6 cycloalkyl; -(X)x- (CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x-(CT5T6)yOT3; -(X)x-(CT5T6)yST3; -(X)x- (CT5T6)yS(0)T3; -(X)x-(CT5T6)yS(0)2T3; -(X)x-(CT5T6)yNT3T4; -(X)x- (CT5T6)yC(0)T3; -(X)x-(CT5T6)yC(0)OT3; -(X)x-(CT5T6)yC(0)NT3T4; -(X)x- (CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; -(X)x-(CT5T6)yNT3C(0)OT4; -(X)x-(CT5T6)yOC(0)NT3T4; _(X)x-(CT5T6)y S(0)2NT3T4 or -(X)x- (CT5T6)yNT3S(0)2T4;
• T2 independently represents a hydrogen atom; a halogen atom; a linear or branched -O-C1-C3 alkyl; a linear or branched Ci-C3 fluoroalkyi; a linear or branched -O-C1-C3 fluoroalkyi; a linear or branched Ci-C3 alkyl; or -CN; optionally two geminal T2 form with the carbon atom to which they are bonded, a C3-C7 cycloalkyl;
• X independently represents an oxygen atom; a sulphur atom; NT3; S=0 or S(0)2;
• T3 and T4, identical or different, independently represent a hydrogen atom; a branched or linear C C6 alkyl or a C3-C6 cycloalkyl; optionally T3, T4 and the nitrogen atom to which they are bonded form a C4-C6 heterocycloalkyl;
• T5 and T6, identical or different, independently represent a hydrogen atom; a fluorine atom or a linear or branched C C3 alkyl or a C3-C6 cycloalkyl; optionally T5, T6 and the carbon atom to which they are bonded form a cyclopropyl;
· x independently represents 0 or 1 ;
• y independently represents 0, 1 , 2 or 3.
The invention also provides compounds of formula (I) wherein;
• R1 and R6, identical or different, independently represent a hydrogen atom; - CN; -OH; -CF3; a halogen atom; a linear or branched C C3 alkyl a linear or branched C C3 heteroalkyl;
• R2, non-substituted or substituted by at least one T1, represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle ; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7- membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7- membered heterocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7-membered heterocycle;
• R3, non-substituted or substituted by at least one T2, represents an aryl; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a heteroaryl; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5- , 6- or 7-membered carbocycle; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle or a C3-C7 cycloalkenyl;
• R4 represents a linear or branched CrC6-alkyl; a linear or branched CrC6 fluoroalkyl or a C3-C6 cycloalkyl;
• R5 represents a halogen atom; a linear or branched C-|-C6 alkyl; a linear or branched fluoroalkyl; a C3-C6 cycloalkyl or -CH2OH;
· R5 and R6 form, with the carbon atoms to which they are bonded, a heteroaryl comprising at least one nitrogen atom;
• T1 represents a hydrogen atom; a halogen atom; an alkyl; -(X)x-d-C6 alkyl; a linear or branched fluoroalkyl; a linear or branched -O-C1-C3 fluoroalkyl; -(X)x- C3-C6 cycloalkyl; -(X)x-(CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x-(CT5T6)yOT3; - (X)x-(CT5T6)yST3; -(X)x-(CT5T6)yS(0)T3; -(X)x-(CT5T6)yS(0)2T3; -(X)x-
(CT5T6)yNT3T4; -(X)x-(CT5T6)yC(0)T3; -(X)x-(CT5T6)yC(0)OT3; -(X)x- (CT5T6)yC(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; - (X)x-(CT5T6)yNT3C(0)OT4; -(X)x-(CT5T6)yOC(0)NT3T4; -(X)x-(CT5T6)y S(0)2NT3T4 or -(X)x-(CT5T6)yNT3S(0)2T4;
· T2 represents a hydrogen atom; a halogen atom; a linear or branched -O-Cr
C3 alkyl; a linear or branched C C3 fluoroalkyl; a linear or branched -0-C-|-C3 fluoroalkyl; a linear or branched C C3 alkyl; cyclopropyl or -CN;
• X represents an oxygen atom; a sulphur atom; NT3; S=0 or S(0)2;
• T3 and T4, identical or different, independently represent a hydrogen atom; a branched or linear CrC6 alkyl or a C3-C6 cycloalkyl;
• T3, T4 and the nitrogen atom to which they are bonded form a C4-C6 heterocycloalkyl;
• T5 and T6, identical or different, independently represent a hydrogen atom; a fluorine atom or a linear or branched C C3 alkyl or a C3-C6 cycloalkyl;
· T5, T6 and the carbon atom to which they are bonded form a cyclopropyl;
• x represents 0 or 1 ;
• y represents 0, 1 , 2 or 3; and a racemate, enantiomer, isomer, atropisomer or diastereoisomer or a pharmaceutically acceptable salt thereof.
Detailed Description of the Invention
Even if described in particular or preferred embodiments, the present invention is not to be understood as being limited to such particular or preferred embodiments.
The term "alkyl" as used herein, either alone or in combination with another radical, refers to acyclic, linear or branched chain alkyl radicals.
The term "heteroalkyl" as used herein, alone or in combination with another radical, refers to an acyclic alkyl wherein one or more carbon atoms are replaced by an oxygen, nitrogen or sulphur atom.
The term "cycloalkyl", as used herein, either alone or in combination with another radical, refers to a monocyclic or polycyclic saturated hydrocarbon radical.
The term "aryl", as used herein, either alone or in combination with another radical, refers to a carbocyclic aromatic monocyclic group containing 6 carbon atoms which can be fused with at least another saturated, unsaturated or aromatic carbocycle..
The term "carbocycle", as used herein and unless specified otherwise, either alone or in combination with another radical, refers to a 3- to 8-membered saturated, unsaturated or aromatic cyclic radical in which all of the ring members are carbon atoms and which can be fused with at least another carbocycle.
The term "heterocycle" as used herein means a saturated, unsaturated or aromatic ring system of 3 to 18 atoms including at least one N, O or S and which can be fused with at least another carbocycle or heterocycle.
The expression "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
The term "enantiomer" is employed herein to refer to one of the two specific stereoisomers which is a non-superimposable mirror image with one other but is related to one other by reflection. The term "diastereoisomer" is employed herein to refer to one of the stereoisomers which is a non-superimposable mirror image with one other but is not related to one other by reflection.
The term "racemate" is employed herein to refer to an equal amount of two specific enantiomers.
The term "atropisomer" is employed herein to refer to stereoisomer obtained by a sterically hindered single bond whereby the free rotation of functional groups on either side of this bond is not allowed.
The term "tautomer" is employed herein to refer to constitutional isomer obtained by a formal migration of a hydrogen atom or a proton accompanied by a switch of a single bond and adjacent double bond. The term "treatment" as used herein is intended to mean the administration of a compound or composition according to the present invention to alleviate or eliminate symptoms of HIV infection and/or to reduce viral load in a patient. The term "treatment" also encompasses the administration of a compound or composition according to the present invention post-exposure of the individual to the virus but before the appearance of symptoms of the disease, and/or prior to the detection of the virus in the blood, to prevent the appearance of symptoms of the disease and/or to prevent the virus from reaching detectible levels in the blood, and the administration of a compound or composition according to the present invention to prevent perinatal transmission of HIV from mother to baby, by administration to the mother before giving birth and to the child within the first days of life. The expression "therapeutically effective amount" refers to an amount of a compound according to the invention, which when administered to a patient in need thereof, is sufficient to effect treatment for disease-states, conditions, or disorders for which the compounds have utility. Such an amount would be sufficient to elicit the biological or medical response of a tissue system, or patient that is sought by a researcher or clinician. The amount of a compound according to the invention which constitutes a therapeutically effective amount will vary depending on such factors as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of the treatment, the type of disease-state or disorder being treated and its severity, drugs used in combination with or coincidentally with the compounds of the invention, and the age, body weight, general health, sex and diet of the patient Such a therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the state of the art, and this disclosure.
The term "mammal " as used herein is intended to encompass humans, as well as non-human mammals which are susceptible to infection by HIV or non human equivalents of HIV. Non-human mammals include but are not limited to domestic animals, such as cows, pigs, dogs, cats, rabbits, rats and mice, and non domestic animals.
The compounds according to the invention are compounds of formula (I) as defined and including the embodiments described in the summary of the invention.
In particular, according to feature (a), the compounds according to the invention are compounds of formula (I) wherein R4 represents tBu.
Particularly, according to feature (b), the compounds according to the invention are compounds of formula (I) wherein
• R2, non-substituted or substituted by at least one T1, represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle or a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated 5-, 6- or 7-membered heterocycle;
• T1 represents a hydrogen atom; a halogen atom; -CH3; -CH2F; -CHF2; -CF3; - OMe; -OCH2F; -OCHF2; -OCF3; -(X)x-C3-C6 cycloalkyl;-(X)x-(CT5T6)y-aryl; - (X)x-(CT5T6)yCN; -(X)x-(CT5T6)yOT3; -(X)x-(CT5T6)yST3; -(X)x-(CT5T6)yS(0)T3;
-(X)x-(CT5T6)yS(0)2T3; -(X)x-(CT5T6)yNT3T4; -(X)x-(CT5T6)yC(0)T3; -(X)x- (CT5T6)yC(0)OT3; -(X)x-(CT5T6)yC(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)NT3T4; - (X)x-(CT5T6)yNT3C(0)T4; -(X)x-(CT5T6)yNT3C(0)OT4; -(X)x-
(CT5T6)yOC(0)NT3T4; -(X)x-(CT5T6)y S(0)2NT3T4 or -(X)x-(CT5T6)yNT3S(0)2T4 ; · X independently represents an oxygen atom; a sulphur atom; NT3; S=0 or
S(0)2;
• T3 and T4, identical or different, independently represent a hydrogen atom; a branched or linear C C6 alkyl or a C3-C6 cycloalkyl;
• T3, T4 and the nitrogen atom to which they are bonded form a C4-C6 heterocycloalkyl;
• T5 and T6, identical or different, independently represent a hydrogen atom; a fluorine atom or methyl;
• x independently represents 0 or 1 ;
• y independently represents 0, 1 , 2 or 3.
Particularly, according to feature (c), the compounds according to the invention are compounds of formula (I) wherein
• R2 represents a partially or totally unsaturated or aromatic 5-, 6- or 7- membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7- membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or
7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; or a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle;
• T1 independently represents a hydrogen atom; a halogen atom; -CH3; - CH2CH3; -(CH2)2CH3; -CH(CH3)2; -CH2CF3; -OCH3; -NH2; -N(CH3)2; -CH2F; - CHF2; -CF3; -OCH2F; -OCHF2; -OCF3; -(X)x-C3-C6 cycloalkyl; -(X)x-(CT5T6)y- C3-C6 cycloalkyl; -(X)x-(CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x-(CT5T6)yOT3; - (X)x-(CT5T6)yST3; -(X)x-(CT5T6)yS(0)T3; -(X)x-(CT5T6)yS(0)2T3; -(X)x-
(CT5T6)yNT3T4; -(X)x-(CT5T6)yC(0)T3; -(X)x-(CT5T6)yC(0)OT3; -(X)x- (CT5T6)yC(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; - (X)x-(CT5T6)yNT3C(0)OT4; -(X)x-(CT5T6)yOC(0)NT3T4; _(X)x-(CT5T6)y S(0)2NT3T4 or -(X)x-(CT5T6)yNT3S(0)2T4;
• X independently represents an oxygen atom; a sulphur atom; NT3; S=0 or S(0)2;
· T3 and T4, identical or different, independently represent a hydrogen atom; a branched or linear CrC6 alkyl or a C3-C6 cycloalkyl;
• T5 and T6, identical or different, independently represent a hydrogen atom; a fluorine atom or methyl;
• x independently represents 0 or 1 ;
· y independently represents 0, 1 , 2 or 3.
Preferably, according to feature (d), the invention provides compounds of formula (I), wherein R3, non-substituted or substituted by at least one T2, represents an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; or a C5-C7 cycloalkenyl.
More preferably, according to feature (e), the invention provides compounds of formula (I), wherein R3, non-substituted or substituted by at least one T2, represents a cyclohexenyl or a dihydrobenzopyranyl.
Preferably, according to feature (f), the invention provides compounds of formula (I), wherein R2, non-substituted or substituted by at least one T1, represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; or a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle. More preferably, according to feature (g), the invention provides compounds of formula (I), wherein R2, non-substituted or substituted by at least one T1, represents a phenyl, a cyclohexenyl, a cyclopentenyl, a thiophenyl, a pyrazolyl, an isothiazolyl, a benzothiazolyl, a pyridinyl, a thiazolyl, an imidazolyl, a pyridinopyrazolyl, a pyrimidinyl, a pyranyl, a pyridinonyl, or a pyridazinyl.
More preferably, according to feature (h), the invention provides compounds of formula (I), wherein R2, non-substituted or substituted by at least one T1, represents a thiophenyl, a pyrazolyl, an isothiazolyl, a benzothiazolyl, a pyridinyl, a thiazolyl, an imidazolyl, a pyridinopyrazolyl, a pyrimidinyl, a pyranyl, a pyridinonyl,or a pyridazinyl.
Preferably, according to feature (i), the invention provides compounds of formula (I), wherein:
• T1 independently represents a hydrogen atom; a halogen atom; an alkyl; - (X)x-Ci-C6 alkyl; a linear or branched fluoroalkyl; -(X)x-C3-C6 cycloalkyl; -(X)x- (CT5T6)y-C3-C6 cycloalkyl; -(X)x-(CT5T6)yOT3; -(X)x-(CT5T6)y-aryl; -(X)x- (CT5T6)yNT3T4; -(X)x-(CT5T6)yC(0)OT3; -(X)x-(CT5T6)yC(0)NT3T4; or -(X)x- (CT5T6)yNT3C(0)T4;
• T2 independently represents a hydrogen atom; a halogen atom; a linear or branched C1-C3 fluoroalkyl; or a linear or branched Ci-C3 alkyl;
• X represents an oxygen atom;
• T3 and T4, identical or different, independently represent a hydrogen atom; or a branched or linear d-C6 alkyl;
• x independently represents 0 or 1 ;
• y independently represents 0, 1 , 2 or 3.
More preferably, according to feature (j), the invention provides compounds of formula (I), wherein:
• T1 independently represents a hydrogen atom; a fluorine atom; a bromine atom; a chlorine atom; -CH3; -CH2CH3; -(CH2)2CH3; -CH2CH(CH3)2; -CF3; - CH2CF3; -OCH3; -NH2; -N(CH3)2; a cyclopropyl; a phenyl; a benzyloxy; a benzyl; a methylcyclopropane; an ethylcyclopropane; a methylcyclobutane; - C(0)OH; -C(0)NH2; -C(0)NH(CH3); or -NHC(0)CH3;
• T2 represents a hydrogen atom.
Preferably, according to feature (k), the invention compounds of formula (I), wherein R5 represents:
· a linear or branched C C3 alkyl;
• a linear or branched fluoroalkyl;
• a halogen atom;
• a C3-C6 cycloalkyl;
• -CH2OH. Preferably, according to feature (I), the invention provides compounds of formula (I) wherein R5 represents:
• a linear or branched C-|-C3 alkyl;
• a linear or branched C1-C3 fluoroalkyl;
· a halogen atom;
• a C3-C6 cycloalkyl; or
• -CH2OH.
Advantageously, according to feature (m), the invention provides compounds of formula (I) wherein R5 represent methyl; ethyl; -CH2F; -CHF2; -CF3; -CH2CH2F; - CH2CHF2; -CH2CF3; -CH2OH.
Advantageously, according to feature (n), the invention provides compounds of formula (I) wherein R5 represents methyl or -CF3.
Preferably, the invention provides compounds of formula (I) comprising the two features: (a) and (b); (a) and (c); (a) and (d); (a) and (e); (a) and (f); (a) and (g); (a) and (h); (a) and (i); (a) and (j); (a) and (k); (a) and (I); (a) and (m); (a) and (n); (b) and
(d) ; (b) and (e); (b) and (k); (b) and (I); (b) and (m); (b) and (n); (c) and (d); (c) and (e); (c) and (k); (c) and (I); (c) and (m); (c) and (n); (d) and (f); (d) and (g); (d) and (h); (d) and (i); (d) and ); (d) and (k); (d) and (I); (d) and (m); (d) and (n); (e) and (h); (e) and (f); (e) and (g); (e) and (h); (e) and (i); (e) and (j); (e) and (k); (e) and (I); (e) and (m);
(e) and (n); (f) and (i); (f) and (j); (f) and (k); (f) and (I); (f) and (m); (f) and (n); (g) and (i); (g) and (j); (g) and (k); (g) and (I); (g) and (m); (g) and (n); (h) and (i); (h) and (j); (h) and (k); (h) and (I); (h) and (m); or (h) and (n).
Preferably, the invention provides compounds of formula (I) comprising the three features: (a), (b) and (d); (a), (b) and (e); (a), (b) and (k); (a), (b) and (I); (a), (b) and (m); (a), (b) and (n); (a), (c) and (d); (a), (c) and (e); (a), (c) and (k); (a), (c) and (I); (a), (c) and (m); (a), (c) and (n); (a), (d) and (f); (a), (d) and (h); (a), (d) and (i); (a), (d) and 0; (a), (d) and (k); (a), (d) and (I); (a), (d) and (m); (a), (d) and (n); (a), (e) and (f); (a), (e) and (g); (a), (e) and (i); (a), (e) and (j); (a), (e) and (k); (a), (e) and (I); (a), (e) and (m); (a), (e) and (n); (a), (f) and (i); (a), (f) and Q); (a), (f) and (k); (a), (f) and (I); (a), (f) and (m); (a), (f) and (n). (a), (g) and (i); (a), (g) and (j); (a), (g) and (k); (a), (g) and (I); (a), (g) and (m); (a), (g) and (n); (a), (h) and (i); (a), (h) and Q); (a), (h) and (k); (a), (h) and (I); (a), (h) and (m); or (a), (h) and (n). Preferably, the invention provides compounds of formula (I) comprising the four features: (a), (d), (f) and (i); (a), (d), (f) and (j); (a), (d), (f) and (k); (a), (d), (f) and (I); (a), (d), (f) and (m); (a), (d), (f) and (n); (a), (d), (g) and (i); (a), (d), (g) and Q); (a), (d), (g) and (k); (a), (d), (g) and (I); (a), (d), (g) and (m); (a), (d), (g) and (n); (a), (d), (h) and (i); (a), (d), (h) and Q); (a), (d), (h) and (k); (a), (d), (h) and (I); (a), (d), (h) and (m); (a), (d), (h) and (n); (a), (e), (f) and (i); (a), (e), (f) and Q); (a), (e), (f) and (k); (a), (e),
(f) and (I); (a), (e), (f) and (m); (a), (e), (f) and (n); (a), (e), (g) and (i); (a), (e), (g) and G); (a), (e), (g) and (k); (a), (e), (g) and (I); (a), (e), (g) and (m); (a), (e), (g) and (n); (a), (e), (h) and (i); (a), (e), (h) and Q); (a), (e), (h) and (k); (a), (e), (h) and (I); (a), (e), (h) and (m); or (a), (e), (h) and (n).
Preferably, the invention provides compounds of formula (I) comprising the five features: (a), (d), (f), (i) and (k); (a), (d), (f), (i) and (I); (a), (d), (f), (i) and (m); (a), (d), (f), (i) and (n); (a), (e), (f), (i) and (k); (a), (e), (f), (i) and (I); (a), (e), (f), (i) and (m); (a), (e), (f), (i) and (n); (a), (d), (g), (i) and (k); (a), (d), (g), (i) and (I); (a), (d), (g), (i) and (m); (a), (d), (g), (i) and (n); (a), (e), (g), (i) and (k); (a), (e), (g), (i) and (I); (a), (e), (g), (i) and (m); (a), (e), (g), (i) and (n); (a), (d), (f), Q) and (k); (a), (d), (f), Q) and (I); (a), (d), (f), 0 and (m); (a), (d), (f), (j) and (n); (a), (e), (f), (j) and (k); (a), (e), (f), 0 and (I); (a), (e), (f), 0 and (m); (a), (e), (f), ) and (n); (a), (d), (g), (j) and (k); (a), (d), (g), ) and (I); (a), (d), (g), (j) and (m); (a), (d), (g), 0 and (n); (a), (e), (g), 0 and (k); (a), (e),
(g) , (j) and (I); (a), (e), (g), (j) and (m); or (a), (e), (g), (j) and (n).
Advantageously, the invention provides compounds of formula (A), (B), (C), (D), (E) or (F)
wherein
• a, b, c, d, e, f, g, h, i, j, k, I, m, n, o and p independently represent 0 or 1 ;
· V represents a substituted or non-substituted partially or totally unsaturated carbocycle or a partially or totally unsaturated or aromatic heterocycle;
• W represents a substituted or non-substituted partially unsaturated carbo- or heterocycle;
• Q1 represents CR7 or N;
· Q2 represents CR8 or N;
• Q3 represents CR9 or N;
• Q4 represents CR10 or N;
• Q5 represents CR11 or N;
• Q6 represents CR12 or N;
· Q7 represents CR13, C=0, NR13, N, S, O, S=0 or S(0)2; Q8 represents CR14, C=0, NR , N, S, O, S=0 or S(0)2;
Q9 represents CR15, C=0, NR15, N, S, O, S=0 or S(0)2;
Q10 represents CR16, NR16, N, S, O, S=0 or S(0)2;
Q11 represents C, CR17, N;
Q12 represents C, CR18, C=0, N, NR18; O, S, S=0 or S(0)2;
Q13 represents C, CR19, C=0, N, NR19; O, S, S=0 or S(0)2;
Q14 represents C, CR20, C=0, N, NR20; O, S, S=0 or S(0)2;
Q15 represents C, CR21 , C=0, N, NR21 ; O, S, S=0 or S(0)2;
Q16 represents C, CR22, C=0, N, NR22; O, S, S=0 or S(0)2;
p7 p8 p9 p10 p11 p12 p13 p14 p15 p16 p17 p18 p19 R 20 R21 and R22, identical or different, independently represent a hydrogen atom; a halogen atom; ; -CH3; -CH2CH3; -(CH2)2CH3; -CH(CH3)2; -CH2CF3; -OCH3; -NH2; - N(CH3)2; -CH2F; -CHF2; -CF3; -OCH2F; -OCHF2; -OCF3; -(X)x-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x- (CT5T6)yOT3; -(X)x-(CT5T6)yST3; -(X)x-(CT5T6)yS(0)T3; -(X)x-(CT5T6)yS(0)2T3; -(X)x-(CT5T6)yNT3T4; -(X)x-(CT5T6)yC(0)T3; -(X)x-(CT5T6)yC(0)OT3; -(X)x- (CT5T6)yC(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; -
(X)x-(CT5T6)yNTaC(0)OT4; (X)x-(CT5T6)yOC(0)NTa 3TT4. -(X)x-(CT5T6)y
S(0)2NT3T4 or -(X)x-(Cr 5T- b6)yN"TS(0)2T
• T2 independently represents a hydrogen atom; a halogen atom; a linear or branched C C3 alkyl; -CH2F; -CHF2; -CF3; -OMe; -OCH2F; -OCHF2; -OCF3; or -CN; optionally two geminal T2 form with the carbon atom to which they are bonded, a C3-C7 cycloalkyl;
• R1, R3, R5, R6, X, x, y and T3 to T6 are independently defined as for the compounds of formula (I).
The invention provides compounds of formula (A), (B), (C), (D), (E) or (F), wherein :
• R7, Q1 , Q2 and R8 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
· R8, Q2 Q3 and R9 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
• R9, Q3 Q4 and R10 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
• R10, Q4 Q5 and R11 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
• R13, Q7 Q8 and R14 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle; • R14, Q8 Q9 and R15 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
• R15, Q9 Q10 and R16 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
· R18, Q12 Q13 and R19 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
• R19, Q13 Q14 and R20 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle;
• R20, Q14 Q15 and R21 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle; or
• R21 , Q15 Q16 and R22 form a saturated, partially or totally unsaturated or aromatic 6-membered carbo- or heterocycle.
More advantageously, the invention provides compounds of formula (A), (B), (C), (D), (E) or (F), wherein R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22, identical or different, independently represent a hydrogen atom; a halogen atom; a linear or branched Ci-C6 alkyl; a linear or branched -0-CrC6 alkyl; -(X)x- (CT5T6)y-aryl; -C(0)NH2. More advantageously, the invention provides compounds of formula (A), (B), (C), (D), (E) or (F), wherein R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22, identical or different, independently represent a hydrogen atom; a halogen atom; a linear or branched Ci-C6 alkyl; a linear or branched -0-CrC6 alkyl; -(X)x-C3- C6 cycloalkyl; -(X)x-(CT5T6)y-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-aryl; -C(0)OH; - C(0)NH2; -C(0)NH(CH3); or -NHC(0)CH3.
Preferably, the invention provides compounds of formulae (A1 ) to (A10), (B1 ) to (B15), (C1 ) to (C9), (D1 ) to (D10), (E1 ) to (E7) or (F1 ) to (F8)
(A6) 22


(D7) (D8)
(E3) (E4)
(F1) (F2) atom; -CH3; -CH2CH3; -(CH2)2CH3; -CH(CH3)2; -CH2CF3; -OCH3; -NH2; - N(CH3)2; -CH2F; -CHF2; -CF3; -OCH2F; -OCHF2; -OCF3; -(X)x-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x- (CT5T6)yOT3; -(X)x-(CT5T6)yST3; -(X)x-(CT5T6)yS(0)T3; -(X)x-(CT5T6)yS(0)2T3; -(X)x-(CT5T6)yNT3T4; -(X)x-(CT5T6)yC(0)T3; -(X)x-(CT5T6)yC(0)OT3; -(X)x-
(CT5T6)yC(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; - (X)x-(CT5T6)yNT3C(0)OT4; -(X)x-(CT5T6)yOC(0)NT3T4; -(X)x-(CT5T6)y S(0)2NT3T4 or -(X)x-(CT5T6)yNT3S(0)2T4;
• T2 represents a hydrogen artom; a halogen atom; -CH2F; -CHF2; -CF3; -OMe; - OCH2F; -OCHF2; -OCF3; an alkyl; a linear or branched alkyl; a cycloalkyl; an alkoxy; a halogenoalkoxy or -CN;
• R1, R5, R6, T3, T4, T5, T6, X, x, y, g, h, i, I, m, n, o, p are as defined for compounds of formula (I), (A), (B), (C), (D), (E) or (F). The invention also provides compounds of formulae (A1 ) to (A10), (B1 ) to (B15), (C1 ) to (C9), (D1 ) to (D10), (E1 ) to (E7) or (F1 ) to (F8) wherein:
• R7, R8 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
• R8, R9 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle
• R9, R10 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
• R10, R11 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle; or
· R12, R13 and the carbon and nitrogen atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle.
More preferably, the invention provides compounds of formulae (A1 ) to (A10), (B1 ) to (B15), (C1 ) to (C9), (D1 ) to (D10), (E1 ) to (E7) or (F1 ) to (F8) wherein R7, R8, R9, R10, R11 , R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22, identical or different, independently represent a hydrogen atom; a halogen atom; a linear or branched C C6 alkyl; a linear or branched -0-CrC6 alkyl; a linear or branched -O-C1-C10 alkylaryl; -(X)x-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-aryl; -C(0)OH; -C(0)NH2; -C(0)NH(CH3); or -NHC(0)CH3.
Advantageously, the invention provides compounds of formulae (A1 a) to (A10a), (A1 b) to (A10b), (A1 c) to (A10c), (Ai d) to (A10d), (B1 a) to (B15a), (B1 b) to (B15b), (B1c) to(B15c), (B1d)to(B15d), (C1a) to (C9a), (C1b) to (C9b), (C1c) to (C9c), (C1d) to (C9d), (D1a) to (D10a), (D1b) to (D10b), (D1c) to (D10c), (Did) to (D10d), (E1a) to (E7a), (E1b) to (E7b), (E1c) to (E7c), (E1d) to (E7d), (F1a) to (F8a), (F1b) to (F8b),
(A1c) (Aid)
(A2c) (A2d)
(A5a) (A5b)
(A6a) (A6b)
(A8a) (A8b)

(B2a) (B2b)
(B3a) (B3b)
(B4a) (B4b)
(B5a) (B5b)
(B8a) (B8b) 
(B11b)
51
(B12c)
(B12d)
(B14a) (B14b)
(B15a) (B15b)
(C1a) (C1b)
(C3a) (C3b)
(C4a) (C4b)
(C9a)
(C9b)
(D1a) (D1b)
(D2a) (D2b)
(D3a) (D3b)
(D4a) (D4b)
(D5a) (D5b)
(D6a) (D6b)
(D7a) (D7b)
(D8a) (D8b)
(D9a) (D9b)
(D10a) (D10b)
(E1a) (E1b)
(E2a) (E2b)
(E3a) (E3b)
(E4a) (E4b)
(E6a) (E6b)
(E7a) (E7b)
(F1a) (F1b)
(F2a) (F2b)
(F3a) (F3b)
84
(F5a) (F5b) 86
(F7a) (F7b)
(F8a) (F8b)
(F8c) (F8d)
wherein
. R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22, identical or different, independently represent a hydrogen atom; a halogen atom; -CH3; -CH2CH3; -(CH2)2CH3; -CH(CH3)2; -CH2CF3; -OCH3; -NH2; - N(CH3)2; -CH2F; -CHF2; -CF3; -OCH2F; -OCHF2; -OCF3; -(X)x-C3-C6 cycloalkyl;
-(X)x-(CT5T6)ycycloalkyl; -(X)x-(CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x- (CT5T6)yOT3; -(X)x-(CT5T6)yST3; -(X)x-(CT5T6)yS(0)T3; -(X)x-(CT5T6)yS(0)2T3; -(X)x-(CT5T6)yNT3T4; -(X)x-(CT5T6)yC(0)T3; -(X)x-(CT5T6)yC(0)OT3; -(X)x- (CT5T6)yC(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; - (X)x-(CT5T6)yNT3C(0)OT4; -(X)x-(CT5T6)yOC(0)NT3T4; -(X)x-(CT5T6)y
S(0)2NT3T4 or -(X)x-(CT5T6)yNT3S(0)2T4 ;
• R1, R5, R6, X, x, y and T3 to T6 are independtly defined as for the compounds of formula (I), (A), (B), (C), (D), (E), (F), (A1) to (A10), (B1) to (B15), (C1) to (C9), (D1) to (D10), (E1) to (E7) or (F1) to (F8).
The invention also provides compounds of formula (A1a) to (A10a), (A1b) to (A10b), (A1c) to (A10c), (Aid) to (A10d), (B1a) to (B15a), (B1b) to (B15b), (B1c) to (B15c), (Bid) to (B15d), (C1a) to (C9a), (C1b) to (C9b), (C1c) to (C9c), (C1d) to (C9d), (D1a) to (D10a), (D1b) to (D10b), (D1c) to (D10c), (Did) to (D10d), (E1a) to (E7a), (E1b) to (E7b), (E1c) to (E7c), (E1d) to (E7d), (F1a) to (F8a), (F1b) to (F8b), (F1c) to (F8c) or (F1d)to (F8d), wherein: • R7, R8 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
• R8, R9 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
· R9, R10 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
• R10, R11 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
• R12, R13 and the carbon or nitrogen atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
• R13, R14 and the carbon or nitrogen atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle; or
• R14, R15 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle.
The invention also provides compounds of formula (A1 a) to (A10a), (A1 b) to (A10b), (A1 c) to (A10c), (Ai d) to (A10d), (B1 a) to (B15a), (B1 b) to (B15b), (B1 c) to (B15c), (Bi d) to (B15d), (C1 a) to (C9a), (C1 b) to (C9b), (C1 c) to (C9c), (C1 d) to (C9d), (D1 a) to (D10a), (D1 b) to (D10b), (D1 c) to (D10c), (Di d) to (D10d), (E1 a) to (E7a), (E1 b) to (E7b), (E1 c) to (E7c), (E1 d) to (E7d), (F1 a) to (F8a), (F1 b) to (F8b), (F1 c) to (F8c) or (F1 d) to (F8d), wherein:
D23 D24 D25 D26 D27 D28 D29 D30 D31 D32 D33 D34 D35 D36 D37 D38 D39
R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51 , R52 and R53, identical or different, independently represent a hydrogen atom or a linear or branched C
C6 alkyl;
• R24, R25 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle;
• R25, R26 and the carbon atoms to which they are bonded form a saturated, partially or totally unsaturated 6-membered carbo- or heterocycle; or
• R31 , R32 and the carbon atom to which they are bounded form a saturated 3-, 4-, 5- or 6-membered carbocyle.
Advantageously, the invention also provides compounds of formulae (A1 a) to (A10a), (A1 b) to (A10b), (A1 c) to (A10c), (Ai d) to (A10d), (B1 a) to (B15a), (B1 b) to (B15b), (B1 c) to (B15c), (B1 d) to (B15d), (C1 a) to (C9a), (C1 b) to (C9b), (C1 c) to (C9c), (C1 d) to (C9d), (D1 a) to (D10a), (D1 b) to (D10b), (D1 c) to (D10c), (Di d) to (D10d), (E1 a) to (E7a), (E1 b) to (E7b), (E1 c) to (E7c), (E1 d) to (E7d), (F1 a) to (F8a), (F1 b) to (F8b), (F1 c) to (F8c) or (F1 d) to (F8d), wherein R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22, identical or different, independently represent a hydrogen atom; a halogen atom; a linear or branched Ci-C6 alkyl; a linear or branched -0-Ci-C6 alkyl; a linear or branched -O-C1-C10 alkylaryl; -C(0)OH; - C(0)NH2; -C(0)NH(CH3); or -NHC(0)CH3.
As examples of compounds of formula (A1 c), the invention provides:
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-phenyl-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-methoxyphenyl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[3-(4-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3[4(methylcarbamoyl)phenyl]-6-(trifluoromethyl)phenyl]acetic acid;
- 2-[3-(4-aminophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-[3-(4-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-[3-(3-aminophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-[3-(3-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-propylphenyl)-6- (trifluoromethyl)phenyl]acetic acid;
- 4-{3-[(ie/f-butoxy)(carboxy)methyl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-4- (trifluoromethyl)phenyl}benzoic acid;
- 3-{3-[(ie/f-butoxy)(carboxy)methyl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-4- (trifluoromethyl)phenyl}benzoic acid.
As examples of compounds of formula (A2c), the invention provides:
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(6-propylpyridin-2-yl)-6- (trifluoromethyl)phenyl]acetic acid; - 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-propylpyridin-2-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(pyridin-2-yl)-6- (trifluoromethyl)phenyl]acetic acid.
As an example of compounds of formula (A4b), the invention provides 2-(ie f-butoxy)-
2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3-(pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid. As examples of compounds of formula (A4c), the invention provides:
- 2-{3-[2-(benzyloxy)pyridin-4-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl}-2-(ie f-butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-fluoropyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(2-propylpyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(pyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid. As an example of compounds of formula (A3c), the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyridin-3-yl)-6- (trifluoromethyl)phenyl]acetic acid.
As an example of compounds of formula (A6c), the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyrimidin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid.
As an example of compounds of formula (A9c), the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyridazin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid.
As an example of compounds of formula (B1 c), the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(thiophen-2-yl)-6- (trifluoromethyl)phenyl]acetic acid. As an example of compounds of formula (B2c), the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2,5-dimethyl-thiophen-3-yl)-6- (trifluoromethyl)phenyl]acetic acid. As examples of compounds of formula (B5c), the invention provides:
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-5- yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1 -methyl-3- (trifluoromethyl)-l H-pyrazol-5-yl]-6-(trifluoromethyl) phenyl]acetic acid.
As an example of compounds of formula (B6c), the invention provides:
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-3- yl)-6-(trifluoromethyl)phenyl]acetic acid. As an example of compounds of formula (B7b), the invention provides:
- 2-(ie/f-butoxy)-2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3-(1 -methyl-1 H-pyrazol-4-yl)- 6-(trifluoromethyl)phenyl]acetic acid.
As examples of compounds of formula (B7c), the invention provides:
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-4- yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-{2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1-(2,2,2-trifluoroethyl)- 1 H-pyrazol-4-yl]-6-(trifluoromethyl)phenyl}acetic. As an example of compounds of formula (B8b), the invention provides 2-(iert-butoxy)- 2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3-(1 H-pyrazol-1-yl)-6- (trifluoromethyl)phenyl]acetic acid.
As examples of compounds of formula (B8c), the invention provides:
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 - yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid;
- 2-[3-(4-chloro-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[3-(dimethylamino)-1 H- pyrazol-1 -yl]-6-(trifluoromethyl)phenyl]acetic acid; - 2-(fe/f-butoxy)-2-[2-(3,4-dihydro^
pyrazol-1 -yl]-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1 - yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1 - yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-methyl-1 H-pyrazol-1 - yl)-6-(trifluoromethyl)phenyl]acetic acid.
As an example of compounds of formula (B9c), the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 H-imidazol-1 -yl)-6- (trifluoromethyl)phenyl]acetic acid.
As examples of compounds of formula (B10c), the invention provides:
- 2-[3-(1 ,3-benzothiazol-2-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,3-thiazol-2-yl)-6- (trifluoromethyl)phenyl]acetic acid.
As an example of compounds of formula (B1 1 c), the invention provides 2-(ierf- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,2-thiazol-4-yl)-6- (trifluoromethyl)phenyl]acetic acid.
As an example of compounds of formula (B12c), the invention provides 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-imidazol-4-yl)-6- (trifluoromethyl)phenyl]acetic acid. As example of compounds of formula (B13c), the invention provides 2-(ie f-butoxy)-2- [2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-{pyrazolo[1 ,5-a]pyridin-3-yl}-6- (trifluoromethyl)phenyl]acetic acid.
As an example of compounds of formula (B14c), the invention provides 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-pyrrol-3-yl)-6- (trifluoromethyl)phenyl]acetic acid. As an example of compounds of formula (B15c), the invention provides 2-(ie f- butoxy)-2-[3-(cyclopent-1-en-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid. As an example of compounds of formula (C3c), the invention provides 2-(iert-butoxy)- 2-{3-[1 -(cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-2-yl]-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetic acid.
As an example of compounds of formula (C5c), the invention provides 2-(ie f-butoxy)- 2-{3-[1 -(cyclobutylmethyl)-2-oxo-1 ,2-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl) phenyl}acetic acid.
As examples of compounds of formula (C6c), the invention provides:
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-methyl-1 H-pyridin-2- one-5-yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(6-oxo-1-propyl-1 ,6- dihydropyridin-3-yl)-6-(trifluoromethyl)phenyl]acetic ;
- 2-[3-(1 -benzyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic ;
- 2-(ie/f-butoxy)-2-{3-[1 -(cyclopropylmethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetic acid;
- 2-(ie/f-butoxy)-2-{3-[1 -(cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl}acetic acid;
- 2-(ie/f-butoxy)-2-{3-[1 -(2-cyclopropylethyl)-6-oxo-1 , 6-d ihyd ropy rid in-3-yl]-2-(3 ,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoro methyl)phenyl}acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[1 -(2-methylpropyl)-6- oxo-1 ,6-dihydropyridin-3-yl]-6-(trifluoromethyl) phenyl]acetic acid ;
- 2-(ie/f-butoxy)-2-[3-(1 -cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-methylphenyl] acetic acid;
- 2-(ie/f-butoxy)-2-[3-(1 -cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)-6-methyl-2- [5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]phenyl]acetic acid; or
- 2-(ie f-butoxy)-2-[3-(1 -cyclopropyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro- 2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetic acid. As an example of compounds of formula (C8c), the invention provides 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -ethyl-2-oxo-1 ,2-dihydropyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic . As an example of compounds of formula (C9c), the invention provides 2-(ie f-butoxy)- 2-[3-(cyclohex-1 -en-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid.
Examples
The following examples are provided for the purpose of illustrating the present invention and by no means should be interpreted to limit the scope of the present invention.
The first part represents the preparation of the compounds (intermediates and final compounds) whereas the second part describes the evaluation of antiviral activity of compounds according to the invention.
Preparation of the compounds
Abbreviations or symbols used herein include:
DMSO: dimethylsulfoxide
MS: Mass Spectrometry
NMR: Nuclear Magnetic Resonance Spectroscopy
s: singlet
bs: broad singlet
d: doublet
t: triplet
q: quadruplet
dd: doubled doublet
ddd: doubled doubled doublet
dt: doubled triplet
m: massif
TLC: Thin Layer Chromatography Example 1 : synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- phenyl-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate 1-fluoro-2-(methoxymethoxy)-4-(trifluoro methyl)benzene (1a)
To a solution of 2-fluoro-5-(trifluoromethyl)phenol (2,0 g, 1 1 .1 mmol) in anhydrous dichloromethane (20 mL) under nitrogen atmosphere at 0°C were successively added diisopropylethylamine (3.87 mL, 22.2 mmol) and chloromethyl methyl ether (1.26 mL, 16.6 mmol). The mixture was stirred at 0°C for 45 minutes before adding water (20 mL). Layers were separated and the aqueous one was extracted with dichloromethane (30 mL). The combined organic layers were washed with a 2 M sodium hydroxide solution (20 mL), dried over sodium sulfate and concentrated in vacuo to provide 1 -fluoro-2-(methoxymethoxy)-4-(trifluoromethyl)benzene (1a) (2.49 g, 1 1.1 mmol, 100%) as a lightly yellow oil.
1H NMR (400 MHz, CDCI3) δ 3.53 (s, 3H), 5.25 (s, 2H), 7.16-7.20 (m, 1 H), 7.24-7.27 (m, 1 H), 7.46 (dd, J = 1 .8 Hz, J = 7.4 Hz, 1 H).
Step 2: preparation of intermediate ethyl 2-[3-fluoro-2-(methoxymethoxy)-6- (trifluoromethyl)phenyl]-2-oxoacetate (1 b)
Under nitrogen atmosphere, a 1.6 M n-butyllithium solution in hexanes (3.5 mL, 5.6 mmol) and a 1 M potassium ie f-butoxide solution in tetrahydrofuran (5.6 mL, 5.6 mmol) were added to anhydrous tetrahydrofuran (30 mL) at -78°C. The mixture was stirred for 15 minutes before adding dropwise a solution of 1-fluoro-2- (methoxymethoxy)-4-(trifluoromethyl)benzene (1a) (1.0 g, 4.46 mmol) in tetrahydrofuran (10 mL). The mixture was stirred at -78°C for 2 hours and was added via cannulation to a solution of ethyl oxalyl chloride (1.4 mL, 9.0 mmol) in tetrahydrofuran (20 mL) at -78°C. The mixture was stirred at -78°C for 45 minutes and water (50 mL) was added. Layers were separated and the aqueous layer was extracted with ethyl acetate (2x30 mL). The combined organic layers were washed with a saturated solution of sodium hydrogenocarbonate (30 mL), brine (30 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 90/10) to provide ethyl 2-[3- fluoro-2-(methoxymethoxy)-6-(trifluoromethyl)phenyl]-2-oxoacetate (840 mg, 2.59 mmol, 58%) (1 b) as a yellow oil.
1H NMR (300 MHz, CDCI3) δ 1.36 (t, J = 7.2 Hz, 3H), 3.45 (s, 3H), 4.38 (q, J = 7.2 Hz, 2H), 5.16 (s, 2H), 7.28-7.34 (m, 1 H), 7.43 (dd, J = 4.4 Hz, J = 8.8 Hz, 1 H).
Step 3: preparation of intermediate ethyl 2-[3-fluoro-2-hydroxy-6- (trifluoromethyl)phenyl]-2-oxoacetate (1 c)
To a solution of ethyl 2-[3-fluoro-2-(methoxymethoxy)-6-(trifluoromethyl)phenyl]-2- oxoacetate (1 b) (500 mg, 1.54 mmol) and p-toluenesulfonic acid (59 mg, 0.31 mmol) in dichloromethane (7.5 mL) and ethanol (1 .5 mL) was heated at 50°C overnight. The mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 60/40) to provide ethyl 2-[3- fluoro-2-hydroxy-6-(trifluoromethyl)phenyl]-2-oxoacetate (1 c) (394 mg, 1 .40 mmol, 91 %) as a yellow oil.
1H NMR (300 MHz, CDCI3) δ 1.38 (t, J = 7.2 Hz, 3H), 4.38 (q, J = 7.2 Hz, 2H), 6.91 (d, J = 2.7 Hz), 7.26-7.35 (m, 2H).
Step 4: preparation of intermediate ethyl 2-{3-fluoro-2-[(trifluoromethane) sulfonyloxy]-6-(trif luoromethyl)phenyl}-2-oxoacetate (1 d)
To a solution of ethyl 2-[3-fluoro-2-hydroxy-6-(trifluoromethyl)phenyl]-2-oxoacetate (394 mg, 1.41 mmol) (1c) in anhydrous dichloromethane (5 mL) under nitrogen atmosphere at -78°C were successively added triethylamine (0.24 mL, 1.69 mmol) and triflic anhydride (0.26 mL, 1.55 mmol). The mixture was stirred at -78°C for 45 minutes before adding water (10 mL). Layers were separated. The aqueous layer was extracted with dichloromethane (10 mL). The combined organic layers were washed with a saturated solution of sodium hydrogenocarbonate (10 mL), dried over sodium sulfate and concentrated in vacuo to ethyl 2-{3-fluoro-2- [(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl)phenyl}-2-oxoacetate (1d) (548 mg, 1.32 mmol, 94%) as a yellow oil which was used without further purification.
1H NMR (300 MHz, CDCI3) δ 1.37 (t, J = 7.2 Hz, 3H), 4.42 (q, J = 7.2 Hz, 2H), 7.55 (t, J = 8.7 Hz), 7.78 (dd, J = 4.5 Hz, J = 8.7 Hz,1 H).
Step 5: preparation of intermediate 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro- 6-(trifluoromethyl)phenyl]-2-oxoacetic acid (1e)
A degassed solution of ethyl 2-{3-fluoro-2-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl}-2-oxoacetate (1d) (8.0 g, 19.41 mmol), potassium carbonate (10.73 g, 77.63 mmol), 6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)chroman (6.56 g, 25.23 mmol) and palladium tetrakis(triphenylphosphine) (2.24 g, 1.94 mmol) in dioxane (167 mL) and water (33.5 mL) was heated at 85°C for 20 hours. Water (30 mL) was added and the reaction mixture was heated at 85°C for 1 h more. Water (170 mL) was added and dioxane was evaporated in vacuo. Diethyl ether (2x80 mL) was added and the layers were separated. The organic layer was washed with a saturated solution of sodium hydrogenocarbonate (170mL). The combined aqueous layers were acidified with 2N hydrochloric acid until pH 2 then extracted with diethyl ether (2x170 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo to provide 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6-(trifluoromethyl)phenyl]-2- oxoacetic acid (1e) (6.09g, 16.54 mmol, 85%) as a orange oil which was used without further purification.
1H NMR (300 MHz, CDCI3) 51.97-2.04 (m, 2H), 2.77 (t, J = 6.5 Hz, 2H), 4.21 (t, J = 5.2 Hz, 2H), 6.81 (s, 1 H), 6.92 (m, 2H), 7.39 (t, J = 8.6 Hz, 1 H), 7.73 (dd, J = 8.6, 4.8 Hz, 1 H).
Step 6: preparation of intermediate methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (1f)
To a suspension of sodium hydride 60% in oil (340 mg, 14.2 mmol) in anhydrous N,N- dimethylformamide (14 mL) at 0°C under nitrogen atmosphere, was dropwise added anhydrous benzyl alcohol (1 .47 mL, 14.2 mmol). The mixture was stirred at room temperature for 30 minutes before adding dropwise a solution of 2-[2-(3,4-dihydro-2H- 1-benzopyran-6-yl)-3-fluoro-6-(trifluoromethyl)phenyl]-2-oxoacetic acid (1e) (1.306 g, 3.55 mmol) in anhydrous Λ/,/V-dimethylformamide (13 mL) at 0 °C. The dark red mixture was stirred at 60°C for 3 hours. The dark green solution was cooled at 0 °C and water (80 mL) was added cautiously. The resulting basic solution was extracted with diethyl ether (2 x 70 mL). The aqueous phase was acidified with 1 M hydrochloric acid until pH 2, then extracted with with AcOEt (3 x 70 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in toluene and concentrated. The residue was dissolved in cyclohexane (41.0 mL) and methanol (20.5 mL) at 0°C and a 2 M solution of trimethylsilyldiazomethane in diethyl ether (4.4 mL, 8.87 mmol) was added. The mixture was stirred at room temperature for 30 minutes before adding acetic acid (0.5mL). The mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (120 mL), washed with a saturated solution of sodium hydrogenocarbonate (120 mL), brine (120 mL), dried over sodium sulfate, concentrated in vacuo an then co-evaporated with toluene to provide methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-6-(trifluoro methyl)phenyl]-2-oxo acetate (1f) (1.31 g, 2.78mmol, 78% ) as a orange oil that was used without further purification.
1H NMR (300 MHz, CDCI3) δ 1.97-2.05 (m, 2H), 2.75 (t, J = 6.4 Hz, 2H), 3.55 (s, 3H), 4.19-4.22 (m, 2H), 5.15 (s, 2H), 6.80 (d, J = 8.4 Hz, 1 H), 6.85 (d, J = 2.1 Hz, 1 H), 6.99 (dd, J = 2.1 Hz, J = 8.4 Hz, 1 H), 7.1 1 (d, J = 8.7 Hz, 1 H), 7.23-7.36 (m, 5H), 7.65 (d, J = 8.7 Hz, 1 H).
Step 7: preparation of intermediate methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (1g)
To a solution of methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-oxoacetate (1f) (1.32 g, 2.81 mmol) in tetrahydrofurane (44 mL) at 0 °C was added portion-wise sodium borohydride (159 mg, 4.21 mmol). The mixture was stirred at 0 °C for 90 minutes. Acetic acid (0.5 mL) was added, followed by water (60 mL). The resulting solution was extracted with ethyl acetate (3 x 50 mL). The organic layer was washed with brine (30 mL) and dried over sodium sulfate. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 80/20) to provide methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (1g) (1.04 g, 2.20 mmol, 78%).
1H NMR (300 MHz, CDCI3) δ 2.01-2.09 (m, 2H), 2.75-2.82 (m, 2H), 3.57 and 3.60 (2 s, 3H), 4.24 (t, J = 5.1 Hz, 2H), 5.07 (s, 2H), 5.38 (bs, 1 H), 6.79-6.85 (m, 2H), 6.97- 7.14 (m, 4H), 7.24-7.31 (m, 3H), 7.65 (d, J = 8.7 Hz, 1 H).
Step 8: preparation of intermediate methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert-butoxy)acetate (1 h)
Under nitrogen, methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (1g) (5.36 g, 1 1.35 mmol) was dissolved in ie/f-butyl acetate (142 mL), cooled at 0 °C and 70% perchloric acid (2.94 mL, 34.04 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. Then the reaction mixture was poured into a saturated solution of sodium hydrogenocarbonate. The mixture was extracted with ethyl acetate. The resulting organic layer was washed with brine, dried over sodium sulfate and concentrated in vacuo. The crude mixture was purified by DCVC (Dry Column Vacuum Chromatography, using 250 mL Silicagel, cyclohexane/ethyl acetate 100/0 to 60/40) to provide methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetate (1 h) (3.58 g, 6.77 mmol, 58%) as a yellow oil.
1H NMR (300 MHz, CDCI3) δ 0.99 and 1.36 and 1.37 (s, 9H), 2.00-2.09 (m, 2H), 2.70- 2.85 (m, 2H), 3.59 and 3.61 and 3.69 and 3.70 (s, 3H), 4.22-4.27 (m, 2H), 5.00-5.41 (m, 3H), 6.81-7.32 (m, 9H), 7.63-7.70 (m, 1 H).
Step 9: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-hydroxy-6-(trifluoromethyl)phenyl]acetate (1 i)
A solution of methyl 2-[3-(benzyloxy)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetate (1 h) (3.48g, 6.57 mmol) in ethyl acetate (130 mL) was passed through the H-Cube (0.8mL/min, full H2 mode, 40 °C). The resulting solution was concentrated in vacuo to provide methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-hydroxy-6-(trifluoromethyl)phenyl]acetate (1i) (2.62 g, 5.97 mmol, 91 %) as a white solid.
1H NMR (300 MHz, CDCI3) 51.00 and 1 .01 (s, 9H), 2.05 (m, 2H), 2.78 (m, 2H), 3.66 (s, 3H), 4.25 (m, 2H), 5.04 and 5.05 (s, 1 H), 5.10 and 5.13 (s, 1 H), 6.89-6.93 (m, 2H), 6.99 (d, J = 10.0 Hz, 1 H), 7.08-7.1 1 (m, 1 H), 7.62 (d, J = 8.7 Hz, 1 H).
MS m/z ([M-H]-) 437.
Step 10: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl)phenyl]acetate
(1j)
To a solution of methyl 2-(fe/t-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- hydroxy-6-(trifluoromethyl)phenyl]acetate (1i) (1.00 g, 2.28 mmol) in anhydrous dichloromethane (16 mL) under nitrogen atmosphere at -78°C were successively added triethylamine (0.95 mL, 6.84 mmol) and triflic anhydride (0.48 mL, 2.85 mmol). The colorless solution was stirred at -78°C for 45 minutes before adding water (30mL). The layers were separated. The aqueous layer was extracted with dichloromethane (30mL). The combined organic layers were washed with a saturated solution of sodium hydrogenocarbonate (30 mL), dried over sodium sulfate and concentrated in vacuo to provide methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6-(tr^
(1j) (1.30 g, 2.28 mmol, 100%) as a orange oil.
1H NMR (300 MHz, CDCI3) δ 0.98 and 0.99 (s, 9H), 1.98-2.10 (m, 2H), 2.65-2.85 (m, 2H), 3.70 (s, 3H), 4.20-4.28 (m, 2H), 5.12 (s, 1 H), 6.80-7.05 (m, 3H), 7.42 (d, J = 8.7 Hz, 1 H), 7.80 (d, J = 8.7 Hz, 1 H).
Step 11 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-phenyl-6-(trifluoromethyl)phenyl]acetate (1 k)
A degassed solution of methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6- yl)-3-[(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl)phenyl]acetate (1j) (200 mg, 0.351 mmol), potassium carbonate (194 mg, 1.40 mmol), phenylboronic acid (52.3 mg, 0.421 mmol) and palladium tetrakis(triphenylphosphine) (40.5 mg, 0.035 mmol) in dioxane (3 mL) and water (0.6 mL) was heated at 85°C overnight. Water (2 mL) was added and dioxane was evaporated in vacuo. The aqueous residue was extracted with ethyl acetate (3 x 4 mL). The combined organics were washed with a saturated solution of sodium hydrogenocarbonate (4 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane/ethyl acetate 90/10) to provide methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro- 2H-1 -benzopyran-6-yl)-3-phenyl-6-(trifluoromethyl)phenyl]acetate (1 k) (128mg, 0.264 mmol, 73%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.95 (s, 9H), 1.84-1.89 (m, 1 H), 1 .98-2.04 (m, 1 H), 2.30- 2.54 (m, 1 H), 2.66-2.80 (m, 1 H), 3.74 (s, 3H), 4.08-4.18 (m, 2H), 5.17 and 5.19 (s, 1 H), 6.39-6.72 (m, 2H), 7.0-7.03 (m, 2 H), 7.10-7.16 (m, 4H), 7.43 (bs, 1 H), 7.75 (d, J = 8.1 Hz, 1 H).
Step 12: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- phenyl-6-(trifluoromethyl)phenyl]acetic acid (example 1)
A lithium hydroxide aqueous solution (2N, 257 μί, 0.513 mmol) was added to a solution of methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-phenyl-6- trifluoromethyl)phenyl]acetate (1 k) (128 mg, 0.256 mmol) in a mixture of tetrahydrofurane (1 .5 mL) and methanol (1.5 mL). The mixture was then heated at 60 °C for 4 hours. The mixture was cooled at room temperature, a lithium hydroxide aqueous solution (2N, 257 μί, 0.513 mmol) was added and the resulting solution was further stirred at 70 °C for 3 hours. A lithium hydroxide aqueous solution (2N, 257 μί, 513 μηηοΙ) was added and the solution was further stirred at 50 °C. The organics were removed in vacuo then dioxane was added (1 .5 mL). The resulting solution was heated at 100 °C under stirring for 6 hours, then placed at 4 °C for 3 days. The solution was then further heated at 100 °C under stirring for 6 hours. The solvents were removed and the residue partially dissolved in water (10 mL). The solution was washed with diethyl ether. The aqueous phase was acidified with HCI 1 N until pH 2 and then extracted with ethyl acetate. The combined organic layers (diethyl ether and ethyl acetate) were dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (pentane/ethyl acetate/acetic acid 70/30/0.07) to provide 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-phenyl-6-(trifluoro methyl)phenyl]acetic acid (example 1 ) (85 mg, 0.175 mmol, 68%) as a white foam. 1H NMR (300 MHz, CDCI3) δ 0.97 (s, 9H), 1.80-2.05 (m, 2H), 2.20-2.60 and 2.75-2.85 (2 m, 2H), 4.12 and 4.17 (2 t, J = 10.5 Hz, 2H), 5.33 and 5.38 (2 s, 1 H), 6.30-6.50 and and 6.70-6.85 (2 m, 2H), 6.98-7.08 (m, 2H), 7.12-7.20 (m, 3H), 7.45-7.55 (m, 2H), 7.76 (d, J = 8.1 Hz, 1 H), 9.60 (bs, 1 H).
MS m/z ([M-H]-) 483. Example 2: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (pyridin-4-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetate (2a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(iert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (95 mg, 0.166 mmol) is converted by reaction with pyridin-4-ylboronic acid (26 mg, 0.2 mmol) into methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(pyridin-4-yl)-6-(trifluoromethyl) phenyl]acetate (2a) (57 mg, 0.1 14 mmol, 69%) as a white solid, after purification by preparative TLC (cyclohexane/ethyl acetate 70/30).
1H NMR (300 MHz, CDCI3) δ 0.94 and 0.96 (s, 9H),1.87-1 .92 (m, 1 H), 1.98-2.04 (m, 1 H), 2.34-2.57 (m, 1 H), 2.69-2.76 (m, 1 H), 3.74 (s, 3H), 4.1 1 -4.20 (m, 2H), 5.18 (bs, 1 H), 6.37-6.74 (m, 2H), 6.96 (d, J = 6.3 Hz, 2H), 7.09-7.16 (m, 1 H), 7.41 and 7.42 (d, J = 8.2 Hz, 1 H), 7.80 (d, J = 8.2 Hz, 1 H), 8.40 (d, J = 6.3 Hz, 2H).
Step 2: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 2) To a solution of methyl 2-(fe/t-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetate (2a) (57 mg, 0.1 14 mmol) in a mixture of dioxane (1 mL) and water (0.5 mL) was added lithium hydroxide (14 mg, 0.333 mmol). The reaction mixture was heated at 95 °C overnight. Dioxane (0.5mL) and water (0.2 mL) were added and the mixture was stirred at 100°C for 9 hours. Further lithium hydroxide (5 mg, 0.1 1 1 mmol) was added and the mixture was stirred at 100 °C for 3 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. Water (4 mL) was added to the residue and the solution was acidified with a 1 M hydrochloric acid solution until pH 5 followed by extraction with ethyl acetate (4x5mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane/ethyl acetate/acetic acid 20/80/0.1 ) to provide 2-(ie/f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 2) (43mg, 0.088 mmol, 78%) as a beige solid.
1H NMR (300MHz, CDCI3) 5 0.97 (s, 9H), 1.80-2.10 (m, 2H), 2.30-2.90 (m, 2H), 4.10- 4.25 (m, 2H), 5.32 and 5.35 (s, 1 H), 6.30-6.90 (m, 2H), 6.98 (d, J = 5.7 Hz, 2H), 7.40- 7.60 (m, 2H), 7.81 (d, J = 8.1 Hz, 1 H), 8.42 (d, J = 5.7 Hz, 2H).
MS m/z ([M+H]+) 486.
MS m/z ([M-H]-) 484.
Example 3: synthesis of 2-(te f-butoxy)-2-r3-(cvclopent-1 -en-1 -yl)-2-(3,4-dihvdro-2H- -benzopyran-6-yl)-6-(trifluoromethyl)phenvHacetic acid
Step 1 : preparation of intermediate methyl 2-(fe/t-butoxy)-2-[3-(cyclopent-1 -en-1 -yl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (3a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (120 mg, 0.210 mmol) is converted by reaction with 1-cyclopentenyl boronic acid (28 mg, 0.252 mmol) into methyl 2-(ie f-butoxy)-2- [3-(cyclopent-1 -en-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (3a) (69 mg, 0.141 mmol, 67%) as a colourless oil, after purification by preparative TLC (cyclohexane/ethyl acetate 90/10). 1H NMR (300 MHz, CDCI3) δ 0.95 (s, 9H), 1.61-1.92 (m, 3H), 1 .95-2.13 (m, 3H), 2.18- 2.33 (m, 2H), 2.64-2.84 (m, 2H), 3.69 (s, 3H), 4.23 (t, J = 5.2 Hz, 2H), 5.14 and 5.16 (s, 1 H), 5.48-5.57 (m, 1 H), 6.71-6.85 (m, 2H), 7.00-7.10 (m, 1 H), 7.34 (d, J = 8.2 Hz, 1 H), 7.61 (d, J = 8.2 Hz, 1 H).
Step 2: preparation of 2-(iert-butoxy)-2-[3-(cyclopent-1-en-1-yl)-2-(3,4-di hydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 3)
Using the procedure described in example 2, step 2, the intermediate methyl 2-(tert- butoxy)-2-[3-(cyclopent-1-en-1-yl)-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoro methyl)phenyl]acetate (3a) (69 mg, 0.141 mmol) is converted into 2-(ie f-butoxy)-2-[3- (cyclopent-1-en-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetic acid (example 3) (40 mg, 0.084 mmol, 59%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.96 (s, 9H), 1.45-1.90 (m, 4H), 1 .92-2.12 (m, 2H), 2.12- 2.36 (m, 2H), 2.60-2.91 (m, 2H), 4.12-4.32 (t, J = 4.6 Hz, 2H), 5.28 and 5.32 (s, 1 H), 5.54 (s, 1 H), 6.67-6.87 (m, 2H), 7.30-7.50 (m, 2H), 7.61 (d, J = 8.2 Hz, 1 H), 9.59 (bs, 1 H).
MS m/z ([M-H]-) 473.
Example 4: synthesis of 2-(te f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3-(1- methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenvHacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenyl]acetate (4a) Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (100 mg, 0.175 mmol) is converted by reaction with 1-methylpyrazole-4-boronic acid pinacol ester (43 mg, 0.210 mmol) into methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-4-yl)- 6-(trifluoromethyl)phenyl] acetate (4a) (44 mg, 0.087 mmol, 50%) as a yellow oil, after purification by preparative TLC (cyclohexane/ethyl acetate 25/75). 1H NMR (300MHz, CDCI3) δ 0.97 (s, 9H), 2.04 (m, 2H), 2.67 (m, 2H), 2.76 (m, 2H), 3.68 (s, 3H), 3.74 (s, 3H), 5.14 (s, 1 H), 6.62-6.85 (m, 3H), 7.04 (m, 1 H), 7.09 (s, 1 H), 7.54 (d, J = 8.4 Hz, 1 H), 7.69 (d, J = 8.4 Hz, 1 H).
MS m/z ([M+H]+) 503.
Step 2: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 - methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 4)
Using the procedure described in example 2, step 2, the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 -methyl-1 H-pyrazol-4-yl)-6- (trifluoromethyl)phenyl]acetate (4a) (44 mg, 0.087 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 -methyl-1 H-pyrazol-4-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 4) (30 mg, 0.061 mmol, 70%) as a white solid.
1H NMR (300MHz, CDCI3) δ 1.01 (s, 9H), 1.98-2.08 (m, 2H), 2.65-2.83 (m, 2H), 3.74 (s, 3H), 4.21 and 4.25 (t, J = 6.0 Hz, 2H), 5.26 (s, 1 H), 6.61-6.73 (m, 3H), 7.1 1 and 7.19 (s, 1 H), 7.40 (m, 1 H), 7.57 (d, J = 8.4 Hz, 1 H), 7.60 (d, J = 8.4 Hz, 1 H), 9.59 (bs, 1 H).
MS m/z ([M+H]+) 489.
MS m/z ([M-H]") 487.
Example 5: synthesis of 2-(te -butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3-(3- phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran 3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (5a) To a solution of 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetic acid (1e) (124 mg, 0.34 mmol) and 3-phenyl-1 H- pyrazole (97 mg, 0.67 mmol) in anhydrous dimethylacetamide (2 mL) at room temperature under nitrogen atmosphere, was added sodium hydride 60% in oil (40 mg, 1.01 mmol). The reaction mixture was heated at 90°C overnight then poured in water (10 mL). The mixture was acidified with 1 M hydrochloric acid until pH 2 and extracted with ethyl acetate (2x10 mL). The organic layer was washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in a mixture of methanol (2 mL) and cyclohexane (4 mL) and a 2 M solution of tnmethylsilyldiazomethane in diethyl ether (0.5 mL, 1 mmol) was added. The mixture was stirred at 0°C for 30 minutes and a few drops of acetic acid was added. The mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (10 mL) and washed with a saturated solution of sodium hydrogenocarbonate (10 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane/ethyl acetate 75/25) to provide methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-oxoacetate (5a) (42 mg, 0.082 mmol, 24%) as a white solid. 1H NMR (300 MHz, CDCI3) δ 1.94-2.02 (m, 2H), 2.62-2.77 (m, 2H), 3.55 (s, 3H), 4.17- 4.21 (m, 2H), 6.49 (d, J = 2.5 Hz, 1 H), 6.70-6.78 (m, 3H), 6.98 (d, J = 2.5 Hz, 1 H), 7.34-7.44 (m, 3H), 7.81-7.87 (m, 3H), 8.08 (d, J = 8.5 Hz, 1 H).
MS m/z ([M+H]+) 507.
Step 2: preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (5b)
To a solution of methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-phenyl-1 H- pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (5a) (42 mg, 0.082 mmol) in anhydrous methanol (3 mL) at 0°C was added sodium borohydride (6.1 mg, 0.153 mmol). The mixture was stirred at room temperature for 45 minutes before adding water (2 mL). Methanol was evaporated in vacuo. The resulting solution was extracted with ethyl acetate (2x5 mL). The organic layer was washed with brine (5 mL) and dried over sodium sulfate to provide methyl 2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxy acetate (5b) (42 mg, 0.082 mmol, 100%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.90-2.07 (m, 2H), 2.50-2.67 (m, 1 H), 2.69-2.84 (m, 1 H), 3.23 (bs, 1 H), 3.51 and 3.54 (s, 3H), 4.16-4.23 (m, 2H), 5.46 and 5.47 (s, 1 H), 6.40- 6.42 (m, 1 H), 6.57-6.80 (m, 2H), 6.91-6.92 (m, 1 H), 7.17-7.20 (m, 1 H), 7.31-7.42 (m, 3H), 7.77-7.81 (m, 2H), 7.85-7.92 (m, 2H). MS m/z ([M+H]+) 509.
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetate (5c) Using the procedure described in example 1 , step 8, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl) phenyl]-2-hydroxy acetate (5b) (42 mg, 0.082 mmol) is converted into methyl 2-(ierf- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (5c) (21 mg, 0.037 mmol, 44%) as a colorless oil, after purification by preparative TLC (cyclohexane/ethyl acetate 80/20).
1H NMR (400 MHz, CDCI3) δ 0.95 and 0.96 (s, 9H), 1.89-1 .95 (m, 1 H), 2.01 -2.07 (m, 1 H), 2.46-2.62 (m, 1 H), 2.71-2.85 (m, 1 H), 3.74 (s, 3H), 4.16-4.23 (m, 2H), 5.21 (s, 1 H), 6.41 and 6.42 (d, J = 2.5 Hz, 1 H), 6.64-6.84 (m, 2H), 6.90 and 6.93 (d, J = 2.5 Hz, 1 H), 7.18-7.23 (m, 1 H), 7.31-7.42 (m, 3H), 7.79-7.85 (m, 4H).
Step 4: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3- phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetic acid (example 5)
A solution of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-phenyl-1 H- pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetate (5c) (21 mg, 0.037 mmol) and potassium hydroxide (21 mg, 0.37 mmol) in a mixture of ethanol (3 mL) and water (1 mL) was stirred at 100°C for 18 hours. Ethanol was evaporated in vacuo. The residue was diluted with water (2 mL) and washed with pentane (5 mL). The aqueous layer was acidified with 1 M hydrochloric acid was added until pH 1 and extracted with diethyl ether (2x5 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (dichloromethane/methanol 95/5) to provide 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetic acid (example 5) (1 1 mg, 0.020 mmol, 55%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.96 (s, 9H), 1.88-1.94 (m, 1 H), 2.01-2.07 (m, 1 H), 2.44- 2.65 (m, 1 H), 2.84-2.86 (m, 1 H), 3.74 (s, 3H), 4.16-4.25 (m, 2H), 5.33 and 5.37 (s, 1 H), 6.41 and 6.43 (d, J = 2.5 Hz, 1 H), 6.63-6.90 (m, 3H), 7.31-7.43 (m, 3H), 7.58 (bs, 1 H), 7.80-7.93 (m, 4H).
MS m/z ([M+H]+) 551. Example 6: synthesis of 2-{3-r2-(benzyloxy)pyridin-4-yll-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl)-2-(te f-butoxy)acetic acid
Step 1 : preparation of intermediate methyl 2-{3-[2-(benzyloxy)pyridin-4-yl]-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl}-2-(iert-butoxy)acetate (6a) Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (120 mg, 0.210 mmol) is converted by reaction with 2-(benzyloxy)-4-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (78 mg, 0.252 mmol) into methyl 2-{3-[2-(benzyloxy)pyridin-4-yl]-2-(3,4-dihydro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl) phenyl}-2-(iert-butoxy) acetate (6a) (74 mg, 0.122 mmol, 58%) as a light yellow oil after purification by preparative TLC (cyclohexane/ethyl acetate 85/15).
1H NMR (300 MHz, CDCI3) δ 0.95 (s, 9H), 1.82-2.02 (m, 2H), 2.34-2.83 (m, 2H), 3.73 (s, 3H), 4.05-4.26 (m, 2H), 5.19 (s, 1 H), 5.24-5.41 (m, 2H), 6.40-6.84 (m, 4H), 7.05- 7.18 (m, 1 H), 7.29-7.52 (m, 6H), 7.76 (d, J = 8.2 Hz, 1 H), 7.91 (m, 1 H)
Step 2: preparation of 2-{3-[2-(benzyloxy)pyridin-4-yl]-2-(3,4-dihydro-2H-1-benzo pyran-6-yl)-6-(trifluoromethyl)phenyl}-2-(ie f-butoxy)acetic acid (example 6)
Using the procedure described in example 2, step 2, the methyl 2-{3-[2- (benzyloxy)pyridin-4-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoro
methyl)phenyl}-2-(ie f-butoxy)acetate (6a) (74 mg, 0.122 mmol) is converted into 2-{3- [2-(benzyloxy)pyridin-4-yl]-2-(3,4-dihydro-2H-1-benzopyran -6-yl)-6-(trifluoromethyl) phenyl}-2-(fe/t-butoxy)acetic acid (example 6) (68 mg, 0.1 15 mmol, 94%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.95 (s, 9H), 1.75-2.09 (m, 2H), 2.22-2.93 (m, 2H), 3.93- 4.28 (m, 2H), 5.21-5.46 (m, 3H), 6.35-6.89 (m, 4H), 7.29-7.57 (m, 7H), 7.77 (d, J = 8.2 Hz, 1 H), 7.86-7.99 (m, 1 H), 9.64 (bs, 1 H).
MS m/z ([M+H]+) 592.
Example 7: synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (thiophen-2-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(thiophen-2-yl)-6-(trifluoromethyl)phenyl]acetate (7a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (120 mg, 0.210 mmol) is converted by reaction with (thiophen-2-yl)boronic acid (32 mg, 0.252 mmol) into methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(thiophen-2-yl)-6-(trifluoromethyl) phenyl] acetate (7a) (71 mg, 0.141 mmol, 67%) as a colourless oil after purification by preparative TLC (cyclohexane/ethyl acetate 85/15).
1H NMR (300 MHz, CDCI3) δ 0.99 (s, 9H), 1.90-2.1 1 (m, 2H), 2.53-2.83 (m, 2H), 3.70 and 3.71 (s, 3H), 4.16-4.28 (m, 2H), 5.16 (s, 1 H), 6.64-6.70 (m, 4H), 7.07-7.13 (m, 1 H), 7.13-7.23 (m, 1 H), 7.58-7.76 (m, 2H). Step 2: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (thiophen-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 7)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(thiophen-2-yl)-6-(trifluoromethyl)phenyl] acetate (7a) (65 mg, 0.128 mmol) is converted into 2-(ie f-butoxy)-2-[2-(3,4-dihydro- 2H-1 -benzopyran-6-yl)-3-(thiophen-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 7) (62 mg, 0.126 mmol, 98%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.00 (s, 9H), 1.87-2.16 (m, 2H), 2.41-2.93 (m, 2H), 4.02- 4.39 (m, 2H), 5.30 (bs, 1 H), 6.61-6.78 (m, 4H), 6.79-6.93 (m, 1 H), 7.37-7.53 (m, 1 H), 7.62-7.78 (m, 2H), 9.57 (bs, 1 H).
MS m/z ([M-H]-) 489.
Example 8: synthesis of 2-(te/ -butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3-(4- methoxyphenyl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(4-methoxyphenyl)-6-(trifluoromethyl)phenyl]acetate (8a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (100 mg, 0.175 mmol) is converted by reaction with (4-methoxyphenyl)boronic acid (32 mg, 0.210 mmol) into methyl 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-methoxyphenyl)-6-(trifluoromethyl) phenyl]acetate (8a) (71 mg, 0.134 mmol, 76%) as a colourless oil, after purification by preparative TLC (cyclohexane/ethyl acetate 80/20).
1H NMR (300MHz, CDCI3) δ 0.94 (s, 9H), 1.90-2.04 (m, 2H), 2.45-2.72 (m, 2H), 3.73 (s, 3H), 3.75 (s, 3H), 4.12-4.18 (m, 2H), 5.17 (bs, 1 H), 6.42-6.68 (m, 4H), 6.94 (m, 2H), 7.10 (m, 1 H), 7.25-7.50 (m, 1 H), 7.71-7.74 (m, 1 H).
MS m/z ([M+Na]+) 551.
Step 2: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4- methoxyphenyl)-6-(trifluoromethyl)phenyl]acetic acid (example 8)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(4-methoxyphenyl)-6-(trifluoromethyl) phenyl]acetate (8a) (71 mg, 0.134 mmol) is converted into 2-(ie/f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(4-methoxyphenyl)-6-(trifluoromethyl)phenyl]acetic acid (example 8) (65 mg, 0.126 mmol, 94%) as a white solid.
1H NMR (300MHz, CDCI3) 5 0.96 (s, 9H), 1.87-1.91 (m, 1 H), 1.98-2.01 (m, 1 H), 2.43- 2.50 (m, 1 H), 2.79-2.81 (m, 1 H), 3.76 (s, 3H), 4.12-4.20 (m, 2H), 5.32 and 5.35 (s, 1 H), 6.40-6.75 (m, 4H), 6.95 (d, J = 8.7 Hz, 2H), 7.42-7.44 (m, 2H), 7.74 (d, J = 8.1 Hz, 1 H), 9.60 (bs, 1 H).
MS m/z ([M+Na]+) 537.
MS m/z ([M-H]") 513. Example 9: synthesis of 2-r3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4-dihvdro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyll-2-(te -butoxy)acetic acid
Step 1 : preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran 3-fluoro-6-(trifluoromethyl)phenyl]-2-oxoacetate (9a)
A degassed solution of ethyl 2-{3-fluoro-2-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl}-2-oxoacetate (1d) (478 mg, 1 .16 mmol), potassium carbonate (641 mg, 4.64 mmol), 6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)chroman (392 mg, 1.51 mmol) and palladium tetrakis(triphenylphosphine) (134 mg, 0.12 mmol) in dioxane (10 mL) and water (2 mL) was heated at 85°C overnight. Water (10 mL) was added and dioxane was evaporated in vacuo. Diethyl ether (10 mL) was added and the layers were separated. The organic layer was washed with a saturated solution of sodium hydrogenocarbonate (10 mL). The combined aqueous layers were acidified with 37% hydrochloric acid until pH 2 then extracted with diethyl ether (2x20 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in cyclohexane (5 mL) and methanol (2.5 mL) at 0°C and a 2M solution of trimethylsilyldiazomethane in diethyl ether (4 mL, 8 mmol) was added. The reaction mixture was stirred at room temperature for 15 minutes, cooled at 0°C and acetic acid was added until the end of bubbling. The reaction mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (10 mL), washed with a saturated solution of sodium hydrogenocarbonate (10 mL), brine (10 mL), dried over sodium sulfate and concentrated in vacuo to provide methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- fluoro-6-(trifluoromethyl)phenyl]-2-oxoacetate (9a) (343 mg, 0.90 mmol, 77%) as a yellow solid which was used without further purification.
1H NMR (400 MHz, CDCI3) δ 1.98-2.04 (m, 2H), 2.77 (t, J = 6.4 Hz, 2H), 3.57 (s, 3H), 4.19-4.22 (m, 2H), 6.81 (d, J = 8.4 Hz, 1 H), 6.86 (d, J = 1.0 Hz, 1 H), 6.95 (dd, J = 1.0 Hz, J = 8.4 Hz, 1 H), 7.35 (t, J = 8.6 Hz, 1 H), 7.73 (dd, J = 4.8 Hz, J = 8.6 Hz, 1 H).
Step 2: preparation of intermediate methyl 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (9b) To a solution of methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetate (9a) (300 mg, 0.78 mmol) and 4-bromo-1 H- pyrazole (231 mg, 1.57 mmol) in anhydrous dimethylacetamide (3 mL), under nitrogen atmosphere, was added sodium hydride 60% in oil (94 mg, 2.35 mmol). The mixture was heated at 70°C for 1 hour then at 100°C for 4 hours. The mixture was then poured in water (10 mL) and 1 M hydrochloric acid was added until pH 2. The reaction mixture was extracted with ethyl acetate (2x10 mL). The organic layer was washed with brine (5 mL), dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in a mixture of cyclohexane (6 mL) and methanol (3 mL) at 0°C and a 2 M solution of trimethylsilyldiazomethane in diethyl ether (1 mL, 2.0 mmol) was added. The mixture was stirred at room temperature for 30 minutes before adding a few drops of acetic acid. The mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (10 mL), washed with a saturated solution of sodium hydrogenocarbonate (10 mL), brine (10 mL), dried over sodium sulfate and concentrated in vacuo The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 85/15) to provide methyl 2-[3-(4-bromo-1 H-pyrazol-1 -yl)-2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (9b) (200 mg, 0.39 mmol, 50%).
1H NMR (400 MHz, CDCI3) δ 1.96-2.03 (m, 2H), 2.67-2.71 (m, 2H), 3.55 (s, 3H), 4.19- 4.22 (m, 2H), 6.67-6.74 (m, 3H), 6.98 (s, 1 H), 7.59 (s, 1 H), 7.84 (d, J = 8.6 Hz, 1 H), 7.90 (d, J = 8.6 Hz, 1 H).
MS m/z ([M+H]+) 509/51 1 .
Step 3: preparation of intermediate methyl 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (9c)
Using the procedure described in example 5, step 2, the intermediate methyl 2-[3-(4- bromo-1 H-pyrazol-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]-2-oxoacetate (9b) (200 mg, 0.39 mmol) is converted into methyl 2-[2-(3,4- dihydro-2/-/-1-benzopyran-6-yl)-3-(4-bromo-1 H-pyrazol-1-yl)-6-(trifluoromethyl) phenyl]-2-hydroxyacetate (9c) (196 mg, 0.38 mmol, 97%).
1H NMR (300 MHz, CDCI3) δ 1.94-2.07 (m, 2H), 2.60 (t, J = 6.6 Hz, 1 H), 2.76 (t, J = 6.6 Hz, 1 H), 3.52 and 3.55 (s, 3H), 4.18-4.24 (m, 2H), 5.44 and 5.45 (s, 1 H), 6.47- 6.55 (m, 1 H), 6.66 and 6.80 (d, J = 8.4 Hz, 1 H), 6.87 and 6.90 (s, 1 H), 7.09-7.16 (m, 1 H), 7.49 and 7.50 (s, 1 H), 7.71 and 7.73 (d, J = 8.5 Hz, 1 H), 7.85 (d, J = 8.5 Hz, 1 H). MS m/z ([M+H]+) 51 1/513. Step 4: preparation of intermediate methyl 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (9d) To a solution of methyl 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (9c) (196 mg, 0.38 mmol) in fe/t-butyl acetate (2 mL) at 0°C was added perchloric acid (0.25 mL). The mixture was stirred at 0°C for 2 hours and 30 minutes before being poured into a saturated aqueous solution of sodium hydrogenocarbonate (15 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 10 mL). The organic layers were washed with brine, dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane/ethyl acetate 80/20) to provide methyl 2-[3-(4-bromo-1 H-pyrazol-1 -yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert-butoxy)acetate (9d) (1 15 mg, 0.20 mmol, 53%) as a colorless oil.
1H NMR (400 MHz, CDCI3) δ 0.94 and 0.95 (s, 9H), 1.94-2.07 (m, 2H), 2.50-2.65 (m, 1 H), 2.67-2.84 (m, 1 H), 3.73 and 3.74 (s, 3H), 4.19-4.24 (m, 2H), 5.17 and 5.20 (s, 1 H), 6.49-6.94 (m, 3H), 7.10-7.18 (m, 1 H), 7.50 and 7.52 (s, 1 H), 7.64-7.69 (m, 1 H), 7.82 and 7.83 (d, J = 8.5 Hz, 1 H).
MS m/z ([M+H]+) 567/569. Step 5: preparation of 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert-butoxy)acetic acid
(example 9)
Using the procedure described in example 5, step 4, methyl 2-[3-(4-bromo-1 H- pyrazol-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f- butoxy)acetate (9d) (85 mg, 0.15 mmol) is converted into 2-[3-(4-bromo-1 H-pyrazol-1- yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoro methyl)phenyl]-2-(ferf- butoxy)acetic acid (example 9) (63 mg, 0.1 1 mmol, 76%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.96 (s, 9H), 1 .95-2.07 (m, 2H), 2.56 (bs, 1 H), 2. 83 (bs, 1 H), 4.19-4.25 (m, 2H), 5.30 and 5.37 (s, 1 H), 6.47-6.93 (m, 3H), 7.50-7.57 (m, 2H), 7.71 -7.76 (m, 1 H), 7.84-7.87 (m, 1 H).
MS m/z ([M+H]+) 553/555.
Example 10: synthesis of 2-r3-(4-chloro-1 H-pyrazol-1 -yl)-2-(3,4-dihvdro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyll-2-(te -butoxy)acetic acid
Step 1 : preparation of intermediate methyl 2-[3-(4-chloro-1 H-pyrazol-1 -yl)-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (10a)
To a solution of methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetate (9a) (201 mg, 0.53 mmol) and 4-chloro-1 H- pyrazole (108 mg, 1.05 mmol) in anhydrous dimethylacetamide (2 mL), under nitrogen atmosphere, was added sodium hydride 60% in oil (63 mg, 1 .58 mmol). The mixture was heated at 100°C for 90 minutes. The reaction mixture was cooled at room temperature and dimethyl sulfate (149 μΙ_, 1 .58 mmol) was added. The mixture was stirred at room temperature for 1 hour then poured in water (10 mL) and extracted with ethyl acetate (2x10 mL). The organic layer was washed with a 2 M sodium hydroxide solution (10 mL), brine (2x10 mL), dried over sodium sulfate and concentrated in vacuo The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 85/15) to provide methyl 2-[3-(4-chloro-1 H-pyrazol-1 -yl)-2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (10a) (130 mg, 0.28 mmol, 53%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 1.97-2.04 (m, 2H), 2.68-2.72 (m, 2H), 3.55 (s, 3H), 4.19- 4.22 (m, 2H), 6.67-6.74 (m, 3H), 6.96 (s, 1 H), 7.56 (s, 1 H), 7.84 (d, J = 8.6 Hz, 1 H), 7.91 (d, J = 8.6 Hz, 1 H).
MS m/z ([M+H]+) 465/467.
Step 2: preparation of intermediate methyl 2-[3-(4-chloro-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (10b) To a solution of methyl 2-[3-(4-chloro-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (10a) (130 mg, 0.28 mmol) in anhydrous dimethyl ethylene glycol (3 mL) at 0°C was added sodium borohydride (21 mg, 0.56 mmol). The mixture was stirred at 0°C for 45 minutes before adding water (2 mL). The resulting solution was extracted with ethyl acetate (2x10 mL). The organic layer was washed with brine (5 mL) and dried over sodium sulfate to provide methyl 2-[3-(4-chloro-1 H-pyrazol-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (10b) (131 mg, 0.28 mmol, 100%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.94-2.07 (m, 2H), 2.61 (t, J = 6.6 Hz, 1 H), 2.77 (t, J = 6.6 Hz, 1 H), 3.52 and 3.55 (s, 3H), 4.18-4.24 (m, 2H), 5.44 and 5.45 (s, 1 H), 6.49- 6.55 (m, 1 H), 6.66 and 6.80 (d, J = 8.4 Hz, 1 H), 6.85 and 6.87 (s, 1 H), 7.10-7.16 (m, 1 H), 7.47 (s, 1 H), 7.72 and 7.73 (d, J = 8.4 Hz, 1 H), 7.85 (d, J = 8.4 Hz, 1 H).
MS m/z ([M+H]+) 467/469.
Step 3: preparation of intermediate methyl 2-[3-(4-chloro-1 H-pyrazol-1-yl)-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (10c) Using the procedure described in example 9, step 4, the intermediate methyl 2-[3-(4- chloro-1 H-pyrazol-1 -yl)-2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]-2-hydroxyacetate (10b) (131 mg, 0.28 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 80/20) into methyl 2-[3-(4-chloro-1 H- pyrazol-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert- butoxy)acetate (10c) (70 mg, 0.13 mmol, 47%) as a colorless oil.
1H NMR (300 MHz, CDCI3) δ 0.93 and 0.94 (s, 9H), 1.93-2.08 (m, 2H), 2.50-2.67 (m, 1 H), 2.69-2.86 (m, 1 H), 3.73 and 3.74 (s, 3H), 4.18-4.24 (m, 2H), 5.16 and 5.19 (s, 1 H), 6.51-6.90 (m, 3H), 7.10-7.18 (m, 1 H), 7.48 and 7.49 (s, 1 H), 7.66-7.67 (d, J = 8.5 Hz, 1 H), 7.83 (d, J = 8.5 Hz, 1 H). Step 4: preparation of 2-[3-(4-chloro-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert-butoxy)acetic acid (example 10) Using the procedure described in example 5, step 4, the intermediate methyl 2-[3-(4- chloro-1 H-pyrazol-1 -yl)-2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]-2-(ie f-butoxy)acetate (10c) (70 mg, 0.13 mmol) is converted, after purification by preparative TLC (dichloromethane/methanol 97/3) into 2-[3-(4-chloro- 1 H-pyrazol-1-yl)-2-(3,4-dihydro-2/-/-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2- (ieri-butoxy)acetic acid (example 10) (36 mg, 0.07 mmol, 53%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.95 (s, 9H), 1 .94-2.04 (m, 2H), 2.56 (bs, 1 H), 2. 82 (bs, 1 H), 4.18-4.24 (m, 2H), 5.28 and 5.34 (s, 1 H), 6.49-6.87 (m, 3H), 7.49-7.51 (m, 2H), 7.70-7.75 (m, 1 H), 7.84 (d, J = 8.4 Hz, 1 H).
MS m/z ([M+H]+) 509/51 1 . Example 11 : synthesis of 2-(te/f-butoxy)-2-r2-(4,4-dimethylcvclohex-1-en-1 -yl)-3- (pyridin-4-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate ethyl 2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3- fluoro-6-(trifluoromethyl)phenyl]-2-oxoacetate (11a)
A degassed solution of ethyl 2-{3-fluoro-2-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl}-2-oxoacetate (1d) (2.1 g, 5.09 mmol), potassium carbonate (2.1 1 g, 15.28 mmol), 2-(4,4-dimethyl-1 -cyclohexen-1-yl)-4,4,5,5-tetramethyl-1 ,3,2- dioxaborolane (1 .99 g, 7.64 mmol) and palladium tetrakis(triphenylphosphine) (589 mg, 0.51 mmol) in tetrahydrofurane (20 mL) and water (5 mL) was heated at 65°C for 2 hours. The mixture was poured in water (30 mL) and extracted with ethyl acetate (2x20 mL). The organic layer was washed with a saturated solution of sodium hydrogenocarbonate (20 mL), brine (20 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 95/5) to provide ethyl 2-[2-(4,4-dimethylcyclohex-1-en-1 - yl)-3-fluoro-6-(trifluoromethyl)phenyl]-2-oxoacetate (11a) (712 mg, 1.91 mmol, 37%) as a colorless oil.
1H NMR (300 MHz, CDCI3) δ 0.94 (s, 6H), 1.33-1.43 (m, 5H), 1 .88-1.91 (m, 2H), 2.24- 2.29 (m, 2H), 4.31 (q, J = 7.2 Hz, 2H), 5.55-5.58 (m, 1 H), 7.23 (t, J = 8.7 Hz, 1 H), 7.63 (dd, J = 4.8 Hz, J = 8.7 Hz, 1 H). Step 2: preparation of intermediate methyl 2-[3-(benzyloxy)-2-(4,4-dimethylcyclohex- 1 -en-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (11 b)
To a solution of ethyl 2-[2-(4,4-dimethylcyclohex-1 -en-1 -yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetate (11a) (712 mg, 1.91 mmol) and anhydrous benzyl alcohol (0.40 mL, 3.86 mmol) in anhydrous Λ/,/V-dimethylformamide (7 mL) at 0°C under nitrogen atmosphere was portion wise added sodium hydride 60% in oil (229 mg, 5.74 mmol). The reaction mixture was stirred at 60°C for 1 hour. The mixture was cooled to room temperature before adding dimethyl sulfate (0.54 mL, 5.74 mmol). The mixture was stirred at room temperature for 30 minutes and poured in water (40 mL). The resulting solution was extracted with ethyl acetate (2x20 mL). The organic layer was washed with a saturated solution of sodium hydrogenocarbonate (20 mL), brine (20 mL), dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in anhydrous dimethoxyethane (7 mL) and sodium borohydride (145 mg, 3.82 mmol) was portion wise added at 0°C. The mixture was stirred at 0 °C for 1 hour. Water (10 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2x10 mL). The unified organic layers were washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 90/10) to provide intermediate methyl 2-[3-(benzyloxy)-2- (4,4-dimethylcyclohex-1-en-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxy acetate (11 b) (566 mg, 1 .26 mmol, 66%).
1H NMR (400 MHz, CDCI3) δ 0.77 and 0.81 (s, 3H), 0.95 and 0.96 (s, 3H), 1.38-1.45 (m, 2H), 1.76-1.99 (m, 2H), 2.16-2.45 (m, 2H), 3.71 and 3.75 (s, 3H), 5.03-5.71 (m, 4H), 6.94 (d, J = 8.7 Hz, 1 H), 7.33-7.37 (m, 5H), 7.58 and 7.59 (d, J = 8.7 Hz, 1 H).
Step 3: preparation of intermediate methyl 2-[3-(benzyloxy)-2-(4,4-dimethylcyclohex- 1 -en-1 -yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (11c)
To a solution of methyl 2-[3-(benzyloxy)-2-(4,4-dimethylcyclohex-1-en-1 -yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (11 b) (377 mg, 0.84 mmol) in ie f-butyl acetate (6 mL) at 0°C was added 70% perchloric acid (0.75 mL). The reaction mixture was stirred at 0°C for 1 hour then poured into a saturated solution of sodium hydrogenocarbonate (50 mL). The mixture was extracted with ethyl acetate (2x20 mL). The resulting organic layer was washed with brine, dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 95/5) to provide methyl 2-[3-(benzyloxy)-2-(4,4- dimethylcyclohex-1 -en-1-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (11 c) (130 mg, 0.257 mmol, 30%) as a colorless oil. 1H NMR (400 MHz, CDCI3) δ 0.84 and 0.85 (s, 3H), 0.99 and 1.00 (s, 3H), 1 .15 and 1.18 (s, 9H), 1.35-1 .48 (m, 2H), 1.83-1 .91 (m, 2H), 2.27-2.70 (m, 2H), 3.63 and 3.68 (s, 3H), 5.05-5.63 (m, 4H), 6.83-6.93 (m, 1 H), 7.29-7.42 (m, 5H), 7.55 and 7.59 (d, J = 8.8 Hz, 1 H).
Step 4: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex- 1-en-1-yl)-3-hydroxy-6-(trifluoromethyl)phenyl]acetate (11 d)
A solution of methyl 2-[3-(benzyloxy)-2-(4,4-dimethylcyclohex-1-en-1 -yl)-6- (trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (11c) (225 mg, 0.446 mmol) in ethyl acetate (5 mL) was stirred under hydrogen atmosphere for 48 hours. The reaction mixture was filtered over Millipore and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 90/10) to provide methyl 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1-yl)-3-hydroxy-6- (trifluoromethyl)phenyl]acetate (11 d) (1 1 1 mg, 0.267 mmol, 60%) as a lightly yellow oil.
1H NMR (400 MHz, CDCI3) 51.02-1 .06 (m, 6H), 1 .16 and 1 .19 (s, 9H), 1 .42-1.60 (m, 2H), 1.96- 2.59 (m, 4H), 3.63 and 3.67 (s, 3H), 5.35-5.76 (m, 2H), 6.95 (d, J = 8.7 Hz, 1 H), 7.22 (d, J = 8.7 Hz, 1 H).
MS m/z ([M-H]") 413.
Step 5: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex- 1-en-1-yl)-3-[(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl) phenyl]acetate (11e) To a solution of methyl 2-(fe/t-butoxy)-2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3- hydroxy-6-(trifluoromethyl)phenyl]acetate (11d) (1 1 1 mg, 0.267 mmol) in anhydrous dichloromethane (3 mL) under nitrogen atmosphere at -78°C were successively added triethylamine (45 μΙ_, 0.330 mmol) and triflic anhydride (50 μΙ_, 0.297 mmol). The mixture was stirred at -78°C for 1 hour before adding water (5 mL). The layers were separated. The aqueous layer was extracted with dichloromethane (10mL). The combined organic layers were washed with a saturated solution of sodium hydrogenocarbonate (10 mL), dried over sodium sulfate and concentrated in vacuo to provide methyl 2-(fe/t-butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1-yl)-3-
[(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl)phenyl]acetate (11e) (137 mg, 0.250 mmol, 94%) as a colorless oil.
1H NMR (400 MHz, CDCI3) «51.01 and 1.04 (s, 6H), 1.15 and 1.18 (s, 9H), 1.48-1.53 (m, 2H), 1.59- 2.47 (m, 4H), 3.65 and 3.69 (s, 3H), 5.29-5.77 (m, 2H), 7.33 (d, J = 8.8 Hz, 1 H), 7.69 and 7.72 (d, J = 8.8 Hz, 1 H). Step 6: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex- 1-en-1-yl)-3-(pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetate (11f)
A degassed solution of methyl 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3- [(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl)phenyl]acetate (11e) (67 mg, 0.122 mmol), potassium carbonate (51 mg, 0.369 mmol), 4-pyridine boronic acid pinacol ester (38 mg, 0.185 mmol) and palladium tetrakis(triphenylphosphine) (14 mg, 0.012 mmol) in dioxane (1 mL) and water (0.25 mL) was heated at 85°C overnight. Water (5 mL) was added. The aqueous layer was extracted with ethyl acetate (2x5 mL). The combined organics were washed with brine (5 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane/ ethyl acetate 60/40) to provide methyl 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en- 1 -yl)-3-(pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetate (11f) (40 mg, 0.084 mmol, 69%).
1H NMR (400 MHz, CDCI3) 50.57 and 0.64 (s, 3H), 0.91 (s, 3H), 1.13 and 1 .17 (s, 9H), 1 .22-1.32 (m, 2H), 1 .48- 2.27 (m, 4H), 3.67 and 3.72 (s, 3H), 5.29-5.83 (m, 2H), 7.20-7.30 (m, 3H), 7.65 and 7.69 (d, J = 8.1 Hz, 1 H), 8.57-8.61 (m, 2H).
Step 7: preparation of 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3-(pyridin-
4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 11)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2-
(4,4-dimethylcyclohex-1-en-1 -yl)-3-(pyridin-4-yl)-6-(trifluoro methyl)phenyl]acetate
(11f) (40 mg, 0.084 mmol) is converted into 2-(iert-butoxy)-2-[2-(4,4- dimethylcyclohex-1 -en-1-yl)-3-(pyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid
(example 11) (33 mg, 0.071 mmol, 84%) as a white solid.
1H NMR (400 MHz, CDCI3) 50.55 and 0.65 (s, 3H), 0.90 (s, 3H), 1.18 and 1 .29 (m,
1 1 H), 1 .65- 2.45 (m, 4H), 5.48-6.25 (m, 2H), 7.22-7.34 (m, 3H), 7.71 (d, J = 8.1 Hz,
1 H), 8.61-8.64 (m, 2H).
MS m/z ([M+H]+) 462.
MS m/z ([M-H]-) 460.
Example 12: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3-
{pyrazoloH ,5-alpyridin-3-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-{pyrazolo[1 ,5-a]pyridin-3-yl}-6-(trifluoromethyl) phenyl]acetate
(12a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (100 mg, 0.175 mmol) is converted by reaction with 3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyrazolo[1 ,5-a]pyridine (64 mg, 0.263 mmol, prepared using the procedure described in Tetrahedron, 2012, 68, 5434-5444), after purification by preparative TLC (cyclohexane/ethyl acetate 50/50), into methyl 2- (ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-{pyrazolo[1 ,5-a]pyridin-3-yl}- 6-(trifluoro methyl)phenyl]acetate (12a) (83 mg, 0.154 mmol, 88%).
1H NMR (400 MHz, CDCI3) δ 0.99 (s, 9H), 1.87-1.95 (m, 1 H), 1 .97-2.07 (m, 1 H), 2.42- 2.60 (m, 1 H), 2.66-2.83 (m, 1 H), 3.72 and 3.73 (s, 3H), 4.10-4.24 (m, 2H), 5.18 and 5.19 (s, 1 H), 6.52-6.76 (m, 3H), 7.08-7.14 (m, 2H), 7.18 and 7.25 (s, 1 H), 7.56-7.59 (m, 2H), 7.76 (d, J = 8.3 Hz, 1 H), 8.36 (d, J = 6.9 Hz, 1 H).
MS m/z ([M+H]+) 539.
Step 2: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- {pyrazolo[1 ,5-a]pyridin-3-yl}-6-(trifluoromethyl)phenyl]acetic acid (example 12)
Using the procedure described in example 2, step 2, methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-{pyrazolo[1 ,5-a]pyridin-3-yl}-6- (trifluoromethyl)phenyl]acetate (12a) (83 mg, 0.154 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-{pyrazolo [1 ,5-a]pyridine-3-yl}-6- (trifluoromethyl)phenyl]acetic acid (example 12) (65 mg, 0.124 mmol, 81 %).
1H NMR (300 MHz, CDCI3) δ 1.00 (bs, 9H), 1.83-1.95 (m, 1 H), 1.95-2.07 (m, 1 H), 2.38-2.61 (m, 1 H), 2.72-2.87 (m, 1 H), 4.06-4.25 (m, 2H), 5.34 and 5.35 (s, 1 H), 6.49- 6.79 (m, 3H), 7.06-7.10 (m, 1 H), 7.21-7.33 (m, 1 H), 7.45-7.58 (m, 2H), 7.62 (d, J = 8.2 Hz, 1 H), 7.78 (d, J = 8.2 Hz, 1 H), 8.35 and 8.36 (d, J = 7.0 Hz, 1 H).
MS m/z ([M+H]+) 525. Example 13: synthesis of 2-(te f-butoxy)-2-r3-(4-carbamoylphenyl)-2-(3,4-dihvdro-2H- -benzopyran-6-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(4-carbamoylphenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (13a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (75 mg, 0.131 mmol) is converted by reaction with (4-carbamoylphenyl)boronic acid (32.5 mg, 0.197 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 50/50) into methyl 2-(ie f-butoxy)-2-[3-(4- carbamoylphenyl)-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl] acetate (13a) (58.8 mg, 0.108 mmol, 82%).
1H NMR (400 MHz, CDCI3) δ 0.95 (s, 9H), 1.81-1.96 (m, 1 H), 1 .95-2.07 (m, 1 H), 2.30- 2.59 (m, 1 H), 2.59-2.83 (m, 1 H), 3.73 (s, 3H), 4.07-4.22 (m, 2H), 5.17 (s, 1 H), 5.66 (bs, 1 H), 6.02 (bs, 1 H), 6.35-6.75 (m, 2H), 7.07-7.18 (m, 3H), 7.42 (d, J = 8.1 Hz, 1 H), 7.62 (d, J = 7.9 Hz, 2H), 7.77 (d, J = 8.1 Hz, 1 H).
MS m/z ([M+H]+) 542.
Step 2: preparation of intermediate benzyl 2-(ie f-butoxy)-2-[3-(4-carbamoylphenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (13b)
To a solution of methyl 2-(ie/f-butoxy)-2-[3-(4-carbamoylphenyl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (13a) (58.8 mg, 0.108 mmol) in a mixture of dioxane (1 .8 mL) and water (0.9 mL) was added lithium hydroxide (29.5 mg, 0.869 mmol). The mixture was heated at 90°C overnight. The reaction mixture was cooled to room temperature and concentrated in vacuo. Water (2 mL) was added to the residue and the aqueous layer was washed with diethyl ether (2 mL), acidified with 1 M hydrochloric acid until pH 3 and extracted with diethyl ether (2 x 3 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in anhydrous Λ/,/V-dimethylformamide (2 mL). Benzyl bromide (39 μΙ_, 0.326 mmol) and potassium carbonate (45 mg, 0.326 mmol) were added, and the reaction mixture was stirred at room temperature for 5 hours. Water (3 mL) was added and the mixture was extracted with ethyl acetate (2 x 5 mL). The organic layer was washed with brine (5 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (dichloromethane/methanol: 97/3) to provide benzyl 2-(ie/f-butoxy)-2-[3-(4-carbamoylphenyl)-2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (13b) (27.8 mg, 0.045 mmol, 41 %).
1H NMR (300 MHz, CDCI3) δ 0.94 (s, 9H), 1.80-1.96 (m, 2H), 2.26-2.42 (m, 1 H), 2.42- 2.59 (m, 1 H), 4.05-4.18 (m, 2H), 5.09-5.27 (m, 3H), 5.70 (bs, 1 H), 6.03 (bs, 1 H), 6.34- 6.58 (m, 2H), 6.94-7.01 (m, 1 H), 7.06-7.14 (m, 2H), 7.25-7.38 (m, 5H), 7.41 (d, J = 8.2 Hz, 1 H), 7.60 (dd, J = 8.4 Hz, J = 2.3 Hz, 2H), 7.78 (d, J = 8.2 Hz, 1 H).
Step 3: preparation of 2-(ie/f-butoxy)-2-[3-(4-carbamoylphenyl)-2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 13)
A mixture of benzyl 2-(ie/f-butoxy)-2-[3-(4-carbamoylphenyl)-2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (13b) (27.8 mg, 0.045 mmol) and palladium on carbon (7 mg) in ethyl acetate (3 mL) was stirred under hydrogen atmosphere for 3 hours. The mixture was filtered over Millipore and the filtrate concentrated in vacuo to provide 2-(ie f-butoxy)-2-[3-(4-carbamoylphenyl)-2-(3,4- dihydro-2/-/-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 13) (20 mg, 0.038 mmol, 84%).
1H NMR (400 MHz, CDCI3) δ 0.97 (s, 9H), 1.79-1.92 (m, 1 H), 1 .94-2.06 (m, 1 H), 2.28- 2.57 (m, 1 H), 2.68-2.85 (m, 1 H), 4.06-4.24 (m, 2H), 5.31 and 5.34 (s, 1 H), 6.00 (bs, 2H), 6.31-6.83 (m, 2H), 7.12 and 7.13 (d, J = 8.4 Hz, 2H), 7.41-7.50 (m, 2H), 7.62 and 7.63 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 528.
Example 14: synthesis of 2-(te f-butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2/-/- 1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(3-carbamoylphenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl] acetate (14a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (79 mg, 0.138 mmol) is converted by reaction with (3-carbamoylphenyl)boronic acid (34 mg, 0.206 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 20/80) into methyl 2-(ie f-butoxy)-2-[3-(3- carbamoylphenyl)-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl] acetate (14a) (54 mg, 0.099 mmol, 72%).
1H NMR (400 MHz, CDCI3) δ 0.95 and 0.96 (s, 9H), 1.83-2.04 (m, 2H), 2.30-2.55 (m, 1 H), 2.66-2.79 (m, 1 H), 3.74 (s, 3H), 4.09-4.18 (m, 2H), 5.19 and 5.20 (s, 1 H), 5.75 (bs, 2H), 6.39-6.75 (m, 2H), 7.13-7.30 (m, 3H), 7.39-7.49 (m, 2H), 7.59 and 7.64 (dt, J = 7.4 Hz, J = 1.6 Hz, 1 H), 7.77 and 7.78 (d, J = 8.2 Hz, 1 H).
Step 2: preparation of intermediate benzyl 2-(ie f-butoxy)-2-[3-(3-carbamoylphenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (14b)
Using the procedure described in example 13, step 2, the intermediate methyl 2-(ie f- butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (14a) (54 mg, 0.099 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 40/60) into benzyl 2-(tert- butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzo pyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (14b) (20 mg, 0.032 mmol, 32%).
1H NMR (300 MHz, CDCI3) δ 0.94 and 0.95 (s, 9H), 1.80-1 .92 (m, 2H), 2.27-2.39 (m, 1 H), 2.45-2.55 (m, 1 H), 4.06-4.12 (m, 2H), 5.13-5.23 (m, 3H), 5.75 (bs, 2H), 6.37-6.57 (m, 2H), 7.00-7.04 (m, 1 H), 7.16-7.25 (m, 2H), 7.28-7.48 (m, 7H), 7.58 and 7.63 (dt, J = 7.7 Hz, J = 1.5 Hz, 1 H), 7.78 (d, J = 8.2 Hz, 1 H). Step 3: preparation of 2-(ie/f-butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 14)
Using the procedure described in example 13, step 3, the intermediate benzyl 2-(tert- butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoro methyl)phenyl]acetate (14b) (20 mg, 0.032 mmol) is converted into 2-(ie f-butoxy)-2- [3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetic acid (example 14) (13 mg, 0.024 mmol, 77%).
1H NMR (400 MHz, CDCI3) δ 0.97 (s, 9H), 1.81-1.91 (m, 1 H), 1 .93-2.04 (m, 1 H), 2.22- 2.53 (m, 1 H), 2.78 (bs, 1 H), 4.10-4.18 (m, 2H), 5.33 and 5.36 (s, 1 H), 5.90 and 5.96 (bs, 2H), 6.38-6.80 (m, 2H), 7.18-7.30 (m, 2H), 7.42-7.65 (m, 4H), 7.78 and 7.79 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 528.
Example 15: synthesis of 2-(te f-butoxy)-2-[2-(4,4-dimethylcvclohex-1-en-1 -yl)-3-(1 - methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : Preparation of intermediate methyl 2-(fe/t-butoxy)-2-[2-(4,4-dimethylcyclohex- 1 -en-1 -yl)-3-(1 -methyl-1 H-pyrazol-4-yl)-6-(trif luoromethyl)phenyl] acetate (15a)
Using the procedure described in example 1 1 , step 6, methyl 2-(ie f-butoxy)-2-[2-(4,4- dimethylcyclohex-1 -en-1-yl)-3-[(trifluoromethane)sulfonyloxy]-6-
(trifluoromethyl)phenyl]acetate (11e) (80 mg, 0.146 mmol) is converted by reaction with 1-methylpyrazole-4-boronic acid pinacol ester (46 mg, 0.22 mmol) after purification by preparative TLC (cyclohexane/ethyl acetate 60/40) into methyl 2-(ie f- butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1 -yl)-3-(1 -methyl-1 H-pyrazol-4-yl)-6- (trifluoromethyl) phenyl]acetate (15a) (44 mg, 0.092 mmol, 63%) as a white solid.
1H NMR (400 MHz, CDCI3) 50.86 and 0.90 (s, 3H), 1.00 and 1.02 (s, 3H), 1 .14 and 1.18 (s, 9H), 1.35-1.68 (m, 2H), 1 .61- 1 .89 (m, 2H), 2.36 (bs, 2H), 3.66 and 3.71 (s, 3H), 3.94 (s, 3H), 5.30-5.80 (m, 2H), 7.33 and 7.34 (d, J = 8.1 Hz, 1 H), 7.46 and 7.48 (s, 1 H), 7.58-7.63 (m, 2H).
MS m/z ([M+H]+) 479. Step 2: preparation of 2-(ie/f-butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1-yl)-3-(1 - methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 15)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (4,4-dimethylcyclohex-1-en-1 -yl)-3-(1-methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl) phenyl]acetate (15a) (44 mg, 0.092 mmol) is converted into 2-(ie/f-butoxy)-2-[2-(4,4- dimethylcyclohex-1 -en-1-yl)-3-(1-methyl-1 H-pyrazol-4-yl)-6-(trifluoromethyl)phenyl] acetic acid (example 15) (26 mg, 0.056 mmol, 60%) as a white solid.
1H NMR (400 MHz, CDCI3) 50.86 and 0.90 (s, 3H), 0.98 (s, 3H), 1.18 and 1 .23 (s, 9H), 1 .29-1.37 (m, 1 H), 1 .60- 2.18 (m, 5H), 3.92 and 3.93 (s, 3H), 5.46-6.23 (m, 2H), 7.35-7.64 (m, 4H).
MS m/z ([M+H]+) 465.
MS m/z ([M-H]-) 463.
Example 16: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (pyrimidin-4-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6-
(trif luoromethyl)phenyl]acetate (16a)
A flame-dried vial containing methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl)phenyl] acetate (1j) (437 mg, 0.766 mmol), [1 ,1 '-bis(diphenylphosphino) ferrocene]dichloropalladium(ll), complex with dichloromethane (125 mg, 0.153 mmol), bis[pinacolato]diboron (389 mg, 1 .53 mmol) and potassium acetate (225 mg, 2.30 mmol) was purged with argon for 10 minutes and then degassed anhydrous dioxane (5 mL) was added. The resulting mixture was placed in a preheated oil bath (80 °C) and stirred for 22 hours. LCMS showed remaining starting triflate and the mixture was cooled to room temperature, anhydrous dioxane (2 mL) was added and the mixture was purged with argon (10min) followed by addition of bis[pinacolato]diboron (194 mg, 0.765 mmol), potassium acetate (1 13 mg, 1.15 mmol) and [1 ,1 - bis(diphenylphosphino) ferrocene]dichloropalladium(ll), complex with dichloromethane (62 mg, 0.076 mmol), further purged with argon and then stirred at 80 °C for further 24 hours. The mixture was cooled to room temperature and diluted in ethyl acetate (100 mL) and washed with water (2x15 mL) and brine (15 mL), dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by Dry Column Vacuum Chromatography on Silicagel (30 mL) (cyclohexane/ethyl acetate 100/0 up to 70/30) to provide methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6-
(trifluoromethyl)phenyl]acetate (16a) (520 mg, quantitative yield) as a yellow oil.
1H NMR (300MHz, CDCI3) δ 0.92 and 0.95 (s, 9H), 1.06 (s, 6H), 1.13 (s, 6H), 2.04 (m, 2H), 2.75 (m, 2H), 3.67 (s, 3H), 4.21 (m, 2H), 5.18 (s, 1 H), 6.74-6.93 (m, 2H), 7.05- 7.10 (m, 1 H), 7.26-7.67 (m, 2H).
Step 2: preparation of intermediate intermediate methyl 2-(fe/t-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(pyrimidin-4-yl)-6-(trifluoromethyl) phenyl]acetate (16b)
To a solution of methyl 2-(fe/t-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)phenyl]acetate (16a) (120 mg, 0.218 mmol) in dioxane (1 .5 mL) was added 4-bromo-pyrimidine hydrochloride (57 mg, 0.291 mmol) and sodium carbonate saturated aqueous solution (1.5 mL). This mixture was stirred at room temperature for 20 minutes while passing a stream of argon. [1 ,1 '-bis(diphenylphosphino)ferrocene] dichloropalladium(ll), complex with dichloromethane (14 mg, 0.018mmol) was added and the resulting mixture was stirred at 80 °C for 72 hours. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (70 mL). The organic phase were washed with water (2x15 mL) and brine (15 mL), dried over sodium sulfate and concentrated in vacuo. The crude residue was purified on preparative TLC (cyclohexane/ ethyl acetate 70/30) to provide methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (1 ,3-thiazol-2-yl)-6-(trifluoromethyl)phenyl]acetate (16b) (38 mg, 0.075 mmol, 35%). 1H NMR (400 MHz, CDCI3) δ 0.91 and 0.92 (s, 9H), 1.89-1 .92 (m, 1 H), 2.00-2.05 (m, 1 H), 2.37-2.58 (m, 1 H), 2.68-2.80 (m, 1 H), 3.74 (s, 3H), 4.13-4.21 (m, 2H), 5.20 (s, 1 H), 6.46-6.80 (m, 3H), 7.18-7.25 (m, 1 H), 7.73-7.77 (m, 1 H), 7.85 (d, J = 8.2 Hz, 1 H), 8.38 and 8.39 (d, J = 5.8 Hz, 1 H), 9.18 and 9.20 (d, J = 1.1 Hz, 1 H).
MS m/z ([M+H]+) 501. Step 3: preparation of 2-(fe/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (pyrimidin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 16)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(pyrimidin-4-yl)-6-(trifluoro
methyl)phenyl]acetate (16b) (50 mg, 0.100 mmol) is converted into 2-(iert-butoxy)-2- [2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyrimidin-4-yl)-6-
(trifluoromethyl)phenyl]acetic acid (example 16) (46 mg, 0.094 mmol, 94%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.94 (s, 9H), 1.87-1.94 (m, 1 H), 2.00-2.08 (m, 1 H), 2.39- 2.53 (m, 1 H), 2.80-2.85 (m, 1 H), 4.14-4.23 (m, 2H), 5.34 and 5.37 (s, 1 H), 6.43-6.88 (m, 3H), 7.59-7.65 (m, 1 H), 7.79-7.84 (m, 1 H), 7.88 (d, J = 7.8 Hz, 1 H), 8.40 and 8.41 (d, J = 4.7 Hz, 1 H), 9.22 and 9.23 (d, J = 0.9 Hz, 1 H).
MS m/z ([M+H]+) 487.
MS m/z ([M+H]+) 485.
Example 17: synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -fluoropyridin-4-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(3-f luoropyridin-4-yl)-6-(trifluoromethyl)phenyl]acetate (17a)
Using the procedure described in example 16, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6- (trifluoromethyl)phenyl]acetate (16a) (48 mg, 0.087 mmol) is converted by reaction with 4-bromo-3-fluoro-pyridine hydrochloride (37 mg, 0.174 mmol) into methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-fluoropyridin-4-yl)-6-
(trifluoromethyl)phenyl]acetate (17a) (37 mg, 0.071 mmol, 82%), after purification by preparative TLC (dichloromethane/ethyl acetate 80/20).
1H NMR (400 MHz, CDCI3) δ 0.96 and 0.97 (s, 9H), 1.88-2.00 (m, 2H), 2.37-2.61 (m, 1 H), 2.69 (t, J = 6.3 Hz, 1 H), 3.71 (s, 3H), 4.10-4.17 (m, 2H), 5.17 (s, 1 H), 6.48-6.69 (m, 2H), 6.91 -6.97 (m, 1 H), 7.03-7.09 (m, 1 H), 7.39 and 7.41 (d, J = 8.1 Hz, 1 H), 7.80 (d, J = 8.1 Hz, 1 H), 8.20-8.23 (m, 1 H), 8.32 and 8.33 (d, J = 4.4 Hz, 1 H).
MS m/z ([M+H]+) 518. Step 2: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-(3- fluoropyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 17)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(3-fluoropyridin-4-yl)-6- (trifluoromethyl)phenyl]acetate (17a) (36 mg, 0.069 mmol) is converted into 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-fluoropyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 17) (26 mg, 0.051 mmol, 74%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.99 (s, 9H), 1.87-2.02 (m, 2H), 2.34-2.59 (m, 1 H), 2.68- 2.81 (m, 1 H), 4.10-4.18 (m, 2H), 5.29 and 5.32 (s, 1 H), 6.47-6.75 (m, 2H), 6.93-6.98 (m, 1 H), 7.37-7.47 (m, 2H), 7.82 (d, J = 8.1 Hz, 1 H), 8.21-8.24 (m, 1 H), 8.37-8.38 (m, 1 H).
MS m/z ([M+H]+) 504. Example 18: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -methyl-1 /-/-pyridin-2-one-5-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1-methyl-1 H-pyridin-2-one-5-yl)-6-(trifluoromethyl) phenyl]acetate (18a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.122 mmol) is converted, by reaction with /V-methyl-1 H-pyridin-2-one-5-boronic acid, pinacol ester (43 mg, 0.183 mmol) into methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H- pyridin-2-one-5-yl)-6-(trifluoromethyl)phenyl] acetate (18a) (35 mg, 0.066 mmol, 54%), after purification by preparative TLC (ethyl acetate).
1H NMR (400 MHz, CDCI3) δ 0.94 and 0.96 (s, 9H), 1.91-2.03 (m, 2H), 2.53-2.65 (m, 1 H), 2.67-2.81 (m, 1 H), 3.42 and 3.43 (s, 3H), 3.71 (s, 3H), 4.16-4.22 (m, 2H), 5.15 and 5.17 (s, 1 H), 6.34 and 6.37 (d, J = 9.5 Hz, 1 H), 6.52-6.79 (m, 2H), 6.96-7.12 (m, 3H), 7.37 and 7.38 (d, J = 8.1 Hz, 1 H), 7.74 (d, J = 8.1 Hz, 1 H).
MS m/z ([M+H]+) 530. Step 2: preparation 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-(1 - methyl-1 H-pyridin-2-one-5-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 18)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1-methyl-1 /-/-pyridin-2-one-5-yl)-6-
(trifluoromethyl)phenyl]acetate (18a) (35 mg, 0.066 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 -methyl- 1 H-pyridin-2-one-5-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 18) (25 mg, 0.048 mmol, 73%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.97 (s, 9H), 1 .95-2.03 (m, 2H), 2.59 (bs, 1 H), 2.79 (bs, 1 H), 3.42 and 3.43 (s, 3H), 4.16-4.21 (m, 2H), 5.30 (bs, 1 H), 6.40-6.45 (m, 1 H), 6.51 - 6.84 (m, 2H), 7.00-7.08 (m, 2H), 7.40-7.48 (m, 2H), 7.75 (d, J = 8.0 Hz, 1 H).
MS m/z ([M+H]+) 516. Example 19: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- [4-(methylcarbamoyl)phenyll-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[4-(methylcarbamoyl)phenyl]-6-(trifluoromethyl)phenyl]acetate (19a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with [4-(methylcarbamoyl)phenyl]boronic acid (33 mg, 0.184 mmol) into the methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzo pyran-6-yl)-3-[4-(methylcarbamoyl)phenyl]-6- (trifluoromethyl)phenyl]acetate (19a) (65 mg, 0.1 17 mmol, 95%) after purification by preparative TLC (cyclohexane/ethyl acetate 30/70).
1H NMR (400 MHz, CDCI3) δ 0.94 (s, 9H), 1.82-1.93 (m, 1 H), 1 .94-2.07 (m, 1 H), 2.29- 2.58 (m, 1 H), 2.65-2.80 (m, 1 H), 2.98-3.03 (m, 3H), 3.73 and 3.74 (s, 3H), 4.08-4.21 (m, 2H), 5.17 (s, 1 H), 6.10 (bs, 1 H), 6.37-6.44 (m, 1 H), 6.46 and 6.70 (d, J = 8.3 Hz, 1 H), 7.06-7.14 (m, 2H), 7.38-7.46 (m, 1 H), 7.53-7.60 (m, 2H), 7.72-7.80 (m, 2H). MS m/z ([M+H]+) 556. Step 2: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-[4- (methylcarbamoyl)phenyl]-6-(trifluoromethyl)phenyl]acetic acid (example 19)
Using the procedure described in example 2, step 2, methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-[4-(methylcarbamoyl)phenyl]-6- (trifluoromethyl)phenyl]acetate (19a) (65 mg, 0.1 17 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[4-(methylcarbamoyl) phenyl]-6- (trifluoromethyl)phenyl]acetic acid (32.5 mg, 0.060 mmol, 51 %) after purification by preparative TLC (cyclohexane/ethyl acetate 20/80).
1H NMR (300 MHz, CDCI3) δ 0.96 (s, 9H), 1.78-1.94 (m, 1 H), 1 .94-2.09 (m, 1 H), 2.28- 2.58 (m, 1 H), 2.68-2.86 (m, 1 H), 2.98 and 3.00 (s, 3H), 4.07-4.22 (m, 2H), 5.31 and 5.34 (s, 1 H), 6.00-6.18 (m, 1 H), 6.29-6.84 (m, 2H), 7.06-7.15 (m, 2H), 7.41 -7.53 (m, 2H), 7.53-7.62 (m, 2H), 7.77 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 542. Example 20: synthesis of 2-[3-(4-aminophenyl)-2-(3,4-dihvdro-2H-1-benzo pyran-6- yl)-6-(trifluoromethyl)phenyll-2-(te -butoxy)acetic acid
Example 21 : synthesis of 2-(te f-butoxy)-2-[3-(4-acetamidophenyl)-2-(3,4-dihvdro-2H- 1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(4-acetamidophenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (20a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with (4-acetamidophenyl)boronic acid (33 mg, 0.184 mmol) into the methyl 2-(ie f-butoxy)- 2-[3-(4-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (20a) (63 mg, 0.1 13 mmol, 92%) after purification by preparative TLC (cyclohexane/ethyl acetate 50/50).
1H NMR (400 MHz, CDCI3) δ 0.94 (s, 9H), 1 .82-2.07 (m, 2H), 2.15 (s, 3H), 2.37-2.61 (m, 1 H), 2.61 -2.85 (m, 1 H), 3.72 and 3.73 (s, 3H), 4.09-4.21 (m, 2H), 5.16 (s, 1 H), 6.40-6.74 (m, 2H), 6.94-7.16 (m, 2H), 7.22 (bs, 1 H), 7.26-7.53 (m, 4H), 7.69-7.80 (m, 1 H).
MS m/z ([M+H]+) 556.
Step 2: preparation of 2-[3-(4-aminophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic acid (example 20) and 2-(ie f-butoxy)-2- [3-(4-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 21)
To a solution of methyl 2-(ie/f-butoxy)-2-[3-(4-acetamidophenyl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (20a) (63 mg, 0.1 13 mmol) in a mixture of dioxane (1 .9 mL) and water (1 .0 mL) was added lithium hydroxide (22 mg, 0.91 mmol). The mixture was stirred at 90°C for 16 hours, followed by 5 hours at 105°C. The mixture was concentrated in vacuo. The residue was dissolved in water (2 mL) and extracted with diethyl ether (2x2 mL). The aqueous layer was acidified with a 1 M hydrochloric acid solution until pH 3 followed by extraction with diethyl ether (2x2 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane/ethyl acetate 20/80) to provide 2-[3-(4-aminophenyl)-2-(3,4-dihydro-2H- 1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid (example 20) (15 mg, 0.03 mmol, 26%) and 2-(ie/f-butoxy)-2-[3-(4-acetamidophenyl)-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetic acid (example 21) (16.4 mg, 0.030 mmol, 27%).
1H NMR (300 MHz, CDCI3) (example 20) δ 0.96 (s, 9H), 1.83-2.07 (m, 2H), 2.38-2.60 (m, 1 H), 2.72-2.85 (m, 1 H), 4.08-4.24 (m, 2H), 5.30 and 5.33 (s, 1 H), 6.33-6.57 (m, 2H), 6.71-7.04 (m, 4H), 7.38-7.56 (m, 2H), 7.69-7.80 (m, 1 H).
MS m/z ([M+H]+) 500.
MS m/z ([M-H]-) 498.
1H NMR (300 MHz, CDCI3) (example 21 ) δ 0.95 (s, 9H), 1.82-1 .95 (m, 1 H), 1 .95-2.06 (m, 1 H), 2.15 (s, 3H), 2.35-2.59 (m, 1 H), 2.71 -2.86 (m, 1 H), 4.09-4.22 (m, 2H), 5.31 and 5.34 (s, 1 H), 6.35-6.81 (m, 2H), 6.93-7.03 (m, 2H), 7.12 (bs, 1 H), 7.27-7.35 (m, 2H), 7.40-7.53 (m, 2H), 7.70-7.80 (m, 1 H).
MS m/z ([M+H]+) 542.
MS m/z ([M-H]") 540. Example 22: synthesis of 2-(te/f-butoxy)-2-{2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -(2,2,2-trifluoroethyl)-1 /-/-pyrazol-4-yll-6-(trifluoromethyl)phenyl)acetic acid
Step 1 : preparation of intermediate 4-(4,4,5,5,-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 - (2,2,2-trifluoroethyl)-1 H-pyrazole (22a)
To a solution of 4-(4, 4,5,5, -tetramethyl-1 ,3, 2-dioxaborolan-2-yl)-1 H-pyrazole (250 mg, 1.29 mmol) in Λ/,/V-dimethylformamide (4 mL) were added cesium carbonate (630 mg, 1.93 mmol) and 2,2,2-trifluoroethyl trifluoro methanesulfonate (0.37 mL, 2.58 mmol). The mixture was stirred at 100°C for 50 minutes. The mixture was then poured in water (15 mL) and extracted with ethyl acetate (2x10 mL). The organic layer was washed with a saturated solution of sodium hydrogenocarbonate (10 mL), brine (10 mL), dried over sodium sulfate and concentrated in vacuo to provide 4-(4, 4,5,5,- tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 -(2,2,2-trifluoroethyl)-1 H-pyrazole (22a) (271 mg, 0.98 mmol, 76%) which was used without further purification.
1H NMR (300 MHz, CDCI3) δ 1.32 (s, 12H), 4.71 (q, J = 8.4 Hz, 2H), 7.80 (s, 1 H), 7.84 (s, 1 H).
Step 2: preparation of intermediate methyl 2-(ie f-butoxy)-2-{2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[1 -(2,2,2-trifluoroethyl)- 1 H-pyrazol-4-yl]-6-(trifluoro
methyl)phenyl}acetate (22b)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (62 mg, 0.108 mmol) is converted by reaction with 4-(4,4,5,5,-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 -(2,2,2-trifluoroethyl)- 1 H-pyrazole
(22a) (45 mg, 0.163 mmol) into methyl 2-(ferf-butoxy)-2-{2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-3-[1 -(2,2,2-trifluoroethyl)-1 H-pyrazol-4-yl]-6- (trifluoromethyl)phenyl}acetate (22b) (51 mg, 0.089 mmol, 82%), after purification by preparative TLC (cyclohexane/ethyl acetate 60/40).
1H NMR (400 MHz, CDCI3) δ 0.98 and 1.00 (s, 9H), 1.95-2.07 (m, 2H), 2.55-2.79 (m, 2H), 3.68-3.69 (m, 3H), 4.18-4.27 (m, 2H), 4.39-4.63 (m, 2H), 5.16 and 5.19 (s, 1 H), 6.55-6.85 (m, 3H), 7.01 -7.1 1 (m, 1 H), 7.33 and 7.45 (s, 1 H), 7.55 (d, J = 8.2 Hz, 1 H), 7.72 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 571.
Step 3: preparation of 2-(iert-butoxy)-2-{2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1 - (2,2,2-trifluoroethyl)-1 H-pyrazol-4-yl]-6-(trifluoromethyl)phenyl}acetic acid (example 22)
Using the procedure described in example 2, step 2, the methyl 2-(ierf-butoxy)-2-{2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1-(2,2,2-trifluoroethyl)-1 H-pyrazol-4-yl]-6- (trifluoromethyl)phenyl}acetate (22b) (59 mg, 0.101 mmol) is converted into 2-(tert- butoxy)-2-{2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1-(2,2,2-trifluoroethyl)-1 H-pyrazol- 4-yl]-6-(trifluoromethyl)phenyl}acetic acid (10 mg, 0.018 mmol, 18%) (example 22) as a white solid after purification by preparative TLC (dichloromethane/methanol 90/10). 1H NMR (300 MHz, CDCI3) δ 1 .01 and 1.03 (s, 9H), 1.96-2.05 (m, 2H), 2.58-2.62 (m, 1 H), 2.78-2.82 (m, 1 H), 4.18-4.26 (m, 2H), 4.40-4.64 (m, 2H), 5.31 (bs, 1 H), 6.55-6.91 (m, 3H), 7.34-7.49 (m, 2H), 7.59 and 7.60 (d, J = 8.3 Hz, 1 H), 7.73 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 557.
Example 23: synthesis of 2-r3-(3-aminophenyl)-2-(3,4-dihvdro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl)phenyll-2-(te -butoxy)acetic acid
Example 24: synthesis of 2-(te f-butoxy)-2-[3-(3-acetamidophenyl)-2-(3,4-dihvdro-2H- 1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyllacetic acid
Example 23 Example 24
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(3-acetamidophenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetate (23a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with (3-acetamidophenyl)boronic acid (33 mg, 0.184 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 70/30) into methyl 2-(ie f-butoxy)-2- [3-(3-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (23a) (46 mg, 0.082 mmol, 67%).
1H NMR (300 MHz, CDCI3) δ 0.94 and 0.95 (s, 9H), 1.82-1 .94 (m, 1 H), 1.94-2.04 (m, 1 H), 2.13 and 2.14 (s, 3H), 2.32-2.61 (m, 1 H), 2.61 -2.84 (m, 1 H), 3.73 (s, 3H), 4.10- 4.18 (m, 2H), 5.17 (s, 1 H), 6.42-6.77 (m, 3H), 6.99-7.15 (m, 3H), 7.15-7.24 (m, 1 H), 7.31 -7.38 (m, 1 H), 7.42 (d, J = 8.1 Hz, 1 H), 7.74 (d, J = 8.1 Hz, 1 H).
MS m/z ([M+H]+) 556.
Step 2: preparation of 2-[3-(3-aminophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic acid (example 23) and 2-(ie f-butoxy)-2- [3-(3-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 24)
Using the procedure described in example 2, step 2, methyl 2-(fe/t-butoxy)-2-[3-(3- acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-
(trifluoromethyl)phenyl]acetate (46 mg, 0.082 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 20/80), into 2-[3-(3-aminophenyl)-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid (example 23) (18 mg, 0.036 mmol, 43%) and 2-(ie/f-butoxy)-2-[3-(3- acetamidophenyl)-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetic acid (example 24) (14 mg, 0.026 mmol, 31 %)
1H NMR (300 MHz, CDCI3) (example 23) δ 0.96 (s, 9H), 1.81-2.09 (m, 2H), 2.32-2.62 (m, 1 H), 2.66-2.87 (m, 1 H), 4.02-4.26 (m, 2H), 5.32 and 5.36 (s, 1 H), 6.33-6.60 (m, 4H), 6.67-7.02 (m, 2H), 7.36-7.57 (m, 2H), 7.68-7.80 (m, 1 H).
MS m/z ([M-H]") 498.
1H NMR (300 MHz, CDCI3) (example 24) δ 0.95 (s, 9H), 1 .80-2.06 (m, 2H), 2.13 (s, 3H), 2.30-2.61 (m, 1 H), 2.67-2.82 (m, 1 H), 4.06-4.22 (m, 2H), 5.32 and 5.35 (s, 1 H), 6.36-6.80 (m, 3H), 7.00-7.26 (m, 3H), 7.36 (bs, 1 H), 7.40-7.53 (m, 2H), 7.74 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 542.
Example 25: synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -oxo-1-propyl-1 ,6-dihvdropyridin-3-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate 5-bromo-1-propyl-1 ,2-dihydropyridin-2-one (25a) Under a nitrogen atmosphere, sodium hydride 60% in oil (0.23 g, 5.75 mmol) was added portionwise to a solution of 5-bromo-2(1 H)-pyridone (1 .00 g, 5.75 mmol) in dry tetrahydrofuran (20 mL). After 10 minutes stirring, iodopropane (1.68 mL, 17.24 mmol) was added and the reaction mixture was stirred at 50°C for 40 hours. Water (10 mL) was added and the mixture was extracted with ethyl acetate (2 x 15 mL). The organic layer was washed with brine (2 x 10 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20) to provide 5-bromo-1-propyl-1 ,2- dihydropyridin-2-one (25a) (776 mg, 3.59 mmol, 62%). 1H NMR (400 MHz, CDCI3) δ 0.96 (t, J = 7.4 Hz, 3H), 1.77 (sext, J = 7.4 Hz, 2H), 3.85 (t, J = 7.4 Hz, 2H), 6.48 (d, J = 9.6 Hz, 1 H), 7.32 (dd, J = 2.7 Hz, J = 9.6 Hz, 1 H), 7.37 (d, J = 2.7 Hz, 1 H).
MS m/z ([M+H]+) 216/218.
Step 2: preparation of intermediate 1-propyl-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 ,2-dihydropyridin-2-one (25b)
[1 ,1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) (293 mg, 0.36 mmol) was added to a previously degassed with argon solution of 5-bromo-1-propyl-1 ,2- dihydropyridin-2-one (25a) (776 mg, 3.59 mmol), bis(pinacolato)diboron (1.37 g, 5.39 mmol) and potassium acetate (1.23 g, 12.57 mmol) in anhydrous N,N- dimethylformamide (20 mL). The reaction mixture was heated at 95°C for 16 hours. Water (50 mL) was added and the reaction mixture was concentrated in vacuo. Water (50 mL) was added to the residue and the mixture was extracted with ethyl acetate (2 x 50 mL). The organic layer was washed with brine (40 mL), dried over sodium sulfate, concentrated in vacuo, and co-evaporated with toluene. The residue was purified by flash chromatography on silica gel (dichloromethane/methanol 100/0 to 95/5) then by preparative TLC (dichloromethane/ethyl acetate 60/40) to provide 1 - propyl-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (25b) (467 mg, 1.77 mmol, 49%).
1H NMR (300 MHz, CDCI3) δ 0.95 (t, J = 7.3 Hz, 3H), 1 .30 (s, 12H), 1.68-1.87 (m, 2H), 3.98 (t, J = 7.3 Hz, 2H), 6.50 (d, J = 8.9 Hz, 1 H), 7.58 (d, J = 8.1 Hz, 1 H), 7.72 (s, 1 H).
MS m/z ([M+H]+) 264.
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-3-(6-oxo-1-propyl-1 ,6-dihydropyridin-3-yl)-6- (trifluoromethyl)phenyl]acetate (25c)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2/-/-1 -benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1 -propyl-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (25b) (64 mg, 0.245 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 50/50) to methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(6-oxo-1 - propyl-1 ,6-dihydropyridin-3-yl)-6-(trifluoromethyl)phenyl]acetate (25c) (43 mg, 0.077 mmol, 63%). 1H NMR (300 MHz, CDCI3) δ 0.83 and 0.84 (t, J = 7.3 Hz, 3H), 0.94 and 0.95 (s, 9H), 1.46-1.64 (m, 2H), 1.89-2.08 (m, 2H), 2.48-2.67 (m, 1 H), 2.69-2.77 (m, 1 H), 3.49-3.68 (m, 1 H), 3.72 (s, 3H), 3.80-3.98 (m, 1 H), 4.10-4.27 (m, 2H), 5.15 and 5.16 (s, 1 H), 6.40 and 6.42 (d, J = 9.3 Hz, 1 H), 6.51-6.57 (m, 1 H), 6.64 and 6.78 (d, J = 8.3 Hz, 1 H), 6.85-6.91 (m, 1 H), 7.07-7.14 (m, 2H), 7.34-7.43 (m, 1 H), 7.74 (d, J = 8.2 Hz, 1 H). MS m/z ([M+H]+) 558.
Step 4: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(6- oxo-1 -propyl-1 ,6-dihydropyridin-3-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 25)
To a solution of methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(6- oxo-1 -propyl-1 ,6-dihydropyridin-3-yl)-6-(trifluoromethyl)phenyl]acetate (25c) (43 mg, 0.077 mmol) in a mixture of dioxane (1.0 mL) and water (0.5 mL) was added lithium hydroxide (15 mg, 0.62 mmol). The mixture was heated at 1 10°C for 80 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. Water (2 mL) was added to the residue and the aqueous layer was washed with diethyl ether (2 mL), acidified with 1 M hydrochloric acid until pH 3 and extracted with diethyl ether (2 x 3 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo to provide 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(6-oxo-1 - propyl-1 ,6-dihydropyridin-3-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 25) (37 mg, 0.068 mmol, 88%).
1H NMR (300 MHz, CDCI3) δ 0.82 and 0.83 (t, J = 7.5 Hz, 3H), 0.97 (s, 9H), 1.44-1 .68 (m, 2H), 1.85-2.12 (m, 2H), 2.45-2.66 (m, 1 H), 2.66-2.94 (m, 1 H), 3.38-3.72 (m, 1 H), 3.77-4.01 (m, 1 H), 4.08-4.30 (m, 2H), 5.29 and 5.32 (s, 1 H), 6.38-6.48 (m, 1 H), 6.48- 6.60 (m, 1 H), 6.61-6.91 (m, 2H), 7.07-7.18 (m, 1 H), 7.38-7.55 (m, 2H), 7.76 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 544.
Example 26: synthesis of 2-[3-(1-benzyl-6-oxo-1 ,6-dihvdropyridin-3-yl)-2-(3,4- dihvdro-2/-/-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyll-2-(te f-butoxy)acetic acid
Step 1 : preparation of intermediate 1-benzyl-5-bromo-1 ,2-dihydropyridin-2-one (26a) Under a nitrogen atmosphere, sodium hydride 60% in oil (0.23 g, 5.75 mmol) was added portionwise to a solution of 5-bromo-2(1 H)-pyridone (1 .00 g, 5.75 mmol) in anhydrous tetrahydrofuran (20 mL). After 10 minutes stirring, benzyl bromide (2.05 mL, 17.24 mmol) was added and the reaction mixture was stirred at 50°C for 5 hours. Water (10 mL) was added and the mixture was extracted with ethyl acetate (2 x 15 mL). The organic layer was washed with brine (2 x 10 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 85/15) to provide 1 -benzyl-5-bromo- 1 ,2-dihydropyridin-2-one (26a) ( 1 .47 g, 5.57 mmol, 97%).
1H NMR (300 MHz, CDCI3) δ 5.09 (s, 2H), 6.53 (d, J = 9.5 Hz, 1 H), 7.27-7.41 (m, 7H). MS m/z ([M+H]+) 264/266. Step 2: preparation of intermediate 1-benzyl-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 ,2-dihydropyridin-2-one (26b)
Using the procedure described in example 25, step 2, the intermediate 1 -benzyl-5- bromo-1 ,2-dihydropyridin-2-one (26a) (1.45 g, 5.49 mmol) is converted, after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20), and trituration in diethyl ether, to 1-benzyl-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (26b) (734 mg, 2.36 mmol, 43%).
1H NMR (300 MHz, CDCI3) δ 1.29 (s, 12H), 5.15 (s, 2H), 6.57 (d, J = 9.1 Hz, 1 H), 7.26-7.38 (m, 5H), 7.60 (dd, J = 1.9 Hz, J = 9.1 Hz, 1 H), 7.78 (d, J = 1.9 Hz, 1 H). MS m/z ([M+H]+) 312.
Step 3: preparation of intermediate methyl 2-[3-(1 -benzyl-6-oxo-1 ,6-dihydropyridin-3- yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert- butoxy)acetate (26c) Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1-benzyl-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (26b) (76 mg, 0.245 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 50/50) to methyl 2-[3-(1 -benzyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(iert-butoxy)acetate (26c) (48 mg, 0.079 mmol, 65%).
1H NMR (300 MHz, CDCI3) δ 0.93 and 0.95 (s, 9H), 1.88-2.06 (m, 2H), 2.43-2.62 (m, 1 H), 2.65-2.74 (m, 1 H), 3.71 (s, 3H), 4.12-4.27 (m, 2H), 4.88-5.09 (m, 2H), 5.12 and 5.13 (s, 1 H), 6.41-6.55 (m, 2H), 6.65 and 6.74 (d, J = 8.3 Hz, 1 H), 6.96-7.14 (m, 5H), 7.27-7.37 (m, 4H), 7.72 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 606. Step 4: preparation of 2-[3-(1-benzyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro- 2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid (example 26)
Using the procedure described in example 25, step 4, the intermediate methyl 2-[3-(1- benzyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetate (26c) (48 mg, 0.079 mmol) is converted to 2-[3-(1 -benzyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid (example 26) (43 mg, 0.073 mmol, 62%).
1H NMR (300 MHz, CDCI3) δ 0.96 (s, 9H), 1.88-2.05 (m, 2H), 2.41-2.62 (m, 1 H), 2.62- 2.85 (m, 1 H), 4.10-4.26 (m, 2H), 4.93 (d, J = 14.2 Hz, 1 H), 5.02 (d, J = 14.2 Hz, 1 H), 5.26 and 5.28 (s, 1 H), 6.40-6.55 (m, 2H), 6.65 and 6.79 (d, J = 8.3 Hz, 1 H), 6.95-6.99 (m, 1 H), 7.04-7.13 (m, 3H), 7.27-7.47 (m, 5H), 7.73 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 592. Example 27: synthesis of 2-(te/f-butoxy)-2-{3-[1-(cvclopropylmethyl)-6-oxo-1 ,6- dihvdropyridin-3-yll-2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl)acetic acid
Step 1 : preparation of intermediate 5-bromo-1-(cyclopropylmethyl)-1 ,2- dihydropyridin-2-one (27a)
Under a nitrogen atmosphere, sodium hydride 60% in oil (0.41 g, 10.34 mmol) was added portionwise to a solution of 5-bromo-2(1 H)-pyridone (1 .50 g, 8.62 mmol) in dry tetrahydrofuran (25 mL). After 10 minutes stirring, (bromomethyl)cyclopropane (1.25 mL, 12.93 mmol) was added and the reaction mixture was stirred at 50°C for 7 days. Water (10 mL) was added and the mixture was extracted with ethyl acetate (2 x 15 mL). The organic layer was washed with brine (2 x 10 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 85/15) to provide 5-bromo-1- (cyclopropylmethyl)-1 ,2-dihydropyridin-2-one (27a) ( 1.45 g, 6.36 mmol, 74%).
1H NMR (300 MHz, CDCI3) δ 0.35-0.42 (m, 2H), 0.59-0.68 (m, 2H), 1.15-1.29 (m, 1 H), 3.76 (d, J = 7.2 Hz, 2H), 6.49 (d, J = 9.6 Hz, 1 H), 7.34 (dd, J = 2.7 Hz, J = 9.6 Hz, 1 H), 7.50 (d, J = 2.7 Hz, 1 H),
MS m/z ([M+H]+) 228/230.
Step 2: preparation of intermediate 1 -(cyclopropylmethyl)-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (27b)
Using the procedure described in example 25, step 2, the intermediate 5-bromo-1- (cyclopropylmethyl)-l ,2-dihydropyridin-2-one (27a) (0.70 g, 3.07 mmol) is converted, after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20), into 1-(cyclopropylmethyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 ,2-dihydropyridin-2-one (27b) (384 mg, 1.40 mmol, 45%).
1H NMR (300 MHz, CDCI3) δ 0.36-0.42 (m, 2H), 0.54-0.62 (m, 2H), 1.26-1.35 (m, 1 H), 1.31 (s, 12H), 3.80 (d, J = 7.2 Hz, 2H), 6.52 (d, J = 9.1 Hz, 1 H), 7.59 (dd, J = 2.0 Hz, J = 9.1 Hz, 1 H), 7.78 (d, J = 2.0 Hz, 1 H),
MS m/z ([M+H]+) 276. Step 3: preparation of intermediate methyl 2-(fe/t-butoxy)-2-{3-[1-(cyclopropylmethyl)- 6-OXO-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl}acetate (27c)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1-(cyclopropylmethyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2- one (27b) (68 mg, 0.245 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 50/50) to methyl 2-(ie/f-butoxy)-2-{3-[1 - (cyclopropylmethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl)phenyl}acetate (27c) (42 mg, 0.074 mmol, 60%).
1H NMR (400 MHz, CDCI3) δ 0.19-0.30 (m, 2H), 0.47-0.58 (m, 2H), 0.94-1.07 (m, 10H), 1.90-2.07 (m, 2H), 2.52-2.66 (m, 1 H), 2.68-2.76 (m, 1 H), 3.48-3.61 (m, 1 H), 3.67-3.79 (m, 4H), 4.12-4.24 (m, 2H), 5.15 and 5.16 (s, 1 H), 6.41 and 6.42 (d, J = 9.3 Hz, 1 H), 6.50-6.60 (m, 1 H), 6.65 and 6.77 (d, J = 8.3 Hz, 1 H), 6.98-7.02 (m, 1 H), 7.07-7.15 (m, 2H), 7.39 (d, J = 8.2 Hz, 1 H), 7.75 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 570. Step 4: preparation of 2-(ie f-butoxy)-2-{3-[1 -(cyclopropylmethyl)-6-oxo-1 ,6- dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl}acetic acid (example 27)
Using the procedure described in example 25, step 4, the intermediate methyl 2-(tert- butoxy)-2-{3-[1-(cyclopropylmethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H- 1-benzopyran-6-yl)-6-(trifluoromethyl) phenyljacetate (27c) (42 mg, 0.074 mmol) is converted into 2-(ie f-butoxy)-2-{3-[1-(cyclopropylmethyl)-6-oxo-1 ,6-dihydropyridin-3- yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyljacetic acid (example 27) (39 mg, 0.070 mmol, 95%).
1H NMR (400 MHz, CDCI3) δ 0.17-0.31 (m, 2H), 0.47-0.59 (m, 2H), 0.97 (s, 10H), 1.89-2.10 (m, 2H), 2.51-2.65 (m, 1 H), 2.70-2.90 (m, 1 H), 3.45-3.62 (m, 1 H), 3.64-3.82 (m, 1 H), 4.10-4.25 (m, 2H), 5.29 and 5.31 (s, 1 H), 6.44 and 6.45 (d, J = 9.3 Hz, 1 H), 6.50-6.59 (m, 1 H), 6.66 and 6.83 (d, J = 8.3 Hz, 1 H), 6.97-7.04 (m, 1 H), 7.10-7.18 (m, 1 H), 7.39-7.57 (m, 2H), 7.76 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 556.
Example 28: synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (2-propylpyridin-4-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate 4-bromo-2-propylpyridine (28a)
Under a nitrogen atmosphere, a suspension of 4-bromopyridine hydrochloride (1 .0 g, 5.14 mmol) in anhydrous tetrahydrofuran (20 mL) was cooled to -78°C. Propylmagnesium chloride 2.0M in diethyl ether (5.66 mL, 1 1.31 mmol) was dropwise added, followed by phenyl chloroformate (0.77 mL, 6.17 mmol) 5 minutes later. The mixture was stirred at -78°C for 15 minutes, then allowed to reach 10°C to be quenched by adding a saturated solution of ammonium chloride (20 mL). Diethyl ether (10 mL) was added, and the organic layer was successively washed with 1 N hydrochloric acid (20 mL), water (20 mL) and brine (20 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in anhydrous toluene (20 mL). To this solution was dropwise added a solution of o- chloranil (1 .39 g, 5.66 mmol) in glacial acetic acid (15 mL). The mixture was stirred at room temperature for 16 hours, then cooled to 0°C, and basified with 1 N sodium hydroxide until pH 10. The mixture was extracted with ethyl acetate (2 x 10 mL). The organic layer was extracted with 1 N hydrochloric acid (2 x 10 mL). The acidic aqueous layer was washed with ethyl acetate (2 x 10 mL), basified with 1 N sodium hydroxide until pH 10, and extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 100/0 to 95/5) to provide 4-bromo-2-propylpyridine (28a) (649 mg, 3.24 mmol, 63%) as a colorless oil.
1H NMR (400 MHz, CDCI3) δ 0.97 (t, J = 7.4 Hz, 3H), 1.45 (sext, J = 7.4 Hz, 2H), 2.74 (t, J = 7.4 Hz, 2H), 7.27 (dd, J = 5.3 Hz, J = 1.8 Hz, 1 H), 7.33 (d, J = 1.8 Hz, 1 H), 8.33 (d, J = 5.3 Hz, 1 H).
Step 2: preparation of intermediate 2-propyl-4-(tetramethyl-1 ,3,2-dioxaborolan-2- yl)pyridine (28b) Di(1-adamantyl)-n-butylphosphine (8.1 mg, 0.022 mmol) and tris(dibenzylideneacetone)dipalladium(0) (6.8 mg, 0.007 mmol) were added to a previously degassed solution of 4-bromo-2-propylpyridine (28a) (150 mg, 0.75 mmol), bis(pinacolato)diboron (228 mg, 0.90 mmol) and potassium acetate (221 mg, 2.25 mmol) in anhydrous dimethylacetamide (0.5 mL). The reaction mixture was heated at 90°C for 16 hours. Water (5 mL) was added and the precipitate was filtrated and rinsed with water (2 mL). The filtrated was extracted with ethyl acetate (2 x 8 mL). The organic layer was washed with brine (10 mL), dried over sodium sulfate, concentrated in vacuo and co-evaporated with toluene to provide 2-propyl-4- (tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (28b) (126 mg, 0.51 mmol, 68%) which was used without further purification.
1H NMR (300 MHz, CDCI3) 5 0.96 (t, J = 7.4 Hz, 3H), 1.35 (s, 12H), 1.76 (sext, J = 7.4 Hz, 2H), 2.77 (m, 2H), 7.43 (d, J = 4.7 Hz, 1 H), 4.49 (s, 1 H), 8.54 (d, J = 4.7 Hz, 1 H). Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-3-(2-propylpyridin-4-yl)-6-(trifluoromethyl) phenyl]acetate (28c)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (80 mg, 0.140 mmol) is converted by reaction with 2-propyl-4-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (28b) (69 mg, 0.280 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 80/20) to methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2-propylpyridin-4-yl)-6- (trifluoromethyl) phenyl]acetate (28c) (45 mg, 0.083 mmol, 59%).
1H NMR (400 MHz, CDCI3) δ 0.82 and 0.83 (t, J = 7.4 Hz, 3H), 0.95 and 0.96 (s, 9H), 1.51 -1.62 (m, 2H), 1.84-1.92 (m, 1 H), 1.94-2.04 (m, 1 H), 2.34-2.57 (m, 1 H), 2.58-2.65 (m, 2H), 2.70-2.75 (m, 1 H), 3.74 (s, 3H), 4.06-4.22 (m, 2H), 5.20 (s, 1 H), 6.37-6.47 (m, 1 H), 6.48-6.78 (m, 2H), 6.81-6.87 (m, 1 H), 7.08-7.17 (m, 1 H), 7.41 and 7.42 (d, J = 8.1 Hz, 1 H), 7.78 (d, J = 8.1 Hz, 1 H), 8.35 (d, J = 5.1 Hz, 1 H).
MS m/z ([M+H]+) 542.
Step 4: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2- propylpyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 28)
Using the procedure described in example 2, step 2, methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2/-/-1-benzopyran-6-yl)-3-(2-propylpyridin-4-yl)-6- (trifluoromethyl)phenyl]acetate (28c) (45 mg, 0.083 mmol) is converted into 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2-propylpyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 28) (35 mg, 0.066 mmol, 80%). 1H NMR (400 MHz, CDCI3) 5 0.82 (t, J = 7.4 Hz, 3H), 0.98 (s, 9H), 1 .49-1.63 (m, 2H), 1.82-1.94 (m, 1 H), 1.94-2.08 (m, 1 H), 2.29-2.89 (m, 4H), 4.05-4.23 (m, 2H), 5.33 and 5.37 (s, 1 H), 6.29-6.47 (m, 1 H), 6.48-6.82 (m, 2H), 6.84-6.89 (m, 1 H), 7.42-7.57 (m, 2H), 7.80 (d, J = 8.2 Hz, 1 H), 8.37 (d, J = 5.0 Hz, 1 H).
MS m/z ([M+H]+) 528.
Example 29: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3-
(3-propylphenyl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate 1-(3-bromophenyl)propan-1-ol (29a)
Under a nitrogen atmosphere, sodium borohydride (106 mg, 2.82 mmol) was portionwise added to a solution of 3'-bromopropiophenone (500 mg, 2.35 mmol) in anhydrous methanol (20 mL). The mixture was stirred for 3 hours and water was added (5 mL). The methanol was removed in vacuo, and the aqueous layer was extracted with ethyl acetate (2 x 6 mL). The organic layer was successively washed with water (3 mL) and brine (3 mL), before being dried over sodium sulfate and concentrated in vacuo to provide 1-(3-bromophenyl)propan-1 -ol (29a) (502 mg, 2.33 mmol, 99%) which was used without further purification.
1H NMR (300 MHz, CDCI3) δ 0.92 (t, J = 7.4 Hz, 3H), 1 .68-1.85 (m, 2H), 4.58 (t, J = 6.5 Hz, 1 H), 7.18-7.28 (m, 2H), 7.37-7.43 (m, 1 H), 7.49-7.52 (m, 1 H).
Step 2: preparation of intermediate 1-bromo-3-propylbenzene (29b)
Under a nitrogen atmosphere, triethylsilane (4.46 mL, 27.90 mmol) and boron trifluoride ethyl etherate (0.92 mL, 7.44 mmol) were successively added to a solution of 1-(3-bromophenyl)propan-1-ol (29a) (400 mg, 1.86 mmol) in anhydrous dichloromethane (30 mL) at -78°C. The mixture was stirred at room temperature overnight. Water (15 mL) was added and layers were separated. The organic layer was washed with water (15 mL), dried over sodium sulfate and concentrated in vacuo to provide 1-bromo-3-propylbenzene (29b) (338 mg, 1.70 mmol, 91 %) which was used without further purification.
1H NMR (300 MHz, CDCI3) δ 0.94 (t, J = 7.4 Hz, 3H), 1.63 (sext, J = 7.4 Hz, 2H), 2.53-2.58 (m, 2H), 7.07-7.17 (m, 2H), 7.28-7.34 (m, 2H). Step 3: preparation of intermediate 4,4,5,5-tetramethyl-2-(3-propylphenyl)-1 ,3,2- dioxaborolane (29c)
Using the procedure described in example 25, step 2, the intermediate 1 -bromo-3- propylbenzene (29b) (100 mg, 0.50 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 95/5) to 4,4,5,5-tetramethyl-2-(3- propylphenyl)-1 ,3,2-dioxaborolane (29c) (122 mg, 0.49 mmol, 99%).
1H NMR (300 MHz, CDCI3) 5 0.94 (t, J = 7.4 Hz, 3H), 1.35 (s, 12H), 1.65 (sext, J = 7.4 Hz, 2H), 2.56-2.62 (m, 2H), 7.27-7.32 (m, 2H), 7.59-7.67 (m, 2H).
MS m/z ([M+H]+) 247. Step 4: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-3-(3-propylphenyl)-6-(trifluoromethyl)phenyl]acetate (29d)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (80 mg, 0.140 mmol) is converted by reaction with 4,4,5,5-tetramethyl-2-(3-propylphenyl)-1 ,3,2-dioxaborolane (29c) (69 mg, 0.280 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 75/25) to methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-propylphenyl)-6- (trifluoromethyl) phenyl]acetate (29d) (62 mg, 0.1 1 mmol, 82%).
1H NMR (400 MHz, CDCI3) δ 0.78 (t, J = 7.3 Hz, 3H), 0.95 and 0.96 (s, 9H), 1.35-1.48 (m, 2H), 1.83-1 .92 (m, 1 H), 1 .94-2.03 (m, 1 H), 2.32-2.57 (m, 3H), 2.71-2.77 (m, 1 H), 3.73 and 3.74 (s, 3H), 4.07-4.21 (m, 2H), 5.19 and 5.21 (s, 1 H), 6.37-6.79 (m, 3H), 6.88-7.19 (m, 4H), 7.42-7.46 (m, 1 H), 7.74 (d, J = 8.2 Hz, 1 H).
Step 5: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-(3- propylphenyl)-6-(trifluoromethyl)phenyl]acetic acid (example 29)
Using the procedure described in example 2, step 2, methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2/-/-1-benzopyran-6-yl)-3-(3-propylphenyl)-6-(trifluoromethyl) phenyl]acetate (29d) (62 mg, 0.1 1 mmol) is converted, after purification by 2 preparative TLC (dichloromethane/methanol 98/2) and (cyclohexane/ethyl acetate 55/45) to 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(3-propylphenyl)-6- (trifluoromethyl)phenyl]acetic acid (exemple 29) (20 mg, 0.038 mmol, 33%).
1H NMR (400 MHz, CDCI3) 5 0.78 (t, J = 7.3 Hz, 3H), 0.97 (s, 9H), 1 .34-1.50 (m, 2H), 1.77-1.90 (m, 1 H), 1.94-2.04 (m, 1 H), 2.26-2.60 (m, 3H), 2.72-2.86 (m, 1 H), 4.03-4.21 (m, 2H), 5.35 and 5.40 (s, 1 H), 6.31-6.82 (m, 3H), 6.87-6.99 (m, 2H), 7.04-7.17 (m, 1 H), 7.42-7.55 (m, 2H), 7.78 (d, J = 8.1 Hz, 1 H).
MS m/z ([M-H]") 525.
Example 30: synthesis of 2-(te f-butoxy)-2-{3-[1 -(cvclobutylmethyl)-6-oxo-1 ,6- dihvdropyridin-3-yll-2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl)acetic acid
Step 1 : preparation of intermediate 5-bromo-1-(cyclobutylmethyl)-1 ,2-dihydropyridin- 2-one (30a)
Potassium ie f-butoxide 1 N in tetrahydrofuran (5.75 mL, 5.75 mmol) was added to a suspension of 5-bromo-2(1 H)-pyridone (1.00 g, 5.75 mmol) in dimethoxyethane (10 mL). After 30 minutes stirring at room temperature, potassium carbonate (0.56 g, 4.02 mmol) and (bromomethyl)cyclobutane (1 .29 mL, 1 1 .49 mmol) were added and the reaction mixture was refluxed for 24 hours. The resultant precipitate was filtered and rinced with ethyl acetate (20 mL). The filtrate was successively washed with water (20 mL) and brine (20 mL), then dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (dichloromethane/ethyl acetate: 100/0 to 80/20) to provide 5-bromo-1 - (cyclobutylmethyl)-1 ,2-dihydropyridin-2-one (30a) ( 1 .10 g, 4.54 mmol, 79%).
1H NMR (400 MHz, CDCI3) δ 1.72-1.85 (m, 2H), 1 .85-1.97 (m, 2H), 2.01 -2.12 (m, 2H), 2.77 (septuplet, J = 7.5 Hz, 1 H), 3.92 (d, J = 7.5 Hz, 2H), 6.47 (d, J = 9.5 Hz, 1 H), 7.31 (dd, J = 2.7 Hz, J = 9.5 Hz, 1 H), 7.34 (d, J = 2.7 Hz, 1 H). MS m/z ([M+H]+) 242/244.
Step 2: preparation of intermediate 1 -(cyclobutylmethyl)-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (30b)
Using the procedure described in example 25, step 2, the intermediate 5-bromo-1- (cyclobutylmethyl)-l ,2-dihydropyridin-2-one (30a) (1.0 g, 4.13 mmol) is converted into 1-(cyclobutylmethyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (30b) (554 mg, 1 .92 mmol, 46%), after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20) and trituration in pentane.
1H NMR (300 MHz, CDCI3) δ 1.30 (s, 12H), 1.72-1.95 (m, 4H), 1.96-2.10 (m, 2H), 2.81 (septuplet, J = 7.5 Hz, 1 H), 3.96 (d, J = 7.5 Hz, 2H), 6.49 (d, J = 9.1 Hz, 1 H), 7.55 (dd, J = 2.0 Hz, J = 9.1 Hz, 1 H), 7.68 (d, J = 2.0 Hz, 1 H),
MS m/z ([M+H]+) 290. Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-{3-[1-(cyclobutylmethyl)- 6-OXO-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl}acetate (30c)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1-(cyclobutylmethyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (30b) (53 mg, 0.183 mmol) into methyl 2-(ie/f-butoxy)-2-{3-[1-(cyclobutylmethyl)-6- oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6- (trifluoromethyl)phenyl}acetate (30c) (59 mg, 0.101 mmol, 81 %), after purification by preparative TLC (dichloromethane/ethyl acetate 70/30).
1H NMR (400 MHz, CDCI3) δ 0.94 and 0.95 (s, 9H), 1.57-1 .73 (m, 2H), 1.81 -2.01 (m, 6H), 2.49-2.65 (m, 2H), 2.72-2.76 (m, 1 H), 3.61-3.77 (m, 4H), 3.84-4.00 (m, 1 H), 4.15-4.25 (m, 2H), 5.13 and 5.14 (s, 1 H), 6.38 (d, J = 9.4 Hz, 1 H), 6.50-6.57 (m, 1 H), 6.65 and 6.79 (d, J = 8.3 Hz, 1 H), 6.86 and 6.89 (d, J = 2.4 Hz, 1 H), 7.02-7.14 (m, 2H), 7.34-7.37 (m, 1 H), 7.74 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 584.
Step 4: preparation of 2-(ie f-butoxy)-2-{3-[1 -(cyclobutylmethyl)-6-oxo-1 ,6- dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl}acetic acid (example 30)
Using the procedure described in example 25, step 4, the intermediate methyl 2-(iert- butoxy)-2-{3-[1-(cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro -2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetate (30c) (59 mg, 0.101 mmol) is converted into 2-(fe/t-butoxy)-2-{3-[1-(cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-3- yl]-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetic acid (example 30) (37 mg, 0.065 mmol, 63%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.96 (s, 9H), 1.58-1.71 (m, 2H), 1 .82-2.04 (m, 6H), 2.49- 2.60 (m, 2H), 2.73-2.84 (m, 1 H), 3.58-3.72 (m, 1 H), 3.85-4.00 (m, 1 H), 4.15-4.22 (m, 2H), 5.27 (bs, 1 H), 6.41 (d, J = 9.3 Hz, 1 H), 6.49-6.89 (m, 3H), 7.07-7.10 (m, 1 H), 7.37-7.50 (m, 2H), 7.75 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 570.
Example 31 : synthesis of 2-(te f-butoxy)-2-{3-[1-(2-cvclopropylethyl)-6-oxo-1 ,6- dihvdropyridin-3-yll-2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-6- (trifluoromethvDphenvDacetic acid
Step 1 : preparation of intermediate 2-cyclopropylethyl-4-methylbenzene-1 -sulfonate (31 a)
Pyridine (1 .41 mL, 17.42 mmol) and p-Toluenesulfonyl chloride (2.10 g, 1 1 .03 mmol) were added to a solution of 2-cyclopropylethanol (1 .00 g, 1 1 .61 mmol) in dichloromethane (10 mL). The reaction mixture was stirred at room temperature overnight. Water (20 mL) was added, and the mixture was extracted with dichloromethane (2 x 20 mL). The organic layer was successively washed with 10% aqueous hydrochloric acid (20 mL) and saturated solution of sodium bicarbonate (20 mL), then dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate: 80/20) to provide 2-cyclopropylethyl 4-methylbenzene-1 -sulfonate (31 a) (2.10 g, 8.74 mmol, 75%) as a colorless oil.
1H NMR (400 MHz, CDCI3) δ -0.02-0.06 (m, 2H), 0.35-0.46 (m, 2H), 0.58-0.74 (m, 1 H), 1.54 (q, J = 6.7 Hz, 2H), 2.43 (s, 3H), 4.09 (t, J = 6.7 Hz, 2H), 7.34 (d, J = 8.1 Hz, 1 H), 7.80 (d, J = 8.1 Hz, 1 H). Step 2: preparation of intermediate 5-bromo-1-(2-cyclopropylethyl)-1 ,2- dihydropyridin-2-one (31 b)
Using the procedure described in example 30, step 1 , the intermediate 2- cyclopropylethyl 4-methylbenzene-1 -sulfonate (31a) (2.02 g, 8.40 mmol) is converted by reaction with 5-bromo-2(1 H)-pyridone (0.75 g, 4.31 mmol) into 5-bromo-1-(2- cyclopropylethyl)-1 ,2-dihydropyridin-2-one (31 b) (743 mg, 3.07 mmol, 71 %) after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 85/15).
1H NMR (400 MHz, CDCI3) δ -0.01-0.08 (m, 2H), 0.43-0.51 (m, 2H), 0.59-0.72 (m, 1 H), 1.58-1.67 (m, 2H), 3.97 (t, J = 7.0 Hz, 2H), 6.47 (d, J = 9.6 Hz, 1 H), 7.33 (dd, J = 2.7 Hz, J = 9.6 Hz, 1 H), 7.41 (d, J = 2.7 Hz, 1 H).
MS m/z ([M+H]+) 242/244. Step 3: preparation of intermediate 1-(2-cyclopropylethyl)-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (31 c)
Using the procedure described in example 25, step 2, the intermediate 5-bromo-1 -(2- cyclopropylethyl)-1 ,2-dihydropyridin-2-one (31 b) (800 mg, 3.31 mmol) is converted into 1-(2-cyclopropylethyl)-5-(tetramethyl-1 ,3,2-dioxa borolan-2-yl)-1 ,2-dihydropyridin- 2-one (31 c) (677 mg, 2.34 mmol, 71 %) after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate: 100/0 to 75/25).
1H NMR (300 MHz, CDCI3) δ -0.02-0.08 (m, 2H), 0.38-0.49 (m, 2H), 0.59-0.75 (m, 1 H), 1.30 (s, 12H), 1.65 (q, J = 7.1 Hz, 2H), 4.01 (t, J = 7.1 Hz, 2H), 6.49 (d, J = 9.1 Hz, 1 H), 7.57 (dd, J = 2.0 Hz, J = 9.1 Hz, 1 H), 7.74 (d, J = 2.0 Hz, 1 H).
MS m/z ([M+H]+) 290.
Step 4: preparation of intermediate methyl 2-(ie f-butoxy)-2-{3-[1 -(2-cyclopropylethyl)- 6-OXO-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl}acetate (31 d)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(iert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1 -(cyclopropylethyl)- 5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (31c) (89 mg, 0.31 mmol) into methyl 2-(ie/f-butoxy)-2-{3-[1-(2-cyclopropylethyl)-6- oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6-
(trifluoromethyl)phenyl}acetate (31 d) (54 mg, 0.092 mmol, 75%), after purification by preparative TLC (dichloromethane/ethyl acetate: 70/30). 1H NMR (400 MHz, CDCI3) δ -0.01-0.01 (m, 2H), 0.39-0.44 (m, 2H), 0.50-0.60 (m, 1 H), 0.94 and 0.96 (s, 9H), 1.31-1 .52 (m, 2H), 1 .93-2.06 (m, 2H), 2.51-2.64 (m, 1 H), 2.73 (t, J = 6.3 Hz, 1 H), 3.64-3.81 (m, 4H), 3.91 -4.04 (m, 1 H), 4.15-4.22 (m, 2H), 5.14 and 5.16 (s, 1 H), 6.36 and 6.39 (d, J = 9.4 Hz, 1 H), 6.50-6.59 (m, 1 H), 6.64 and 6.76 (d, J = 8.3 Hz, 1 H), 6.91 and 6.94 (d, J = 2.4 Hz, 1 H), 7.02-7.12 (m, 2H), 7.37 and 7.38 (d, J = 8.2 Hz, 1 H), 7.74 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 584.
Step 5: preparation of 2-(ie f-butoxy)-2-{3-[1-(2-cyclopropylethyl)-6-oxo-1 ,6- dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl}acetic acid (example31)
Using the procedure described in example 25, step 4, the methyl 2-(ie f-butoxy)-2-{3- [1-(2-cyclopropylethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetate (31 d) (54 mg, 0.092 mmol) is converted into 2-(fe/t-butoxy)-2-{3-[1 -(2-cyclopropylethyl)-6-oxo-1 ,6-dihydropyridin-3- yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoro methyl) phenyl}acetic acid (example 31) (35 mg, 0.061 mmol, 66%) as a white solid.
1H NMR (400 MHz, CDCI3) δ -0.02 (s, 2H), 0.40-0.43 (m, 2H), 0.50-0.58 (m, 1 H), 0.96 (s, 9H), 1.22-1 .49 (m, 2H), 1.90-2.00 (m, 2H), 2.51 -2.61 (m, 1 H), 2.72-2.84 (m, 1 H), 3.64-3.73 (m, 1 H), 3.93-4.03 (m, 1 H), 4.16-4.21 (m, 2H), 5.28 (s, 1 H), 6.39 and 6.43 (d, J = 9.4 Hz, 1 H), 6.49-6.84 (m, 2H), 6.90-6.93 (m, 1 H), 7.06-7.15 (m, 1 H), 7.39- 7.50 (m, 2H), 7.78 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 570. Example 32: synthesis of 2-(te/ -butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- ri-(2-methylpropyl)-6-oxo-1 ,6-dihvdropyridin-3-yll-6-(trifluoromethyl) phenyllacetic acid
Step 1 : preparation of intermediate 5-bromo-1-(2-methylpropyl)-1 ,2-dihydropyridin-2- one (32a)
Using the procedure described in example 30, step 1 , 5-bromo-2(1 H)-pyridone (0.5 g, 2.87 mmol) is converted by reaction with 1-bromo-2-methylpropane (0.63 mL, 5.75 mmol), after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20) to 5-bromo-1 -(2-methylpropyl)-1 ,2-dihydropyridin-2-one (32a) (416 mg, 1 .81 mmol, 63%).
1H NMR (400 MHz, CDCI3) δ 0.93 (d, J = 6.7 Hz, 6H), 2.07-2.21 (m, 1 H), 3.69 (d, J = 7.6 Hz, 2H), 6.44-6.51 (m, 1 H), 7.29-7.35 (m, 2H).
MS m/z ([M+H]+) 230/232.
Step 2: preparation of intermediate 1-(2-methylpropyl)-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (32b)
Using the procedure described in example 25, step 2, the intermediate 5-bromo-1 -(2- methylpropyl)-1 ,2-dihydropyridin-2-one (32a) (400 mg, 1 .74 mmol) is converted, after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate
100/0 to 90/10) and trituration in pentane, to 1-(2-methylpropyl)-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (32b) (250 mg, 0.90 mmol, 52%).
1H NMR (400 MHz, CDCI3) δ 0.93 (d, J = 6.7 Hz, 6H), 1.31 (s, 12H), 2.14-2.26 (m, 1 H), 3.75 (d, J = 7.5 Hz, 1 H), 6.50 (d, J = 9.1 Hz, 1 H), 7.57 (dd, J = 2.0 Hz, J = 9.1
Hz, 1 H), 7.66 (d, J = 2.0 Hz, 1 H),
MS m/z ([M+H]+) 278.
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[1 -(2-methylpropyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-6- (trifluoromethyl)phenyl]acetate (32c)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1 -(2-methylpropyl)-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (32b) (85 mg, 0.307 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 60/40) to methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H- 1 -benzopyran-6-yl)-3-[1-(2-methylpropyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-6- (trifluoromethyl)phenyl]acetate (32c) (58 mg, 0.101 mmol, 82%).
1H NMR (300 MHz, CDCI3) δ 0.76-0.86 (m, 6H), 0.94 and 0.95 (s, 9H), 1.81 -2.07 (m, 3H), 2.46-2.66 (m, 1 H), 2.68-2.76 (m, 1 H), 3.38-3.53 (m, 1 H), 3.62-3.82 (m, 4H), 4.10-4.26 (m, 2H), 5.13 and 5.15 (s, 1 H), 6.38 and 6.39 (d, J = 9.3 Hz, 1 H), 6.48-6.60 (m, 1 H), 6.64 and 6.77 (d, J = 8.3 Hz, 1 H), 6.84 and 6.87 (d, J = 2.5 Hz, 1 H), 7.02- 7.16 (m, 2H), 7.36 (d, J = 8.2 Hz, 1 H), 7.74 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 572. Step 4: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[1 -(2- methylpropyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-6-(trifluoromethyl) phenyljacetic acid (example 32)
Using the procedure described in example 25, step 4, methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-[1-(2-methylpropyl)-6-oxo-1 ,6-dihyd ropyridin-3-yl]-6- (trifluoromethyl)phenyl]acetate (32c) (57 mg, 0.100 mmol) is converted to 2-(ierf- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1-(2-methylpropyl)-6-oxo-1 ,6- dihydropyridin-3-yl]-6-(trifluoromethyl) phenyljacetic acid (example 32) (45 mg, 0.081 mmol, 80%).
1H NMR (300 MHz, CDCI3) δ 0.77-0.83 (m, 6H), 0.97 (s, 9H), 1 .83-2.08 (m, 3H), 2.50- 2.65 (m, 1 H), 2.66-2.86 (m, 1 H), 3.31-3.53 (m, 1 H), 3.61-3.86 (m, 1 H), 4.10-4.26 (m, 2H), 5.28 and 5.30 (s, 1 H), 6.41 and 6.42 (d, J = 9.3 Hz, 1 H), 6.47-6.59 (m, 1 H), 6.61- 6.89 (m, 2H), 7.05-7.15 (m, 1 H), 7.36-7.56 (m, 2H), 7.75 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 558. Example 33: synthesis of 2-(terf-butoxyV2-r2-(3,4-dihvdro-2H-1-benzoDyran-6-vn-3- (1-ethyl-2-oxo-1 ,2-dihvdropyridin-4-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate 4-bromo-1-ethyl-1 ,2-dihydropyridin-2-one (33a) Using the procedure described in example 25, step 1 , 2-hydroxy-4-bromopyridine (1.00 g, 5.75 mmol) is converted by reaction with iodoethane (1.39 ml_, 17.24 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 100/0 to 85/15) into 4-bromo-1 -ethyl-1 ,2-dihydropyridin-2-one (33a) (981 mg, 4.86 mmol, 84%). 1H NMR (300 MHz, CDCI3) δ 1 .34 (t, J = 7.2 Hz, 3H), 3.94 (q, J = 7.2 Hz, 2H), 6.33 (dd, J = 2.1 Hz, J = 7.2 Hz, 1 H), 6.82 (d, J = 2.1 Hz, 1 H), 7.13 (d, J = 7.2 Hz, 1 H). MS m/z ([M+H]+) 202/204. Step 2: preparation of intermediate 1-ethyl-4-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)- 1 ,2-dihydropyridin-2-one (33b)
Using the procedure described in example 28, step 2, 4-bromo-1 -ethyl-1 ,2- dihydropyridin-2-one (33a) (300 mg, 1.48 mmol) is converted , after purification by preparative TLC (dichloromethane/methanol 95/5), into 1 -ethyl-4-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (33b) (70 mg, 0.28 mmol, 19%).
1H NMR (300 MHz, CDCI3) δ 1.31 (s, 12H), 1 .33 (t, J = 7.2 Hz, 3H), 3.97 (q, J = 7.2 Hz, 2H), 6.40 (dd, J = 1.2 Hz, J = 6.7 Hz, 1 H), 7.00 (bs, 1 H), 7.22 (d, J = 6.7 Hz, 1 H).
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1-ethyl-2-oxo-1 ,2-dihydropyridin-4-yl)-6- (trifluoromethyl)phenyl]acetate (33c)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1-ethyl-4-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (33b) (37 mg, 0.147 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 50/50) to methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-ethyl-2- oxo-1 ,2-dihydropyridin-4-yl)-6-(trifluoromethyl)phenyl]acetate (33c) (37 mg, 0.068 mmol, 55%).
1H NMR (400 MHz, CDCI3) δ 0.93 (s, 9H), 1.26-1.33 (m, 3H), 1 .87-1.98 (m, 1 H), 1.98- 2.06 (m, 1 H), 2.47-2.65 (m, 1 H), 2.65-2.82 (m, 1 H), 3.72 (s, 3H), 3.78-4.01 (m, 2H), 4.12-4.24 (m, 2H), 5.15 and 5.16 (s, 1 H), 5.63 and 5.68 (dd, J = 1.9 Hz, J = 7.0 Hz, 1 H), 6.42 and 6.49 (d, J = 1.7 Hz, 1 H), 6.53-6.76 (m, 2H), 6.92 and 6.95 (d, J = 7.0 Hz, 1 H), 7.05-7.15 (m, 1 H), 7.36-7.43 (m, 1 H), 7.75 and 7.76 (d, J = 8.2 Hz, 1 H). MS m/z ([M+H]+) 544.
Step 4: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 - ethyl-2-oxo-1 ,2-dihydropyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 33) Using the procedure described in example 25, step 4, methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(1 -ethyl-2-oxo-1 ,2-dihydropyridin-4-yl)-6-
(trifluoromethyl)phenyl]acetate (33c) (37 mg, 0.068 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 -ethyl-2-oxo-1 ,2-dihydropyridin- 4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 33) (25 mg, 0.047 mmol, 69%). 1H NMR (400 MHz, CDCI3) δ 0.94 (s, 9H), 1.25-1.35 (m, 3H), 1 .87-1.97 (m, 1 H), 1.97- 2.07 (m, 1 H), 2.47-2.67 (m, 1 H), 2.67-2.86 (m, 1 H), 3.76-4.05 (m, 2H), 4.17 and 4.20 (t, J = 5.1 Hz, 2H), 5.29 and 5.33 (s, 1 H), 5.62 and 5.67 (dd, J = 1.6 Hz, J = 7.0 Hz, 1 H), 6.43-6.84 (m, 3H), 6.92 and 6.95 (d, J = 7.0 Hz, 1 H), 7.40-7.54 (m, 2H), 7.75 and 7.78 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 530. Example 34: synthesis of 2-(te f-butoxy)-2-[3-(1-cvclobutylmethyl-6-oxo-1 ,6-dihydro- Pyridin-3-yl)-2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-6-methylphenyll acetic acid
Step 1 : preparation of intermediate 2-bromo-4-methoxymethoxy-1 -methyl-benzene (34a)
To a solution of 3-bromo-4-methylphenol (3,87 g, 20.7 mmol) in anhydrous dichloromethane (40 mL) under nitrogen atmosphere at 0°C were successively added diisopropylethylamine (5,4 mL, 31.0 mmol) and chloromethyl methyl ether (2.0 mL, 26.9 mmol). The mixture was stirred at 0°C for 3 hours before adding water (40 mL). Layers were separated and the aqueous one was extracted with dichloromethane (40 mL). The combined organic layers were washed with a 2 M sodium hydroxide solution (30 mL), dried over sodium sulfate and concentrated in vacuo to provide 2-bromo-4- methoxymethoxy-1 -methyl-benzene (34a) (4.55 g, 19.7 mmol, 95%) as a yellow oil. 1H NMR (400 MHz, CDCI3) δ 2.33 (s, 3H), 3.46 (s, 3H), 5.13 (s, 2H), 6.89 (dd, J = 2.4 Hz, J = 8.4 Hz, 1 H), 7.12 (d, J = 8.4 Hz, 1 H), 7.25 (d, J = 2.4 Hz, 1 H).
Step 2: preparation of intermediate 5-methoxymethox-2-methyl-benzaldehyde (34b) To a solution of 2-bromo-4-methoxymethoxy-1 -methyl-benzene (34a) (4.54 g, 19.6 mmol) in anhydrous tetrahydrofuran (100 mL) under nitrogen atmosphere at -78°C was dropwise added a 1.6 M n-butyllithium solution in hexanes (15.3 mL, 24.5 mmol). The mixture was stirred at -78°C for 30 minutes and Λ/,/V-dimethylformamide (2.3 mL, 29.7 mmol) was added. After 30 minutes at -78°C, water was added (100 mL). The layers were separated. The aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate and concentrated in vacuo to provide 5-methoxymethox-2-methyl- benzaldehyde (34b) (3.29 g, 18.2 mmol, 93%) as a yellow oil.
1H NMR (300 MHz, CDCI3) δ 2.60 (s, 3H), 3.48 (s, 3H), 5.20 (s, 2H), 7.14-7.20 (m, 2H), 7.47 (s, 1 H), 10.24 (s, 1 H).
Step 3: preparation of intermediate 2-bromo-3-methoxymethox-6-methyl- benzaldehyde (34c)
To a solution of Λ/,Λ/',Λ/'-trimethylethylenediamine (2.6 mL, 20 mmol) in anhydrous toluene (30 mL) at 0°C under nitrogen atmosphere was dropwise added a 1.6 M n- butyllithium solution in hexanes (12 mL, 19.2 mmol). The mixture was stirred at room temperature for 15 minutes before adding a solution of 5-methoxymethox-2-methyl- benzaldehyde (34b) (3.28 g, 18.2 mmol) in anhydrous toluene (10 mL). After 15 minutes at room temperature, the mixture was cooled with an ice bath and a 1 .8 M phenyllithium solution in dibutyl ether (30 mL, 54 mmol) was dropwise added. The mixture was stirred at room temperature overnight. Anhydrous tetrahydrofuran (50 mL) was added to the resulting suspension and the mixture was cooled at -78°C. Dibromotetrachloroethane (17.8 g, 54.6 mmol) was portionwise added. The mixture was stirred at room temperature for 90 minutes before adding water (100 mL). The layers were separated. The aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with 1 M hydrochloric acid (100 mL), brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (dichloromethane / ethyl acetate 30/70) to provide 2-bromo-3-methoxymethox-6-methyl-benzaldehyde (34c) (2.78 g, 10.7 mmol, 59%) as a yellow solid.
1H NMR (300 MHz, CDCI3) δ 2.50 (s, 3H), 3.53 (s, 3H), 5.25 (s, 2H), 7.13 (d, J = 8.4 Hz, 1 H), 7.23 (d, J = 8.4 Hz, 1 H), 10.55 (s, 1 H). MS m/z ([M+H]+) 259 / 261.
Step 4: preparation of intermediate 2-(2-bromo-3-methoxymethoxy-6-methylphenyl)- 2-trimethylsilanyloxy-acetonitrile (34d)
To a solution of 2-bromo-3-methoxymethox-6-methyl-benzaldehyde (34c) (2.78 g, 10.7 mmol) in anhydrous dichloromethane (40 mL) at 0°C under nitrogen atmosphere, were successively added zinc iodide (685 mg, 2.15 mmol) and trimethylsilylcyanide (2.0 mL, 16.1 mmol). The mixture was stirred at 0°C for 90 minutes before adding a saturated solution of sodium hydrogenocarbonate (40 mL). The layers were separated. The aqueous layer was extracted with dichloromethane (40 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to provide 2-(2-bromo-3-methoxymethoxy-6-methyl-phenyl)-2- trimethylsilanyloxy-acetonitrile (34d) (3.78 g, 10.5 mmol, 98%) as a yellow oil.
1H NMR (300 MHz, CDCI3) δ 0.20 (s, 9H), 2.61 (s, 3H), 3.51 (s, 3H), 5.22 (s, 2H), 6.40 (s, 1 H), 7.08 (d, J = 8.4 Hz, 1 H), 7.13 (d, J = 8.4 Hz, 1 H).
Step 5: preparation of intermediate methyl 2-(2-bromo-3-hydroxy-6-methylphenyl)-2- hydroxyacetate (34e)
To a solution of 2-(2-bromo-3-methoxymethoxy-6-methyl-phenyl)-2- trimethylsilanyloxy-acetonitrile (34d) (3.78 g, 10.5 mmol) in anhydrous methanol (50 mL) at 0°C under nitrogen atmosphere was dropwise added sulfuric acid (23 mL). The mixture was refluxed overnight then cooled at room temperature and poured in water (150 mL). The aqueous layer was extracted with diethyl ether (2x50 mL) then with ethyl acetate (2x50 mL). The combined organic layers were washed with a saturated solution of sodium hydrogenocarbonate (100 mL), brine (100 mL), dried over sodium sulfate and concentrated in vacuo to provide methyl 2-(2-bromo-3- hydroxy-6-methyl-phenyl)-2-hydroxyacetate (34e) (2.58 g, 9.38 mmol, 89%) as a brown oil.
1H NMR (300 MHz, CDCI3) δ 2.33 (s, 3H), 3.43 (d, J = 3.6 Hz, 1 H), 3.79 (s, 3H), 5.56 (s, 1 H), 5.72 (d, J = 3.6 Hz, 1 H), 6.93 (d, J = 8.4 Hz, 1 H), 7.04 (d, J = 8.4 Hz, 1 H).
Step 6: preparation of intermediate methyl 2-(3-benzyloxy-2-bromo-6-methylphenyl)- 2-hydroxyacetate (34f)
To a solution of methyl 2-(2-bromo-3-hydroxy-6-methyl-phenyl)-2-hydroxyacetate (34e) (2.58 g, 9.38 mmol) in acetone (50 mL) were successively added cesium carbonate (3.67 g, 1 1.25 mmol) benzyl bromide (1 .23 mL, 10.32 mmol) and sodium iodide (281 mg, 1.88 mmol). The mixture was refluxed for 45 minutes then concentrated in vacuo. Water (50 mL) was added to the residue. The aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with a 2M sodium hydroxide solution (30 mL), brine (30 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate: 80/20) to provide methyl 2- (3-benzyloxy-2-bromo-6-methylphenyl)-2-hydroxyacetate (34f) (2.38 g, 6.51 mmol, 69%) as a white solid.
1H NMR (300 MHz, CDCI3) 5 2.34 (s, 3H), 3.49 (d, J = 4.4 Hz, 1 H), 3.78 (s, 3H), 5.13 (s, 2H), 5.86 (d, J = 4.4 Hz, 1 H), 6.84 (d, J = 8.4 Hz, 1 H), 7.06 (d, J = 8.4 Hz, 1 H), 7.30-7.34 (m, 1 H), 7.37-7.41 (m, 2H), 7.47 (d, J = 7.4 Hz, 2H).
MS m/z ([M+H-H20]+) 347/349.
Step 7: preparation of intermediate methyl 2-[3-benzyloxy-2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-6-methylphenyl]-2-hydroxyacetate (34g)
To a degassed mixture of methyl 2-(3-benzyloxy-2-bromo-6-methylphenyl)-2- hydroxyacetate (34f) (383 mg, 1.05 mmol), sodium carbonate (333 mg, 3.15 mmol), 6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)chroman (327 mg, 1 .26 mmol) in dioxane (4 mL) and water (0.8 mL) was added palladium tetrakis(triphenylphosphine) (121 mg, 0.10 mmol). The mixture was heated at 120°C overnight. Water (10 mL) was added. The aqueous layer was extracted with ethyl acetate (2x10 mL). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate: 80/20) to provide methyl 2-[3-benzyloxy-2-(3,4- dihydro-2/-/-1 -benzopyran-6-yl)-6-methylphenyl]-2-hydroxyacetate (34g) (347 mg, 0.83 mmol, 79%) as a yellow foam.
1H NMR (300 MHz, CDCI3) δ 2.01-2.08 (m, 2H), 2.26 and 2.28 (s, 3H), 2.78-2.82 (m, 2H), 3.09 and 3.1 1 (d, J = 2.8 Hz, 1 H), 3.70 and 3.72 (s, 3H), 4.21 -4.26 (m, 2H), 4.97 (s, 2H), 5.26 (d, J = 2.8 Hz, 1 H), 6.81-6.89 (m, 2H), 6.98-7.16 (m, 5H), 7.22-7.30 (m, 3H).
Step 8: preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-benzyloxy-2-(3,4- dihydro-2/-/-1 -benzopyran-6-yl)-6-methylphenyl]acetate (34h)
Using the procedure described in example 1 , step 8, the intermediate methyl 2-[3- benzyloxy-2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-6-methylphenyl]-2-hydroxyacetate (34g) (347 mg, 0.83 mmol) is converted into the intermediate methyl 2-(ie f-butoxy)-2- [3-benzyloxy-2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-6-methylphenyl]acetate (34h) (263 mg, 0.55 mmol, 66%) after purification by preparative TLC (cyclohexane/ethyl acetate 80/20).
1H NMR (300 MHz, CDCI3) δ 0.96 (s, 9H), 2.00-2.09 (m, 2H), 2.35 and 2.36 (s, 3H), 2.72-2.82 (m, 2H), 3.70 and 3.71 (s, 3H), 4.22-4.26 (m, 2H), 4.88-5.01 (m, 2H), 5.16 and 5.18 (s, 1 H), 6.81-6.87 (m, 2H), 6.99-7.29 (m, 8H).
MS m/z ([M+Na]+) 497.
Step 9: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-hydroxy-6-methylphenyl]acetate (34i)
A suspension of methyl 2-(ie f-butoxy)-2-[3-benzyloxy-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-methylphenyl]acetate (34h) (263 mg, 0.55 mmol) and palladium on carbon (30 mg) in ethyl acetate (5 mL) was stirred at room temperature under hydrogen atmosphere for 36 hours. The mixture was filtered over Millipore and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate: 80/20) to provide methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro- 2H-1-benzopyran-6-yl)-3-hydroxy-6-methylphenyl]acetate (34i) (120 mg, 0.31 mmol, 56%).
1H NMR (300 MHz, CDCI3) δ 0.97 and 0.98 (s, 9H), 2.01 -2.09 (m, 2H), 2.34 and 2.35 (s, 3H), 2.71-2.86 (m, 2H), 3.67 and 3.68 (s, 3H), 4.24-4.27 (m, 2H), 4.63 and 4.67 (s, 1 H), 4.99 and 5.00 (s, 1 H), 6.82-7.05 (m, 4H), 7.12-7.19 (m, 1 H).
MS m/z ([M+Na]+) 407.
MS m/z ([M-H]-) 383.
Step 10: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-methyl-3-trifluoromethanesulfonyloxy-phenyl]acetate (34j)
A solution of methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- hydroxy-6-methylphenyl]acetate (34i) (145 mg, 0.038 mmol) in anhydrous dichloromethane (5 mL) under nitrogen atmosphere at -78°C were successively added triethylamine (158 μί, 1.136 mmol), and trifluoromethanesulfonic anhydride (79 μί, 0.47 mol). The mixture was stirred at this temperature for 1 hour before adding water (5 mL). Layers were separated. The aqueous layer was extracted with dichloromethane (5 mL). The combined organic layers were washed with a saturated solution of sodium hydrogenaocarbonate (5 mL), dried over sodium chloride and concentrated in vacuo to provide methyl 2-(fe/t-butoxy)-2-[2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-6-methyl-3-trifluoromethanesulfonyloxy-phenyl]acetate (34j) (193 mg, 0.37 mmol, 99%) as a colorless oil. 1H NMR (300 MHz, CDCI3) δ 0.95 and 0.96 (s, 9H), 2.00-2.09 (m, 2H), 2.43 and 2.45 (s, 3H), 2.68-2.87 (m, 2H), 3.70 and 3.71 (s, 3H), 4.22-4.26 (m, 2H), 5.1 1 and 5.13 (s, 1 H), 6.82-6.87 (m, 1 H), 6.94-7.1 1 (m, 2H), 7.15-7.21 (m, 2H).
MS m/z ([M-H]") 515.
Step 11 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(1-cyclobutylmethyl- 6-OXO-1 ,6-dihydro-pyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- methylphenyl]acetate (34k)
A degassed solution of methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6- yl)-6-methyl-3-trifluoromethanesulfonyloxy-phenyl]acetate (34j) (31 mg, 0.06 mmol), 1 -cyclobutylmethyl-5-(4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-1 H-pyridin-2-one (30b) (26 mg, 0.09 mmol), potassium carbonate (22 mg, 0.16 mmol) and palladium tetrakis(triphenylphosphine) (7 mg, 0.006 mmol) in dioxane (0.5 mL) and water (0.125 mL) was heated in microwaves at 1 10°C for 1 hour. Water (5 mL) was added. The aqueous layer was extracted with ethyl acetate (2x5 mL). The combined organic layers were washed with brine (5 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane / ethyl acetate: 50/50) to provide methyl 2-(ie f-butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro- pyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-methylphenyl]acetate (34k) (21 mg, 0.039 mmol, 65%) as a yellow oil.
1H NMR (300 MHz, CDCI3) δ 0.92 and 0.93 (s, 9H), 1.60-1 .73 (m, 2H), 1.80-2.05 (m, 6H), 2.44 and 2.45 (s, 3H), 2.53-2.61 (m, 2H), 2.76 (t, J = 6.4 Hz, 1 H), 3.60-3.99 (m, 5H), 4.13-4.23 (m, 2H), 5.20 (s, 1 H), 6.34 (d, J = 9.3 Hz, 1 H), 6.53-6.86 (m, 3H), 7.00- 7.05 (m, 1 H), 7-10-7.18 (m, 3H).
Step 12: Preparation of 2-(ie f-butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro- pyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-methylphenyl]acetic acid (example 34)
Using the procedure described in example 25, step 4, the methyl 2-(ie f-butoxy)-2-[3- (1-cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran- 6-yl)-6-methylphenyl]acetate (34k) (21 mg, 0.039 mmol) is converted into 2-(ie f- butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)-2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-6-methylphenyl]acetic acid (example 34) (9 mg, 0.017 mmol, 45%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.95 (s, 9H), 1.56-1.72 (m, 2H), 1 .78-2.07 (m, 6H), 2.43 (s, 3H), 2.47-2.58 (m, 2H), 2.75-2.85 (m, 1 H), 3.54-3.72 (m, 1 H), 3.85-4.03 (m, 1 H), 4.1 1 -4.25 (m, 2H), 5.33 and 5.34 (s, 1 H), 6.39 and 6.40 (d, J = 9.3 Hz, 1 H), 6.50-6.84 (m, 3H), 7.05-7.10 (m, 1 H), 7-13-7.19 (m, 2H), 7.36 (bs, 1 H).
MS m/z ([M+H]+) 516.
MS m/z ([M-H]") 514.
Example 35: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2/-/-1-benzopyran-6-yl)-3- -propylpyridin-2-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : Preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6- (trifluoromethyl)phenyl]acetate (35a)
A flame-dried vial containing methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-3-[(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl)phenyl] acetate (1j) (437 mg, 0.766 mmol), [1 ,1 '-Bis(diphenylphosphino)ferrocene] dichloropalladium(ll), complex with dichloromethane (125 mg, 0.153 mmol), bis[pinacolato]diboron (389 mg, 1 .53 mmol) and potassium acetate (225 mg, 2.30 mmol) was purged with argon for 10 minutes and then degassed anhydrous dioxane (5 mL) was added. The resulting mixture was placed in a preheated oil bath (80 °C) and stirred for 22 hours. LCMS showed remaining starting triflate and the mixture was cooled to room temperature, anhydrous dioxane (2 mL) was added and the mixture was purged with argon (10min) followed by addition of bis[pinacolato]diboron (194 mg, 0.765 mmol), potassium acetate (1 13 mg, 1.15 mmol) and [1 ,1 - Bis(diphenylphosphino) ferrocene]dichloropalladium(ll), complex with dichloromethane (62 mg, 0.076 mmol), further purged with argon and then stirred at 80 °C for further 24 hours. The mixture was cooled to room temperature and diluted in ethyl acetate (100 mL) and washed with water (2x15 mL) and brine (15 mL), dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by DCVC on Silicagel (30 mL) (cyclohexane/ethyl acetate 100/0 up to 70/30) to provide methyl 2-(ie/f-butoxy)-2-[2-(3!4-dihydro-2H-1-benzopyran-6-yl)-3-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-6-(trifluoromethyl)phenyl]acetate (35a) (520 mg, quantitative yield) a yellow oil.
1H NMR (300MHz, CDCI3) δ 0.92 and 0.95 (s, 9H), 1.06 (s, 6H), 1.13 (s, 6H), 2.04 (m, 2H), 2.75 (m, 2H), 3.67 (s, 3H), 4.21 (m, 2H), 5.18 (s, 1 H), 6.74-6.93 (m, 2H), 7.05- 7.10 (m, 1 H), 7.26-7.67 (m, 2H).
Step 2: Preparation of intermediate methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(6-propylpyridin-2-yl)-6-(trifluoromethyl) phenyl]acetate (35b)
To a solution of methyl 2-(fe/t-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)phenyl]acetate (35a) (50 mg, 0.091 mmol) in dioxane (1 .0 mL) was added 2-bromo-6-propylpyridine (36 mg, 0.182 mmol) and sodium carbonate saturated aqueous solution (1.0 mL). This mixture was stirred at room temperature for 20 minutes while passing a stream of argon. [1 ,1 - Bis(diphenylphosphino) ferrocene]dichloropalladium(ll), complex with dichloromethane (7.45 mg, 0.009 mmol) was added and the resulting mixture was stirred at 80 °C for 16 hours. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (15 mL). The organic phase were washed with water (2x10 mL) and brine (10 mL), dried over sodium sulfate and concentrated in vacuo. The crude residue was purified on preparative TLC (cyclohexane/ ethyl acetate 70/30) to provide methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(6- propylpyridin-2-yl)-6-(trifluoromethyl)phenyl]acetate (35b) (22 mg, 0.041 mmol, 44%). 1H NMR (300 MHz, CDCI3) δ 0.90 (t, J = 7.3 Hz, 3H), 0.94 and 0.95 (s, 9H), 1.58-1.73 (m, 2H), 1.82-2.04 (m, 2H), 2.31-2.59 (m, 1 H), 2.63-2.76 (m, 3H), 3.73 (s, 3H), 4.07- 4.20 (m, 2H), 5.20 and 5.22 (s, 1 H), 6.43-6.65 (m, 2H), 6.71 (d, J = 8.2 Hz, 1 H), 6.90 (d, J = 7.7 Hz, 1 H), 7.13-7.20 (m, 1 H), 7.26-7.35 (m, 1 H), 7.61 -7.66 (m, 1 H), 8.76- 7.81 (m, 1 H).
MS m/z ([M+H]+) 542.
Step 3: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(6- propylpyridin-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 35)
Using the procedure described in example 25, step 4, the intermediate methyl 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(6-propylpyridin-2-yl)-6- (trifluoromethyl)phenyl]acetate (35b) (22 mg, 0.041 mmol) is converted, after purification by trituration in diethyl ether into 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(6-propylpyridin-2-yl)-6-(trifluoromethyl) phenyl]acetic acid (example 35) (20 mg, 0.038 mmol, 93%) as a white solid.
1H NMR (400 MHz, DMSO) δ 0.76-0.87 (m,12H), 1.39-1.65 (m, 2H), 1.68-1 .98 (m, 2H), 2.50-2.73 (m, 4H), 3.97-4.17 (m, 2H), 5.03 (s, 1 H), 6.31 -6.76 (m, 2H), 6.80 and 6.88 (d, J = 7.8 Hz, 1 H), 7.02 (t, J = 7.8 Hz, 1 H), 7.07-7.29 (m, 1 H), 7.44-7.52 (m, 1 H), 7.59 and 7.63 (m, 1 H), 7.82 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 528.
Example 36: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -propylpyridin-2-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(4-propylpyridin-2-yl)-6-(trifluoromethyl) phenyl]acetate (36a)
Using the procedure described in example 35, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6-
(trifluoromethyl)phenyl]acetate (35a) (50 mg, 0.091 mmol) is converted by reaction with 2-bromo-4-propyl-pyridine (36 mg, 0.180 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate: 70/30) to methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H- 1-benzopyran-6-yl)-3-(4-propyl pyridin-2-yl)-6-(trifluoromethyl)phenyl]acetate (36a) (39 mg, 0.072 mmol, 79%).
1H NMR (400 MHz, CDCI3) δ 0.71 and 0.75 (t, J = 7.2 Hz, 3H), 0.91 and 0.92 (s, 9H), 1.25-1.40 (m, 2H), 1.80-2.07 (m, 2H), 2.28-2.57 (m, 3H), 2.75 (t, J = 6.4 Hz, 1 H), 3.75 (s, 3H), 4.04-4.22 (m, 2H), 5.22 (s, 1 H), 6.47-6.76 (m, 3H), 6.85-6.88 (m, 1 H), 7.20- 7.23 (m, 1 H), 7.70 and 7.72 (d, J = 8.1 Hz, 1 H), 7.80 (d, J = 8.1 Hz, 1 H), 8.43-8.46 (m, 1 H).
MS m/z ([M+H]+) 542.
Step 2: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4- propylpyridin-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 36)
Using the procedure described in example 25, step 4, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(4-propylpyridin-2-yl)-6-
(trifluoromethyl)phenyl]acetate (36a) (39 mg, 0.072 mmol) is converted to 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(4-propylpyridin-2-yl)-6- (trifluoromethyl)phenyl]acetic acid (example36) (20 mg, 0.038 mmol, 52%) a white solid.
1H NMR (400 MHz, CD3OD) δ 0.74 and 0.75 (t, J = 7.2 Hz, 3H), 0.92 (s, 9H), 1 .30- 1.45 (m, 2H), 1.81-2.04 (m, 2H), 2.32-2.61 (m, 3H), 2.78-2.81 (m, 1 H), 4.04-4.20 (m, 2H), 5.26 and 5.27 (s, 1 H), 6.46-6.77 (m, 3H), 7.05-7.08 (m, 1 H), 7.30-7.37 (m, 1 H), 7.65 and 7.66 (d, J = 8.1 Hz, 1 H), 7.85 (d, J = 8.1 Hz, 1 H), 8.34-8.37 (m, 1 H).
MS m/z ([M+H]+) 528.
Example 37: synthesis of 2-(te f-butoxy)-2-[3-(1-cvclobutylmethyl-6-oxo-1 ,6-dihvdro- pyridin-3-yl)-6-methyl-2-r5-methyl-(3,4-dihvdro-2H-1-benzopyran-6-yl)lphenyllacetic acid
Step 1 : preparation of intermediate 1-chloro-4-methyl-2-(prop-2-en-1-yloxy)benzene (37a)
To a suspension of 2-chloro-5-methylphenol (10.0 g, 0.07 mol) and potassium carbonate (1 1.7 g, 0.08 mol) in acetonitrile (200 mL) at 82°C, was dropwise added a solution of allyl bromide (9.6 mL, 0.1 1 mol) in acetonitrile (50 mL). The mixture was reflux overnight. Once at room temperature, the mixture was filtered and the precipitate rinsed with diethyl ether. The filtrate was then concentrated in vacuo. The residue was dissolved in diethyl ether (250 mL) and washed with a 2N sodium hydroxide solution (150 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo to provide 1 -chloro-4-methyl-2-(prop-2-en-1-yloxy)benzene (37a) (12.72 g, 0.07 mol, 99%) which was used without further purification.
1H NMR (300 MHz, CDCI3) 5 2.31 (s, 3H), 4.58-4.61 (m, 2H), 5.28-5.32 (m, 1 H), 5.43- 5.50 (m, 1 H), 6.01-6.14 (m, 1 H), 6.69-6.73 (m, 2H), 7.22 (d, J = 8.0 Hz, 1 H).
MS m/z ([M+H]+) 183.
Step 2: preparation of intermediate 6-chloro-3-methyl-2-(prop-2-en-1-yl)phenol (37b) 1-chloro-4-methyl-2-(prop-2-en-1-yloxy)benzene (37a) (12.6 g, 0.07 mol) was irradiated in a microwaves for 20 minutes at 240°C to provide 6-chloro-3-methyl-2- (prop-2-en-1-yl)phenol (37b) (12.6 g, 0.07 mol, 100%) which was used without further purification.
1H NMR (300 MHz, CDCI3) δ 2.26 (s, 3H), 3.45 (dt, J = 5.9 Hz, J = 1.6 Hz, 2H), 4.90- 5.07 (m, 2H), 5.56 (s, 1 H), 5.85-6.01 (m, 1 H), 6.69 (d, J = 8.2 Hz, 1 H), 7.08 (d, J = 8.2 Hz, 1 H). Step 3: preparation of intermediate 6-chloro-2-(3-hydroxypropyl)-3-methylphenol (37c)
Under nitrogen atmosphere, a solution of 6-chloro-3-methyl-2-(prop-2-en-1 -yl)phenol (37b) (8.70 g, 47.6 mmol) in anhydrous tetrahydrofuran (300 mL) was cooled to 0°C. Borane-tetrahydrofuran complex, 1.0M solution in tetrahydrofuran (100 mL, 0.10 mol) was dropwise added. The reaction mixture was stirred at room temperature for 2 hours then cooled again to 0°C. A 10N sodium hydroxide solution (32.7 mL) was added dropwise, followed by a 30% hydrogen peroxide solution. The resulting mixture was warm to room temperature and stirred for 90 minutes. The reaction mixture was quenched with a 10% hydrochloric acid solution (163 mL). Layers were separated and the aqueous layer was extract with ethyl acetate (2 x 70 mL). The combined organics layers were washed with brine (3 x 100 mL) then cooled with an ice bath. A saturated solution of sodium sulfite (150 mL) was carefully added and the mixture was stirred for few minutes. The organic layer was separated, dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 100/0 to 75/25), to provide 6-chloro-2-(3- hydroxypropyl)-3-methylphenol (37c) (6.74 g, 33.6 mmol, 70%).
1H NMR (300 MHz, CDCI3) δ 1.76-1.88 (m, 2H), 2.28 (s, 3H), 2.81 (t, J = 7.2 Hz, 2H), 3.63 (t, J = 6.0 Hz, 2H), 6.69 (d, J = 8.2 Hz, 1 H), 7.08 (d, J = 8.2 Hz, 1 H).
Step 4: preparation of intermediate 8-chloro-5-methyl-3,4-dihydro-2H-1-benzopyran (37d)
Under nitrogen atmosphere, a solution of 6-chloro-2-(3-hydroxypropyl)-3- methylphenol (37c) (6.74 g, 33.6 mmol) in anhydrous tetrahydrofuran (500 mL) was cooled to 0°C. Triphenylphosphine (1 1 .45 g, 43.7 mmol) was added, followed by diisopropyl azodicarboxylate (8.60 mL, 43.7 mmol). The reaction mixture was stirred for 16 hours at room temperature. After concentration in vacuo, the residue was dissolved in diethyl ether and the precipitate was filtered off. The filtrate was concentrated in vacuo and the residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 100/0 to 90/10), to provide 8-chloro-5-methyl-3,4- dihydro-2H-1-benzopyran (37d) (5.74 g, 31 .4 mmol, 94%), as a light yellow oil.
1H NMR (300 MHz, CDCI3) δ 2.00-2.1 1 (m, 2H), 2.18 (s, 3H), 2.65 (t, J = 6.6 Hz, 2H), 4.21 -4.28 (m, 2H), 6.65 (d, J = 8.1 Hz, 1 H), 7.08 (d, J = 8.1 Hz, 1 H).
Step 5: preparation of intermediate 6-bromo-8-chloro-5-methyl-3,4-dihydro-2H-1- benzopyran (37e)
A mixture of the 8-chloro-5-methyl-3,4-dihydro-2H-1-benzopyran (37d) (5.74 g, 31.4 mmol) and acetic acid (75 mL) is treated with bromine (1 .93 mL, 37.7 mmol) in AcOH (35 mL). The mixture was stirred at room temperature for 15 minutes, then diluted with toluene (100 mL). The mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (70 mL) and successively washed with a 15% sodium thiosulfate solution (50 mL) and a saturated solution of sodium hydrogenocarbonate (50 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The product was recrystallized in ethanol, to provide 6-bromo-8-chloro-5-methyl-3,4- dihydro-2H-1-benzopyran (37e) (4.44 g, 17.0 mmol, 54%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.99-2.1 1 (m, 2H), 2.27 (s, 3H), 2.71 (t, J = 6.6 Hz, 2H), 4.18-4.26 (m, 2H), 7.41 (s, 1 H).
Step 6: preparation of intermediate 2-(8-chloro-5-methyl-3,4-dihydro-2H-1- benzopyran-6-yl)-4,4,5,5-tetramethyl-1 ,3,2-dioxaborolane (37f) [1 ,1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) (761 mg, 0.93 mmol) was added to a previously degassed solution of 6-bromo-8-chloro-5-methyl-3,4-dihydro- 2H-1-benzopyran (37e) (2.44g, 9.33 mmol), bis(pinacolato)diboron (3.55 g, 14.0 mmol) and potassium acetate (3.20 g, 32.6 mmol) in anhydrous N,N- dimethylformamide (100 mL). The reaction mixture was heated at 95°C for 16 hours. Water (50 mL) was added and the reaction mixture was concentrated in vacuo. The residue was taken in water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The organic layer was washed with brine (30 mL) then dried over sodium sulfate, concentrated in vacuo, and co-elutated with toluene. The crude was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 100/0 to 98/2). The product was triturated in cyclohexane and filtered to provide 2-(8-chloro-5-methyl-3,4-dihydro- 2H-1-benzopyran-6-yl)-4,4,5,5-tetramethyl-1 ,3,2-dioxaborolane (37f) (1.62 g, 5.24 mmol, 58%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.33 (s, 12H), 1.99-2.1 1 (m, 2H), 2.40 (s, 3H), 2.65 (t, J = 6.6 Hz, 2H), 4.19-4.30 (m, 2H), 7.63 (s, 1 H).
Step 7: preparation of intermediate 4,4,5,5-tetramethyl-2-(5-methyl-3,4-dihydro-2H-1- benzopyran-6-yl)-1 ,3,2-dioxaborolane (37g)
Palladium on activated charcoal (10% Pd by weight, 120 mg) was added to a solution of 2-(8-chloro-5-methyl-3,4-dihydro-2H-1-benzopyran-6-yl)-4,4,5,5-tetramethyl-1 ,3,2- dioxaborolane (37f) (1.20 g, 3.89 mmol) and ammonium formate (2.45 g, 38.89 mmol) in methanol (20 mL). The mixture was refluxed for 60 minutes. The mixture was then cooled to room temperature, filtered through a pad of Celite® and rinsed with methanol. The filtrate was concentrated in vacuo. The residue was dissolved in ethyl acetate (20 mL) and washed with water (20 mL). The organic layer was dried over sodium sulfate, concentrated in vacuo to provide 4,4,5,5-tetramethyl-2-(5-methyl-3,4- dihydro-2H-1-benzopyran-6-yl)-1 ,3,2-dioxaborolane (37g) (1.00 g, 3.66 mmol, 94%) as a white solid, which was used without further purification.
1H NMR (300 MHz, CDCI3) δ 1.32 (s, 12H), 1.96-2.10 (m, 2H), 2.43 (s, 3H), 2.65 (t, J = 6.6 Hz, 2H), 4.09-4.17 (m, 2H), 6.66 (d, J = 8.3 Hz, 1 H), 7.55 (d, J = 8.3 Hz, 1 H).
Step 8: preparation of intermediate methyl 2-(3-benzyloxy-2-bromo-6-methylphenyl)- 2-(ie/f-butoxy)-acetate (37h)
To a suspension of methyl 2-(3-benzyloxy-2-bromo-6-methylphenyl)-2- hydroxyacetate (34f) (500 mg, 1.37 mmol) in ie/f-butyl acetate (14 mL) at 0°C was added sulfuric acid (0.292 mL, 5.48 mmol). The mixture was stirred at room temperature for 8 hours. The mixture was diluted with ethyl acetate (50 mL), washed with a saturated solution of sodium hydrogenocarbonate (50 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 90/10) to provide methyl 2-(3-benzyloxy-2- bromo-6-methylphenyl)-2-(ierf-butoxy)-acetate (37h) (469 mg, 1.1 1 mmol, 81 %) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.23 (s, 9H), 2.36 (s, 3H), 3.68 (s, 3H), 5.12 (s, 2H), 5.96 (s, 1 H), 6.80 (d, J = 8.4 Hz, 1 H), 7.01 (d, J = 8.4 Hz, 1 H), 7.29-7.42 (m, 3H), 7.48-7.51 (m, 2H). Step 9: preparation of intermediate methyl 2-[3-benzyloxy-6-methyl-2-[5-methyl-(3,4- dihydro-2H-1 -benzopyran-6-yl)]]-2-(ie f-butoxy)acetate (37i)
To a degassed mixture of methyl 2-(3-benzyloxy-2-bromo-6-methylphenyl)-2-(ie f- butoxy)-acetate (37h) (70 mg, 0.17 mmol), sodium carbonate (53 mg, 0.50 mmol) and 3,4-dihydro-5-methyl-6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-2H-1- benzopyran (37g) (55 mg, 0.20 mmol) in dioxane (1 mL) and water (0.2 mL) was added palladium tetrakis(triphenylphosphine) (19 mg, 0.02 mmol). The mixture was heated at 120°C overnight. Water (5 mL) was added. The aqueous layer was extracted with ethyl acetate (2x5 mL), dichloromethane (2x5 mL) and tetrahydrofuran (2x5 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 up to 98/2) to provide a mixture of methyl 2-[3- benzyloxy-6-methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]]-2-(ie f- butoxy)acetate (37i) and methyl 2-(3-benzyloxy-6-methylphenyl)-2-(ie f-butoxy)- acetate (37j) (84 mg, ratio 75/25) which was used without further purification.
1H NMR (300 MHz, CDCI3) δ 1.12 (s, 9H), 1 .87 (s, 3H), 2.09-2.14 (m, 2H), 2.46 (s, 3H), 2.62-2.78 (m, 2H), 3.57 (s, 3H), 4.20-4.24 (m, 2H), 4.88-4.97 (m, 2H), 5.1 1 (s, 1 H), 6.72 (d, J = 8.3 Hz, 1 H), 6.81 (d, J = 8.3 Hz, 1 H), 6.90 (d, J = 8.3 Hz, 1 H), 7.02- 7.08 (m, 3H), 7.20-7.24 (m, 3H).
MS m/z ([M+Na]+) 51 1.
Step 10: preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-hydroxy-6-methyl-2- [5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]-phenyl]acetate (37j)
A suspension of a mixture of methyl 2-[3-benzyloxy-6-methyl-2-[5-methyl-(3,4- dihydro-2H-1-benzopyran-6-yl)]]-2-(ie f-butoxy)acetate (37i) and methyl 2-(3- benzyloxy-6-methylphenyl)-2-(fe/t-butoxy)-acetate (37j) (84 mg, 75/25) and palladium on carbon (18 mg) in methanol (5 mL) was stirred at room temperature under a 5 bar hydrogen pressure for 3.5 hours. The mixture was filtered over Millipore and concentrated in vacuo. The residue was purified by preparative TLC (dichloromethane/ethyl acetate 98/2) to provide methyl 2-(ie f-butoxy)-2-[3-hydroxy-6- methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]-phenyl]acetate (37j) (30 mg, 0.075 mmol, 45% over 2 steps).
1H NMR (400 MHz, CDCI3) δ 1.08 (s, 9H), 1 .91 (s, 3H), 2.06-2.15 (m, 2H), 2.43 (s, 3H), 2.64-2.77 (m, 2H), 3.57 (s, 3H), 4.16-4.25 (m, 2H), 4.42 (bs, 1 H), 4.93 (s, 1 H), 6.76 (d, J = 8.3 Hz, 1 H), 6.83 (d, J = 8.2 Hz, 1 H), 6.93 (d, J = 8.3 Hz, 1 H), 7.05 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+Na]+) 421.
MS m/z ([M-H]") 397.
Step 11 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[6-methyl-2-[5-methyl-
(3,4-dihydro-2H-1-benzopyran-6-yl)]-3-trifluoromethanesulfonyloxy-phenyl]acetate
(37k)
Using the procedure described in example 34, step 10, the intermediate methyl 2- (ie f-butoxy)-2-[3-hydroxy-6-methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]- phenyl]acetate (37j) (30 mg, 0.075 mmol) is converted into intermediate methyl 2- (ie/f-butoxy)-2-[6-methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]-3- trifluoromethanesulfonyloxy-phenyl]acetate (37k) (40 mg, 0.075 mmol, 100%) as a colorless oil.
1H NMR (300 MHz, CDCI3) δ 1.09 (s, 9H), 1 .84 (s, 3H), 2.06-2.13 (m, 2H), 2.53 (s, 3H), 2.68 (t, J = 6.6 Hz, 2H), 3.58 (s, 3H), 4.17-4.21 (m, 2H), 5.08 (s, 1 H), 6.72 (d, J = 8.4 Hz, 1 H), 6.88 (d, J = 8.4 Hz, 1 H), 7.16 (d, J = 8.5 Hz, 1 H), 7.21 (d, J = 8.5 Hz, 1 H).
MS m/z ([M+Na]+) 553.
Step 12: preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(1-cyclobutylmethyl- 6-OXO-1 ,6-dihydro-pyridin-3-yl)-6-methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6- yl)]phenyl]acetate (37I)
Using the procedure described in example 34, step 1 1 , the intermediate methyl 2- (ie/f-butoxy)-2-[6-methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]-3- trifluoromethanesulfonyloxy-phenyl]acetate (37k) (40 mg, 0.075 mmol) is converted, after purification by preparative TLC (dichloromethane/ethyl acetate 50/50) to intermediate methyl 2-(iert-butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin- 3-yl)-6-methyl-2-[5-methyl-(3,4-dihydro-2H-1 -benzopyran-6-yl)]phenyl]acetate (37I) (27 mg, 0.049 mmol, 65%). 1H NMR (300 MHz, CDCI3) δ 1.12 (s, 9H), 1.60-1.70 (m, 5H), 1 .81-2.06 (m, 6H), 2.39- 2.63 (m, 6H), 3.55 (s, 3H), 3.76 (d, J = 7.5 Hz, 2H), 4.04-4.18 (m, 2H), 5.12 (s, 1 H), 6.30 (d, J = 9.3 Hz, 1 H), 6.67 (d, J = 8.3 Hz, 1 H), 6.78 (d, J = 2.5 Hz, 1 H), 6.90 (d, J = 8.3 Hz, 1 H), 7.00 (dd, J = 2.5 Hz, J = 9.3 Hz, 1 H), 7.10 (d, J = 7.8 Hz, 1 H), 7.19 (d, J = 7.8 Hz, 1 H).
MS m/z ([M+H]+) 544.
Step 13: preparation of 2-(ie f-butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro- pyridin-3-yl)-6-methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]phenyl]acetic acid (example 37)
Using the procedure described in example 25, step 4, the intermediate methyl 2-(iert- butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)-6-methyl-2-[5-methyl- (3,4-dihydro-2H-1-benzopyran-6-yl)]phenyl]acetate (37I) (27 mg, 0.049 mmol) is converted to 2-(ie f-butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)-6- methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]phenyl]acetic acid (example 37) (15 mg, 0.028 mmol, 57%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.12 (s, 9H), 1 .60-1 .69 (m, 2H), 1.75 (s, 3H), 1.80-1.94 (m, 4H), 1.97-2.04 (m, 2H), 2.41-2.62 (m, 6H), 3.77 (d, J = 7.6 Hz, 2H), 4.07-4.16 (m, 2H), 5.19 (s, 1 H), 6.34 (d, J = 9.3 Hz, 1 H), 6.65 (d, J = 8.3 Hz, 1 H), 6.80 (d, J = 2.5 Hz, 1 H), 6.85 (d, J = 8.3 Hz, 1 H), 7.04 (dd, J = 2.5 Hz, J = 9.3 Hz, 1 H), 7.15 (d, J = 7.8 Hz, 1 H), 7.21 (d, J = 7.8 Hz, 1 H).
MS m/z ([M+H]+) 530.
MS m/z ([M-H]-) 528. Example 38: synthesis of 2-(te f-butoxy)-2-{3-[1 -(cvclobutylmethyl)-2-oxo-1 ,2- dihvdropyridin-3-yll-2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl)acetic acid
Step 1 : preparation of intermediate 3-bromo-1-(cyclobutylmethyl)-1 ,2-dihydropyridin- 2-one (38a)
Using the procedure described in example 30, step 1 , the intermediate 3-bromo-2- hydroxypyridine (500 mg, 2.87 mmol) is converted, after purification by flash chromatography on silica gel (dichloromethane/ethyl acetate 100/0 to 80/20), into 3- bromo-1-(cyclobutylmethyl)-1 ,2-dihydropyridin-2-one (38a) (310 mg, 1 .28 mmol, 45%).
1H NMR (400 MHz, CDCI3) δ 1.73-1.94 (m, 4H), 2.00-2.10 (m, 2H), 2.81 (sept, J = 7.6 Hz, 1 H), 4.00 (d, J = 7.6 Hz, 2H), 6.03 (t, J = 7.0 Hz, 1 H), 7.23 (dd, J = 1.9 Hz, J = 7.0 Hz, 1 H), 7.70 (dd, J = 1.9 Hz, J = 7.0 Hz, 1 H).
MS m/z ([M+H]+) 242/244.
Step 2: preparation of intermediate 1 -(cyclobutylmethyl)-3-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (38b)
Using the procedure described in example 25, step 2, the intermediate 3-bromo-1- (cyclobutylmethyl)-l ,2-dihydropyridin-2-one (38a) (300 mg, 1.24 mmol) is converted, after purification by preparative TLC (ethyl acetate/methanol 95/5) into 1- (cyclobutylmethyl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (38b) (60 mg, 0.21 mmol, 17%).
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-{3-[1-(cyclobutylmethyl)- 2-OXO-1 ,2-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl}acetate (38c)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with 1-(cyclobutylmethyl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 ,2-dihydropyridin-2-one (38b) (60 mg, 0.207 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 80/20) to methyl 2-(ie/f-butoxy)-2-{3-[1 - (cyclobutylmethyl)-2-oxo-1 ,2-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl)phenyl}acetate (38c) (45 mg, 0.077 mmol, 63%).
1H NMR (400 MHz, CDCI3) δ 0.96 and 0.97 (s, 9H), 1.64-1 .74 (m, 2H), 1.81 -2.01 (m, 6H), 2.49-2.76 (m, 3H), 3.69 and 3.70 (s, 3H), 3.76-3.86 (m, 1 H), 3.90-4.02 (m, 1 H), 4.09-4.20 (m, 2H), 5.15 (s, 1 H), 5.94 and 5.95 (t, J = 6.8 Hz, 1 H), 6.53 and 6.66 (d, J = 8.4 Hz, 1 H), 6.68-6.79 (m, 1 H), 6.88-6.95 (m, 1 H), 7.00-7.05 (m, 1 H), 7.06 and 7.08 (d, J = 6.8 Hz, 1 H), 7.36-7.43 (m, 1 H), 7.71 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 584. Step 4: preparation of 2-(ie f-butoxy)-2-{3-[1 -(cyclobutylmethyl)-2-oxo-1 ,2- dihydropyridin-3-yl]-2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl}acetic acid (example 38)
Using the procedure described in example 25, step 4, methyl 2-(fe/t-butoxy)-2-{3-[1- (cyclobutylmethyl)-2-oxo-1 ,2-dihydropyridin-3-yl]-2-(3,4-dihydro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl)phenyl}acetate (38c) (45 mg, 0.077 mmol) is converted into 2- (ie/f-butoxy)-2-{3-[1-(cyclobutylmethyl)-2-oxo-1 ,2-dihydropyridin-3-yl]-2-(3,4-dihydro- 2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl}acetic acid (example 38) (15 mg, 0.026 mmol, 34%).
1H NMR (400 MHz, CD3OD) 5 0.94 and 0.96 (s, 9H), 1.59-1.80 (m, 2H), 1.80-2.10 (m, 6H), 2.50-2.70 (m, 2H), 2.72-2.77 (m, 1 H), 3.65-4.05 (m, 2H), 4.05-4.25 (m, 2H), 5.19 (s, 1 H), 6.17-6.24 (m, 1 H), 6.50 and 6.66 (d, J = 8.3 Hz, 1 H), 6.67-6.79 (m, 1 H), 7.06- 7.30 (m, 2H), 7.38-7.49 (m, 2H), 7.76 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 570.
Example 39: synthesis of 2-(te/f-butoxy)-2-r3-(1 -cvclopropyl-6-oxo-1 ,6-dihvdropyridin-
3-yl)-2-(3,4-dihvdro-2/-/-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyllacetic acid
Step 1 : Preparation of intermediate 5-bromo-1-cyclopropyl-1 H-pyridin-2-one (39a)
A mixture of 5-bromo-2(1 H)-pyridone (217 mg, 1.25 mmol), cyclopropylboronic acid (214 mg, 2.49 mmol), 2,2'-bipyridine (205 mg, 1.31 mmol), copper(l) acetate (236 mg, 1.30 mmol) and sodium carbonate (291 mg, 2.74 mmol) in 1 ,2-dichloroethane (7 mL) was stirred at 70°C overnight. A saturated solution of ammonium chloride was added (20 mL). The layers were separated. The aqueous layer was extracted with dichloromethane (2x15 mL). The organic layer was washed with water (20 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 50/50 to 0/100) to provide 5- bromo-1-cyclopropyl-1 H-pyridin-2-one (39a) (127 mg, 0.59 mmol, 47%).
1H NMR (300 MHz, CDCI3) δ 0.84-0.90 (m, 2H), 1.1 1 -1.18 (m, 2H), 3.27-3.35 (m, 1 H), 6.46 (d, J = 9.6 Hz, 1 H), 7.31 (dd, J = 2.7 Hz, J = 9.6 Hz, 1 H), 7.40 (d, J = 2.7 Hz, 1 H).
MS m/z ([M+H]+) 214/216.
Step 2: preparation of intermediate 1-cyclopropyl-5-(tetramethyl-1 ,3,2-dioxaborolan-
2-yl)-1 H-pyridin-2-one (39b)
Using the procedure described in example 25, step 2, the intermediate 35-bromo-1- cyclopropyl-1 H-pyridin-2-one (39a) (127 mg, 0.59 mmol) is converted, after purification by preparative TLC (ethyl acetate) into 1-cyclopropyl-5-(tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 H-pyridin-2-one (39b) (35 mg, 0.13 mmol, 22%).
1H NMR (300 MHz, CDCI3) δ 0.85-0.90 (m, 2H), 1.08-1.15 (m, 2H), 1.28 (s, 12H), 3.26-3.34 (m, 1 H), 6.47 (d, J = 9.5 Hz, 1 H), 7.54 (dd, J = 2.0 Hz, J = 9.5 Hz, 1 H), 7.72
(d, J = 2.0 Hz, 1 H).
Step 3: preparation of intermediate methyl 2-(iert-butoxy)-2-[3-(1-cyclopropyl-6-oxo- 1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (39c)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (50 mg, 0.087 mmol) is converted by reaction with 1-cyclopropyl-5-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-pyridin-2-one (39b) (34 mg, 0.130 mmol), after purification by preparative TLC (ethyl acetate) to methyl 2-(ie f- butoxy)-2-[3-(1-cyclopropyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (39c) (36 mg, 0.065 mmol, 73%). 1H NMR (300 MHz, CDCI3) δ 0.45-0.59 (m, 2H), 0.87-1 .06 (m, 1 1 H), 1 .84-2.04 (m, 2H), 2.48-2.67 (m, 1 H), 2.76 (t, J = 6.3 Hz, 1 H), 3.20-3.29 (m, 1 H), 3.72 (s, 3H), 4.17- 4.23 (m, 2H), 5.14 and 5.15 (s, 1 H), 6.40 and 6.41 (d, J = 9.3 Hz, 1 H), 6.49-6.53 (m, 1 H), 6.62-6.84 (m, 2H), 7.10-7.15 (m, 2H), 7.37 (d, J = 8.2 Hz, 1 H), 7.74 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 556. Step 4: preparation of 2-(ie f-butoxy)-2-[3-(1 -cyclopropyl-6-oxo-1 ,6-dihydropyridin-3- yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 39) Using the procedure described in example 25, step 4, the intermediate methyl 2-(ie f- butoxy)-2-[3-(1-cyclopropyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (39c) (36 mg, 0.065 mmol) is converted into 2-(ie f-butoxy)-2-[3-(1 -cyclopropyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2- (3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl) phenyl]acetic acid (example 39) (19 mg, 0.035 mmol, 54%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.45-0.59 (m, 2H), 0.87-1 .06 (m, 1 1 H), 1 .93-2.04 (m, 2H), 2.53-2.91 (m, 2H), 3.21 -3.30 (m, 1 H), 4.16-4.27 (m, 2H), 5.28 and 5.30 (s, 1 H), 6.42-6.52 (m, 2H), 6.62-6.91 (m, 2H), 7.13-7.19 (m, 1 H), 7.41 (d, J = 8.2 Hz, 1 H), 7.48 (bs, 1 H), 7.75 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+H]+) 542.
Example 40: synthesis of 2-(te/f-butoxy)-2-{3-[1 -(cvclobutylmethyl)-6-oxo-1 ,6- dihvdropyridin-2-yll-2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl)acetic acid
Step 1 : preparation of intermediate 6-bromo-1 ,2-dihydropyridin-2-one (40a)
Potassium fe/t-butoxide (4.74 g, 42.2 mmol) was added to a solution of 2,6- dibromopyridine (1 .00 g, 4.22 mmol) in ie f-Butyl alcohol (25 mL). The reaction mixture was refluxed for 18 hours, and concentrated in vacuo. A mixture of ice and water (20 mL) was added to the residue. The aqueous layer was washed with ethyl acetate (2 x 25 mL), acidified with concentrated hydrochloric acid until pH 3 and extracted with dichloromethane (2 x 30 mL). The organic layer was washed with brine (30 mL), then dried over sodium sulfate and concentrated in vacuo to provide 6- bromo-1 ,2-dihydropyridin-2-one (40a) ( 125 mg, 0.72 mmol, 17%).
1H NMR (300 MHz, CDCI3) δ 6.70 (dd, J = 0.5 Hz, J = 8.6 Hz, 1 H), 6.83 (dd, J = 0.5 Hz, J = 7.4 Hz, 1 H), 7.44 (dd, J = 7.4 Hz, J = 8.6 Hz, 1 H), 12.05 (bs, 1 H). Step 2: preparation of intermediate 6-bromo-1-(cyclobutylmethyl)-1 ,2-dihydropyridin- 2-one (40b)
Potassium fe/t-butoxide 1 N in tetrahydrofuran (0.72 mL, 0.72 mmol) was added to a suspension of 6-bromo-1 ,2-dihydropyridin-2-one (40a) (125 mg, 0.72 mmol) in dimethoxyethane (1 .2 mL). After 30 minutes stirring at room temperature, potassium carbonate (69 mg, 0.50 mmol) and (bromomethyl)cyclobutane (0.16 mL, 1.44 mmol) were added, and the reaction mixture was refluxed for 4 days. The resultant precipitate was filtered, and rinced with ethyl acetate (5 mL). The filtrate was successively washed with water (20 mL) and brine (20 mL), then dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane/ethyl acetate 80/20) to provide 6-bromo-1-(cyclobutylmethyl)-1 ,2- dihydropyridin-2-one (40b) (61 mg, 40.25 mmol, 35%).
1H NMR (400 MHz, CDCI3) δ 1.79-1.97 (m, 4H), 1.99-2.07 (m, 2H), 2.83 (sept, J = 7.5 Hz, 1 H), 4.34 (d, J = 7.5 Hz, 2H), 6.43 (dd, J = 1 .2 Hz, J = 7.2 Hz, 1 H), 6.48 (dd, J = 1.2 Hz, J = 9.1 Hz, 1 H), 7.09 (dd, J = 7.2 Hz, J = 9.1 Hz, 1 H).
MS m/z ([M+H]+) 242/244.
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-{3-[1-(cyclobutylmethyl)- 6-OXO-1 ,6-dihydropyridin-2-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl}acetate (40c)
Using the procedure described in example 35, step 2, the intermediate methyl 2-(ierf- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2- yl)-6-(trifluoromethyl)phenyl]acetate (35a) (70 mg, 0.128 mmol) is converted by reaction with 6-bromo-1-(cyclobutylmethyl)-1 ,2-dihydropyridin-2-one (40b) (46 mg, 0.191 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 60/40) to methyl 2-(ieri-butoxy)-2-{3-[1-(cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-2- yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetate (40c) (50 mg, 0.086 mmol, 72%).
1H NMR (300 MHz, CDCI3) δ 0.91 and 0.93 and 1 .02 and 1 .03 (s, 9H), 1.24-1 .37 (m, 1 H), 1 .46-1.80 (m, 4H), 1.80-2.10 (m, 3H), 2.40-2.80 (m, 3H), 2.98-3.10 and 3.27- 3.42 (m, 1 H), 3.68 and 3.69 and 3.74 and 3.75 (s, 3H), 3.86-3.95 and 4.10-4.24 (m, 3H), 5.1 1 and 5.15 and 5.17 and 5.18 (s, 1 H), 5.66-5.72 and 6.01-6.08 (m, 1 H), 6.31- 6.42 (m, 1 H), 6.53-7.24 (m, 4H), 7.40-7.48 (m, 1 H), 7.82 (d, J = 8.1 Hz, 1 H).
MS m/z ([M+H]+) 584. Step 4: preparation of 2-(ie f-butoxy)-2-{3-[1 -(cyclobutylmethyl)-6-oxo-1 ,6- dihydropyridin-2-yl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl}acetic acid (example 40)
Using the procedure described in example 25, step 4, methyl 2-(ie f-butoxy)-2-{3-[1- (cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-2-yl]-2-(3,4-dihydro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl)phenyl}acetate (40c) (50 mg, 0.086 mmol) is converted to 2-(tert- butoxy)-2-{3-[1-(cyclobutylmethyl)-6-oxo-1 ,6-dihydro pyridin-2-yl]-2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-6-(trifluoromethyl) phenyl}acetic acid (example 40) (38 mg, 0.067 mmol, 78%).
1H NMR (300 MHz, CDCI3) δ 0.95 and 1.07 (s, 9H), 1.23-1 .37 (m, 1 H), 1.45-1 .81 (m, 4H), 1 .81-2.08 (m, 3H), 2.40-2.80 (m, 3H), 2.96-3.40 (m, 1 H), 3.84-3.99 and 4.10- 4.26 (m, 3H), 5.16-5.37 (m, 1 H), 5.60-5.79 and 5.96-6.1 1 (m, 1 H), 6.32-6.46 (m, 1 H), 6.49-6.80 (m, 2H), 6.98-7.56 (m, 3H), 7.83 (d, J = 8.1 Hz, 1 H).
MS m/z ([M+H]+) 570.
Example 41 : synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (pyridazin-4-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(pyridazin-4-yl)-6-(trif luoromethyl)phenyl]acetate (41 a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.122 mmol) is converted, by reaction with 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridazine (38 mg, 0.184 mmol), after purification by preparative TLC (dichloromethane/ethyl acetate 50/50) to methyl 2- (ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyridazin-4-yl)-6- (trifluoromethyl)phenyl] acetate (41a) (19 mg, 0.038 mmol, 31 %).
1H NMR (400 MHz, CDCI3) δ 0.95 and 0.96 (s, 9H), 1.87-1 .93 (m, 1 H), 1.99-2.05 (m, 1 H), 2.38-2.63 (m, 1 H), 2.66-2.81 (m, 1 H), 3.73 (s, 3H), 4.12-4.20 (m, 2H), 5.18 (s, 1 H), 6.37-6.43 (m, 1 H), 6.53 and 6.77 (d, J = 8.3 Hz, 1 H), 7.14-7.22 (m, 2H), 7.44- 7.48 (m, 1 H), 7.86 (d, J = 8.1 Hz, 1 H), 8.87 and 8.93 (dd, J = 1 .1 Hz, J = 2.3 Hz, 1 H), 9.00 and 9.03 (dd, J = 1.1 Hz, J = 5.3 Hz, 1 H).
MS m/z ([M+H]+) 501. Step 2: preparation 2-(fe/t-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (pyridazin-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 41)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyridazin-4-yl)-6-
(trifluoromethyl)phenyl]acetate (41a) (19 mg, 0.038 mmol) is converted to 2-(ierf- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyridazin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 41 ) (17 mg, 0.035 mmol, 92%) a yellow solid.
1H NMR (400 MHz, CDCI3) δ 0.97 (s, 9H), 1.85-1.95 (m, 1 H), 1 .96-2.08 (m, 1 H), 2.33- 2.58 (m, 1 H), 2.76-2.80 (m, 1 H), 4.12-4.21 (m, 2H), 5.30 and 5.33 (s, 1 H), 6.36-6.83 (m, 2H), 7.16-7.26 (m, 1 H), 7.49-7.53 (m, 2H), 7.89 (d, J = 8.2 Hz, 1 H), 8.91 and 8.98 (s, 1 H), 9.03 and 9.06 (d, J = 5.3 Hz, 1 H).
MS m/z ([M+H]+) 487.
Example 42: synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (1-methyl-1 /-/-pyrrol-3-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1-methyl-1 H-pyrrol-3-yl)-6-(trifluoromethyl)phenyl] acetate (42a) Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.122 mmol) is converted, by reaction with 1-methylpyrrole-3-boronic acid, pinacol ester (38 mg, 0.183 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate: 80/20) to methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-methyl-1 H-pyrrol-3-yl)-6- (trifluoromethyl)phenyl] acetate (42a) (45 mg, 0.089 mmol, 73%).
1H NMR (400 MHz, CDCI3) δ 0.92 and 0.93 (s, 9H), 1.89-2.04 (m, 2H), 2.46-2.63 (m, 1 H), 2.64-2.79 (m, 1 H), 3.1 1 and 3.18 (s, 3H), 3.74 (s, 3H), 4.13-4.20 (m, 2H), 5.17 and 5.21 (s, 1 H), 5.82 and 5.88 (d, J = 3.5 Hz, 1 H), 5.99 (d, J = 3.5 Hz, 1 H), 6.42 (bs, 1 H), 6.52-6.70 (m, 2H), 7.08-7.14 (m, 1 H), 7.41-7.47 (m, 1 H), 7.72 (d, J = 8.1 Hz, 1 H). MS m/z ([M+Na]+) 524, ([M+H]+) 502. Step 2: preparation 2-(ferf-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 - methyl-1 H-pyrrol-3-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 42)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1-methyl-1 H-pyrrol-3-yl)-6-
(trifluoromethyl)phenyl]acetate (42a) (45 mg, 0.089 mmol) is converted, after purification by preparative TLC (dichloromethane/methanol: 97/3) to 2-(iert-butoxy)-2- [2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-methyl-1 H-pyrrol-3-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 42) (10 mg, 0.020 mmol, 23%) a white solid.
1H NMR (300 MHz, CDCI3) δ 0.94 (s, 9H), 1.90-1.96 (m, 1 H), 1 .97-2.04 (m, 1 H), 2.48- 2.60 (m, 1 H), 2.70-2.84 (m, 1 H), 3.08 and 3.15 (s, 3H), 4.14-4.20 (m, 2H), 5.32 and 5.40 (s, 1 H), 5.86-6.02 (m, 2H), 6.40-6.76 (m, 3H), 7.46-7.51 (m, 2H), 7.73 (d, J = 8.1 Hz, 1 H).
MS m/z ([M+H]+) 488.
MS m/z ([M-H]-) 486.
Example 43: synthesis of 4-{3-r(te -butoxy)(carboxy)methyll-2-(3,4-dihvdro-2H-1- benzopyran-6-yl)-4-(trifluoromethyl)phenyl)benzoic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(4-cyanophenyl)-2- (3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl] acetate (43a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (82 mg, 0.143 mmol) is converted by reaction with (4-cyanophenyl)boronic acid (32 mg, 0.218 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 80/20) to methyl 2-(ie f-butoxy)-2-[3-(4-cyanophenyl)- 2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl] acetate (43a) (48 mg, 0.091 mmol, 61 %).
1H NMR (400 MHz, CDCI3) δ 0.93 and 0.94 (s, 9H), 1.88-1 .92 (m, 1 H), 1.98-2.03 (m, 1 H), 2.33-2.56 (m, 1 H), 2.66-2.80 (m, 1 H), 3.73 (s, 1 H), 4.12-4.20 (m, 2H), 5.17 and 5.18 (s, 1 H), 6.33-6.40 (m, 1 H), 6.49 and 6.72 (d, J = 8.3 Hz, 1 H), 7.09-7.15 (m, 3H), 7.40 and 7.41 (d, J = 8.1 Hz, 1 H), 7.44 and 7.46 (d, J = 8.4 Hz, 2H), 7.78 (d, J = 8.1 Hz, 1 H).
Step 2: preparation 4-{3-[(ie/f-butoxy)(carboxy)methyl]-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-4-(trifluoromethyl)phenyl}benzoic acid (example 43)
To a solution of methyl 2-(fe/t-butoxy)-2-[3-(4-cyanophenyl)-2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (43a) (48 mg, 0.091 mmol) in dioxane (1 .5 mL) and water (0.75 mL) was added lithium hydroxide (18 mg, 0.75 mmol). The mixture was heated at 95°C for 18 hours. Further lithium hydroxide (18 mg, 0.75 mmol) was added and the mixture was heated at 1 10°C for 24 hours. The mixture was poured in water (10 mL) and acidified with 1 M hydrochloric acid until ph 2. The mixture was extracted with ethyl acetate (2x5 mL). The organic layer was washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuo to provide 4-{3-[(ie f-butoxy)(carboxy)methyl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-4- (trifluoromethyl)phenyl}benzoic acid (example 43) (39 mg, 0.073 mmol, 81 %) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.97 (s, 9H), 1.86-1.91 (m, 1 H), 1 .97-2.05 (m, 1 H), 2.30- 2.50 (m, 1 H), 2.75-2.80 (m, 1 H), 4.10-4.20 (m, 2H), 5.33 and 5.37 (s, 1 H), 6.37-6.80 (m, 2H), 7.13-7.17 (m, 2H), 7.46-7.50 (m, 2H), 7.80 (d, J = 8.2 Hz, 1 H), 7.91 (d, J = 8.0 Hz, 2H).
MS m/z ([M-H]-) 527.
Example 44: synthesis of 3-{3-r(te -butoxy)(carboxy)methyll-2-(3,4-dihvdro-2H-1- benzopyran-6-yl)-4-(trifluoromethyl)phenyl)benzoic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(3-cyanophenyl)-2- (3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl] acetate (44a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.123 mmol) is converted by reaction with (3-cyanophenyl)boronic acid (27 mg, 0.184 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate: 60/40) to methyl 2-(iert-butoxy)-2-[3-(3- cyanophenyl)-2-(3,4-dihydro-2H-1-benzo
(44a) (52 mg, 0.099 mmol, 81 %).
1H NMR (300 MHz, CDCI3) δ 0.95 and 0.96 (s, 9H), 1.84-1 .96 (m, 1 H), 1.96-2.07 (m, 1 H), 2.33-2.63 (m, 1 H), 2.63-2.87 (m, 1 H), 3.73 and 3.74 (s, 3H), 4.09-4.23 (m, 2H), 5.19 (s, 1 H), 6.35-6.42 (m, 1 H), 6.49 and 6.72 (d, J = 8.4 Hz, 1 H), 7.07-7.14 (m, 1 H), 7.18-7.30 (m, 2H), 7.30-7.48 (m, 3H), 7.79 (d, J = 8.2 Hz, 1 H).
MS m/z ([M+Na]+) 546.
Step 2: preparation of 3-{3-[(ie/f-butoxy)(carboxy)methyl]-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-4-(trifluoromethyl)phenyl}benzoic acid (example 44)
Using the procedure described in example 43, step 2, the intermediate methyl 2-(iert- butoxy)-2-[3-(3-cyanophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (51 mg, 0.097 mmol) is converted into 3-{3-[(ie f- butoxy)(carboxy)methyl]-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-4-(trifluoro
methyl)phenyl}benzoic acid (example 44) (45 mg, 0.088 mmol, 91 %).
1H NMR (300 MHz, CDCI3) δ 0.99 (s, 9H), 1.80-1.93 (m, 1 H), 1 .93-2.06 (m, 1 H), 2.27- 2.63 (m, 1 H), 2.72-2.88 (m, 1 H), 4.04-4.22 (m, 2H), 5.35 and 5.37 (s, 1 H), 6.33-6.84 (m, 2H), 7.14-7.32 (m, 2H), 7.42-7.56 (m, 2H), 7.80 (d, J = 8.2 Hz, 1 H), 7.83-7.95 (m, 2H).
Example 45: synthesis of 2-(te -butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -methyl-1 H-imidazol-4-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 -2: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1- methyl-1 H-imidazol-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 45)
To a solution of methyl 2-(fe/t-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)phenyl]acetate (35a) (100 mg, 0.182 mmol) in dioxane (1 mL) was added 4-bromo-1-methylimidazole (36 μΙ_, 0.36 mmol) and sodium carbonate saturated aqueous solution (1. mL). This mixture was stirred at room temperature for 20 minutes while passing a stream of argon. [1 ,1 - Bis(diphenylphosphino) ferrocene]dichloropalladium(ll), complex with dichloromethane (14 mg, 0.018mmol) was added and the resulting mixture was stirred at 80 °C for 24 hours. Further 4-bromo-1 -methylimidazole (36 μί, 0.36 mmol) and [1 ,1 '-Bis(diphenylphosphino) ferrocene]dichloropalladium(ll), complex with dichloromethane (14 mg, 0.018mmol) were added and the resulting mixture was stirred at 80 °C for 24 hours. Water (10 mL) was added and the mixture was extracted with ethyl acetate (2x10 mL). The organic phase were washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuo. The crude residue was purified on preparative TLC (dichloromethane/ethyl acetate: 90/10). The residue (42 mg) was dissolved in a mixture of dioxane (1.5 mL) and water (0.75 mL) and lithium hydroxide (16 mg, 0.67 mmol) was added. The mixture was heated at 1 10°C overnight. The mixture was poured in water (5 mL), acidified with a 1 M hydrochloric acid solution until pH 4 followed by extraction with ethyl acetate (2x5 mL). The combined organic layers were washed with brine (5 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by trituration in diethyl ether (2 mL) to provide 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 -methyl- 1 H-imidazol-4-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 45) (3 mg, 0.006 mmol, 3%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 1.00 (s, 9H), 2.02-2.05 (m, 2H), 2.69-2.80 (m, 2H), 3.58 (s, 3H), 4.24-4.27 (m, 2H), 5.20 (bs, 1 H), 5.52-5.56 (m, 1 H), 6.76-6.94 (m, 2H), 7.40- 7.44 (m, 1 H), 7.81-7.83 (m, 1 H), 8.02-8.12 (m, 1 H), 8.28-8.30 (m, 1 H).
MS m/z ([M+H]+) 489.
MS m/z ([M-H]-) 487.
Example 46: synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2/-/-1-benzopyran-6-yl)-3- -thiazol-4-yl)-6-(trifluoromethyl)phenvHacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2/-/-1- benzopyran-6-yl)-3-(1 ,2-thiazol-4-yl)-6-(trifluoromethyl)phenyl]acetate (46a)
Using the procedure described in example 35, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6- (trifluoromethyl)phenyl]acetate (35a) (100 mg, 0.182 mmol) is converted by reaction with 4-bromoisothiazole (59mg, 0.36 mmol), after purification by preparative TLC (cyclohexane/ethyl acetat 70/30) into methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-3-(1 ,2-thiazol-4-yl)-6-(trifluoromethyl)phenyl]acetate (46a) (51 mg, 0.100 mmol, 56%). 1H NMR (400 MHz, CDCI3) δ 0.97 (s, 9H), 1.92-1.98 (m, 1 H), 2.01-2.07 (m, 1 H), 2.47- 2.63 (m, 1 H), 2.68-2.82 (m, 1 H), 3.72 (s, 3H), 4.17-4.23 (m, 2H), 5.17 and 5.18 (s, 1 H), 6.49-6.80 (m, 2H), 7.10-7.15 (m, 1 H), 7.52 and 7.53 (d, J = 8.1 Hz, 1 H), 7.77 (d, J = 8.1 Hz, 1 H), 8.08 (s, 1 H), 8.12 (s, 1 H).
MS m/z ([M+H]+) 506.
MS m/z ([M-H]-) 504.
Step 2: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,2- thiazol-4-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 46)
To a solution of methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,2- thiazol-4-yl)-6-(trifluoromethyl)phenyl]acetate (46a) (51 mg, 0.100 mmol) in a mixture of dioxane (1 .5 mL) and water (0.75 mL) was added lithium hydroxide (19 mg, 0.81 mmol). The mixture was heated at 90°C for 3 days. Further lithium hydroxide (19 mg, 0.81 mmol) was added and the mixture was stirred at 1 10°C for 18 hours. The mixture was poured in water (5 mL), acidified with a 1 M hydrochloric acid solution until pH 2 followed by extraction with ethyl acetate (2x5 mL). The combined organic layers were washed with brine (5 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (dichloromethane/methanol 97/3) to provide 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,2-thiazol-4-yl)- 6-(trifluoromethyl)phenyl]acetic acid (example 46) (22 mg, 0.044 mmol, 44%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 1.00 (s, 9H), 1.91-1.97 (m, 1 H), 2.01-2.07 (m, 1 H), 2.47- 2.60 (m, 1 H), 2.79-2.83 (m, 1 H), 4.17-4.23 (m, 2H), 5.31 and 5.35 (s, 1 H), 6.46-6.86 (m, 2H), 7.52 and 7.48 (bs, 1 H), 7.57 and 7.58 (d, J = 8.2 Hz, 1 H), 7.79 (d, J = 8.2 Hz, 1 H), 8.08-8.14 (m, 2H).
MS m/z ([M+H]+) 492.
Example 47: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (pyridin-2-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(pyridin-2-yl)-6-(trifluoromethyl)phenyl]acetate (47a) Using the procedure described in example 35, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6- (trifluoromethyl)phenyl]acetate (35a) (100 mg, 0.182 mmol) is converted by reaction with 2-bromopyridine (57 mg, 0.36 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 70/30) into methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-3-(pyridin-2-yl)-6-(trifluoromethyl)phenyl]acetate (47a) (31 mg, 0.062 mmol, 34%).
1H NMR (400 MHz, CDCI3) δ 0.91 and 0.92 (s, 9H),1.83-1 .91 (m, 1 H), 1.98-2.04 (m, 1 H), 2.32-2.56 (m, 1 H), 2.67-2.81 (m, 1 H), 3.74 (s, 3H), 4.12-4.19 (m, 2H), 5.20 and 5.21 (s, 1 H), 6.47-6.80 (m, 3H), 7.06 and 7.08 (dd, J= 1.0 Hz, J = 4.9 Hz, 1 H), 7.17- 7.22 (m, 1 H), 7.33-7.39 (m, 1 H), 7.68 and 7.70 (d, J = 8.1 Hz, 1 H), 7.81 (d, J = 8.1 Hz, 1 H), 8.55-8.59 (m, 1 H).
MS m/z ([M+H]+) 500. Step 2: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (pyridin-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 47)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(pyridin-2-yl)-6-(trifluoromethyl)phenyl]acetate (47a) (31 mg, 0.062 mmol) is converted into 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1 - benzopyran-6-yl)-3-(pyridin-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 47) (24 mg, 0.049 mmol, 79%) as a white solid.
1H NMR (400MHz, CDCI3) δ 0.91 (s, 9H), 1.94 (m, 1 H), 1 .83-1.88 (m, 1 H), 1 .96 (bs, 1 H), 2.26-2.55 (m, 2H), 4.10-4.16 (m, 2H), 5.24-5.29 (m, 1 H), 6.40-6.69 (m, 2H), 6.86-7.04 (m, 1 H), 7.15 (bs, 1 H), 7.37-7.53 (m, 2H), 7.64-7.70 (m, 1 H), 7.82-7.85 (m, 1 H), 8.60-8.62 (m, 1 H).
MS m/z ([M+H]+) 486.
Example 48: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3-
(pyridin-3-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihyd benzopyran-6-yl)-3-(pyridin-3-yl)-6-(trifluoromethyl)phenyl]acetate (48a) Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (70 mg, 0.122 mmol) is converted by reaction with 3-Pyridineboronic acid (29 mg, 0.244 mmol) into methyl 2-(ie f-butoxy)-2-[2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-3-(pyridin-3-yl)-6-(trifluoromethyl)phenyl]acetate (48a) (46 mg, 0.092 mmol, 75%) after purification by preparative TLC (cyclohexane/ethyl acetate 50/50).
1H NMR (400 MHz, CDCI3) δ 0.96 (s, 9H), 1.86-1.93 (m, 1 H), 1 .98-2.04 (m, 1 H), 2.38- 2.57 (m, 1 H), 2.66-2.81 (m, 1 H), 3.72 and 3.73 (s, 3H), 4.10-4.19 (m, 2H), 5.18 (s, 1 H), 6.39-6.43 (m, 1 H), 6.51 and 6.73 (d, J = 8.4 Hz, 1 H), 7.1 1 -7.23 (m, 2H), 7.38- 7.48 (m, 2H), 7.81 (d, J = 8.2 Hz, 1 H), 8.34-8.43 (m, 2H).
MS m/z ([M+H]+) 500.
Step 2: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3- (pyridin-3-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 48)
Using the procedure described in example 5, step 4, the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(pyridin-3-yl)-6-(tri
fluoromethyl)phenyl]acetate (48a) (46 mg, 0.092 mmol) is converted into 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(pyridin-3-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 48) (20 mg, 0.041 mmol, 44%) as a yellow solid, after purification by preparative TLC (dichloromethane/methanol 95/5). 1H NMR (300 MHz, CDCI3) δ 0.97 (s, 9H), 1.86-1.91 (m, 1 H), 1 .95-2.04 (m, 1 H), 2.22- 2.55 (m, 1 H), 2.75-2.80 (m, 1 H), 4.10-4.19 (m, 2H), 5.30 and 5.33 (s, 1 H), 6.39-6.78 (m, 2H), 7.09-7.16 (m, 1 H), 7.29-7.49 (m, 3H), 7.81 (d, J = 8.2 Hz, 1 H), 8.38-8.44 (m, 2H).
MS m/z ([M+H]+) 486.
Example 49: synthesis of 2-r3-(1 ,3-benzothiazol-2-yl)-2-(3,4-dihvdro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyll-2-(te -butoxy)acetic acid
Step 1 : preparation of intermediate methyl 2-[3-(1 ,3-benzothiazol-2-yl)-2-(3,4-dihydro- 2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (49a) Using the procedure described in example 35, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6- (trifluoromethyl)phenyl]acetate (35a) (1 10 mg, 0.200 mmol) is converted by reaction with 2-bromobenzothiazole (85 mg, 0.4 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 70/30), into methyl 2-[3-(1 ,3-benzothiazol-2-yl)-2-(3,4- dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetate (49a) (35 mg, 0.063 mmol, 31 %).
1H NMR (300MHz, CDCI3) 5 0.99 (s, 9H), 1.96 (m, 1 H), 2.07 (m, 1 H), 2.61 (m, 1 H), 2.78 (m, 1 H), 3.72 (s, 3H), 4.22-4.26 (m, 2H), 5.16 and 5.17 (s, 1 H), 6.70-6.89 (m, 2H), 7.17 (m, 1 H), 7.38-7.50 (m, 2H), 7.73 (m, 1 H), 7.85 (m, 1 H), 8.04 (m, 1 H), 8.28 (m, 1 H).
MS m/z ([M+H]+) 556
Step 2: preparation of 2-[3-(1 ,3-benzothiazol-2-yl)-2-(3,4-dihydro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic acid (example 49)
Using the procedure described in example 2, step 2, the methyl 2-[3-(1 ,3- benzothiazol-2-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2- (ieri-butoxy)acetate (49a) (35 mg, 0.063 mmol) is converted after purification by preparative TLC (cyclohexane/ethyl acetate/acetic acid: 70/30/0.1 ) into 2-[3-(1 ,3- benzothiazol-2-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]-2- (ieri-butoxy)acetic acid (example 49) (24 mg, 0.044 mmol, 70%) as a white solid. 1H NMR (300MHz, CDCI3) δ 1 .03 (s, 9H), 1.94 (m, 1 H), 2.05-2.10 (m, 1 H), 2.56 (m, 1 H), 2.81-2.89 (m, 1 H), 4.20-4.29 (m, 2H), 5.31 and 5.41 (s, 1 H), 6.68-6.96 (m, 2H), 7.32 (t, J = 8.1 Hz, 1 H), 7.44-7.47 (m, 1 H), 7.55-7.60 (m, 1 H), 7.74 (d, J = 8.1 Hz, 1 H), 7.87 (d, J =8.4 Hz, 1 H), 8.06 (d, J =8.1 Hz, 1 H), 8.31 (d, J =8.4 Hz, 1 H).
MS m/z ([M+H]+) 542.
Example 50: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -thiazol-2-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : Preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihyd benzopyran-6-yl)-3-(1 ,3-thiazol-2-yl)-6-(trifluoromethyl)phenyl]acetate (50a) Using the procedure described in example 35, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(tetramethyl-1 ,3,2-dioxaborolan-2-yl)-6- (trifluoromethyl)phenyl]acetate (35a) (120 mg, 0.218 mmol) is converted by reaction with 2-bromothiazole (72 mg, 0.438 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 70/30) into (3-cyanophenyl)boronic acid (27 mg, 0.184 mmol), methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,3-thiazol- 2-yl)-6-(trifluoromethyl )phenyl]acetate (40a) (38 mg, 0.075 mmol, 35%).
1H NMR (300MHz, CDCI3) δ 1.01 (s, 9H), 2.03-2.07 (m, 2H), 2.67 (m, 1 H), 2.78 (m, 1 H), 3.69 (s, 3H), 4.25-4.28 (m, 2H), 5.16 (s, 1 H), 6.78-6.88 (m, 2H), 7.12 (m, 1 H), 7.45 (m, 1 H), 7.78 (m, 1 H), 7.80 (m, 1 H), 8.28 (m, 1 H).
MS m/z ([M+H]+) 506.
Step 2: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,3- thiazol-2-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 50)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 ,3-thiazol-2-yl)-6-
(trifluoromethyl)phenyl]acetate (50a) (38 mg, 0.075 mmol) is converted into 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,3-thiazol-2-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 50) (20 mg, 0.040 mmol, 54%) as a white solid after purification by preparative TLC (cyclohexane/ethyl acetate/acetic acid 70/30/0.1 ).
1H NMR (300MHz, CDCI3) δ 1.02 (s, 9H), 2.07 (m, 2H), 2.85 (m, 2H), 4.26 (m, 2H), 5.28 (s, 1 H), 6.77 (m, 2H), 7.26 (s, 1 H), 7.48 (m, 1 H), 7.78-7.82 (m, 2H), 8.29 (m, 1 H), 9.53 (bs, 1 H).
MS m/z ([M+H]+) 492.
MS m/z ([M-H]") 490.
Example 51 : synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (1-methyl-1 H-pyrazol-3-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-3-yl)-6-(trifluoromethyl) phenyl]acetate (51a) Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (100 mg, 0.175 mmol) is converted by reaction with 1 -methyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-pyrazole (55 mg, 0.264 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 70/30) into methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H- pyrazol-3-yl)-6-(trifluoromethyl)phenyl]acetate (51a) (47 mg, 0.093 mmol, 53%).
1H NMR (300MHz, CDCI3) δ 0.96 (s, 9H), 1 .99-2.04 (m, 2H), 2.63 (m, 1 H), 2.76 (m, 1 H), 3.70 (s, 3H), 3.86 (s, 3H), 4.20 (m, 2H), 5.15-5.19 (m, 2H), 6.67-6.82 (m, 2H), 7.03 (s, 1 H), 7.05-7.13 (m, 1 H), 7.73 (d, J =8.4 Hz, 1 H), 7.96 (d, J = 8.4 Hz, 1 H). MS m/z ([M+H]+) 503.
Step 2: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 - methyl-1 H-pyrazol-3-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 51 )
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-3-yl)-6- (trifluoromethyl)phenyl]acetate (47 mg, 0.093 mmol) is converted after purification by preparative TLC (cyclohexane/ethyl acetate/acetic acid 50/50/0.1 ) into 2-(ie f-butoxy)- 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-pyrazol-3-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 51) (43 mg, 0.088 mmol, 95%) as a white solid.
1H NMR (300MHz, CDCI3) δ 0.96 (s, 9H), 1 .95-2.06 (m, 2H), 2.60 (m, 1 H), 2.83 (m, 1 H), 3.87 (s, 3H), 4.1 1-4.25 (m, 2H), 5.16 and 5.19 (s, 1 H), 5.30 (m, 1 H), 6.65-6.88 (m, 2H), 7.04 (m, 1 H), 7.47 (bs, 1 H), 7.73 (d, J =8.4 Hz, 1 H), 7.99 (d, J = 8.4 Hz, 1 H), 9.50 (bs, 1 H)
MS m/z ([M+H]+) 489.
MS m/z ([M-H]-) 487.
Example 52: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (1-methyl-1 H-pyrazol-5-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-5-yl)-6-(trifluoromethyl)phenyl]acetate (52a) Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (100 mg, 0.175 mmol) is converted by reaction with 1 -methyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 H-pyrazole (44 mg, 0.210 mmol, after purification by preparative TLC (cyclohexane/ethyl acetate 60/40) into methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H- pyrazol-5-yl)-6-(trifluoromethyl)phenyl]acetate (52a) (41 mg, 0.082 mmol, 47%).
1H NMR (300MHz, CDCI3) <5 0.94 and 0.95 (s, 9H), 1 .95 (m, 2H), 2.55 (m, 1 H), 2.70 (m, 1 H), 3.43 and 3.46 (s, 3H), 3.74 (s, 3H), 4.14 (m, 2H), 5.16 and 5.18 (s, 1 H), 5.98 (m, 1 H), 6.49-6.72 (m, 2H), 7.03-7.10 (m, 1 H), 7.31 (s, 1 H), 7.41 (m, 1 H), 7.78 (d, J = 8.1 Hz, 1 H).
MS m/z ([M+H]+) 503.
Step 2: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 - methyl-1 H-pyrazol-5-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 52)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-5-yl)-6- (trifluoromethyl)phenyl]acetate (52a) (41 mg, 0.082 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate/acetic acid 50/50/0.1 ) into 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1-methyl-1 H-pyrazol-5-yl)- 6-(trifluoromethyl)phenyl]acetic acid (example 52) (33 mg, 0.067 mmol, 83%) as a white solid.
1H NMR (300MHz, CDCI3) δ 0.98 (s, 9H), 1.99 (m, 2H), 2.25 (m, 1 H), 2.74 (m, 1 H), 3.42 and 3.45 (s, 3H), 4.17 (m, 2H), 5.30 and 5.36 (s, 1 H), 6.01 (m, 1 H), 6.49-6.75 (m, 2H), 7.32 (s, 1 H), 7.47 (m, 2H), 7.79 (d, J = 8.1 Hz, 1 H), 9.59 (bs, 1 H).
MS m/z ([M+H]+) 489.
MS m/z ([M-H]-) 487.
Example 53: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (2,5-dimethyl-thiophen-3-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(2,5-dimethyl-thiophen-3-yl)-6-(trifluoromethyl) phenyl]acetate (53a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (200 mg, 0.350 mmol) is converted by reaction with (2,5-dimethyl-3-thienyl)boronic acid (66 mg, 0.420 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 85/15) to methyl 2-(fe/t-butoxy)-2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(2,5-dimethyl-thiophen-3-yl)-6-
(trifluoromethyl)phenyl]acetate (53a) (154 mg, 0.289 mmol, 82%) as a yellow oil. 1H NMR (300 MHz, CDCI3) δ 0.94 (s, 9H), 1 .84-2.12 (m, 5H), 2.24 (s, 3H), 2.38-2.80 (m, 2H), 3.73 (s, 3H), 4.03-4.26 (m, 2H), 5.17 and 5.20 (s, 1 H), 6.07 and 6.1 1 (s, 1 H), 6.40-6.71 (m, 2H), 6.97-7.10 (m, 1 H), 7.28-7.37 (m, 1 H), 7.69 (d, J = 8.1 Hz, 1 H).
Step 2: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2,5- dimethyl-thiophen-3-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 53)
Using the procedure described in example 2, step 2, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(2,5-dimethyl-thiophen-3-yl)-6- (trifluoromethyl)phenyl]acetate (53a) (50 mg, 0.094 mmol) is converted into 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2,5-dimethyl-thiophen-3-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 53) (46 mg, 0.088 mmol, 94%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.94 (s, 9H), 1 .83-2.04 (m, 2H), 2.05 (s, 3H), 2.24 (s, 3H), 2.39-2.86 (m, 2H), 4.05-4.26 (m, 2H), 5.31 and 5.38 (s, 1 H), 6.10 and 6.12 (s, 1 H), 6.35-6.80 (m, 2H), 7.37-7.48 (m, 2H), 7.70 (d, J = 8.1 Hz, 1 H), 9.57 (bs, 1 H). MS m/z ([M-H]") 517.
Example 54: synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2/-/-1-benzopyran-6-yl)-3- [3-(dimethylamino)-1 /-/-pyrazol-1-yll-6-(trifluoromethyl)phenyllacetic acid
(trifluoromethyl)benzene (54a)
To a solution of 2-fluoro-5-(trifluoromethyl)phenol (2.0 g, 1 1 .1 mmol) in anhydrous dichloromethane (20 mL) under nitrogen atmosphere at 0°C were successively added diisopropylethylamine (3.87 mL, 22.2 mmol) and chloromethyl methyl ether (1.26 mL, 16.6 mmol). The mixture was stirred at 0°C for 45 minutes before adding water (20 mL). Layers were separated and the aqueous one was extracted with dichloromethane (30 mL). The combined organic layers were washed with a 2 M sodium hydroxide solution (20 mL), dried over sodium sulfate and concentrated in vacuo to provide 1 -fluoro-2-(methoxymethoxy)-4-(trifluoromethyl)benzene (54a) (2.49 g, 1 1.1 mmol, 100%) as a lightly yellow oil.
1H NMR (400 MHz, CDCI3) δ 3.53 (s, 3H), 5.25 (s, 2H), 7.16-7.20 (m, 1 H), 7.24-7.27 (m, 1 H), 7.46 (dd, J = 1 .8 Hz, J = 7.4 Hz, 1 H).
Step 2: preparation of intermediate ethyl 2-[3-fluoro-2-(methoxymethoxy)-6- (trifluoromethyl)phenyl]-2-oxoacetate (54b)
Under nitrogen atmosphere, a 1.6 M n-butyllithium solution in hexanes (3.5 mL, 5.6 mmol) and a 1 M potassium ie f-butoxide solution in tetrahydrofuran (5.6 mL, 5.6 mmol) were added to anhydrous tetrahydrofuran (30 mL) at -78°C. The mixture was stirred for 15 minutes before adding dropwise a solution of 1-fluoro-2- (methoxymethoxy)-4-(trifluoromethyl)benzene (54a) (1.0 g, 4.46 mmol) in tetrahydrofuran (10 mL). The mixture was stirred at -78°C for 2 hours and was added via cannulation to a solution of ethyl oxalyl chloride (1.4 mL, 9.0 mmol) in tetrahydrofuran (20 mL) at -78°C. The mixture was stirred at -78°C for 45 minutes and water (50 mL) was added. Layers were separated and the aqueous layer was extracted with ethyl acetate (2x30 mL). The combined organic layers were washed with a saturated solution of sodium hydrogenocarbonate (30 mL), brine (30 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 90/10) to provide ethyl 2-[3- fluoro-2-(methoxymethoxy)-6-(trifluoromethyl)phenyl]-2-oxoacetate (34b) (840 mg, 2.59 mmol, 58%) as a yellow oil.
1H NMR (300 MHz, CDCI3) δ 1.36 (t, J = 7.2 Hz, 3H), 3.45 (s, 3H), 4.38 (q, J = 7.2 Hz, 2H), 5.16 (s, 2H), 7.28-7.34 (m, 1 H), 7.43 (dd, J = 4.4 Hz, J = 8.8 Hz, 1 H).
Step 3: preparation of intermediate ethyl 2-[3-fluoro-2-hydroxy-6- (trifluoromethyl)phenyl]-2-oxoacetate (54c)
To a solution of ethyl 2-[3-fluoro-2-(methoxymethoxy)-6-(trifluoromethyl)phenyl]-2- oxoacetate (54b) (500 mg, 1.54 mmol) and p-toluenesulfonic acid (59 mg, 0.31 mmol) in dichloromethane (7.5 mL) and ethanol (1 .5 mL) was heated at 50°C overnight. The mixture was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 60/40) to provide ethyl 2-[3- fluoro-2-hydroxy-6-(trifluoromethyl) phenyl]-2-oxoacetate (54c) (394 mg, 1.40 mmol, 91 %) as a yellow oil.
1H NMR (300 MHz, CDCI3) δ 1.38 (t, J = 7.2 Hz, 3H), 4.38 (q, J = 7.2 Hz, 2H), 6.91 (d, J = 2.7 Hz), 7.26-7.35 (m, 2H).
Step 4: preparation of intermediate ethyl 2-{3-fluoro-2-[(trifluoromethane)sulfonyloxy]- 6-(trifluoromethyl)phenyl}-2-oxoacetate (54d)
To a solution of ethyl 2-[3-fluoro-2-hydroxy-6-(trifluoromethyl)phenyl]-2-oxoacetate (54c) (394 mg, 1.41 mmol) in anhydrous dichloromethane (5 mL) under nitrogen atmosphere at -78°C were successively added triethylamine (0.24 mL, 1.69 mmol) and triflic anhydride (0.26 mL, 1.55 mmol). The mixture was stirred at -78°C for 45 minutes before adding water (10 mL). Layers were separated. The aqueous layer was extracted with dichloromethane (10 mL). The combined organic layers were washed with a saturated solution of sodium hydrogenocarbonate (10 mL), dried over sodium sulfate and concentrated in vacuo to ethyl 2-{3-fluoro-2- [(trifluoromethane)sulfonyloxy]-6-(trifluoromethyl) phenyl}-2-oxoacetate (54d) (548 mg, 1.32 mmol, 94%) as a yellow oil which was used without further purification.
1H NMR (300 MHz, CDCI3) δ 1.37 (t, J = 7.2 Hz, 3H), 4.42 (q, J = 7.2 Hz, 2H), 7.55 (t, J = 8.7 Hz), 7.78 (dd, J = 4.5 Hz, J = 8.7 Hz,1 H).
Step 5: preparation of intermediate 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro- 6-(trifluoromethyl)phenyl]-2-oxoacetic acid (54e)
A degassed solution of ethyl 2-{3-fluoro-2-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl}-2-oxoacetate (54d) (2.00 g, 4.88 mmol), potassium carbonate (2.68 g, 19.4 mmol), 6-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)chroman (1.64 g, 6.31 mmol) and palladium tetrakis(triphenylphosphine) (0.56 g, 0.49 mmol) in dioxane (40 mL) and water (10 mL) was heated at 85°C overnight. Dioxane was evaporated in vacuo. Diethyl ether (20 mL) was added and the layers were separated. The organic layer was washed with a saturated solution of sodium hydrogenocarbonate (10 mL). The combined aqueous layers were acidified with 37% hydrochloric acid until pH 2 then extracted with diethyl ether (2x20 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in toluene (30 mL) and concentrated in vacuo. The operation was repeated twice to provide 2-[2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-3-fluoro-6-(trifluoromethyl) phenyl]-2-oxoacetic acid (54e) (0.736 mg, 2.0 mmol, 41 %) as an oil which crystallized.
1H NMR (400 MHz, CDCI3) δ 1.98-2.05 (m, 2H), 2.76 (t, J = 6.4 Hz, 2H), 4.19-4.22 (m, 2H), 4.35 (bs, 1 H), 6.80 (d, J = 8.3 Hz, 1 H), 6.90-6.94 (m, 2H), 7.28-7.39 (m, 2H), 7.72 (dd, J = 4.5 Hz, J = 8.7 Hz, 1 H).
MS m/z ([M-H]-) 367.
Step 6: preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(3-nitro-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (54f)
To a solution of 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetic acid (54e) (100 mg, 0.27 mmol) and 3-nitro-1 H- pyrazole (61 mg, 0.54 mmol) in anhydrous dimethylacetamide (2 mL) at room temperature under nitrogen atmosphere, was added sodium hydride 60% in oil (33 mg, 0.81 mmol). The mixture was heated at 150°C overnight. The mixture was poured in water (10 mL), acidified with 1 M hydrochloric acid until pH 2 and extracted with ethyl acetate (2x10 mL). The organic layer was washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in methanol (2 mL) and cyclohexane (4 mL) and a 2 M solution of trimethylsilyldiazomethane in diethyl ether (0.9 mL, 1.8 mmol) was added. The mixture was stirred at 0°C for 30 minutes and a few drops of acetic acid were added. The mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (10 mL) and washed with a saturated solution of sodium hydrogenocarbonate (10 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 70/30) to provide methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-nitro-1 H- pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (54f) (69 mg, 0.145 mmol, 53%). 1H NMR (300 MHz, CDCI3) δ 1.95-2.04 (m, 2H), 2.60-2.75 (m, 2H), 3.57 (s, 3H), 4.19 (t, J = 5.2 Hz, 2H), 6.71 (s, 2H), 6.73 (s, 1 H), 6.78 (d, J = 2.8 Hz, 1 H), 7.05 (d, J = 2.8 Hz, 1 H), 7.90 (d, J = 8.4 Hz, 1 H), 7.98 (d, J = 8.4 Hz, 1 H).
Step 7: preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(3-nitro-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (54g)
To a solution of methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-nitro-1 H-pyrazol- 1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (54f) (69 mg, 0.145 mmol) in anhydrous methanol (4 mL) at 0°C was added sodium borohydride (12 mg, 0.29 mmol). The mixture was stirred at room temperature for 45 minutes before adding water (2 mL). Methanol was evaporated in vacuo. The resulting solution was extracted with ethyl acetate (2x5 mL). The organic layer was washed with brine (5 mL) and dried over sodium sulfate to provide methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-nitro- 1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (54g) (66 mg, 0.138 mmol, 95%).
1H NMR (400 MHz, CDCI3) δ 1.93-2.06 (m, 2H), 2.52-2.65 (m, 1 H), 2.68-2.82 (m, 1 H), 3.52 and 3.55 (s, 3H), 4.17-4.23 (m, 2H), 5.45 (s, 1 H), 6.52-6.78 (m, 3H), 6.99-7.01 (m, 1 H), 7.14-7.16 (m, 1 H), 7.78 (d, J = 8.5 Hz, 1 H), 7.90 (d, J = 8.0 Hz, 1 H).
MS m/z ([M+H]+) 478.
Step 8: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(3-nitro-1 H-pyrazol-1 -yl)-6-(trifluoromethyl) phenyl]acetate (54h) Using the procedure described in example 1 , step 8, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-nitro-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (54g) (66 mg, 0.138 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 70/30) into intermediate methyl 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3- nitro-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetate (54h) (32 mg, 0.060 mmol, 43%) as a colorless oil. 1H NMR (400 MHz, CDCI3) δ 0.93 and 0.94 (s, 9H), 1.91-2.06 (m, 2H), 2.47-2.64 (m, 1 H), 2.68-2.81 (m, 1 H), 3.74 (s, 3H), 4.17-4.22 (m, 2H), 5.16 and 5.17 (s, 1 H), 6.58- 6.82 (m, 3H), 6.98 and 7.00 (d, J = 2.6 Hz, 1 H), 7.13-7.18 (m, 1 H), 7.71 and 7.73 (d, J = 8.5 Hz, 1 H), 7.87 and 7.88 (d, J = 8.5 Hz, 1 H).
Step 9: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[3-(dimethylamino)-1 H-pyrazol-1 -yl]-6- (trifluoromethyl)phenyl]acetate (54i)
A suspension of methyl 2-(fe/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(3- nitro-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetate (54g) (32 mg, 0.060 mmol) and palladium on carbon (8 mg) in methanol (3 mL) was stirred at room temperature for 1 hour. The mixture was filtered over Millipore and concentrated in vacuo. The residue was dissolved in methanol (1 mL) and tetrahydrofurane (1 mL). To the mixture was added 37% aqueous formaldehyde (47 μί, 0.60 mmol) and sodium cyanoborohydride (19 mg, 0.30 mmol) maintaining at pH 5 with addition of acetic acid. The mixture was stirred at room temperature for 1 hour before adding a saturated solution of sodium hydrogenocarbonate (5 mL). The Aqueous layer was extracted with ethyl acetate (2x5 mL). The organic layer was washed with brine (5 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane/ethyl acetate: 60/40) to provide methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[3-(dimethylamino)-1 H-pyrazol-1 - yl]-6-(trifluoromethyl)phenyl]acetate (54i) (20 mg, 0.037 mmol, 62%) as a colorless oil.
1H NMR (400 MHz, CDCI3) δ 0.93 and 0.94 (s, 9H), 1.94-2.07 (m, 2H), 2.62 (t, J = 6.4 Hz, 1 H), 2.69-2.82 (m, 1 H), 2.86 and 2.87 (s, 6H), 3.71 (s, 3H), 4.19-4.24 (m, 2H), 5.15 (s, 1 H), 5.52 and 5.53 (d, J = 2.6 Hz, 1 H), 6.59 (d, J = 2.6 Hz, 1 H), 6.70-6.84 (m, 2H), 7.14-7.18 (m, 1 H), 7.75 (d, J = 8.5 Hz, 1 H), 7.81 and 7.82 (d, J = 8.5 Hz, 1 H). MS m/z ([M+H]+) 532. Step 10: Preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[3- (dimethylamino)-l H-pyrazol-1 -yl]-6-(trifluoromethyl)phenyl]acetic acid (example 54) Using the procedure described in example 5, step 4, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[3-(dimethylamino)-1 H-pyrazol-1 -yl]-6- (trifluoromethyl)phenyl]acetate (54i) (20 mg, 0.037 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[3-(dimethylamino)-1 H-pyrazol-1 - yl]-6-(trifluoromethyl)phenyl]acetic acid (example 54) (9 mg, 0.017 mmol, 47%) as a white solid. 1H NMR (300 MHz, CDCI3) δ 0.94 (s, 9H), 1.95-2.06 (m, 2H), 2.61-2.63 (m, 1 H), 2.82- 2.89 (m, 7H), 4.19-4.25 (m, 2H), 5.28 and 5.30 (s, 1 H), 5.55-5.57 (m, 1 H), 6.58-6.91 (m, 3H), 7.53 (bs, 1 H), 7.77 (d, J = 8.6 Hz, 1 H), 7.87 (d, J = 8.6 Hz, 1 H).
MS m/z ([M+H]+) 518.
Example 55: synthesis of 2-(te -butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -(dimethylamino)-1 H-pyrazol-1-yll-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(4-nitro-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (55a)
To a solution of 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetic acid (54e) (150 mg, 0.41 mmol) and 4-nitro-1 H- pyrazole (92 mg, 0.81 mmol) in anhydrous dimethylacetamide (2 mL) at room temperature under nitrogen atmosphere, was added sodium hydride 60% in oil (49 mg, 1 .22 mmol). The mixture was heated at 70°C for 1 hour then at 1 10°C for 2 hours. The mixture was poured in water (10 mL) and washed with ethyl acetate (10 mL). The aqueous layer was acidified with 1 M hydrochloric acid until pH 2 and extracted with ethyl acetate (2x10 mL). The organic layer was washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in methanol (2 mL) and cyclohexane (4 mL) and a 2 M solution of tnmethylsilyldiazomethane in diethyl ether (0.5 mL, 1 mmol) was added. The mixture was stirred at 0°C for 30 minutes and a few drops of acetic acid were added. The mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (10 mL) and washed with a saturated solution of sodium hydrogenocarbonate (10 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate: 75/25) to provide methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-nitro- 1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (55a) (104 mg, 0.218 mmol, 53%) as a white solid. 1H NMR (300 MHz, CDCI3) δ 1.96-2.02 (m, 2H), 2.70 (t, J = 6.3 Hz, 2H), 3.58 (s, 3H), 4.18-4.22 (m, 2H), 6.65-6.74 (m, 3H), 6.70-6.78 (m, 3H), 7.73 (s, 1 H), 7.88-7.95 (m, 2H), 8.18 (s, 1 H).
MS m/z ([M+H]+) 476.
MS m/z ([M-H]-) 474.
Step 2: preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(4-nitro-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (55b)
Using the procedure described in example 54, step 7, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-nitro-1 H-pyrazol-1 -yl)-6-
(trifluoromethyl)phenyl]-2-oxoacetate (55a) (104 mg, 0.219 mmol) is converted into methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-nitro-1 H-pyrazol-1 -yl)-6-
(trifluoromethyl)phenyl]-2-hydroxyacetate (55b) (100 mg, 0.209 mmol, 96%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.93-2.07 (m, 2H), 2.62 and 2.78 (t, J = 6.4 Hz), 3.53 and 3.58 (s, 3H), 4.17-4.23 (m, 2H), 5.46 (s, 1 H), 6.47-6.53 (m, 1 H), 6.64 and 6.80 (d, J = 8.4 Hz, 1 H), 7.09-7.15 (m, 1 H), 7.64 and 7.65 (s, 1 H), 7.75 (d, J = 8.6 Hz, 1 H), 7.92 (d, J = 8.6 Hz, 1 H), 8.08 and 8.09 (s, 1 H). Step 3: preparation of intermediate methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(4-nitro-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl] acetate (55c) Using the procedure described in example 1 , step 8, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-nitro-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (55b) (100 mg, 0.209 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 75/25) into intermediate methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4- nitro-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetate (55c) (44 mg, 0.082 mmol, 39%) as a colorless oil.
1H NMR (300 MHz, CDCI3) δ 0.96 and 0.97 (s, 9H), 1.91-2.08 (m, 2H), 2.49-2.87 (m, 2H), 3.73 (s, 3H), 4.17-4.23 (m, 2H), 5.18 (s, 1 H), 6.54-6.58 (m, 1 H), 6.65 and 6.84 (d, J = 8.4 Hz, 1 H), 7.14-7.17 (m, 1 H), 7.63 and 7.66 (s, 1 H), 7.69 and 7.71 (d, J = 8.4 Hz, 1 H), 7.89 (d, J = 8.4 Hz, 1 H), 8.10 and 8.12 (s, 1 H).
Step 4: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[4-(dimethylamino)-1 H-pyrazol-1 -yl]-6- (trifluoromethyl)phenyl]acetate (55d) Using the procedure described in example 54, step 9, the intermediate methyl 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-nitro-1 H-pyrazol-1-yl)-6- (trifluoromethyl)phenyl]acetate (55c) (44 mg, 0.082 mmol) is converted, after purification by preparative TLC (dichloromethane/methanol 97/3) into
methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[4-(dimethyl amino)- 1 H-pyrazol-1-yl]-6-(trifluoromethyl)phenyl]acetate (55d) (23 mg, 0.043 mmol, 52%) 1H NMR (400 MHz, CDCI3) δ 0.93 and 0.95 (s, 9H), 1.93-2.05 (m, 2H), 2.47 and 2.48 (s, 6H), 2.52-2.64 (m, 1 H), 2.74-2.77 (m, 1 H), 3.72 and 3.73 (s, 3H), 4.15-4.22 (m, 2H), 5.21 (s, 1 H), 6.24 and 6.29 (s, 1 H), 6.54-6.62 (m, 1 H), 6.67 and 6.82 (d, J = 8.4 Hz, 1 H), 7.13-7.20 (m, 1 H), 7.25 and 7.27 (s, 1 H), 7.71 and 7.72 (d, J = 8.5 Hz, 1 H), 7.78 and 7.79 (d, J = 8.5 Hz, 1 H).
MS m/z ([M+H]+) 532.
Step 5: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[4- (dimethylamino)-l H-pyrazol-1 -yl]-6-(trifluoromethyl)phenyl]acetic acid (example 55) Using the procedure described in example 5, step 4, the methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[4-(dimethylamino)-1 H-pyrazol-1 -yl]-6- (trifluoromethyl)phenyl]acetate (55d) (23 mg, 0.043 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[4-(dimethylamino)-1 H-pyrazol-1 - yl]-6-(trifluoromethyl)phenyl]acetic acid (example 55) (18 mg, 0.034 mmol, 81 %) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.96 (s, 9H), 1 .94-2.03 (m, 2H), 2.47 and 2.49 (s, 6H), 2.52-2.60 (m, 1 H), 2.74-2.78 (m, 1 H), 4.13-4.22 (m, 2H), 5.33 and 5.37 (s, 1 H), 6.25 and 6.32 (s, 1 H), 6.52-6.89 (m, 2H), 7.28 and 7.30 (s, 1 H), 7.51-7.56 (m, 1 H), 7.74- 7.82 (m, 2H).
MS m/z ([M+H]+) 518.
Example 56: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- Γ1 -methyl-3-(trif luoromethyl)-1 H-pyrazol-5-yll-6-(trifluoromethyl) phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-[1 -methyl-3-(trifluoromethyl)-1 H-pyrazol-5-yl]-6- (trifluoromethyl)phenyl]acetate (56a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (100 mg, 0.175 mmol) is converted by reaction with (1-methyl-3-(trifluoromethyl)-1 H-pyrazol-5-yl)boronic acid (41 mg, 0.210 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 25/75) into methyl 2- (ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1-methyl-3-(trifluoromethyl)- 1 H-pyrazol-5-yl]-6-(trifluoromethyl)phenyl]acetate (56a) (39 mg, 0.068 mmol, 39%) as a colourless oil.
1H NMR (300 MHz, CDCI3) δ 0.93 and 0.95 (s, 9H), 1.86-2.07 (m, 2H), 2.42-2.82 (m, 2H), 3.42 and 3.47 (s, 3H), 3.73 and 3.74 (s, 3H), 4.10-4.23 (m, 2H), 5.17 and 5.21 (s, 1 H), 6.25 and 6.29 (s, 1 H), 6.45-6.76 (m, 2H), 7.01 -7.12 (m, 1 H), 7.40-7.45 (m, 1 H), 7.79 (d, J = 8.1 Hz, 1 H).
Step 2: preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1 - methyl-3-(trifluoromethyl)-1 H-pyrazol-5-yl]-6-(trifluoromethyl)phenyl]acetic acid (example 56)
Using the procedure described in example 2, step 12, the intermediate 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[1-methyl-3-(trifluoromethyl) -1 H- pyrazol-5-yl]-6-(trifluoromethyl)phenyl]acetate (56a) (39 mg, 0.068 mmol) is converted after purification by preparative TLC (cyclohexane/ethyl acetate/acetic acid 70/30/0.1 ) into 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[1 -methyl-3- (trifluoromethyl)-1 H-pyrazol-5-yl]-6-(trifluoromethyl)phenyl]acetic acid (example 56) (24 mg, 0.043 mmol, 63%) as a beige solid.
1H NMR (300 MHz, CDCI3) δ 0.97 (s, 9H), 1.83-2.18 (m, 2H), 2.34-2.90 (m, 2H), 3.41 and 3.46 (s, 3H), 4.05-4.31 (m, 2H), 5.30 and 5.38 (s, 1 H), 6.27-6.85 (m, 3H), 7.40- 7.50 (m, 2H), 7.81 (d, J = 8.1 Hz, 1 H).
MS m/z ([M-H]-) 557.
Example 57: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (5-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyllacetic acid
Example 57
Step 1 : preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(5-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (57a) and methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1-yl)-6- (trifluoromethyl)phenyl]-2-oxoacetate (57b)
To a solution of 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetic acid (54e) (150 mg, 0.41 mmol) and 3- methylpyrazole (66 μί, 0.81 mmol) in anhydrous dimethylacetamide (2 mL) at room temperature under nitrogen atmosphere, was added sodium hydride 60% in oil (49 mg, 1.22 mmol). The mixture was heated at 70°C for 5 hours then poured in water (10 mL). The mixture was acidified with 1 M hydrochloric acid until pH 2 and extracted with diethyl ether (2x10 mL). The organic layer was washed with brine (10 mL), dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in methanol (2 mL) and cyclohexane (4 mL) and a 2 M solution of tnmethylsilyldiazomethane in diethyl ether (0.5 mL, 1 mmol) was added. The mixture was stirred at 0°C for 30 minutes and a few drops of acetic acid was added. The mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (10 mL) and washed with a saturated solution of sodium hydrogenocarbonate (10 mL). The organic layer was dried over sodium sulfate and concentrated in vacuo. The residue was purified by preparative TLC (cyclohexane/ethyl acetate 75/25) to provide and methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1 -yl)-6- (trifluoro methyl)phenyl]-2-oxoacetate (57a) (30 mg, 0.067 mmol, 16%) as a colorless oil and methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1 -yl)- 6-(trifluoromethyl)phenyl]-2-oxoacetate (57b) (90 mg, 0.20 mmol, 49%) as a colorless oil.
(57b) 1H NMR (400 MHz, CDCI3) δ 1.96-1 .99 (m, 2H), 2.30 (s, 3H), 2.65-2.71 (m, 2H), 3.53 (s, 3H), 4.17-4.19 (m, 2H), 5.94 (d, J = 2.4 Hz, 1 H), 6.70 (s, 2H), 6.73 (s, 1 H), 6.80 (d, J = 2.4 Hz, 1 H), 7.79 (d, J = 8.8 Hz, 1 H), 7.96 (d, J = 8.8 Hz, 1 H).
MS m/z ([M+H]+) 445.
(57a) 1H NMR (400 MHz, CDCI3) δ 1.79 (s, 3H), 1.90-1.96 (m, 2H), 2.61 (bs, 2H), 3.48 (s, 3H), 4.12-4.15 (m, 2H), 5.93 (d, J = 1 .6 Hz, 1 H), 6.58-6.65 (m, 3H), 7.48 (d, J = 1.6 Hz, 1 H), 7.67 (d, J = 8.4 Hz, 1 H), 7.84 (d, J = 8.4 Hz, 1 H).
MS m/z ([M+H]+) 445.
Step 2: preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(5-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (57c)
Using the procedure described in example 54, step 7, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-oxoacetate (54a) (30 mg, 0.067 mmol) is converted into methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (57c) (25 mg, 0.056 mmol, 83%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.86 (s, 3H), 1 .90-1 .99 (m, 2H), 2.26 (s, 3H), 2.53-2.77 (m, 2H), 3.32 (bs, 1 H), 3.49 and 3.51 (s, 3H), 4.10-4.17 (m, 2H), 5.43 and 5.44 (s, 1 H), 5.83-5.84 (m, 1 H), 6.51 -6.63 (m, 2H), 7.05-7.07 (m, 1 H), 7.35 (s, 1 H), 7.15 (m, 1 H), 7.48 and 7.49 (d, J = 8.3 Hz, 1 H), 7.84 (d, J = 8.3 Hz, 1 H).
MS m/z ([M+H]+) 447.
MS m/z ([M-H]") 445.
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetate (57d) Using the procedure described in example 1 , step 8, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (57c) (25 mg, 0.56 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 60/40) into methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (57d) (1 1 mg, 0.022 mmol, 39%) as a colorless oil. 1H NMR (400 MHz, CDCI3) δ 0.91 and 0.93 (s, 9H), 1.81-2.01 (m, 5H), 2.46-2.63 (m, 1 H), 2.64-2.73 (m, 1 H), 3.74 and 3.75 (s, 3H), 4.12-4.18 (m, 2H), 5.17 and 5.20 (s, 1 H), 5.84 and 5.87 (s, 1 H), 6.53-6.69 (m, 2H), 7.06-7.1 1 (m, 1 H), 7.38 and 7.40 (s, 1 H), 7.46 and 7.49 (d, J = 8.3 Hz, 1 H), 7.82 and 7.83 (d, J = 8.3 Hz, 1 H).
MS m/z ([M+H]+) 503.
MS m/z ([M-H]") 501.
Step 4: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(5- methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetic acid (example 57)
Using the procedure described in example 5, step 4, the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (57d) (1 1 mg, 0.022 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetic acid (example 57) (10 mg, 0.020 mmol, 91 %) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.94 (s, 9H), 1.80-1.99 (m, 5H), 2.46-2.76 (m, 2H), 4.13- 4.18 (m, 2H), 5.28 and 5.36 (s, 1 H), 5.85 and 5.88 (s, 1 H), 6.53-6.73 (m, 2H), 7.43- 7.56 (m, 3H), 7.85 (d, J = 8.3 Hz, 1 H).
MS m/z ([M+H]+) 489.
MS m/z ([M-H]") 487.
Example 58: synthesis of 2-(te f-butoxy)-2-r3-(cvclohex-1-en-1 -yl)-2-(3,4-dihvdro-2H- -benzopyran-6-yl)-6-(trifluoromethyl)phenvHacetic acid
Step 1 : preparation of intermediate methyl 2-(ie f-butoxy)-2-[3-(cyclohex-1 -en-1-yl)-2- (3,4-dihydro-2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetate (58a)
Using the procedure described in example 1 , step 1 1 , the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[(trifluoromethane) sulfonyloxy]-6- (trifluoromethyl)phenyl]acetate (1j) (100 mg, 0.175 mmol) is converted by reaction with (1-cyclohexen-1-yl-boronic acid pinacol ester (44 mg, 0.210 mmol), after purification by preparative TLC (cyclohexane/ethyl acetate 90/10) into methyl 2-(ie f- butoxy)-2-[3-(cyclohex-1-en-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetate (58a) (58 mg, 0.1 15 mmol, 66%) as a colourless oil. 1H NMR (300 MHz, CDCI3) δ 0.93 and 0.94 (s, 9H), 1.21-1 .80 (m, 6H), 1.92-2.08 (m, 4H), 2.65-2.80 (m, 2H), 3.70 (s, 3H), 4.22 (t, J = 5.02 Hz, 2H), 5.15 and 5,18 (s, 1 H), 5.46-5.55 (m, 1 H), 6.72-6.89 (m, 2H), 6.98-7.08 (m, 1 H), 7.22 (d, J = 8,1 Hz, 1 H), 7.60 (d, J = 8.1 Hz, 1 H).
MS m/z ([M+Na]+) 525.
Step 2: preparation of 2-(ie/f-butoxy)-2-[3-(cyclohex-1-en-1 -yl)-2-(3,4-dihydro-2H-1- benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid (example 58)
Using the procedure described in example 2, step 12, the intermediate 2-(tert- butoxy)-2-[3-(cyclohex-1-en-1 -yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-
(trifluoromethyl)phenyl]acetate (58a) (57 mg, 0.1 13 mmol) is converted after purification by preparative TLC (cyclohexane/ethyl acetate/acetic acid 20/80/0.1 ) into 2-(ie/f-butoxy)-2-[3-(cyclohex-1 -en-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 58) (30 mg, 0.061 mmol, 54%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.95 (s, 9H), 1.17-1.78 (m, 6H), 1 .92-2.08 (m, 4H), 2.69- 2.82 (m, 2H), 4.23 (t, J = 5.1 Hz, 2H), 5.30 and 5.36 (s, 1 H), 5.52 (s, 1 H), 6.70-6.88 (m, 2H), 7.29-7.86 (m, 2H), 7.62 (d, J = 8.1 Hz, 1 H), 9.59 (bs, 1 H).
MS m/z ([M-H]-) 487.
Example 59: synthesis of 2-(te -butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- -methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyllacetic acid
Example 59
Step 1 : preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(3-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (59a)
Using the procedure described in example 54, step 7, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-oxoacetate (57b) (90 mg, 0.20 mmol) is converted to methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1-yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (59a) (90 mg, 0.20 mmol, 100%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.93-2.07 (m, 2H), 2.26 (s, 3H), 2.58-2.62 (m, 1 H), 2.63- 2.85 (m, 1 H), 3.21 (bs, 1 H), 3.50 and 3.53 (s, 3H), 4.17-4.23 (m, 2H), 5.43 and 5.44 (s, 1 H), 5.86-5.87 (m, 1 H), 6.50-6.79 (m, 3H), 7.12-7.15 (m, 1 H), 7.77-7.83 (m, 2H). MS m/z ([M+H]+) 447. Step 2: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1-yl)-6-(trifluoromethyl)phenyl]acetate (59b) Using the procedure described in example 1 , step 8, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1-yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (59a) (90 mg, 0.20 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 80/20) into methyl 2-(ie f- butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (59b) (48 mg, 0.095 mmol, 45%) as a colorless oil. 1H NMR (400 MHz, CDCI3) δ 0.91 and 0.92 (s, 9H), 1.92-1 .97 (m, 1 H), 2.00-2.06 (m, 1 H), 2.27 and 2.28 (s, 3H), 2.49-2.64 (m, 1 H), 2.68-2.83 (m, 1 H), 3.73 (s, 3H), 4.16- 4.22 (m, 2H), 5.15 and 5.16 (s, 1 H), 5.85 and 5.87 (d, J = 2.4 Hz, 1 H), 6.57-6.81 (m, 3H), 7.13-7.18 (m, 1 H), 7.72 (d, J = 8.6 Hz, 1 H), 7.79 (d, J = 8.6 Hz, 1 H).
MS m/z ([M+H]+) 503.
Step 3: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3- methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetic acid (example 59)
Using the procedure described in example 5, step 4, the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (59b) (45 mg, 0.089 mmol) is converted to 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetic acid (example 59) (30 mg, 0.061 mmol, 68%) as a white solid.
1H NMR (400 MHz, CDCI3) δ 0.94 (s, 9H), 1.92-1.99 (m, 1 H), 2.00-2.07 (m, 1 H), 2.29 and 2.30 (s, 3H), 2.52-2.60 (m, 1 H), 2.82-2.85 (m, 1 H), 4.18-4.24 (m, 2H), 5.29 and 5.33 (s, 1 H), 5.88 and 5.90 (d, J = 2.4 Hz, 1 H), 6.56-6.89 (m, 3H), 7.54-7.57 (m, 1 H), 7.78-7.83 (m, 2H).
MS m/z ([M+H]+) 489.
MS m/z ([M-H]") 487. Example 60: synthesis of 2-(te/f-butoxy)-2-r2-(4,4-dimethylcvclohex-1 -en-1-yl)-3-(1 H- pyrazol-1 -yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate 2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetic acid (60a)
A degassed solution of ethyl 2-{3-fluoro-2-[(trifluoromethane)sulfonyloxy]-6- (trifluoromethyl)phenyl}-2-oxoacetate (54d) (100 mg, 0.24 mmol), sodium carbonate (77 mg, 0.73 mmol), 2-(4,4-dimethyl-1-cyclohexen-1-yl)-4,4,5,5-tetramethyl-1 ,3,2- dioxaborolane (74 mg, 0.32 mmol) and palladium tetrakis(triphenylphosphine) (28 mg, 0.02 mmol) in tetrahydrofurane (1.7 mL) and water (0.3 mL) was irradiated at 60°C for 1 hour. The mixture was poured in water (5 mL) and extracted with ethyl acetate. The organic layer was washed with a saturated solution of sodium hydrogenocarbonate (5 mL), dried over sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (cyclohexane/ethyl acetate 90/10) to provide 2- [2-(4,4-dimethylcyclohex-1-en-1-yl)-3-fluoro-6-(trifluoromethyl) phenyl]-2-oxoacetic acid (60a) (64 mg, 0.17 mmol, 71 %) as a colorless oil.
1H NMR (300 MHz, CDCI3) δ 0.94 (s, 6H), 1.33-1.43 (m, 5H), 1 .88-1.91 (m, 2H), 2.24- 2.29 (m, 2H), 4.31 (q, J = 7.2 Hz, 2H), 5.55-5.58 (m, 1 H), 7.23 (t, J = 8.7 Hz, 1 H), 7.63 (dd, J = 4.8 Hz, J = 8.7 Hz, 1 H).
Step 2: preparation of intermediate methyl 2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3-
(1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (60b)
Using the procedure described in example 57, step 1 , the intermediate 2-[2-(4,4- dimethylcyclohex-1 -en-1-yl)-3-fluoro-6-(trifluoromethyl)phenyl]-2-oxo acetic acid (60a) (31 1 mg, 0.84 mmol) is converted by reaction with pyrazole (1 14 mg, 1 .67 mmol), after purification by flash chromatography on silica gel (cyclohexane/ethyl acetate 80/20) into methyl 2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3-(1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-oxoacetate (60b) (177 mg, 0.43 mmol, 52%) as a colorless oil. 1H NMR (300 MHz, CDCI3) δ 0.84 (s, 6H), 1.13-1.32 (m, 3H), 1 .71-1.93 (m, 3H), 3.86 (s, 3H), 5.74-5.76 (m, 1 H), 6.44-6.46 (m, 1 H), 7.72-7.76 (m, 4H).
MS m/z ([M+H]+) 407. Step 3: preparation of intermediate methyl 2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3- (1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (60c)
Using the procedure described in example 54, step 7, the intermediate methyl 2-[2- (4,4-dimethylcyclohex-1-en-1 -yl)-3-(1 H-pyrazol-1 -yl)-6-(trifluoromethyl) phenyl]-2- oxoacetate (177 mg, 0.44 mmol) (60b) (90 mg, 0.20 mmol) is converted into methyl 2- [2-(4,4-dimethylcyclohex-1-en-1-yl)-3-(1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2- hydroxyacetate (60c) (178 mg, 0.44 mmol, 100%) as a colorless oil.
1H NMR (400 MHz, CDCI3) δ 0.72 (s, 3H), 0.93 (s, 3H), 1.14-1 .19 (m, 1 H), 1.30-1.35 (m, 1 H), 1.55-2.17 (m, 4H), 3.74 and 3.76 (s, 3H), 5.41 and 5.95 (bs, 1 H), 5.61 (s, 1 H), 6.39 (s, 1 H), 7.53-7.56 (m, 1 H), 7.62 (s, 1 H), 7.67-7.69 (m, 1 H), 7.74-7.76 (m, 1 H).
MS m/z ([M+H]+) 409.
MS m/z ([M-H]-) 407.
Step 4: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(4,4-dimethylcyclohex- 1-en-1-yl)-3-(1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl] acetate (60d)
Using the procedure described in example 1 , step 8, the intermediate methyl 2-[2- (4,4-dimethylcyclohex-1-en-1 -yl)-3-(1 H-pyrazol-1 -yl)-6-(trifluoromethyl) phenyl]-2- hydroxyacetate (60c) (178 mg, 0.44 mmol) is converted, after purification by flash chromatography on silica gel (cyclohexane/ethyl acetate 90/10) into methyl 2-(tert- butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1-yl)-3-(1 H-pyrazol-1 -yl)-6-
(trifluoromethyl)phenyl]acetate (60d) (69 mg, 0.148 mmol, 34%) as a colorless oil. 1H NMR (300 MHz, CDCI3) δ 0.79 and 0.84 (s, 3H), 0.95 and 0.97 (s, 3H), 1.12-1.40 (m, 12H), 1.79 (s, 1 H), 1 .92-1.94 (m, 1 H), 2.21 -2.27 (m, 1 H), 3.67 and 3.73 (s, 3H), 5.32 and 5.80 and 5.88 (bs, 1 H), 6.37 and 6.39 and 6.42 (t, J = 2.1 Hz, 1 H), 7.48-7.54 (m, 1 H), 7.61-7.76 (m, 3H).
MS m/z ([M+H]+) 465.
Step 4: preparation of 2-(ie/f-butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1 -yl)-3-(1 H- pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetic acid (example 60)
Using the procedure described in example 5, step 4, the intermediate methyl 2-(tert- butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1 -yl)-3-(1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (60d) (69 mg, 0.15 mmol) is converted into 2-(tert- butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1-yl)-3-(1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetic acid (example 60) (50 mg, 0.1 1 mmol, 74%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.78 and 0.85 (s, 3H), 0.94 (s, 3H), 1.13-1.30 (m, 1 1 H), 1.40-1.50 (m, 1 H), 1 .79-2.01 (m, 3H), 5.51-5.59 and 6.31-5.35 (m, 2H), 6.39 and 6.42 and 6.42 (t, J = 2.1 Hz, 1 H), 7.54-7.71 (m, 3H), 7.75 and 7.76 (d, J = 8.5 Hz, 1 H). MS m/z ([M+H]+) 451.
MS m/z ([M-H]") 449. Example 61 : synthesis of 2-(te/f-butoxy)-2-r2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3-
(4-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(4-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (61a)
Using the procedure described in example 57, step 1 , the intermediate 2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6-(trifluoromethyl)phenyl]-2-oxoacetic acid (54e) (150 mg, 0.39 mmol) is converted by reaction with 4-methylpyrazole (65 μΙ_, 0.78 mmol), after purification by flash chromatography on silica gel (cyclohexane/ethyl acetate 80/20) into methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-methyl-1 H- pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (61a) (1 16 mg, 0.26 mmol, 66%) as a colorless oil.
1H NMR (300 MHz, CDCI3) δ 1.92 (s, 3H), 1.96-2.02 (m, 2H), 2.66-2.73 (m, 2H), 3.53 (s, 3H), 4.17-4.20 (m, 2H), 6.69-6.72 (m, 4H), 7.43 (s, 1 H), 7.80 (d, J = 8.4 Hz, 1 H), 7.92 (d, J = 8.4 Hz, 1 H).
MS m/z ([M+H]+) 445. Step 2: preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(4-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (61 b)
Using the procedure described in example 54, step 7, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-oxoacetate (61a) (1 16 mg, 0.26 mmol) is converted, after recrystallization in cyclohexane, into methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(4-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (61 b) (32 mg, 0.07 mmol, 27%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 1.89 (s, 3H), 1.93-2.06 (m, 2H), 2.57-2.61 (m, 1 H), 2.74- 2.78 (m, 1 H), 3.51 and 3.54 (s, 3H), 4.17-4.23 (m, 2H), 5.44 and 5.45 (s, 1 H), 6.51- 6.97 (m, 3H), 7.12-7.16 (m, 1 H), 7.35 (s, 1 H), 7.74 (d, J = 8.7 Hz, 1 H), 7.22 (d, J = 8.7 Hz, 1 H).
MS m/z ([M+H]+) 447.
MS m/z ([M-H]") 445.
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(4-methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl) phenyl]acetate (61c) Using the procedure described in example 1 , step 8, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]-2-hydroxyacetate (61 b) (32 mg, 0.07 mmol) (178 mg, 0.44 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 70/30) into methyl 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4- methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl) phenyl]acetate (61c) (20 mg, 0.039 mmol, 55%) as a colorless oil.
1H NMR (300 MHz, CDCI3) δ 0.93 and 0.94 (s, 9H), 1.89 and 1.90 (s, 3H), 1.90-2.07 (m, 2H), 2.47-2.66 (m, 1 H), 2.67-2.86 (m, 1 H), 3.73 and 3.74 (s, 3H), 4.16-4.23 (m, 2H), 5.16 and 5.18 (s, 1 H), 6.52-6.82 (m, 3H), 7.12-7.19 (m, 1 H), 7.35 and 7.36 (s, 1 H), 7.67 and 7.68 (d, J = 8.6 Hz, 1 H), 7.77 and 7.80 (d, J = 8.6 Hz, 1 H).
MS m/z ([M+H]+) 503.
Step 4: Preparation of 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4- methyl-1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetic acid (example 61 )
Using the procedure described in example 5, step 4, the intermediate methyl 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(4-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl) phenyl]acetate (61c) (20 mg, 0.039 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(4-methyl-1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetic acid (example 61) (12 mg, 0.024 mmol, 63%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.94 (s, 9H), 1.88-2.07 (m, 5H), 2.47-2.66 (m, 1 H), 2.79- 2.83 (m, 1 H), 4.16-4.24 (m, 2H), 5.29 and 5.35 (s, 1 H), 6.51-6.89 (m, 3H), 7.38 and 7.39 (s, 1 H), 7.51 -7.55 (m, 1 H), 7.71-7.83 (m, 2H).
MS m/z ([M+H]+) 489.
MS m/z ([2M-H]-) 975.
Example 62: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (1 H-imidazol-1-yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-
3-(1 H-imidazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (62a)
To a solution of 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-fluoro-6- (trifluoromethyl)phenyl]-2-oxoacetic acid (54a) (1 17 mg, 0.32 mmol) and imidazole (43 mg, 0.64 mmol) in anhydrous dimethylacetamide (2 mL) at 0°C under nitrogen atmosphere, was added sodium hydride 60% in oil (51 mg, 1.27 mmol). The mixture was heated at 1 10°C for 3 hours. At room temperature, 5 drops of water were added to the mixture. The mixture was then diluted with ethyl acetate, dried over sodium sulfate and concentrated in vacuo. The residue was dissolved in toluene and concentrated in vacuo. The procedure was carried out twice. The residue was dissolved in methanol (5 mL) and a 2 M solution of trimethylsilyldiazomethane in diethyl ether (1 mL, 2 mmol) was added. The mixture was stirred at room temperature for 30 minutes and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (100% ethyl acetate) to provide methyl 2-[2-(3,4- dihydro-2H-1-benzopyran-6-yl)-3-(1 H-imidazol-1 -yl)-6-(trifluoromethyl)phenyl]-2- oxoacetate (62a) (57 mg, 0.13 mmol, 41 %) as a colorless oil. 1H NMR (400 MHz, CDCI3) δ 1.91-1.98 (m, 2H), 2.62-2.70 (m, 2H), 3.55 (s, 3H), 4.14- 4.17 (t, J = 5.2 Hz, 2H), 6.60-6.67 (m, 3H), 6.82 (s, 1 H), 6.99 (s, 1 H), 7.35 (s, 1 H), 7.59 (d, J = 8.4 Hz, 1 H), 7.84 (d, J = 8.4 Hz, 1 H). Step 2: preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(1 H-imidazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (62b)
Using the procedure described in example 54, step 7, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 H-imidazol-1 -yl)-6-(trifluoro methyl)phenyl]-2- oxoacetate (62a) (56 mg, 0.13 mmol) is converted, after purification by preparative TLC (dichloromethane/methanol 95/5) into methyl 2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1 H-imidazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (62b) (40 mg, 0.095 mmol, 71 %) as a colorless oil.
1H NMR (400 MHz, CDCI3) δ 1.92-2.03 (m, 2H), 2.56-2.60 (m, 1 H), 2.63-2.78 (m, 1 H), 3.54 and 3.57 (s, 3H), 4.14-4.20 (m, 2H), 5.44 and 5.45 (s, 1 H), 6.45-6.74 (m, 3H), 6.89-6.91 (m, 1 H), 7.05-7.07 (m, 1 H), 7.28 (s, 1 H), 7.46 (d, J = 8.4 Hz, 1 H), 7.85 (d, J = 8.4 Hz, 1 H).
MS m/z ([M+H]+) 433.
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1 H-imidazol-1 -yl)-6-(trifluoromethyl)phenyl]acetate (62c)
Using the procedure described in example 1 , step 8, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 H-imidazol-1 -yl)-6-(trifluoro methyl)phenyl]-2- hydroxyacetate (62b) (40 mg, 0.09 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 80/20) into methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 H-imidazol-1 -yl)-6-
(trifluoromethyl)phenyl]acetate (62c) (16 mg, 0.032 mmol, 35%) as a colorless oil. 1H NMR (400 MHz, CDCI3) δ 0.95 and 0.96 (s, 9H), 1.92-2.04 (m, 2H), 2.50-2.60 (m, 1 H), 2.65-2.79 (m, 1 H), 3.72 (s, 3H), 4.15-4.20 (m, 2H), 5.17 (s, 1 H), 6.45-6.78 (m, 3H), 6.91 and 6.93 (s, 1 H), 7.05-7.1 1 (m, 1 H), 7.25-7.31 (m, 1 H), 7.41 (d, J = 8.4 Hz, 1 H), 7.82 (d, J = 8.4 Hz, 1 H).
MS m/z ([M+H]+) 489.
Step 4: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 H- imidazol-1 -yl)-6-(trifluoromethyl)phenyl]acetic acid (example 62)
Using the procedure described in example 5, step 4, the intermediate methyl 2-(iert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 H-imidazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (62c) (16 mg, 0.032 mmol) is converted into 2-(tert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 H-imidazol-1-yl)-6- (trifluoromethyl)phenyl]acetic acid (example 62) (1 1 mg, 0.023 mmol, 68%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.98 (s, 9H), 1.92-2.05 (m, 2H), 2.53-2.57 (m, 1 H), 2.75- 2.79 (m, 1 H), 4.14-4.21 (m, 2H), 5.26 and 5.29 (s, 1 H), 6.45-6.82 (m, 3H), 6.94 and 6.95 (s, 1 H), 7.42-7.47 (m, 3H), 7.84 (d, J = 8.4 Hz, 1 H).
MS m/z ([M+H]+) 475.
Example 63: synthesis of 2-(te/f-butoxy)-2-[2-(3,4-dihvdro-2H-1-benzopyran-6-yl)-3- (1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyllacetic acid
Step 1 : preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-oxoacetate (63a)
Using the procedure described in example 62, step 1 , the intermediate 2-[2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-3-fluoro-6-(trifluoromethyl)phenyl]-2-oxoacetic acid (54e) (50 mg, 0.14 mmol) is converted by reaction with pyrazole (18 mg, 0.27 mmol), after purification by flash chromatography on silica gel (cyclohexane/ethyl acetate 70/30) to provide methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 H-pyrazol-1 -yl)- 6-(trifluoromethyl)phenyl]-2-oxoacetate (63a) (33 mg, 0.076 mmol, 57%) as a colorless oil.
1H NMR (400 MHz, CDCI3) δ 1.94-2.03 (m, 2H), 2.61 -2.72 (m, 2H), 3.54 (s, 3H), 4.16- 4.19 (m, 2H), 6.16-6.17 (m, 1 H), 6.68 (s, 2H), 6.71 (s, 1 H), 6.97 (d, J = 2.5 Hz, 1 H), 7.63 (d, J = 1.4 Hz, 1 H), 7.82 (d, J = 8.5 Hz, 1 H), 7.95 (d, J = 8.5 Hz, 1 H).
MS m/z ([M+H]+) 431.
Step 2: preparation of intermediate methyl 2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)- 3-(1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]-2-hydroxyacetate (63b) Using the procedure described in example 54, step 7, the intermediate methyl 2-[2- (3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 H-pyrazol-1 -yl)-6-(trifluoromethyl) phenyl]-2- oxoacetate (63a) (33 mg, 0.076 mmol) is converted into methyl 2-[2-(3,4-dihydro-2H- 1 -benzopyran-6-yl)-3-(1 H-pyrazol-1-yl)-6-(trifluoromethyl) phenyl]-2-hydroxyacetate (63b) (30 mg, 0.07 mmol, 91 %) as a colorless oil.
1H NMR (300 MHz, CDCI3) δ 1.90-2.06 (m, 2H), 2.49-2.66 (m, 1 H), 2.67-2.84 (m, 1 H), 3.50 and 3.53 (s, 3H), 4.14-4.22 (m, 2H), 5.44 and 5.45 (s, 1 H), 6.07-6.10 (m, 1 H), 6.49-6.53 (m, 1 H), 6.61 and 6.76 (d, J = 8.4 Hz, 1 H), 6.88 (d, J = 2.4 Hz, 1 H), 7.13- 7.17 (m, 1 H), 7.54 (d, J = 1.7 Hz, 1 H), 7.76 (d, J = 8.6 Hz, 1 H), 7.84 (d, J = 8.6 Hz, 1 H).
MS m/z ([M+H]+) 433.
Step 3: preparation of intermediate methyl 2-(ie f-butoxy)-2-[2-(3,4-dihydro-2H-1- benzopyran-6-yl)-3-(1 H-pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetate (63c)
Using the procedure described in example 1 , step 8, the intermediate methyl 2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 H-pyrazol-1 -yl)-6-(trifluoro methyl)phenyl]-2- hydroxyacetate (63b) (30 mg, 0.07 mmol) is converted, after purification by preparative TLC (cyclohexane/ethyl acetate 70/30) into methyl 2-(ie f-butoxy)-2-[2- (3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (63c) (20 mg, 0.04 mmol, 58%) as a colorless oil.
1H NMR (300 MHz, CDCI3) δ 0.93 and 0.94 (s, 9H), 1.90-2.07 (m, 2H), 2.45-2.64 (m, 1 H), 2.67-2.84 (m, 1 H), 3.73 and 3.74 (s, 3H), 4.16-4.23 (m, 2H), 5.17 and 5.18 (s, 1 H), 6.08-6.1 1 (m, 1 H), 6.52-6.58 (m, 1 H), 6.62 and 6.80 (d, J = 8.4 Hz, 1 H), 6.87 and 6.90 (d, J = 2.4 Hz, 1 H), 7.14-7.20 (m, 1 H), 7.55-7.56 (m, 1 H), 7.72 (d, J = 8.5 Hz, 1 H), 7.83 (d, J = 8.5 Hz, 1 H).
MS m/z ([M+H]+) 489.
Step 4: preparation of 2-(iert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 H- pyrazol-1 -yl)-6-(trifluoromethyl)phenyl]acetic acid (example 63)
Using the procedure described in example 5, step 4, the intermediate methyl 2-(iert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetate (63c) (20 mg, 0.04 mmol) is converted to 2-(iert- butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetic acid (example 63) (12 mg, 0.025 mmol, 63%) as a white solid.
1H NMR (300 MHz, CDCI3) δ 0.95 (s, 9H), 1.90-1.96 (m, 1 H), 2.00-2.07 (m, 1 H), 2.46- 2.59 (m, 1 H), 2.79-2.84 (m, 1 H), 4.16-4.23 (m, 2H), 5.30 and 5.34 (s, 1 H), 6.09-6.12 (m, 1 H), 6.50-6.90 (m, 3H), 7.52-7.58 (m, 2H), 7.77 (d, J = 8.5 Hz, 1 H), 7.84 (d, J =
8.5 Hz, 1 H).
MS m/z ([M+H]+) 475.
MS m/z ([M-H]-) 473.
Antiviral activity
The antiviral activity, particularly against HIV, of compounds according to the invention is evaluated by the protocol described below.
Preparation of Virus stock of the NL4-3 strain of HIV-1 (Adachi et al, J Virol, 1986, 59(2):284-91 ).
The virus was prepared as described in Lopez et al (Lopez et al, Proc Natl Acad Sci U S A., 2006, 103(40): 14947-52, by transfecting 2 x 106 293T cells (CRL-1573, ATCC ) with following modifications: 6μg of NL4-3 proviral DNA molecular clone were mixed with Fugene 6 transfection reagent from Roche, and used according to manufacturer's instructions. Forty eight hours later, transfected cell supernatants were harvested, filtered through 0.45^m-pore-size filters, quantified for HIV-1 p24 antigen by using a Innotest HIV antigen mAb assay (Ingen) according to manufacturer's instructions, and used in infection experiments. Preparation of compounds:
Serial dilutions of compounds to be tested were prepared in complete RPMI medium from 10mM DMSO stock solutions, and distributed in a volume of 20 μί in 96 well Falcon 353072 Microtest™ tissue culture plate, in order to get 0.5% DMSO final concentration in each well, after the addition of infected cells. Control wells contained also 0.5% DMSO final concentration but no compound.
Infection of cells:
MT4 cells (from the NIH AIDS Research and Reference Reagent Program) in RPMI complete medium were counted (10X106 cells per well in Falcon 353047 Multiwell™ 24 well) and infected for 2 hours at 37°, at a multiplicity of infection (moi) of 0.0001-0.00001. Cells were then centrifuged 3min at 3000rpm, and washed two times in 1 ml PBS to remove viruses that have not entered in cells. Infected cells were resuspended in complete RPMI at 1.25x106 cells/ml, and 80μΙ of infected cells were distributed in each well containing compounds to be tested or control wells. The plates were then incubated at 37° for 5 days. Assay used to measure the inhibition of HIV replication by the compounds (according to (according to Gregg S. Jones et al., Antimicrobial Agents and Chemotherapy, 2009, 53 (3): 1194-1203).
After 5 days of incubation, 50μΙ of CellTiter-Glo reagent (Promega Biosciences, Inc., Madison Wl, USA) were added to each well. Cell lysis was carried out at room temperature during 10min, 150μΙ of lysates were transferred in Packard Optiplate 96 well, and luminescence was read on a Fluoroskan (Thermo Scientific).
The EC50, or effective concentration 50, is the concentration of compound leading to 50% of cyto-protection in a Cell-Titer-Glo® viability assay based on MT4 cells infected with NL4-3 virus (table 1 ).
Table 1
The results show that the compounds according to the invention can inhibit the HIV replication and thus can be used as anti-HIV compounds.

Claims

1. A compound according to formula (I) :
R1 and R6, identical or different, independently represent a hydrogen atom; - CN; -OH; -CF3; a halogen atom; a linear or branched C-|-C3 alkyl a linear or branched C1-C3 heteroalkyl;
R2, non-substituted or substituted by at least one T1, represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle ; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle ;
R3 non-substituted or substituted by at least one T2, represents an aryl; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7- membered carbocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7- membered heterocycle and further fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; a heteroaryl; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5- , 6- or 7-membered carbocycle; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a C5-C7 cycloalkenyl; a C5-C7 cycloalkenyl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; or a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle;
• R4 represents a linear or branched Ci-C6-alkyl; a linear or branched Ci-C6 fluoroalkyi or a C3-C6 cycloalkyl;
· R5 represents a halogen atom; -CF3; a linear or branched Ci-C6 alkyl; a linear or branched C2-C6 alkenyl; a linear or branched C2-C6 alkynyl; a linear or branched fluoroalkyi; a C3-C6 cycloalkyl; -CH2OH; or -CH2-0-CH3;
• T1 independently represents a hydrogen atom; a halogen atom; an alkyl; - (X)x-Ci-C6 alkyl; a linear or branched fluoroalkyi; a linear or branched -O-Cr C3 fluoroalkyi; -(X)x-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-C3-C6 cycloalkyl; -(X)x-
(CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x-(CT5T6)yOT3; -(X)x-(CT5T6)yST3; -(X)x- (CT5T6)yS(0)T3; -(X)x-(CT5T6)yS(0)2T3; -(X)x-(CT5T6)yNT3T4; -(X)x- (CT5T6)yC(0)T3; -(X)x-(CT5T6)yC(0)OT3; -(X)x-(CT5T6)yC(0)NT3T4; -(X)x- (CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; -(X)x-(CT5T6)yNT3C(0)OT4; -(X)x-(CT5T6)yOC(0)NT3T4; -(X)x-(CT5T6)y S(0)2NT3T4 or -(X)x-
(CT5T6)yNT3S(0)2T4;
• T2 independently represents a hydrogen atom; a halogen atom; a linear or branched -0-Ci-C3 alkyl; a linear or branched Ci-C3 fluoroalkyi; a linear or branched -0-Ci-C3 fluoroalkyi; a linear or branched Ci-C3 alkyl; or -CN; optionally two geminal T2 form with the carbon atom to which they are bonded, a C3-C7 cycloalkyl;
• X independently represents an oxygen atom; a sulphur atom; NT3; S=0 or S(0)2;
• T3 and T4, identical or different, independently represent a hydrogen atom; a branched or linear C†-C6 alkyl or a C3-C6 cycloalkyl; optionally T3, T4 and the nitrogen atom to which they are bonded form a C4-C6 heterocycloalkyl;
• T5 and T6, identical or different, independently represent a hydrogen atom; a fluorine atom or a linear or branched Ci-C3 alkyl or a C3-C6 cycloalkyl; optionally T5, T6 and the carbon atom to which they are bonded form a cyclopropyl;
• x independently represents 0 or 1 ;
• y independently represents 0, 1 , 2 or 3; or • R5 and R6 form, with the carbon atoms to which they are bonded, a heteroaryl comprising at least one nitrogen atom;
and a racemate, enantiomer, atropisomer, diastereoisomer or a pharmaceutically acceptable salt thereof.
2. Compound according to claim 1 , wherein :
• R1 and R6 represent a hydrogen atom;
• R2, non-substituted or substituted by at least one T1, represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle ; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic
5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle ;
• R3, non-substituted or substituted by at least one T2, represents an aryl; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; an aryl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7- membered heterocycle and further fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; a heteroaryl; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5- , 6- or 7-membered carbocycle; a heteroaryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a C5-C7 cycloalkenyl; a C5-C7 cycloalkenyl fused with a saturated, partially or totally unsaturated or aromatic 4-, 5-, 6- or 7-membered heterocycle; or a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle;
• R4 represents a linear or branched Ci-C6-alkyl; a linear or branched C-|-C6 fluoroalkyl or a C3-C6 cycloalkyl;
• R5 represents a halogen atom; a linear or branched Ci-C6 alkyl; a linear or branched fluoroalkyl; a C3-C6 cycloalkyl or -CH2OH; • T1 independently represents a hydrogen atom; a halogen atom; an alkyl; - (X)x-Ci-C6 alkyl; a linear or branched fluoroalkyi; a linear or branched -O-Cr C3 fluoroalkyi; -(X)x-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-C3-C6 cycloalkyl; -(X)x- (CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x-(CT5T6)yOT3; -(X)x-(CT5T6)yST3; -(X)x- (CT5T6)yS(0)T3; -(X)x-(CT5T6)yS(0)2T3; -(X)x-(CT5T6)yNT3T4; -(X)x-
(CT5T6)yC(0)T3; -(X)x-(CT5T6)yC(0)OT3; -(X)x-(CT5T6)yC(0)NT3T4; -(X)x- (CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; -(X)x-(CT5T6)yNT3C(0)OT4; -(X)x-(CT5T6)yOC(0)NT3T4; -(X)x-(CT5T6)y S(0)2NT3T4 or -(X)x- (CT5T6)yNT3S(0)2T4;
· T2 independently represents a hydrogen atom; a halogen atom; a linear or branched -O-C1-C3 alkyl; a linear or branched C1-C3 fluoroalkyi; a linear or branched -O-C1-C3 fluoroalkyi; a linear or branched C1-C3 alkyl; or -CN; optionally two geminal T2 form with the carbon atom to which they are bonded, a C3-C7 cycloalkyl;
· X independently represents an oxygen atom; a sulphur atom; NT3; S=0 or
S(0)2;
• T3 and T4, identical or different, independently represent a hydrogen atom; a branched or linear d-C6 alkyl or a C3-C6 cycloalkyl; optionally T3, T4 and the nitrogen atom to which they are bonded form a C4-C6 heterocycloalkyl;
· T5 and T6, identical or different, independently represent a hydrogen atom; a fluorine atom or a linear or branched C1-C3 alkyl or a C3-C6 cycloalkyl; optionally T5, T6 and the carbon atom to which they are bonded form a cyclopropyl;
• x independently represents 0 or 1 ;
· y independently represents 0, 1 , 2 or 3.
3. Compound according to claim 1 or 2 wherein R4 represents tBu.
Compound according to any of the preceding claims, wherein:
• R2 represents a partially or totally unsaturated or aromatic 5-, 6- or 7- membered carbocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; or a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7- membered carbocycle; • T1 independently represents a hydrogen atom; a halogen atom; -CH3; - CH2CH3; -(CH2)2CH3; -CH(CH3)2; -CH2CF3; -OCH3; -NH2; -N(CH3)2; -CH2F; -CHF2; -CF3; -OCH2F; -OCHF2; -OCF3; -(X)x-C3-C6 cycloalkyl; -(X)x- (CT5T6)y-C3-C6 cycloalkyl; -(X)x-(CT5T6)y-aryl; -(X)x-(CT5T6)yCN; -(X)x- (CT5T6)yOT3; -(X)x-(CT5T6)yST3; -(X)x-(CT5T6)yS(0)T3; -(X)x-
(CT5T6)yS(0)2T3; -(X)x-(CT5T6)yNT3T4; -(X)x-(CT5T6)yC(0)T3; -(X)x- (CT5T6)yC(0)OT3; -(X)x-(CT5T6)yC(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)NT3T4; -(X)x-(CT5T6)yNT3C(0)T4; -(X)x-(CT5T6)yNT3C(0)OT4; -(X)x-
(CT5T6)yOC(0)NT3T4; -(X)x-(CT5T6)y S(0)2NT3T4 or -(X)x- (CT5T6)yNT3S(0)2T4 ;
• X independently represents an oxygen atom; a sulphur atom; NT3; S=0 or S(0)2;
• T3 and T4, identical or different, independently represent a hydrogen atom; a branched or linear C†-C6 alkyl or a C3-C6 cycloalkyl;
· T5 and T6, identical or different, independently represent a hydrogen atom; a fluorine atom or methyl;
• x independently represents 0 or 1 ;
• y independently represents 0, 1 , 2 or 3. 5. Compound according to any of the preceding claims wherein R5 represents a linear or branched Ci-C3 alkyl; a linear or branched Ci-C3 fluoroalkyi; a halogen atom; a C3-C6 cycloalkyl or -CH2OH.
6. Compound according to any of the preceding claims wherein R2, non-substituted or substituted by at least one T1, represents a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; or a partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered carbocycle.
7. Compound according to any of the preceding claims wherein R3, non-substituted or substituted by at least one T2, represents an aryl fused with a saturated, partially or totally unsaturated or aromatic 5-, 6- or 7-membered heterocycle; or a C5-C7 cycloalkenyl.
8. Compound according to any of the preceding claims wherein:
• T1 independently represents a hydrogen atom; a halogen atom; an alkyl; - (X^-C Ce alkyl; a linear or branched fluoroalkyl; -(X)x-C3-C6 cycloalkyl; -(X)x- (CT5T6)y-C3-C6 cycloalkyl; -(X)x-(CT5T6)yOT3; -(X)x-(CT5T6)y-aryl; -(X)x- (CT5T6)yNT3T4; -(X)x-(CT5T6)yC(0)OT3; -(X)x-(CT5T6)yC(0)NT3T4; or -(X)x-
(CT5T6)yNT3C(0)T4;
• T2 independently represents a hydrogen atom; a halogen atom; a linear or branched C1-C3 fluoroalkyl; or a linear or branched C1-C3 alkyl;
• X represents an oxygen atom;
· T3 and T4, identical or different, independently represent a hydrogen atom; or a branched or linear C Ce alkyl;
• x independently represents 0 or 1 ;
• y independently represents 0, 1 , 2 or 3. 9. Compound according to any of the preceding claims selected in the group consisting of:
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-phenyl-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-methoxyphenyl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[3-(4-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[3-(3-carbamoylphenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[4-
(methylcarbamoyl)phenyl]-6-(trifluoromethyl)phenyl]acetic acid;
- 2-[3-(4-aminophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-[3-(4-acetamidophenyl)-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-[3-(3-aminophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid ;
- 2-(ie/f-butoxy)-2-[3-(3-acetamidophenyl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-propylphenyl)-6- (trifluoromethyl)phenyl]acetic acid; - 4-{3-[(ie/f-butoxy)(carboxy)methyl]-2-(3,4-dihydro-2/-/-1 -benzopyran-6-yl)-4- (trifluoromethyl)phenyl}benzoic acid;
- 3-{3-[(ie/f-butoxy)(carboxy)methyl]-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-4- (trifluoromethyl)phenyl}benzoic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(6-propylpyridin-2-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-propylpyridin-2-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyridin-2-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1-yl)-3-(pyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-{3-[2-(benzyloxy)pyridin-4-yl]-2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-6- (trifluoromethyl)phenyl}-2-(ie -butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(3-fluoropyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(2-propylpyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyridin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(pyridin-3-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(pyrimidin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(pyridazin-4-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(thiophen-2-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-pyrazol-5- yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[4-(dimethylamino)-1 H- pyrazol-1-yl]-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-pyrazol-3- yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(3-methyl-1 H-pyrazol-1 - yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(3-phenyl-1 H-pyrazol-1 - yl)-6-(trifluoromethyl)phenyl]acetic acid; - 2-[3-(4-bromo-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic acid;
- 2-[3-(4-chloro-1 H-pyrazol-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(fe/t-butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(4-methyl-1 H-pyrazol-1 - yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[3-(dimethylamino)-1 H- pyrazol-1 -yl]-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[1 -methyl-3- (trifluoromethyl)-1 /-/-pyrazol-5-yl]-6-(trifluoromethyl) phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[3-(cyclohex-1 -en-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(4,4-dimethylcyclohex-1-en-1 -yl)-3-(1 H-pyrazol-1-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 H-pyrazol-1 -yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-(1 H-imidazol-1-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-[3-(1 ,3-benzothiazol-2-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]-2-(ie -butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,3-thiazol-2-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 ,2-thiazol-4-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-imidazol- 4-yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(4,4-dimethylcyclohex-1 -en-1-yl)-3-(1-methyl-1 H-pyrazol-4-yl)- 6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-pyrazol-4- yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2/-/-1-benzopyran-6-yl)-3-{pyrazolo[1 ,5-a]pyridin- 3-yl}-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-{2-(3,4-dihydro-2H-1 -benzopyran-6-yl)-3-[1 -(2,2,2-trifluoroethyl)- 1 H-pyrazol-4-yl]-6-(trifluoromethyl)phenyl}acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-pyrrol-3- yl)-6-(trifluoromethyl)phenyl]acetic acid; - 2-(ie/f-butoxy)-2-[3-(cyclopent-1-en-1-yl)-2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6- (trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-{3-[1-(cyclobutylmethyl)-6-oxo-1 !6-dihydropyridin-2-yl]-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetic acid;
- 2-(ie/f-butoxy)-2-{3-[1-(cyclobutylmethyl)-2-oxo-1 ,2-dihydropyridin-3-yl]-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -methyl-1 H-pyridin-2- one-5-yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(6-oxo-1 -propyl-1 ,6- dihydropyridin-3-yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-[3-(1-benzyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro-2H-1-benzopyran-6- yl)-6-(trifluoromethyl)phenyl]-2-(ie f-butoxy)acetic acid;
- 2-(ie/f-butoxy)-2-{3-[1-(cyclopropylmethyl)-6-oxo-1 !6-dihydropyridin-3-yl]-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetic acid;
- 2-(ie/f-butoxy)-2-{3-[1-(cyclobutylmethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoromethyl)phenyl}acetic acid;
- 2-(ie/f-butoxy)-2-{3-[1-(2-cyclopropylethyl)-6-oxo-1 ,6-dihydropyridin-3-yl]-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-(trifluoro methyl)phenyl}acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-[1-(2-methylpropyl)-6- oxo-1 ,6-dihydropyridin-3-yl]-6-(trifluoromethyl)phenyl]acetic acid ;
- 2-(ie/f-butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 !6-dihydro-pyridin-3-yl)-2-(3,4- dihydro-2H-1 -benzopyran-6-yl)-6-methylphenyl] acetic acid;
2-(ie f-butoxy)-2-[3-(1-cyclobutylmethyl-6-oxo-1 ,6-dihydro-pyridin-3-yl)-6-methyl-2- [5-methyl-(3,4-dihydro-2/-/-1 -benzopyran-6-yl)]phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[3-(1-cyclopropyl-6-oxo-1 ,6-dihydropyridin-3-yl)-2-(3,4-dihydro- 2H-1-benzopyran-6-yl)-6-(trifluoromethyl)phenyl]acetic acid;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(1 -ethyl-2-oxo-1 ,2- dihydropyridin-4-yl)-6-(trifluoromethyl)phenyl]acetic;
- 2-(ie/f-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-(5-methyl-1 H-pyrazol-1- yl)-6-(trifluoromethyl)phenyl]acetic acid.
10. Compound according to any of the preceding claims for use as a medicine.
11. Compound according to claim 10 for use for the prevention or for the treatment of a viral infection.
12. Compound according to claim 10 or 1 1 for use for the prevention or for the treatment of a retroviral infection.
13. Compound according to claims 10 to 12 for use for the prevention or for the treatment of HIV.
14. A pharmaceutical composition comprising a compound according to any of claims 1 to 13 as an active ingredient and at least a pharmaceutically acceptable carrier. 15. Pharmaceutical composition according to claim 14 further comprising a further antiviral agent.
16. Pharmaceutical composition according to claim 14 or 15 for use for the prevention or for the treatment of a viral infection.
17. Pharmaceutical composition according to claims 14 to 16 for use for the prevention or for the treatment of a retroviral infection.
18. Pharmaceutical composition according to claims 14 to 17 for use for the treatment of an HIV infection in a mammal being infected or having a risk to be infected by the HIV.
EP13774453.8A 2012-10-11 2013-10-11 Inhibitors of viral replication, their process of preparation and their therapeutical uses Not-in-force EP2906539B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13774453.8A EP2906539B1 (en) 2012-10-11 2013-10-11 Inhibitors of viral replication, their process of preparation and their therapeutical uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261712674P 2012-10-11 2012-10-11
EP12306244.0A EP2719685A1 (en) 2012-10-11 2012-10-11 Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP13774453.8A EP2906539B1 (en) 2012-10-11 2013-10-11 Inhibitors of viral replication, their process of preparation and their therapeutical uses
PCT/EP2013/071321 WO2014057103A1 (en) 2012-10-11 2013-10-11 Inhibitors of viral replication, their process of preparation and their therapeutical uses

Publications (2)

Publication Number Publication Date
EP2906539A1 true EP2906539A1 (en) 2015-08-19
EP2906539B1 EP2906539B1 (en) 2017-06-21

Family

ID=47018938

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12306244.0A Withdrawn EP2719685A1 (en) 2012-10-11 2012-10-11 Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP13774453.8A Not-in-force EP2906539B1 (en) 2012-10-11 2013-10-11 Inhibitors of viral replication, their process of preparation and their therapeutical uses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12306244.0A Withdrawn EP2719685A1 (en) 2012-10-11 2012-10-11 Inhibitors of viral replication, their process of preparation and their therapeutical uses

Country Status (7)

Country Link
US (1) US9475802B2 (en)
EP (2) EP2719685A1 (en)
JP (1) JP6266001B2 (en)
AU (1) AU2013328609B2 (en)
CA (1) CA2885139A1 (en)
ES (1) ES2641372T3 (en)
WO (1) WO2014057103A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2821104A1 (en) * 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
US9975906B2 (en) 2014-05-16 2018-05-22 Shionogi & Co., Ltd. Tricyclic heterocycle derivatives having HIV replication inhibitory effect
CA2987384A1 (en) 2015-05-29 2016-12-08 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity
RU2018106501A (en) 2015-08-12 2019-09-13 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД Derivatives of 5- (N- [6.5] -condensed bicyclic aryl-tetrahydroisoquinolin-6-yl) -pyridin-3-yl-acetic acid as inhibitors of human immunodeficiency virus replication
AU2016305339A1 (en) * 2015-08-12 2018-03-01 VIIV Healthcare UK (No.5) Limited 5-(n-fused tricyclic Aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of Human Immunodeficiency Virus replication

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2705318C (en) 2007-11-15 2013-12-31 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
RU2503679C2 (en) 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Replication inhibitors of human immunodeficiency virus
JP5285709B2 (en) 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド Human immunodeficiency virus replication inhibitor
JP5269087B2 (en) 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド Inhibitors of human immunodeficiency virus replication
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
WO2011076765A1 (en) 2009-12-23 2011-06-30 Katholieke Universiteit Leuven Novel antiviral compounds
US8535919B2 (en) 2010-06-30 2013-09-17 Coskata, Inc. Process for converting gas stream comprising CO, CO2 and H2 to liquid products by fermentation
MX2012015097A (en) 2010-07-02 2013-05-28 Gilead Sciences Inc Napht- 2 -ylacetic acid derivatives to treat aids.
TWI458711B (en) 2010-07-02 2014-11-01 Gilead Sciences Inc Therapeutic compounds
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9029391B2 (en) 2011-01-24 2015-05-12 Viiv Healthcare Uk Limited Isoquinoline compounds and methods for treating HIV
EP2821104A1 (en) * 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses

Also Published As

Publication number Publication date
CA2885139A1 (en) 2014-04-17
US20150274718A1 (en) 2015-10-01
US9475802B2 (en) 2016-10-25
JP6266001B2 (en) 2018-01-24
EP2906539B1 (en) 2017-06-21
AU2013328609B2 (en) 2018-01-18
WO2014057103A1 (en) 2014-04-17
JP2015536916A (en) 2015-12-24
AU2013328609A1 (en) 2015-04-09
ES2641372T3 (en) 2017-11-08
EP2719685A1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
JP6078640B2 (en) Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9604900B2 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
CA3093851A1 (en) Substituted 1,1&#39;-biphenyl compounds, analogues thereof, and methods using same
AU2018331172A1 (en) Influenza virus replication inhibitor and use thereof
JP2019512485A (en) Tricyclic compounds useful for the treatment of orthomyxovirus infections
AU2013328609B2 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
AU2015220551B2 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
JP2011526294A (en) Disubstituted phenyl compounds as phosphodiesterase 10 inhibitors
US10358435B2 (en) Triazolyl pyrimidinone compounds as PDE2 inhibitors
WO2021239133A1 (en) Pyrimidine compound as axl inhibitor
WO2015057626A1 (en) QUINOLINYL MODULATORS OF RORyT
JPWO2005087749A1 (en) 2-Aminoquinazoline derivatives
AU2013403335B2 (en) Methylene linked quinolinyl modulators of ROR-gamma-t
US20220119355A1 (en) Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof
JP2019511466A (en) Halo substituted piperidines as orexin receptor modulators
US20160159814A1 (en) Glycine transporter inhibitor
US20180111932A1 (en) Novel naphthyridinone derivatives and their use in the treatment of arrhythmia
US9260395B2 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
KR20210022646A (en) Cyanotriazole compounds and uses thereof
JP2021519316A (en) Compounds as regulators of TLR2 signaling
US11111230B2 (en) Indoleamine 2,3-dioxygenase inhibitors and use of same in medicine
EP2821104A1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2903983A1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
JP2022528705A (en) Compounds for the treatment of oncovirus-induced cancer and their usage
US20230027362A1 (en) Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150318

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEDOUSSAL, BENOIT

Inventor name: BENAROUS, RICHARD

Inventor name: CHASSET, SOPHIE

Inventor name: LE STRAT, FREDERIC

Inventor name: CHEVREUIL, FRANCIS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160428

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/352 20060101ALI20161219BHEP

Ipc: C07D 233/60 20060101ALI20161219BHEP

Ipc: A61K 31/4433 20060101ALI20161219BHEP

Ipc: A61K 31/341 20060101ALI20161219BHEP

Ipc: C07D 231/12 20060101ALI20161219BHEP

Ipc: A61K 31/506 20060101ALI20161219BHEP

Ipc: A61K 31/416 20060101ALI20161219BHEP

Ipc: A61K 45/06 20060101ALI20161219BHEP

Ipc: C07D 213/55 20060101AFI20161219BHEP

Ipc: C07D 405/10 20060101ALI20161219BHEP

Ipc: C07D 311/04 20060101ALI20161219BHEP

Ipc: A61K 31/4155 20060101ALI20161219BHEP

Ipc: A61P 31/18 20060101ALI20161219BHEP

Ipc: A61K 31/4418 20060101ALI20161219BHEP

Ipc: A61K 31/4409 20060101ALI20161219BHEP

Ipc: C07D 417/10 20060101ALI20161219BHEP

Ipc: C07D 409/10 20060101ALI20161219BHEP

Ipc: A61K 31/381 20060101ALI20161219BHEP

Ipc: A61K 31/415 20060101ALI20161219BHEP

Ipc: A61K 31/437 20060101ALI20161219BHEP

Ipc: A61K 31/47 20060101ALI20161219BHEP

INTG Intention to grant announced

Effective date: 20170116

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HIVIH

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170511

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 902812

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170715

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013022601

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170922

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170921

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2641372

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20171108

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 902812

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170921

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171021

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013022601

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

26N No opposition filed

Effective date: 20180322

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171011

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20171031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20131011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20191009

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20191016

Year of fee payment: 7

Ref country code: ES

Payment date: 20191119

Year of fee payment: 7

Ref country code: FR

Payment date: 20191007

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20191018

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170621

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013022601

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20201011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210501

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201011

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201012